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ABSTRACT 
 
The concept of aggressive non-Hodgkin lymphoma (NHL) originates in the 
Working Formulation classification of NHL and describes a heterogeneous group of 
NHLs. Despite the introduction of the WHO classification the term ‘aggressive non-
Hodgkin lymphoma’ still remains in clinical use. This work will focus on some 
important aspects of epidemiology, clinical presentation, prognosis, treatment and 
treatment outcome in two main subtypes of aggressive lymphoma: diffuse large B-cell 
lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL). 
DLBCL is the most common NHL occurring more frequently in older patients 
and is characterised by heterogeneous histology. The current standard treatment is 
immunochemotherapy with cyclophosphamide, doxorubicine, vincristine, prednisone 
(CHOP) and anti-CD20 antibody rituximab. Approximately 50-60% of patients 
eventually die from DLBCL. Depending on the patient’s age, two different approaches 
can be defined in order to improve the outcome in DLBCL. In younger patients, the 
better risk stratification and prediction of response to standard therapy can help to 
define the high-risk groups suitable for new, more intensive therapy approaches. In 
elderly patients, where already delivery of standard chemotherapy is difficult, the 
introduction of the targeted therapies and its combination with new less toxic 
chemotherapy regimens could be seen as a future approach. Targeted therapies can be 
also adopted in younger patients. 
It was aimed to describe DLBCL in a population-based setting in order to obtain 
the realistic picture of disease, define the needs of patients and develop a prognostic 
model based on expression of molecular factors in routine formalin fixed paraffin 
embedded (FFPE) tissue samples using quantitative polymerase chain reaction (qPCR) 
for identification of high risk patients. 
A population-based study on 1863 DLBCL patients described picture of disease, 
therapy and outcome. Importantly, it revealed that a significant number of patients 
(30%) who did not receive standard chemotherapy were characterised by a very bad 
prognosis. Additionally, the duration of first remission was one of the most important 
factors for patient survival, suggesting first-line treatment should be escalated in 
suitable high-risk patients. 
 iv 
The model based on expression of MYC, HLA-DRΒ and variant 2 of the 
C13orf25 locus (v2-transcript) using qPCR was successfully established in FFPE tissue. 
Unfortunately, we could not confirm its predictive value in patient cohort. The 
preliminary work on expression of microRNA encoded in v2-transcript as predictive 
biomarker was performed in FFPE tissue and delivered promising results. 
PTCL is characterised by dismal outcome when treated with standard CHOP. 
The rarity and heterogeneity of the PTCL, lack of prospective trials in homogenous 
types of the PTCL as well as hesitation to use high intensity treatments can contribute to 
the poor outcome. 
It was aimed to collect prospective data in a population-based setting on clinical 
presentation, treatment and outcome of patients with enteropathy associated T-cell 
lymphoma (EATL), a subtype of PTCL, and to assess the role of a novel high-dose 
chemotherapy with ifosfamide, epirubicin, etoposide/methotrexate and autologous stem 
cell transplantation (IVE/MTX-ASCT) in EATL and other PTCL subtypes. 
The incidence of EATL in the studied population was 0.14/100 000 per year. 
The detailed picture of the disease at presentation was obtained. The prognosis was 
dismal when treated with conventional treatment with 5-years PFS and OS of 18% and 
20%, respectively. The new IVE/MTX–ASCT regimen improved the patient outcome 
with the 5-years PFS and OS of 52% and 60%, respectively. The results of IVE/MTX-
ASCT in other PTCL were also promising with 3-years PFS and OS of 65% and 72%, 
respectively. 
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Chapter 1. Introduction 
 
1.1 Lymphomas 
 
1.1.1 Definition and classification of lymphomas 
Lymphomas and leukaemias are both malignancies of the haemopoietic and 
lymphoid system. Traditionally, in accordance with histopathological findings, 
lymphoma can be divided into two main groups; Hodgkin lymphoma (HL) and non-
Hodgkin lymphoma (NHL) (Cannelos et al., 2006). The World Health Organisation 
(WHO) classification of tumours of haematopoietic and lymphoid tissues introduced the 
new term “lymphoid neoplasms” covering both lymphoma and leukaemia of lymphoid 
origin (Swerdlow et al., 2008). This new term overcomes the artificial separation 
between leukaemia and lymphoma used in previous classifications. Lymphoid 
neoplasms are subdivided into two classes; B-cell neoplasms and natural killer (NK) / 
T-cell neoplasms. The previously separate group of HL is now included with the B-cell 
neoplasms, after the recent discovery of its cell of origin. In both classes two separate 
groups are defined: precursor and mature neoplasms. This new definition is a significant 
step forwards in the classification of lymphoid neoplasms; however, the old 
classification is still in use particularly in clinical and epidemiological studies. 
Looking backwards, the first description of what we now recognize as a 
lymphoma is attributed to Thomas Hodgkin in 1832 (Hodgkin, 1832). Subsequently 
thirty years passed until the term lymphosarcoma was first introduced by Rudolf 
Virchow in 1863 (Jaffe et al., 2008) and another forty years before in 1898 and 1902 
Carl Sternberg and Dorothy Reed described independently Reed-Sternberg cells in 
Hodgkin lymphoma (Dawson, 1999). Several years later, Ewing, Oberling and Roulet 
introduced the term “reticulum cell sarcoma” for tumours of large cells and postulated 
their origin in the supporting fibrous reticulum of lymphoid tissue. This was in contrast 
to “lymphosarcoma” a term, which was applied to small cell neoplasms with their origin 
in lymphocytes (Jaffe et al., 2008). The next important step in the history of lymphoma 
classification was the description of patients with lymphadenopathy and splenomegaly 
characterized pathologically by a proliferation of lymphoid follicles. Brill et al. in 1925 
(Brill et al., 1925) and Symmers et al in 1927 (Symmers, 1927) both described this 
entity and its progression to a large cell neoplasm (Symmers, 1938). 
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The first proposed morphological classification of lymphoma was introduced in 
1941 in the United States by E.A. Gall and T.B. Mallory (pathologists from the 
Massachusetts General Hospital), more than 100 years after the discovery of Thomas 
Hodgkin (Gall and Mallory, 1942). This classification recognized follicular lymphoma 
(FL) as a distinctive morphologic and clinical entity and included Hodgkin’s disease as 
a separate type of lymphoma. 
The modern era in lymphoma classification began with the introduction of the 
Rappaport classification by the Armed Forces Institute of Pathology in 1966 (the initial 
version was published in 1956) (Hicks et al., 1956). Despite its revolutionary character, 
in some areas this classification was a step backwards. Rappaport questioned the idea 
that FL could arise from reactive follicles and replaced the term follicular with nodular. 
Rappaport’s classification was based on the stratification of tumours either in a nodular 
or diffuse pattern; the former usually had a better prognosis. Consequently the 
previously well-defined FL was split into four separate categories. The origin of 
tumours with large cells was thought to be from non-lymphoid stromal or other cells 
despite the recent discovery of lymphocyte transformation. Despite these drawbacks the 
classification was highly clinically useful and widely employed in the United States, 
mostly due to the high frequency of FL in that country. 
In the same era, a new classification of Hodgkin’s disease was published by 
Lukes and Butler (Lukes et al., 1966a). It was subsequently modified in 1974 (Lukes et 
al., 1966b). This classification distinguishes between four types of Hodgkin’s disease. 
In the following 50 years it remained in common use undergoing only a few changes. 
In the 1960s several discoveries contributed to a better understanding of the 
immune system and its neoplasms; firstly the potential of lymphocytes to transform into 
large proliferating cells in response to mitogens and antigens (Nowell, 1960) secondly 
the recognition of the existence of several distinct lymphocyte lineages (B, T and NK) 
that could be not predicted by morphology but have distinctive functions and 
physiologies (Papermaster and Good, 1962) (Cooper et al., 1965). Additionally, in the 
early 1970’s lymphoid cells were found to express surface antigens or receptors that 
could be exploited to identify the lineage of both normal and neoplastic cells (Shevach 
et al., 1973) (Jaffe et al., 1977). This led to the recognition that i) lymphomas were 
tumours of the immune system, ii) nodular lymphoma is the same as FL, iii) “reticulum 
cell sarcomas” are of B-cell origin and iv) the cells of Sezary syndrome and most 
lymphoblastic lymphomas are of T-cell origin (Jaffe et al., 2008). 
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Pathologists were quick to apply this new information to further refine the 
classification of lymphoma. The first and most important work came from Karl Lennert 
from Kiel (Lennert, 1978). His classification was based on ultrastructural studies and 
linkage of lymphoma cells with the hypothetical scheme of lymphocyte differentiation, 
particularly with cells within the lymphoid follicle. He separated the neoplasms into two 
cell lineages (B- and T-cell), and grouped them into low and high-grade malignancies. 
Despite employing the recent discoveries in the field of immunology the classification 
was lacking a practical approach in everyday clinical practice and became widely used 
in Europe only. It never replaced the Rapapport classification in the United States. 
In parallel clinicians were improving their knowledge of treatments and staging 
of lymphomas. The heterogeneity between different types of lymphoma became 
increasingly obvious in clinical practice. However use of different classification systems 
made it difficult to compare published results from different centres. This prompted 
clinicians and pathologists to seek a consensus in a new classification of lymphoma. 
Despite several meetings, (the last was held in Airline House in Warrenton, Virginia in 
1975), such a consensus was never reached (Jaffe et al., 2008). As a compromise the 
Working Formulation (WF) for NHL was developed (NationalCancerInstitute, 1982). 
The WF stratified lymphomas according to clinical outcome, based on the survival of 
patients in clinical trials conducted in the 1970s. The neoplasms were divided into ten 
major types (A – J) and a miscellaneous group (see table 1.1). The ten major types 
could be subdivided into three groups: low grade lymphomas (types A – C), 
intermediate grade lymphomas (D – G) and high-grade lymphomas (H – J). This was 
intended to provide a clinical grade to aid patient management. The categories closely 
followed those of the Rappaport classification. Immunophenotyping was not applied 
and since the system attempted to cover all entities in only a few groups the categories 
were heterogeneous and were not reproducible by pathologists. In many respects the 
WF was a step backwards (Jaffe et al., 2008). It did not recognize well-defined entities 
such as centrocytic lymphoma from the Kiel classification (now known as mantle cell 
lymphoma). Diffuse large B-cell lymphoma (DLBCL) was divided into two categories: 
large cell and large cell immunoblastic. Finally no use was made of widely available 
immunologic techniques. Therefore both T-cell lymphomas and many DLBCL were 
lumped together in a single category (diffused mixed small and large cell). 
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Low grade lymphoma group 
Type Name 
A 
 
B 
 
C 
 
Malignant lymphoma; small lymphocytic, consistent with CLL, 
plasmocytoid 
Malignant lymphoma; follicular. Predominantly small cleaved cell, 
diffuse areas, sclerosis 
Malignant lymphoma; follicular. Mixed, small cleaved and large cell, 
diffuse areas, sclerosis 
Intermediate grade lymphoma group 
Type Name 
D 
 
E 
F 
 
G 
 
Malignant lymphoma; follicular. Predominantly large cells, diffuse 
areas, sclerosis 
Malignant lymphoma; diffuse. Small cleaved cells, sclerosis 
Malignant lymphoma; diffuse. Mixed, small and large cell, sclerosis, 
epitheloid cell component 
Malignant lymphoma; diffuse. Large cell, cleaved cells, noncleaved 
cell, sclerosis 
High grade lymphoma group 
Type Name 
H 
 
I 
J 
Malignant lymphoma; large cell, immunoblastic, plasmacytoid, clear 
cell, polymorphous, epitheloid cell component 
Malignant lymphoma; lymphoblastic, convulted cell, nonconvulted cell 
Malignant lymphoma; small noncleaved cell, Burkitt’s, follicular areas 
Miscelaneous group 
• Composite 
• Mycosis fungoides 
• Histiocytic 
• Extramedullary plasmocytoma 
• Unclassifiable 
• Other 
Table 1.1 Classification of non-Hodgkin lymphoma according to Working Formulation 
(NationalCancerInstitute, 1982). 
 
Despite all these controversies the WF gained a positive response from many 
clinicians and became very popular in the U.S. particularly for clinical trials where it 
replaced the Rappaport classification. Unfortunately it was employed in several 
important trials and biased their results, which has consequences until the present day. 
In Europe and in Asia the Kiel classification remained the leading tool for the 
classification of lymphoma. 
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With so many different classifications in use it remained difficult for both 
pathologists and clinicians to interpret the results of published studies. Furthermore in 
the 1980s and 1990s numerous new diseases were defined that were not included in any 
classification e.g. anaplastic large cell lymphoma (ALCL), lymphomas of mucosa 
associated lymphoid tissues (MALT) and adult T-cell lymphoma (Jaffe et al., 2008). 
Additionally fundamental discoveries were being made in immunology and genetics 
with potential applications in lymphoma research and disease classification. One of 
these discoveries was the development of monoclonal antibodies (Kohler and Milstein, 
1975). This led on to the discovery of a whole range of cell-markers so called “clusters 
of differentiation (CD)”. Monoclonal antibodies were employed in 
immunohistochemistry (IHC) studies first in cell suspension or cryostat sections and 
later on formalin-fixed paraffin embedded (FFPE) sections (Taylor and Mason, 1974) 
(Mason et al., 1982). Simultaneously a dramatic increase in the understanding of the 
genetics of normal lymphocytes and lymphoma happened. Recurrent cytogenetic 
abnormalities were identified including the translocations in FL, Burkitt lymphoma 
(BL) and Mantle Cell Lymphoma (MCL) (Zech et al., 1976) (Fukuhara et al., 1979) 
(Dalla-Favera et al., 1982) (Taub et al., 1982) (Yunis et al., 1982) (Tsujimoto and 
Croce, 1984). The process of rearrangement of immunoglobulin (Ig) and T-cell 
receptors (TCR) during normal lymphoid cell development was discovered and 
described (Arnold et al., 1989) (Kuppers et al., 1993) (Kuppers et al., 1999). Techniques 
like fluorescence in situ hybridisation (FISH) and polymerase chains reaction (PCR) 
were developed and allowed the analysis of antigen receptor genes and oncogene 
rearrangements on FFPE sections together with genetic alterations at a single-cell level 
(Deane and Norton, 1990) (Ngan et al., 1989) (Wlodarska et al., 1995). The latter was 
employed in studies on Hodgkin’s disease samples and led to the demonstration of Ig 
heavy chain gene rearrangements in Reed-Sternberg cells thus defining the origin of the 
malignant cell as a B-cell. Consequently Hodgkin’s disease was renamed as HL 
(Kuppers et al., 1994). 
To try and overcome this stalemate and promote a better understanding between 
European and American haematopathologists Peter Isaacson and Harald Stein formed 
an international group of pathologist in 1991 naming it The International Lymphoma 
Study Group (ILSG) (Jaffe et al., 2008). During the first meeting a broad consensus was 
reached and a first common paper on mantle cell lymphoma was published (Banks et 
al., 1992). This initial success was followed by a series of frequent meetings and the 
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group worked through the long list of lymphoid neoplasms. The outcome of these 
meetings formed the basis of a new classification called the Revised European-
American Classification of Lymphoid Neoplasms (REAL), published in 1994 (Harris et 
al., 1994). The ILSG defined all individual entities by a combination of morphology, 
immunophenotype, genetic anomalies and characteristic clinical profile including the 
site of presentation. The inclusion of clinical criteria was one of the novel aspects of the 
REAL classification. The clinical criteria played an important role particularly in the 
classification of T-cell neoplasms or MALT and primary mediastinal large B-cell 
lymphoma (PMLBL). The REAL classification focused on identification of “real” 
diseases rather than a global theoretical framework such as survival in WF, or cellular 
differentiation in the Kiel and Lukes-Collins classifications (Jaffe et al., 2008). 
Recognizing that HL and plasma cell myeloma are both lymphoid in origin, and 
that lymphoid neoplasms can present in solid and circulating phases the classification 
included all lymphoid neoplasms: NHL, HL, lymphoid leukaemias (chronic and acute) 
and plasma cell disorders (Harris et al., 1994). The tumours were stratified according to 
lineage; B-cell vs. T/NK cell and further into precursor and mature neoplasms. Hodgkin 
lymphoma remained a separate category. The REAL classification recognized that 
because of limitations in current knowledge some broad categories of disease could not 
be further subdivided, for example, DLBCL or peripheral T-cell lymphoma (PTCL) 
NOS. These categories should be the subject of future studies. Importantly the REAL 
classification did not attempt to stratify lymphomas according to a histologic or clinical 
“grade”, as was the case in the WF or Kiel classifications. It was recognized that 
lymphomas are a heterogeneous group of distinct diseases mostly unrelated to one 
another, and not a single disease with a spectrum of histologic grade and clinical 
behavior. In the REAL classification grading was used within some disease entities such 
as FL but not across a range of different diseases. The main goals of the REAL 
classification were proven in an international study by James Armitage et al and the 
conclusion of the study affirmed its principles (The Non-Hodgkin's Lymphoma 
Classification Project, 1997). 
Briefly, after the publication of the REAL classification the WHO published an 
update of its classification of tumours of hematopoietic and lymphoid tissues (Jaffe et 
al., 2008). A common steering committee of the Society of Haematology and of the 
European Association of Haematopathology was appointed and work started under its 
supervision (Jaffe et al., 1999). The new WHO classification was developed over 7 
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years. Its development was intensively discussed in the international arena in order to 
achieve worldwide acceptance. In general the WHO classification was based on the 
REAL classification. Importantly it was again concluded that clinical grouping for 
either protocol treatment or routine clinical practice is not feasible. Each disease needs 
to be treat individually when new therapies are introduced. The basis of the 
classification was the fact that B-cell and NK/T-cell neoplasms in many respects appear 
to replicate normal B-cell or NK/T-cell differentiation. However, some common 
neoplasms do not clearly correspond to a currently recognized normal differentiation 
stage. Other tumours exhibit lineage heterogeneity or plasticity. Obviously in these 
cases the normal counterparts cannot be the sole basis for the classification. The WHO 
classification was published in 2001 (Jaffe et al., 2001). In order to include continuous 
developments in immunology, genetics and haematology the WHO classification has 
been reviewed and updated; the new version was published in 2008, see table 1.2 
(Swerdlow et al., 2008). 
 
Precursor lymphoid neoplasm 
• B lymphoblastic leukaemia / lymphoma 
• B lymphoblastic leukaemia / lymphoma, NOS 
• B lymphoblastic leukaemia / lymphoma, with recurrent genetic abnormalities 
• B lymphoblastic leukaemia / lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 
• B lymphoblastic leukaemia / lymphoma with t(v; 11q23); MLL rearranged 
• B lymphoblastic leukaemia / lymphoma with t(12;21)(p13;q22); TEL-AML1 
(ETV6-RUNX1) 
• B lymphoblastic leukaemia / lymphoma with hyperdiploidy 
• B lymphoblastic leukaemia / lymphoma hypodiploidy (hypodiploid ALL) 
• B lymphoblastic leukaemia / lymphoma with t(5;14)(q31;q32); IL3-IGH 
• B lymphoblastic leukaemia / lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 
(TCF3-PBX1) 
• T lymphoblastic leukaemia / lymphoma 
Table 1.2 2008 WHO classification of lymphoid malignancies (Swerdlow et al., 2008). 
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Mature B-cell neoplasm 
• Chronic lymphocytic leukaemia / small lymphocytic lymphoma 
• B-cell prolymphocytic leukaemia 
• Splenic marginal zone lymphoma 
• Hairy cell leukaemia 
• Splenic B-cell lymphoma / leukaemia, unclassifiable 
Splenic diffuse red pulp small B-cell lymphoma 
Hairy cell leukaemia - variant 
• Lymphoplasmacytic lymphoma 
• Waldenstroem macroglobulinaemia 
• Heavy chain diseases 
Apha heavy chain disease 
Gamma heavy chain disease 
Mu heavy chain disease 
• Plasma cell myeloma 
• Solitary plasmacytoma of bone 
• Extraosseous plasmacytoma 
• Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue 
(MALT lymphoma) 
• Nodal mariginal zone lymphoma 
• Paediatric nodal mariginal zone lymphoma 
• Follicular lymphoma 
• Paediatric follicular lymphoma 
• Primary cutaneous follicle centre lymphoma 
• Mantel cell lymphoma 
• Diffuse large B-cell lymphoma (DLBCL), NOS 
T-cell / histiocyte rich large B-cell lymphoma 
Primary DLBCL of the CNS 
Primary cutaneous DLBCL, leg type 
EBV positive DLBCL of the elderly 
• DLBCL associated with chronic inflammation 
• Lymphomatoid granulomatosis 
• Primary mediastinal (thymic) large B-cell lymphoma 
• Intravascular large B-cell lymphoma 
• ALK positive large B-cell lymphoma 
• Plasmablastic lymphoma 
Table 1.2 2008 WHO classification of lymphoid malignancies (Swerdlow et al., 2008). 
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Mature B-cell neoplasm (continuation) 
• Large B-cell lymphoma arising in HHV8—associated multicentre Castelman 
disease 
• Primary effusion lymphoma 
• Burktitt lymphoma 
• B-cell lymphoma, unclassifiable, with features intermediate between diffuse 
large B-cell lymphoma and Burkitt lymphoma 
• B-cell lymphoma, unclassifiable, with features intermediate between diffuse 
large B-cell lymphoma and classical Hodgkin lymphoma 
Mature T-cell and NK-cell neoplasm 
• T-cell prolymphocytic leukaemia 
• T-cell large granular lymphocytic leukaemia 
• Chronic lymphoproliferative disorders of NK cells* 
• Aggressive NK-cell leukaemia 
• Systemic EBV-positive T-cell lymphoproliferative disorders of childhood 
• Hydroavacciniforme-like lymphoma 
• Adult T-cell lymphoma/leukaemia 
• Extranodal NK/T-cell lymphoma, nasal type 
• Enteropathy-associated T-cell lymphoma 
• Hepatosplenic T-cell lymphoma 
• Subcutaneous panniculitis-like T-cell lymphoma 
• Mycosis fungoides 
• Sezary syndrome 
• Primary cutaneous CD30+ lymphoproliferative disorder 
• Lymphomatoidpapulosis 
• Primary cutaneous anaplastic large cell lymphoma 
• Primary cutaneous gamma-delta T-cell lymphoma* 
• Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell 
lymphoma 
• Primary cutaneous CD4 positive small/medium T-cell lymphoma 
• Peripheral T-cell lymphoma, not otherwise specified 
• Angioimmunoblastic T-cell lymphoma 
• Anaplastic large cell lymphoma, ALK-positive 
• Anaplastic large cell lymphoma, ALK-negative* 
Table 1.2 2008 WHO classification of lymphoid malignancies (Swerdlow et al., 2008). 
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Hodgkin lymphoma 
• Nodular lymphocyte predominant Hodgkin lymphoma 
• Classical Hodgkin lymphoma 
Nodular sclerosis classical Hodgkin lymphoma 
Lymphocyte-rich classical Hodgkin lymphoma 
Mixed cellularity classical Hodgkin lymphoma 
Lymphocyte-depleted classical Hodgkin lymphoma 
Posttranspantation lymphoproliferative disorders (PTLD) 
• Early lesions 
• Plasmacytic hyperplasia 
• Infectious mononucleosis-like PTLD 
• Polymorphic PTLD 
• Monomorphic PTLD (B- and T/NK-cell types) 
• Classical Hodgkin lymphoma type PTLD 
Table 1.2 2008 WHO classification of lymphoid malignancies (Swerdlow et al., 2008). 
 
During the updating process special attention was paid to heterogeneous and 
ambiguous categories e.g. FL and DLBCL. One of the major changes included the 
introduction of provisional borderline categories: i) B-cell lymphoma unclassifiable, 
with features intermediate between DLBCL and BL and ii) B-cell lymphoma, 
unclassifiable, with features intermediate between DLBCL and classical HL. The other 
alteration was the identification of diseases characterized by involvement of specific 
anatomic sites, or by other clinical features e.g. age. Both B-cell and T-cell lymphomas 
involving cutaneous or other extranodal sites such as the central nervous system (CNS), 
paediatric marginal zone lymphomas, paediatric FLs and Epstein-Barr virus (EBV) 
positive DLBCL in elderly persons are now recognised as distinct entities. One 
unresolved issue is the difficulty of pathological prognostication in big, heterogeneous 
categories like FL or DLBCL. Despite the inclusion of specific new types of DLBCL, a 
heterogeneous category of DLBCL NOS remains for which pathologic features are 
lacking to further stratify them for predicting prognosis or response to therapy. 
Development of targeted therapies and recognition of additional markers of clinical 
behaviour will likely result in additional modification to this category in the future. 
Furthermore the new WHO classification emphasises other future areas of research such 
as studies on early events in lymphomagenesis, the recognition of small clonal 
lymphoid populations or lineage plasticity in hematopoietic cells and their neoplasms. 
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1.1.2 Epidemiology of lymphomas 
The American Cancer Society estimated there were 71,380 new cases of 
lymphoma in 2007, including 8,190 cases of HL and 63,190 cases of NHL 
(AmericanCancerSociety, 2007). The survey from the Surveillance, Epidemiology and 
End Results program in the United States indicated an incidence rate per 100,000 
persons per year of 33.65 for all lymphoid neoplasms, 26.13 for B-cell neoplasms, 1.79 
for T-cell neoplasms and 2.67 for HL (Morton et al., 2006). According to these data the 
incidence rates for NHL have nearly doubled since the early 1970s. Although some of 
this increase is due to AIDS-related NHL in general it remains unexplained, (see more 
in the aetiology section) (AmericanCancerSociety, 2007). According to epidemiological 
data precursor and mature lymphoid neoplasms comprise approximately 10% and 90% 
of lymphoid neoplasms respectively (Armitage and Weisenburger, 1998) (The Non-
Hodgkin's Lymphoma Classification Project, 1997). Precursor lymphoid neoplasms are 
primarily diseases of children (approximately 75% of cases are diagnosed in children 
aged <6 years) and more common in males (Swerdlow et al., 2008). A B-cell origin is 
more common in leukemic variants and a T-cell origin in lymphoma variants 
(Swerdlow et al., 2008). The vast majority of mature neoplasms are of B-cell origin 
(approximately 90%) with NK/T-cell neoplasms making up the remaining 10% 
(Armitage and Weisenburger, 1998) (The Non-Hodgkin's Lymphoma Classification 
Project, 1997). DLBCL and FL are the most common variants of mature B-cell 
neoplasms, together accounting for more than 60% of all cases (see figure 1.1) 
(Anderson et al., 1998) (The Non-Hodgkin's Lymphoma Classification Project, 1997). 
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Figure 1.1 Relative frequencies of B-cell lymphoma subtypes in adults (The Non-
Hodgkin's Lymphoma Classification Project, 1997). 
 
PTCL NOS and angioimmunoblastic T-cell lymphoma (AITL) are the main 
subtypes of mature T-cell neoplasms (see figure 1.2) (Vose et al., 2008). 
 
 
Figure 1.2 Relative frequencies of T-cell lymphoma subtypes in adults (Vose et al., 
2008). 
 
There are significant international differences in frequency of individual 
lymphoma types. As a rule T-cell lymphomas are more frequent in Asia, and B-cell 
lymphomas in developed western countries (United States, Australia, New Zealand and 
Western Europe) (Swerdlow et al., 2008). DLBCL shows a more or less equal 
distribution worldwide whereas FL is more common in the United States and Western 
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Europe and is uncommon in South America, Eastern Europe, Africa or Asia. By 
contrast BL is very common in Africa (particularly in the equatorial part where the 
disease is endemic), but very rare in Europe and North America (Swerdlow et al., 2008). 
For NK/T-cell lymphomas, adult T-cell leukaemia/lymphoma (ATLL) is the most 
common lymphoma in Japan and the Caribbean basin. EBV associated NK/T-cell 
neoplasms are much more common in Asians as compared with other races e.g. in 
Hong-Kong extranodal NK/T-cell lymphoma nasal type is one of the most common 
subtypes, whereas in other regions it is an extremely rare disease (Vose et al., 2008). By 
contrast type 1 enteropathy associated T-cell lymphoma (EATL) is more common in 
northwest Europe than anywhere else in the world, particularly in individuals of Welsh 
and Irish descent. 
Generally there is a male predominance amongst patients with B-cell lymphoma, 
however, there are types with a female predominance: FL or even more significantly 
PMLBL (Swerdlow et al., 2008). B-cell neoplasms are tumours of elderly people with a 
median age at diagnosis of 60 – 70 years with the exception of HL and PMLBL The 
median age at diagnosis is lower in patients with NK/T-cell neoplasms. 
Survival rates in patients with lymphoma vary depending on the type and stage 
of disease. The average five-year survival for HL is 86% and for NHL 63%. It had been 
predicted that in 2007 an estimated 19,730 deaths will occur in the USA due to 
lymphoma; HL 1,070 and NHL 18,660 (AmericanCancerSociety, 2007). 
 
1.1.3 Aetiology of lymphomas 
The main cause of the majority of lymphomas is still unknown. The most 
studied are infectious agents and among them EBV is the most common (Swerdlow et 
al., 2008). It is present in 100% of endemic BL cases and 15-35% of sporadic and HIV-
associated BL cases (Hamilton-Dutoit et al., 1993). Additionally EBV is involved in the 
pathogenesis of many other B-cell lymphomas such as post-transplant 
lymphoproliferative disorders (PTLD), plasmablastic lymphomas, EBV+ large B-cell 
lymphoma of the elderly, extranodal NK/T-cell lymphoma and HL (Kanegane et al., 
1998) (Quintanilla-Martinez et al., 2000). Human T-cell leukaemia/lymphoma virus-I 
(HTLV-1) is the causative agent of ATLL (Takatsuki, 1995) and human herpesvirus-8 
(HHV8) is found in primary effusion lymphoma and the lymphomas associated with 
multicentric Castelman’s disease (Cesarman et al., 1995). Infection with hepatitis C 
virus (HCV) may be linked to the development of lymphoplasmacytic lymphoma 
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associated with type II cryoglobulinaemia, splenic marginal zone lymphoma, nodal 
marginal zone lymphoma or DLBCL (Agnello et al., 1992) (Swerdlow et al., 2008) (de 
Sanjose et al., 2008). The HCV does not seem to directly infect neoplastic B-cells but 
appears to influence the lymphoma development through activation of a B-cell immune 
response (Swerdlow et al., 2008). Infections with Helicobacter pylori are associated 
with the development of gastric MALT lymphoma (Hussell et al., 1993) (Wotherspoon 
et al., 1991) (Wotherspoon et al., 1993), B. burgdorferi with cutaneous MALT 
lymphoma (Swerdlow et al., 2008), Clamydia psitttaci, C. pneumoniae and C. 
trachomatis in ocular adnexal MALT lymphomas (Chanudet et al., 2006) (Ruiz et al., 
2007) and Campylobacter jejuni with intestital MALT lymphoma associated with alpha 
heavy chain disease (Price, 1990). 
Other known risk factors include severely reduced immune function like 
immunosuppression after organ transplant which predisposes not only to hepatosplenic 
T-cell lymphoma and PTLD but also primary cutaneous and mucosa associated B-cell 
lymphomas. Other severe autoimmune conditions and infections with human 
immunodeficiency virus (HIV) are associated DLBCL, BL and other HIV associated 
lymphomas (Swerdlow et al., 2008). A family history, as well as exposure to certain 
chemicals; like herbicides or chlorinated organic compounds are further risk factors 
particularly for the development of follicular lymphoma (Colt et al., 2006). 
 
1.1.4 Pathobiology of lymphomas 
 The mechanisms involved in the pathogenesis of B-cell and NK/T-cell 
neoplasms in many respects are based on the physiology of lymphoid cells. Likewise 
the clinical manifestations of lymphomas reflect the normal function of lymphoid cells 
in vivo. The former is particularly the case in B-cell neoplasms and the latter more 
significant for NK/T-cell neoplasms (Jaffe et al., 2008). 
 
1.1.4.a Pathobiology of B-cell lymphomas 
Normal B-cell differentiation begins in bone marrow (BM) with precursor B-
cells known as progenitor B-cells (B lymphoblasts). These cells undergo 
immunoglobulin VDJ gene rearrangement (first heavy chain gene rearrangement in pre-
B cells and subsequently heavy and light chain gene rearrangement in immature B-
cells), and finally differentiate into mature surface immunoglobulin positive (IgM+ and 
IgD+) naïve B-cells (Inghirami et al., 1991). Neoplasms with their origin in the above 
 15 
cells include B lymphoblastic leukaemia / lymphoma and they are called precursor B-
cell neoplasms. Naïve B-cells are small resting lymphocytes, that circulate in the 
peripheral blood (PB) and also occupy primary lymphoid follicles and follicle mantle 
zones. Most cases of mantle cell lymphoma have their origin in CD5+ naïve B-cells; 
they belong to the group of pre-germinal centre (GC) neoplasms (Hummel et al., 1994). 
During further differentiation processes in the interfollicular area naïve B-cells undergo 
transformation, proliferation and ultimately maturation into short lived plasma cell or 
memory B-cells when encountering antigen that fits their surface Ig receptors. 
Alternatively they migrate into the centre of a primary follicle, proliferate and fill the 
follicular dendritic cell meshwork, forming a GC (Liu et al., 1991) (MacLennan, 1994). 
In the GC naïve B-cells transform into centroblasts expressing low sIg and switch off 
the expression of B-cell lymphoma 2 (BCL2) protein, thus becoming susceptible to 
death through apoptosis (Reed, 2008). Centroblasts also express CD10 and B-cell 
lymphoma 6 (BCL6) proteins, which are characteristics of GC cells (Pittaluga et al., 
1996). Somatic hypermutation in the Ig heavy and light chain variable region genes and 
switch of Ig type from IgM to IgG or IgA also occurs in the germinal centre 
(MacLennan et al., 1990). BCL6 also undergoes somatic hypermutation, albeit with a 
lower frequency (Pasqualucci et al., 1998). IGV region gene mutations and BCL6 
mutations serve as markers of cells which have been through the GC. Centroblasts 
mature to centrocytes, and these cells are seen predominantly in the light zone of the 
GC. Centrocytes express the altered sIg and those with mutations resulting in increased 
affinity re-express BCL2 and escape from apoptosis (MacLennan, 1994). Through the 
interaction with the follicular dendritic cells (Cattoretti et al., 1995) (Pittaluga et al., 
1996) and through the overexpression of interferon regulatory factor-4 / multiple 
myeloma oncogene 1 (IRF4/MUM1) (Falini et al., 2000) (Saito et al., 2007) 
centroblasts switch off BCL6 protein and differentiate into post-GC B-cells: either 
memory B-cells or plasma cells (MacLennan, 1994). Neoplasms having their origin in 
GC B-cells are FL, BL, some DLBCL and HL (Swerdlow et al., 2008). Post-germinal 
memory cells circulate in the PB and constitute at least some of the cells in the follicular 
marginal zones of lymph nodes, spleen and mucosa-associated lymphoid tissue 
(MALT). These cells usually express pan-B antigens surface IgM, and at low level, IgD 
and are negative for CD5 and CD10 (van den Oord et al., 1989). Plasma cells produced 
in the germinal centre enter the PB and home to the BM. These cells contain IgG or 
IgA, they lack soluble Ig and CD20, but express IRF4/MUM1, CD79a, CD38 and 
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CD138 (Swerdlow et al., 2008). Both cells have mutated IGV regions. Neoplasms 
derived from post-germinal centre cells are: MZL of MALT, splenic and nodal 
lymphoplasmacytic lymphoma, chronic lymphocytic leukaemia / small lymphocytic 
leukaemia (CLL/SLL), DLBCL and plasma cell myeloma (Swerdlow et al., 2008). A 
simplified diagram of normal B-cell differentiation is shown in figure 1.3. 
 
 
Figure 1.3 Diagrammatic representations of B-cell differentiation and relationship to 
major B-cell neoplasms (Swerdlow et al., 2008). 
 
1.1.4.b Pathobiology of T-cell lymphomas 
 By contrast to the current classification of B-cell neoplasms the classification of 
NK/T-cell neoplasms is based more on clinical characteristics of the disease including 
involved site and clinical course. Nevertheless, some aspects of normal NK/T-cell 
development and differentiation are important and helpful for understanding of their 
classification and pathology. The characteristic feature of T-cells is expression of the 
TCR. Depending on the structure of the TCR, there are two classes of T-cells; α/β and 
γ/δ (Brown et al., 2002). By contrast NK cells do not express TCR, CD3 or BCR. They 
usually express the surface markers CD16 (FcγRIII) and CD56 in humans. 
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T-cells arise from a BM precursor progenitor T-cell (prothymocyte). The 
progenitor T-cells subsequently migrate into the thymus gland and settle down in the 
thymic cortex as subcapsular cortical thymocytes. Antigen specific α/β T-cells mature 
from cortical thymocytes. The cortical thymocytes have an immature T-cell phenotype 
and express terminal deoxynucleotidyl transferase (TDT), CD1a, CD3, CD5 and CD7 
and are initially double negative for both CD4 and CD8. Subsequently these antigens 
are co-expressed in maturing thymocytes. The T lymphoblastic / leukaemias have their 
origin in the immature T-cells described above (Swerdlow et al., 2008). The cortical 
thymocytes develop into medullary thymocytes, which express only CD4 or CD8 like 
mature α/β T-cells. Medullary thymocytes give rise to naïve α/β T-cells and all these 
cells have a similar phenotype. Naive α/β T-cells leave the thymus and upon antigen 
stimulation they may undergo blast transformation (T-blast) and develop further into 
CD4+ and CD8+ effector and memory cells; components of an adaptive immune 
system. The CD4+ T cells have mostly a regulatory function and can be divided into 
two major classes: helper T-cell 1 and 2 (Th1 and Th2). Th1 provide the help to other 
T-cells and macrophages and Th2 to the B-cells (Brugieres et al., 1998). Recently two 
new classes of CD4+ cells have been described; follicular T-helper cells (FTH) are 
present in germinal centres and provide help to B-cells in the context of germinal centre 
reaction (Grogg et al., 2006) and regulatory T cells (Treg) that play an important role in 
preventing autoimmunity (Roncador et al., 2005). The FTH are postulated to be the cell 
of origin for angioimmunoblastic T-cell lymphoma (Dupuis et al., 2006) and Treg for 
ATLL (Roncador et al., 2005). The CD8+ cells have a cytotoxic function. The precise 
pathway of maturation of γ/δ T-cells is not fully understood. It is postulated that these 
cells also originate from a cortical thymocyte. The mature γ/δ T-cells do not express 
CD5, CD4 or usually CD8. They comprise about 5% of all normal T-cells and are 
mostly present in the splenic red pulp and epithelial tissue (Swerdlow et al., 2008). The 
γ/δ T-cells recognize a limited range of antigens, mostly heat shock proteins (Brown et 
al., 2002). 
NK cells have their origin in progenitor T-cells and they do not undergo thymic 
differentiation. Mature NK cells express CD2, CD7, sometimes CD8 but not surface 
CD3. NK cells and γ/δ T-cells are major component parts of the innate immune system 
and are present in the spleen, intestine, other epithelial sites and skin. Figure 1.4 
presents a simplified diagram of normal NK/T-cell differentiation. 
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Figure 1.4 Diagrammatic representation of T-cell differentiation and relationship to 
major T-cell neoplasms (Swerdlow et al., 2008). 
 
Mature NK/T-cell lymphomas can be divided into lymphomas of the innate 
immune system and lymphomas of the adaptive immune system. The former are 
predominantly extranodal in presentation and are observed in paediatric and young adult 
age groups and originate in NK or γ/δ T-cells, e.g. aggressive NK-cell leukaemia, 
systemic EBV-positive T-cell lymphoproliferative disease of childhood, most 
hepatosplenic T-cell lymphomas (γ/δ – origin) and γ/δ T-cell lymphomas affecting 
cutaneous and mucosal sites (Jaffe, 2006). By contrast the latter are mostly nodal 
lymphomas of adult age groups, e.g. PTCL NOS, AILT, anaplastic large cell lymphoma 
(ALCL), anaplastic lymphoma kinase (ALK) positive or negative (Jaffe, 2006). 
 
1.1.5 Genetics of lymphomas 
 In general lymphoid neoplasms lack universal genetic abnormalities. However, 
some can be found in several lymphomas of B-cell origin. The most widespread are: 
t(11;14) in MCL, t(14;18) in FL, t(8;14) and its variants in BL and t(11; 18) in MALT 
lymphoma (de Boer et al., 1995) (Kanungo et al., 2006) (Levine et al., 1989). The most 
common paradigm of these translocations is involvement of the Ig heavy chain gene on 
14q. A cellular proto-oncogene comes under the influence of an Ig heavy chain gene 
enhancer. By contrast only two T-cell neoplasms have been associated with specific 
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genetic abnormalities: ALCL with a translocation involving the ALK gene on 
chromosome 5: t(2;5) and hepatosplenic T-cell lymphoma with isochromosome 7q 
(Swerdlow et al., 2008). However, the next generation whole genome / exome 
sequencing characterised several new genetic changes in PTCL, they need more re-
valuation, for more details see section 1.4.4.b Biological and molecular prognostic 
factors. 
 
1.1.6 Basic of pharmacological therapy of lymphoma 
The systemic anticancer drugs can be classified into two main groups: 
conventional cytostatic drugs and molecular targeted drugs. Multiple drugs are often 
combined in a treatment regimen. The combined drugs usually have different 
mechanisms of action and toxicity profiles, so they can be given close to their individual 
maximal dose. In this way the combination of drugs may overcome tumour resistance to 
an individual drug and at least in theory is more effective. Below we will briefly 
characterize the mechanism of action of the most important drugs and possible 
resistance mechanisms. We will focus on the drugs used in the treatment of 
lymphoproliferative disorders. 
 
1.1.6.a Conventional cytostatic drugs 
The conventional cytostatic drugs are traditionally divided into several groups 
This division can sometimes be confusing, as individual groups are defined by different 
criteria like mechanism of action (eg. alkylating agents, antimetabolites, topoisomerase 
inhibitors or antimicrotubular agents) or structure (antibiotics or platinating agents). The 
following groups are usualy described: alkylating agents, platinating agents, 
antimetabolites, topoisomerase inhibitors, antimicrotubular agents, antibiotics and 
miscellaneous cytotoxic drugs 
 
Alkylating agents 
Alkylating agents were the first cytostatic drugs introduced in cancer treatment 
(Tannock et al., 2013). The group is heterogenous chemically but all the substances 
include alkyl groups (eg. –CH2Cl) and cause alkylating of biological molecules via the 
nucleophile substitution reaction (Forth et al., 2001). In detail, alkyl groups generate 
highly reactive, electrophile (positively charged) intermediates, which then react with 
nucleophile (negatively charged) groups like amino, phosphate, sulfhydryl, or 
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hydroxymoietes on intracellular macromolecules like DNA. Alkylating agents may 
contain one or two reactive groups and respectively are described as mono- or bi-
functional. The major mechanism of action of bi-functional agents is building the 
crosslinks between DNA strands. This inter-strand linking prevents cell replication. By 
contrast the mono-functional agents causes single-strand brakes in DNA or damage to 
bases. The vast majority of alkylating agents used in clinical practice are bi-functional. 
The most common side of alkylation of DNA by nitrogen is N-7 or O-6 position 
(dacarbazine) on the guanine. As alkylating agents bind directly to DNA they lack cell 
cycle specificity, however the proliferating cells are more vulnerable. The resistance 
mechanisms to alkylating agents include: decrease transport across the cell membrane, 
increased intracellular thiol concentration, increased enzymatic detoxification of 
reactive intermediates and alternations in DNA repair enzymes. 
Alkylating agents include a big family of nitrogen mustard derivatives e.g. 
nitrogen mustard (mechlorethamine), cyclophosphamide, trophosphamide, ifosfamide, 
melphalan, chlorambucil and bendamustine. Cyclophosphamide is the most used drug 
from this group. It requires activation by hepatic microsomal enzymes to 4-
hydroxycylclophospahmide, which exists in equilibrium with its acyclic isomer 
aldophosphamide. 4-hydroxycyclophosphamide after entering the cells spontaneously 
decomposes to active phosphoramid mustard and acrolein. Two other 
cyclophosphamide derivatives: ifosfamide and trofosfamide undergo a similar hepatic 
activation process. Another group of alkylating agents are nitrosourea derivates: 
carmustine (BCNU) and lomustin (CCNU). Thiotepa, procarbazine, dacarbazine, 
temozolomide and busulphan are other components with alkylating potential with 
diverse chemical structure, e.g. busulphan is a bi-functional alkyl alkane sulfonate and 
reacts with thiol groups of aminoacids and proteins, but its ability to crosslink the DNA 
is uncertain. 
 
Platinating agents 
Platinating agents are planar platinum complexes. The central atom of the 
complexe is a platinum atom in 2+ oxidation state (Forth et al., 2001). It has four 
linking bonds to attached groups. Two of these groups are considered carrier groups and 
two active–leaving groups. In cisplatin two carrier groups are amine ligands and two 
leaving groups are chloride ligands. In carboplatin the leaving groups are replaced by a 
bidentate: ciclobutan dicarboxylic acid. By contrast in oxaliplatin both carer and leaving 
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groups were replaced by bidenates: 1,2-diaminocyclohexan and oxalate, respectively. 
During the activation process the active groups after dissociation from the platinum 
atom leave a positively charged electrophile complex, which reacts in nucleophilic 
substitution mechanism with nucleophile groups of molecules similar to mustard 
nitrogen. The preferred sites of the substitution are N-7 atoms of guanine and adenosine. 
Cisplatin binds in two sites of DNA, in 95% causing intra-strand cross linkages between 
two adjacent guanine bases or guanine and adenosine and in the remaining 5% inter-
strand guanine linkages. Carboplatin and oxaliplatin produce the same type of adducts 
like cisplatin, however oxaliplatin more often causes cell death, most likely due to the 
tertiary structure of substitution products.  Cisplatin and carboplatin have similar 
activity profile and show cross resistance and have different toxicity profiles. The 
resistance mechanisms are decreased uptake and increased binding to intracellular 
scavengers e.g. gluthiation or SH-positive metalloproteins and also increased activity of 
DNA repair. 
 
Antimetabolites 
The antimetabolites are cytotoxic agents, which interfere with the synthesis of 
DNA (Forth et al., 2001). Usually their structure resembles the structure of 
physiological elements of DNA e.g. purines and pyrimidines. Currently used 
antimetabolites can be divided into three categories: i) anti-folates, ii) purine and purine 
nucleoside analogues and iii) pyrimidine and pyrimidine nucleoside analogues. 
Antimetabolites are usually cell cycle specific in S-phase. As they do not interact 
directly with DNA, they do not cause late cancerogenesis problems. 
i) Antifolates. Methotrexate is the first and the most commonly used anti-
metabolite (Forth et al., 2001). It is an analogue of the vitamin folic acid. It binds and 
inhibits the enzyme di-hydrofolate reductase, which catalyses a reduction of di-
hydrofolate to tetra-hydrofolate. Tetra-hydrofolate is used as donor of active carbon 
groups in reaction of conversion of deoxyuridine monophosphate to thymidine 
monophosphate catalysed by thymidil synthase. In this reaction the tetra-hydrofolate is 
binge oxidised to di-hydrofolate. The di-hydrofolate reductase guarantees the 
appropriate concentration of tetra-hydrofolate in the cell and its inhibition stops 
synthesis of DNA. Methotrexate passively crosses the cell membrane and undergoes 
polyglutamation, this prevents the efflux of the drug and polyglutamed derivatives are 
also more potent (Tannock et al., 2013). The cytotoxic action of methotrexate depends 
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not only on the dose but also on the time of exposure. The toxicity of methotrexate can 
be reversed by administration of thymidine and exogenous purines or sources of 
reduced folate. Methotrexate can be given in standard doses and in high doses with 
leucovorin cover (reduced form of folate). It can be given orally, intramuscularly, 
intravenously and intrathecally. Methotrexate crosses the blood–brain barrier but 
achieves the cytotoxic concentration in cerbro-spinal fluid only if given in high 
concentration or intrathecally. The toxic profile includes myelosupression and 
mucositis, damage to liver, lung and central nervous system. 
Pemetrexed is another antifolate, a derivative of folic acid, which inhibits 
directly thymidylate synthase, di-hydrofolate transferase and glycinamid rybocucleotide 
formytransferase (enzyme involved in purine synthesis) (Tannock et al., 2013). The 
main toxicities are myelosupression, mucositis and skin rash. Ralitrexed is another 
inhibitor of thymidyl synthase, similar to pemetrexed. 
ii) Purine and purine nucleoside analogues. 6-mercaptopurine and 6-thioguanin 
are analogues of hypoxantines and guanine. Both drugs are metabolized by 
hypoxantine-guanin-phosphoribosyltranspherase to active metabolites 6’-thioinosin-5’-
phosphate (thio-IMP) and thioguanosin-5-phosphate (thio-GMP) (Tannock et al., 2013). 
Thio-IMP and thio-GMP inhibit the conversion of IMP to AMP and GMP and are 
feedback inhibitors of purine-biosynthesis. Further, thio-GTP and desoxy-thio-GTP are 
incorporated into RNA and DNA as false nucleotides. The main toxicities are 
myelosupression and hepatotoxicity. 
Fludarabine and cladribine are purine nucleoside analogues, specifically 
adenosine analogues (Tannock et al., 2013). Fludarabine after administration is 
dephosphorylated to 2-fluoro-ara-A which is thereafter transferred into the cells and 
converted to active triphosphate derivative. The mechanism of action is inhibition of 
DNA polymerase and termination of DNA and RNA synthesis. The majority of the drug 
is eliminated renally. The common toxicities are myelosupression and 
immunosuppression. Rarely fludarabine can cause autoimmune disorders like 
haemolytic anaemia, autoimmune thrombocytopenia or CNS toxicity. Cladribine has a 
similar mechanism of action and toxicological profile to fludarabine. 
iii) Pyrimidine and pyrimidine nucleoside analogues. 5-fluorouracil is an 
analogue of pyrimidine bases uracil and thymine. It penetrates quickly into cells where 
is metabolized in nucleosides and nucleotides to 5-fluoro-uridine-triphospate (5-FUTP), 
5-fluoro-deoxyuridine-triphosphate (5-FdUTP) and 5-fluoro-deoxyuridine-
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monophosphate (5-FdUMP) (Tannock et al., 2013). 5-FUTP and 5-FdUTP are built as 
false nucleotides into RNA and DNA causing inhibition of the nuclear processing. The 
5-FdUMP together with the cofactor 5,10-methyl-N-tetrahydrofolate binds to and 
irreversibly inhibits thymidylate synthase. The excess of 5,10-methyl-N-
tetrahydrofolate stabilizes this complex. 5-fluorouracil is administered parenterally as 
the oral route cannot guarantee predictable, appropriate drug levels. The most common 
toxicities of 5-flurouracil are myelotoxicity and mucositis, followed by skin rashes, 
conjunctivitis, neuro and cardio-toxicities. Approximately 80% of 5-fluorouracil is 
metabolized to carbondioxide, urea and alfa-fluoro-beta-alanine by di-hydropyrimidine 
dehydrogenase. Patients with partial or complete deficiency of the enzyme are at risk of 
severe toxicities. 
Capecitabine is an oral fluoropyrimidine derivative which is metabolized in liver 
to 5’-deoxy-5-fluorocytidine by carboxyesterase and then to to 5’-deoxyfluorouridine 
by cytidine deaminase (Tannock et al., 2013). 5’-deoxyfluorouridine is finally converted 
to 5-fluoruracil by thymidine phosphorylase. This enzyme is present in higher 
concentrations in tumour cells, where the latter reaction usually takes place. The 
toxicities of capecitabine are similar to those of 5-fluorouracil with lower frequencies of 
mylotoxicities and mucositis and higher of palmar-plantar syndrome. 
Cytosine arabinoside (ara-C) and gemcitabine are purine nucleotide analogues 
(Forth et al., 2001). Cytosine arabinoside following the conversion to arabinoside-CTP 
by kinases is incorporated into DNA, which stops DNA-polymerase. Additionally 
arabinoside-CTP is a direct inhibitor of DNA-polymerase. The availability of the active 
form of the drug depends on activity of kinases activating the pro-drug and aminazes 
which deactivate it. Cytosine arabinoside is highly efficient in tumours with high kinase 
activity e.g. AML. The main toxicity is myelosupression, nausea and vomiting, 
diarrhoea, mucositis and fever. Gemcitabine (2’,2’-difluorodeoxycitidine) is a cytosine 
analogue which like Cytosine arabinoside requires intracellular activation to 
triphosphate derivatives dFdCTP which is then incorporated into DNA and inhibits 
further DNA synthesis. Gemcitabine is less active in DNA chain elimination as 
compared with cytosine arabinoside, however it shows other intracellular effects 
contributing to its cytotoxicity e.g. inhibition of ribonucleotide reductase, stimulation of 
deoxycytidine kinase and inhibition of cytidine deaminase. Gemcitabine is effective in a 
larger number of tumours as compared with cytosine arabinoside. Toxicity is primarily 
myelosupression with thrombocytopenia. 
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Topoisomerase inhibitors 
DNA topoisomerases are enzymes that introduce or eliminate supercoils in 
double DNA strand. Type I topoisomerases catalyse the relaxation of supercoiled DNA 
and type II topoisomerases add negative supercoils to DNA (Tannock et al., 2013). 
Torsional strain occurring during the processes described above is relieved by the 
formation of a single-strand nick (topoisomerase I) or double-strand nick 
(topoisomerase II). Topoisomerase inhibitor binds to the DNA/topoisomerase cleavable 
complex preventing the relegation of DNA strands. Irreversible damage results when an 
advancing replication fork encounters topoisomerase inhibitor/DNA/topoisomerase 
stabilized cleavable complex leading to lethal double strand breaks and cell death. 
Topoisomerase I inhibitors are derivatives of campothecin, an extract from the 
wood of the Chinese tree Campotheca acuminate. They selectively bind to 
topoisomerase I/DNA complex, mostly in S phase. Currently there are two 
topoisomerase I inhibitors in clinical use; topotecan and irinotecan. Topotecan in 
contrast to irinotecan does not undergo any metabolic changes and it is eliminated in 
unchanged form via the kidneys. The dose limiting toxicity is myelosupression. 
Irinotecan requires esterification to its active metabolite SN38, which is subsequently 
inactivated by glucorinidation by the uridine diphosphate (UDP) – 
glucuronosyltransferase 1A1 (UGT1A1) and it is eliminated with bile. A dose limiting 
toxicity is myelosupression and diarrhoea. Irinotecan can cause two different types of 
diarrhoea – one with an early onset associated with cholinergic syndrome which can be 
treated / prevented with the dose of atropine and second type with later onset. The latter 
one is associated with polymorphism of UGT1A1 resulting in slower metabolisms of 
SN38 causing damage to interstitial mucosa and profound myelosupression and can be 
life threatening. 
Two topoisomerase II inhibitors currently in clinical use: etoposide and 
teniposide are glycoside derivatives of Podophylotoxines, an antimitotic agent derived 
from the mandrake plant. The resistance mechanism is associated with overexpression 
of P170-glycoprotein and changes in topoisomerase II. Both agents are administered 
parenterally, however etoposide can be given orally. The limiting toxicity is 
myelosupression and etoposide is associated with development of secondary AML 
usualy 2 -3 years post etoposide application. 
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Antimicrotubular agents 
This group of cytotoxic agents consists of two separate subgroups i) vinca 
alkaloids and ii) taxanes. 
i) Vinca alkaloids. The naturally occurring in peri-winkle plants vinblastine and 
vincristine and their semisynthetic derivatives belong to this group (Tannock et al., 
2013). All these components have same basic structure and are characterized by the 
same mechanism of action. They all bind to protein tubulin and prevent its 
polymerisation and building microtubules. The main function of microtubules are 
formatting of the mitotic spindle responsible for separating of chromosomes during 
metaphase of mitosis or meiosis and structural and transport functions in cells, 
particularly they are crucial for the function of nerve axons. Hence vinca alkaloids 
interrupt the metaphase and the lethally damaged cell undergoes apoptotic death. They 
belong to cell cycle specific cytostatic drugs with the action time-point of mitosis or S-
phase. All vinca-alkaloids with the exception of vinorelbin have to be administered i.v. 
They are lipofilic and have a large volume of distribution, undergo hepatic metabolism 
and biliary secretion. The resistance mechanism is an over-expression of P170-
Glykoprotein and changes in tubulin structure. Despite their similarities in the structure 
and mechanism of action, the vinca alkaloids differ in their clinical spectra and their 
toxicity profiles. Vincristine is characterized by neurotoxiciy to peripheral nerves, by 
contrast the dose limiting toxicity of vinblastine is myelotoxicity and neurotoxicity to 
the autonomic nervous system. Vinorelbine has a toxicity profile similar to vinblastine 
with a difference to neurotoxicity which affects more peripheral nerve system (this 
doesn’t quite make sense, but not quite sure what you are saying). 
ii) Taxanes. Taxanes are a second group of antimicrotubular agents (Tannock et al., 
2013). Two drugs belonging to this group are currently in clinical use: Paclitaxel 
originally delivered from the needles of the Pacific Yew tree Taxus brevifolia and its 
semi-syntetic derivative Docetaxel. Both drugs bind to polymerised tubulin inhibiting 
microtubular dissemble and causing aborted mitosis leading to apoptotic cell death. 
Taxanes have a large distribution volume with extensive tissue building and undergo 
hepatic metabolism through the cytochrome P450 enzyme complex. The resistance 
mechanism is like in vinca-aloids an overexpression of P-170 protein. The common 
toxicities are myelosupression, conduit disturbances in the heart and peripheral 
neuropathies. Doxetaxel is often associated with fluid retention and peripheral oedema. 
Both drugs can cause severe allergic reactions. 
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Antibiotics 
This group is very heterogenous in structure and mechanism of action of its 
components with the exception of the fact that all these drugs are antibiotics with 
cytotoxic activity. The group includes a subgroup of cytostatic agents anthracyclines, 
and individual drugs like mitoxantrone, dactinomycin, amsacrin, mitomycin C and 
bleomycin (Tannock et al., 2013). 
Anthracyclines are ones of the most common used cytostatic drugs. 
daunorubicin and doxorubicin are antibiotics originally isolated from Streptomyces 
peucetius. Epirubicin and indarubicine are semi-synthetic derivatives. All drugs have 
tetracyclic ring attached via glycoside bound to aminosugar daunosamin. The 
mechanism of action is similar in all anthracyclines and includes: DNA intercalation, 
interactions with topoisomerase II and building of free radicals. Anthracyclines are S-
phase cell cycle specific drugs. All anthracyclines with exception of idarubicin are 
given parenterally and undergo hepatic metabolism. The resistance mechanism is 
increased concentration and activity of radical scavenger system (e.g. gluthation) and 
increased drug efflux caused by P-170 glycoprotein. The toxicity profile includes 
myelosupression, cardiotoxicity (most likely due to free radicals), gastrointestinal side 
effects and local tissue necrosis. 
Mitoxantrone is a syntetic antrhacenedione derivate. It has a tricyclic structure 
with two secondary amine groups. Mitoxantrone has a mechanism of action similar to 
that of anthracyclines including DNA intercalation, interactions with topoisomerase II 
and synthesis of free radicals. It is however less potent, but is also characterized by a 
milder toxicity profile. 
Dactinorubicine is a cytotoxic drug isolated from Streptomycess spp. It consists 
of a tricyclic phenoxasone ring which is connected to two identical pentapeptid rings. 
The mechanism of action is a DNA intercalation, which results in RNA and protein 
synthesis. It is administered parenterally and is eliminated in unmetabolised form in bile 
and urine. The common toxicities are myelosupression, nausea and vomiting and 
mucositis. 
Amsacrine is an acridine derivative, which causes DNA intercalation and 
interferes with topoisomerase II. The common side effects are myelosupression and 
cadiotoxicity. 
Mitomycin C is an antibiotic isolated form Streptomyces caespitosus with a 
bifunctional DNA alkylating potential. Mitomycin C is an indol derivative and is 
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charachterized by an aziridine ring. It requires activation by reductive metabolism. It is 
usually used locally in treatment of bladder or anal canal cancers. It can cause 
myelosupression, gastric side effects and rarely but importantly a severe, often letal 
microangiopathy with haemolitic uraemic syndrome or interstitial lung fibrosis.  
Bleomycin consists of a family of metal binding glycoproteins isolated from 
Streptomyces verticullis. The dominant active components are Bleomycin A2 and B2. 
The mechanism of action includes DNA intercalation and consequently fragmentation 
of DNA, and aborts DNA synthesis. Bleomycin is a G2 phase cell cycle specific 
molecule; however it shows also an action in plateau phase as well. Because of its large 
size bleomycin crosses the cell membrane very slowly and subsequently is activated by 
bleomycin hydrolase, this enzyme is also responsible for breaking down the drug. 
Bleomycin is usually administered intravenously, but can be given intramuscularly and 
subcutaneously. Approximately 60% of Bleomycin is eliminated in the urine. The most 
important toxicities are fever, headache, allergic reactions including common skin 
reactions and interstitial lung fibrosis. 
 
Miscellaneous cytotoxic drugs 
Asparginase is an enzyme deaminating asparagine to aspartic acid (Tannock et 
al., 2013). It is isolated from the bacterium Erwinia-chrisanthemi. For normal, healthy 
cells asparagine is not an essential amino acid; however it is for the fast dividing 
leukaemia and lymphoma cells. The side effects are severe allergic reactions, 
coagulopathies, hyperglycemia, pancreatitis and encephalopathy. 
Mitelfosin is a phospholipid derivative with an unclear cytostatic mechanism. It 
is an inhibitor of membrane phospholipids, and interferes with phospholipid dependent 
singnal pathways and induces  apoptosis. Its clinical use is limited. 
 
1.1.6.b Molecular-targeted agents 
Molecular-targeted agents are a new class of anticancer drugs that target changes 
in molecular pathways rather than in DNA, as the conventional drugs do. They have a 
better toxicological profile as they are more specific. At the moment there are 
approximately 50 different drugs in clinical use. They usually belong to the 
mononoclonal antibody group or small molecule group. Here we describe closer those 
which are important for the general understanding of the group  (inhibitors of 
angiogenesis, epidermal growth factor inhibitor and tyrosine kinases or proteasome 
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inhibitors) or are important in the treatment of lymphoproliferative disorders (anti CD20 
or anti CD52 antibodies or brentuximab vedotin). 
 
Inhibitors of angiogenesis 
One of the first and the most important group of the molecular-targeted drugs 
are inhibitors of angiogenesis, a necessary process for tumour growth (Tannock et al., 
2013). The crucial factor stimulating the angiogenesis is vascular endothelial growth 
factor (VEGF) which binds to its receptors (VEGFR) and activates the intercellular 
tyrosine kinases. There are currently two groups of drugs inhibiting the angiogenesis – 
the monoclonal antibodies directed against VEGF (e.g. bevacizumab)  and inhibitors of 
intracellular kinases associated with VEGFR pathways (sunitinib, sorafenib and 
pazopanib). The mechanism of action of thalidomide and lenalidomide is also 
associated with angiogenesis, however is not fully understood. 
 
Epidermal growth factor inhibitors 
Other important group of molecular- targeted drugs are associated with 
epidermal growth factor (EGF) (Tannock et al., 2013). The epidermal growth factor is 
polypeptide that binds to its cell surface receptor. There are four subgroups of EGF 
receptors (EGFR): EGFR, HER 2/c-neu, Her 3 and Her 4. The activation of EGFR 
initiates cascades of intracellular RAS-RAF-MAPK and PI3K-AKT pathways which 
stimulate transcription of genes that promote cell proliferation and survival including 
tumour growth, angiogenesis, invasion and metastasis and also apoptosis. There are two 
groups of drugs which interfere with the EGF pathway: antibodies against cell surface 
receptors (cetuximab and panitumumab – against EGFR and trastuzumab against HER 
2/c-neu) and small molecules inhibiting the kinases associated with EGFR (erlotinib and 
gefitinib) or with HER 2/c-neu (lapatinib). 
 
Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors are the first successfully used drugs targeting 
signalling pathways. The first agent was imatinib inhibiting the tyrosine kinase activity 
of the constitutively active fusion protein BCR-ABL arising from the Philadelphia 
chromosome of CML (Tannock et al., 2013). Imatinib also inhibits c-KIT tyrosine 
kinase, which is overexpressed in 80% of GISTs. Resistance to imatinib results from 
mutations that alter amino acid sequences at the drug binding side or prevent 
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achievement of the inactive confirmation of the kinase, which is necessary for binding 
of the drug. Imatinib is well tolerated with common side effects including mild nausea, 
diarrhoea, fluid retention, muscle cramps and fatigue. The other two tyrosine kinases are 
dasatinib and nilotinib, which can be successfully used in most of patients who have 
developed resistance to imatinib. 
 
Proteasome inhibitors 
This is a new group of anti-cancer agents. The oldest representative of the group 
is bortezomib (Velcade) (Tannock et al., 2013). Proteasomes are intracellular 
organelles, responsible for degradation of cellular protein including ubiquitylated 
molecules, damaged or misfiled or regulatory proteins. During the cell-cycle multiple 
proteins are produced in cells in a synchronized way and they have to be switched off at 
appropriate moments in order to allow the progression of the cell to the next stage. The 
proteasomes are responsible for appropriate turnover of these molecules and their 
inhibition can lead to cell death. The inhibition of proteasomes can lead to stress 
reaction of endoplasmic reticulum, inhibition of NF-kB, inflammatory pathway, 
increased generation of reactive oxygen species and activation of Caspase 8 and 
apoptosis. In the tumour cells bortezomib may prevent degradation of pro-apoptotic 
factors, permitting activation of apoptosis pathways. Bortezomib is an N-protected 
dipeptide (pyrazinoic acid - phenylalanine – leucine with bronic acid instead of 
carboxylic acid). Its boron atom binds covalently but reversible to catalytic site of the 
26S ribosome. It can be administered subcutaneously of intravenously. It is approved to 
be used in multiple myeloma and mantle cell lymphoma. The adverse events are 
neuropathy, myelosupression, immunosuppression or acute interstitial nephritis. New 
proteasome inhibitors are in development e.g. carfizomib which inhibits the active site 
of the proteasome irreversibly and as a more powerful agent can overcome resistance to 
bortezomib. 
 
Anti-CD20 antibodies 
The CD20 is a target of several monoclonal antibodies used in treatment of 
lymphoproliferative disorders, rheumatology or autoimmundiseases (Lim et al., 2010). 
The CD20 is an activated-glycosylated phosphoprotein expressed on the surface of 
normal and malignant B-cells (Lim et al., 2010). In normal B-cells it begins to be 
expressed at the stage of late pro-B cells through all developmental stages till memory 
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cells. It is not expressed on plasma cells. CD20 does not have a natural ligand and it acts 
as a calcium channel in the cell membrane. Its function is to enable optimal B-cell 
immune response against T-independent antibodies, it also plays a role in 
microenvironmental interaction of B-cells.  
The CD20 is the first antigen which has been targeted clinically. Currently there 
are several non-conjugated anti CD20 antibodies in clinical use: chimeric e.g. rituximab 
and humanized antibodies e.g. ofatumumab and obinutuzumab or conjugates with 
radioactive molecules e.g. ibritumomab tiuxetan and tositumomab. 
The anti-CD20 antibodies can be divided into two groups: type I and type II 
antibodies depending on their in vivo activities in various assays like: ability of 
antibodies to redistribute CD20 in Triton X-100-insoluble lipid rafts, induce homotypic 
adhesion, evoke complement dependent cytotoxicity or direct cell death (Lim et al., 
2010). In vivo studies of Type I antibodies (rituximab or ofatumumab) are more 
powerful at translocating CD20 into lipid rafts and inducing complement dependent 
cytotoxicity and Type II antibodies (obinutuzumab or tositumomab) are more potent at 
inducing homotypic adhesion and direct cell death induction (Lim et al., 2010). 
Rituximab was the first approved chimeric anti-CD20 monoclonal antibody. 
Currently it is being used as monotherapy in the treatment of B-cell lymphoma, 
autoimmune disorders including multiple sclerosis and rheumatological disorders. In 
haemato-oncology is also used in combination with chemotherapy. The mechanism of 
action includes: i) Fc:FcR dependent mechanism including antibody directed cellular 
cytotoxicity and antibody directed cellular phagocytosis), ii) complement dependent 
cytotoxicity, iii) programed cell death and iiii) through T-cell mediated immunity (Lim 
and Levy, 2014). The resistance mechanism to rituximab include i) trygocytosis, a 
process of selective cleavage of antigen/antibody complexes from the surface of the 
target cells by phagocytic cells, ii) loss of expression of CD20 following the treatment 
with rituximab iii) internalization of antigen/antibody complexes (Lim and Levy, 2014). 
The success of rituximab stimulated the development of new antiCD20 
monoclonal antibodies. The new drugs can belong to 2nd generation antibodies where 
the IgG1 monoclonal antibody is humanized or fully human in order immunogenicity 
(not sure what you are saying) (eg ocrelizumab, veltuzumab or ofatumumab) or to 3rd 
generation antibodies which are humanized and additionaly have an engineered FC 
region in order to improve the affinity to FcR (e.g. obinutuzumab, ocaratuzumab and 
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Pro13192) (Lim and Levy, 2014). Among the new substances ofatumumab and 
obinutuzumab are clinically the most advanced. 
Ofatumumab is a new type I, humanized anti CD20 antibody. In contrast to 
rituximab it recognizes a distinct epitope of CD20 and has a slower dissociation rate 
from CD20 resulting in greater complement dependent cytotoxicity activity and ability 
to lyse the tumour cells (Lim and Levy, 2014). Ofatumumab is characterized by more 
effective induction of antibody directed cellular phagocytosis by macrophages. 
Obinutuzumab is a type II, humanized anti CD20 antibody. It has a sugar residue 
removed from its Fc domain resulting in higher affinity to the Fc receptor (Lim and 
Levy, 2014). The antibody is known for its high effectiveness in inducing lysosomal-
mediated cell death. Obinutuzumab is superior at enhancing NK cell activation and 
antibody directed cellular cytotoxicity. 
 
Anti CD52 antibodies 
Alemtuzumab targets CD52 antigen, a glycoprotein, which in humans is 
encoded by the CD52 gene and is present on the surface of mature lymphocytes, 
monocytes and dendritic cells. It is a peptide of 12 aminoacids, is highly negatively 
charged and its function is anti-adhesion. Altemtuzumab, after binding to its antigen, 
causes a cell death via antibody-dependent cell-mediated cytotoxicity. 
 
Brentuximab vedotin 
Brentuximab vedotin is an antibody drug conjugate consisting of a 
chimeric monoclonal anti CD30 antibody brentuximab linked to an antimitotic 
agentmonomethyl auristatin E molecule – vedotin. CD30 (TNFRSF8) is a cell 
membrane protein of the tumour necrosis factor receptor family and tumour marker. It 
is expressed on activated B-cells and T-cells. During the pathological state it is 
expressed on ALCL, embryonal carcinoma and HL Reed-Sterberg cells. TNF receptor-
associated factor 2 and 5 are natural ligands of CD30. Their binding to the receptor 
activates NF-κβ pathway and apoptosis. Brentuximab vedotin is approved for the 
treatment of relapsed and refractory HL and ALCL. 
 
1.2 A concept of aggressive non-Hodgkin lymphomas (NHL) 
The concept of “aggressive / high grade NHL” as opposed to “indolent / low 
grade lymphoma NHL” has its origin in the WF classification of NHLs. The WF 
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stratified NHL according to differences in survival and other clinical parameters e.g. age 
and curability (NationalCancerInstitute, 1982). Unfortunately the formulation ignored 
some already well-described pathological features and did not include the 
immunophenotypes of tumours. Despite its limitations the WF gained broad clinical 
acceptance, particularly in North America, and numerous crucial clinical trials in NHL 
lymphomas included patients according to the WF. Probably one of the most important 
trials was the Intergroup trial on aggressive lymphomas (WF D-H and J) comparing the 
efficacy of new generation regimens with conventional chemotherapy with 
cyclophosphamide, doxorubicine, vincristine, prednisolone (CHOP) (Fisher et al., 
1993). Further important clinical trials were designed for aggressive lymphomas 
including studies of the German High Grade non-Hodgkin Lymphoma Study Group 
(DSHNHL) (Pfreundschuh et al., 2004a) (Pfreundschuh et al., 2004b) and French Adult 
Lymphoma Study Group (GELA) (Gisselbrecht, 2002). The term aggressive lymphoma 
covers a number of currently individual entities with different survival rates e.g. 
PMLBL, DLBCL NOS or almost all subtypes of PTCL. It is likely that the inclusion of 
different categories of lymphomas in the same trials has biased the results. 
This thesis aims to give some solutions for the most significant problems in the 
management of patients and some direction for future translational research in patients 
with certain types of aggressive NHLs (DLBCL and PTCL). In the following part of 
this introduction there will be a closer focus on these types. 
 
1.3 Diffuse large B-cell lymphoma (DLBCL) 
 
1.3.1 Definition and classification of DLBCL 
According to the current WHO classification of tumours of haematopoietic and 
lymphoid tissues DLBCL is a neoplasm of large B lymphoid cells with a nuclear size 
equal to or exceeding normal macrophage nuclei, or more than twice the size of a 
normal lymphocyte, and is characterized by a diffuse growth pattern (Swerdlow et al., 
2008). The postulated normal counterpart of DLBCL NOS tumour cells is a peripheral 
B-cell of either GC or post-GC (activated B-cell) origin (Swerdlow et al., 2008). 
In the recent classification several distinct disease entities have been re-defined 
and selected from the former category of DLBCL (see table 1.3) (Swerdlow et al., 
2008). For the remaining large number of cases there are no clear and accepted criteria 
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for subdivision, although they appear to be biologically heterogeneous. These cases are 
currently classified as DLBCL NOS (Swerdlow et al., 2008). 
 
New defined entities selected for former category of DLBCL 
• Diffuse large B-cell lymphoma associated with chronic inflammation 
• Lymphomatoid granulomatosis 
• Primary mediastinal (thymic) large B-cell lymphoma 
• Intravascular large B-cell lymphoma 
• ALK positive large B-cell lymphoma 
• Plasmablastic lymphoma 
• Large B-cell lymphoma arising in HHV8 associated multicentre Castelman disease 
• Primary effusion lymphoma 
• B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-
cell lymphoma and Burkit lymphoma 
• B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-
cell lymphoma and classical Hodgkin lymphoma	
Table 1.3 Other subtypes of large B-cell lymphomas according to 2008 WHO 
classification of lymphoid malignancies (Swerdlow et al., 2008). 
 
Among DLBCL NOS already several subtypes have been described and defined 
(see table 1.4). In the section on epidemiology of DLBCL in this thesis the definition of 
DLBCL from the previous classification was used as the new one was not available at 
the time of publication of the quoted papers. By contrast in the laboratory-based 
research section patients with a diagnosis of DLBCL NOS according to the 2008 WHO 
classification were included. 
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Morphologic variants 
Common morphologic variants 
• Centroblastic 
• Immunoblastic 
• Anaplastic 
Rare morphologic variants 
Molecular subgroups 
• Germinal centre B-cell-like (GCB) 
• Activated B-cell-like (ABC) 
Immunohistochemical subgroups 
• CD5-positive DLBCL 
• Germinal centre B-cell-like (GCB) 
• Non-germinal centre B-cell-like (non-GCB) 
Table 1.4 DLBCL NOS, variants, subgroups and DLBCL subtypes according to 2008 
WHO classification of lymphoid malignancies (Swerdlow et al., 2008). 
 
1.3.2 Epidemiology of DLBCL 
DLBCL is the most common NHL with an annual incidence of over 25,000/year 
and it accounts for about 40% of all cases worldwide. DLBCL NOS accounts for 
approximately 25-30% of adult NHL in western countries and an even a higher 
percentage in developing countries (Swerdlow et al., 2008). 
More than half of patients with DLBCL and DLBCL NOS are over 60 years of 
age (median age at presentation is in mid-60s – 70s) (Feugier et al., 2005) (Shipp, 1993) 
(The Non-Hodgkin's Lymphoma Classification Project, 1997), are male and present 
with advance-stage disease (American Cancer Society, 2007). 
 
1.3.3 Clinical presentation of DLBCL 
The disease presents in lymph nodes or in extranodal sites with up to 40% being 
at least initially confined to extranodal sites (Harris et al., 1994). The most common 
extranodal site is the gastrointestinal tract (stomach and ileocoecal region), other sites 
include: bone, testis, spleen, Waldeyer’s ring, salivary gland, thyroid, liver, kidney, 
adrenal gland and lung (Swerdlow et al., 2008). BM involvement is reported in 11 – 
27% of cases (Chung et al., 2007). Approximately one third of patients with BM 
involvement has evidence of malignant cells in PB smears. 
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Patients usually present with a rapidly enlarging mass at single or multiple nodal 
sites with or without extranodal involvement. Approximately half of the patients have 
stage 1 or 2 disease. The majority of patients are asymptomatic but when symptoms are 
present then they are highly dependent on the site of involvement (The Non-Hodgkin's 
Lymphoma Classification Project, 1997) (Armitage and Weisenburger, 1998). 
The extent of the disease is evaluated using the Ann Arbor staging system, 
which is based on the results obtained from physical examination, BM biopsy, and 
imaging studies. The criteria for staging are given in table 1.5. 
Patients are further sub staged into A or B according to absence or presence of systemic 
symptoms (fever >38˚C, night sweats and/or weight loss >10% of body weight in the 6 
months preceding presentation) respectively. 
 
Stage Definition 
I 
II 
 
 
III 
 
 
IV 
 
Involvement of a single lymph node or of a single extranodal organ or site (IE) 
Involvement of two or more lymph node regions on the same side of 
diaphragm, or localized involvement of an extranodal site or organ (IIE) and 
one or more lymph node regions on the same side of the diaphragm 
Involvement of lymph node regions on both sides of the diaphragm, which may 
also be accompanied by localized involvement of an extranodal organ or site 
(IIIE) or spleen (IIIS), or both (IIISE) 
Diffuse or disseminated involvement of one or more distant extranodal organs 
with or without associated lymph node involvement 
Table 1.5 Ann Arbor staging system (Carbone et al., 1971). 
 
1.3.4 Aetiology of DLBCL 
The aetiology of DLBCL NOS is unknown. The tumour usually arises de novo 
but some of the cases are transformed from a less aggressive lymphoma: CLL/SLL, FL, 
MZL or nodular lymphocyte predominant HL. Immunodeficiency is a well-known risk 
factor particularly for EBV positive variants. EBV positive cases account for 
approximately 10% of DLBCL NOS in patients without immunodeficiency (Hummel et 
al., 1995) (Park et al., 2007). 
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1.3.5 Pathology of DLBCL 
 
1.3.5.a Morphology 
DLBCL is an aggressive NHL of B-cell origin characterised by a diffuse growth 
pattern of large lymphoid cells with a high proliferation fraction. The architecture of the 
involved nodes is totally (more common pattern) or at least partially (interfollicular 
and/or sinusoidal) affected. Perinodal tissue is often infiltrated (Swerdlow et al., 2008). 
The morphology of DLBCL is diverse and three common (centroblastic, immunoblastic 
and anaplastic) and other rare morphological variants of DLBCL have been defined 
(Swerdlow et al., 2008). These are illustrated in table 1.4. The morphological division 
of DLBCL NOS has neither therapeutic nor prognostic implication. 
 
1.3.5.b Immunophenotype 
The tumour cells express pan-B-cells markers such as CD19, CD20, CD22 and 
CD79a, but may lack some of them (Swerdlow et al., 2008). 50-75% of cases are 
positive for surface and/or cytoplasmic immunoglobulin (IgM>IgG>IgA) 
(Loddenkemper et al., 2004). CD30 expression is usually present in the anaplastic 
variant (Piris et al., 1990) and approximately 10% of tumours are CD5 positive (Tagawa 
et al., 2005). The reported expression of CD10, BCL6 and IRF4/MUM1 varies between 
studies (Amen et al., 2007) (Berglund et al., 2005) (Colomo et al., 2003) (de Leval and 
Harris, 2003) (Muris et al., 2006). Importantly co-expression of IRF4/MUM1 and 
BCL6, which is mutually exclusive in normal GC B-cells, was found in 50% of DLBCL 
(Falini et al., 2000). The proliferation fraction measured by Ki67 expression is high 
(usually >40%) but may be greater than 90% in some cases (Miller et al., 1994). p53 is 
expressed in 20-60% of cases (Chilosi et al., 1996) (Koduru et al., 1997) (Young et al., 
2007). 
The subdivision of DLBCL NOS by immunophenotyping into germinal centre-
like (GCB) and non-germinal centre-like (non GCB) subgroups has been proposed by 
several groups and will be introduced in a section on prognostic factors in DLBCL, see 
table 1.4. 
 
1.3.5.c Genetics 
As described previously, diffuse large B-cell lymphoma arises from the clonal 
expansion of B cells in the GC (Klein and Dalla-Favera, 2008). During their 
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development in GC, naïve B-cells are the subject of complex processes of somatic 
hypermutation and class switch recombination in order to develop antibodies with 
higher affinity and capable of distinct functions (Muramatsu et al., 2000). These 
processes are associated with single and double DNA strands breaks and can succeed 
successfully only with switched off DNA damage responses, pro-apoptotic mechanisms 
and inhibition of activation and differentiation. Additionally, during the GC reaction B-
cells undergo very rapid proliferation with <12 hours doubling time and are at constant 
risk of mutations (Victora and Nussenzweig, 2012). If the class-switch recombinations 
affect not only constant immunoglobulin genes, they can cause chromosomal 
translocations. Furthermore if the somatic hypermutations are not limited to variable 
regions of immunoglobulin genes, they can cause aberrant hypermutations in other 
genes including oncogenes and tumour suppressor genes and contribute to 
lymphomagenesis (Pasqualucci and Dalla-Favera, 2015). 
Clonally rearranged Ig heavy and light chains genes are detectable. They show 
somatic hypermutations in the variable regions (Swerdlow et al., 2008). 
Approximately 50% of DLBCL cases show aberrant somatic hypermutations 
targeting multiple genetic loci, including PIMI, c-MYC (v-myc avian myelocytomatosis 
oncogene homolog), RHOH/TTF (ARHH) and PAX5. These mutations can contribute to 
the oncogenesis of this lymphoma (Pasqualucci et al., 2001). 
The translocation involving the BCL6 gene is the most common in DLBCL 
NOS, accounting for up to 30% of cases (Offit et al., 1994) (Ohno and Fukuhara, 1997). 
Translocation of the BCL2 gene occurs in 20-30% of cases (Weiss et al., 1987) (Lipford 
et al., 1987) and a c-MYC re-arrangement was observed in approximately 10% of cases 
in an unselected series (Yunis et al., 1989). The c-MYC break partner is an Ig gene in 
60% and a non Ig gene in 40% of cases (Hummel et al., 2006). Approximately 20% of 
cases with a c-MYC translocation have a concurrent BCL2 and or a BCL6 translocation 
(Hummel et al., 2006). These cases are characterised by very high proliferation rates 
(>90% Ki67), and it is suggested that they can be better categorized as “B-cell 
lymphomas, unclassifiable with features intermediate between DLBCL and BL” 
(Swerdlow et al., 2008). 
 Gene expression profiling (GEP) identified two distinctive subgroups in 
DLBCL: germinal centre B-cell-like (GCB) and activated B-cell like (ABC) (Alizadeh 
et al., 2000) (Rosenwald et al., 2002). The GCB subgroup has the gene expression 
profile of GC B-cells and the ABC subgroup has the profile of activated peripheral B-
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cells. Initially a third group was defined (termed type 3) but it has turned out to be a 
collection of undefined cases and not a distinct group (Hummel et al., 2006) (Wright et 
al., 2003). The two defined groups are characterised by different chromosomal 
aberrations. The ABC cases have frequent gains of 3q, 18q21-q22 and losses of 6q21-
q22 and by contrast GCB cases show frequent gains at 12q12 (Bea et al., 2005) 
(Tagawa et al., 2005) and BCL2 rearrangements (Huang et al., 2002). 
The recent expansion of sequencing technologies, allowing studies on the whole 
genome / exome, has delivered a new comprehensive and unbiased view of the genetics 
basis of DLBCL (Pasqualucci and Dalla-Favera, 2015). The above described known 
abnormalities have been confirmed and put in the context of oncogenic pathways and 
new alternations have been described. Importantly, it has been revealed that the coding 
genome has approximately 50 – 100 lesions/case and great variability as compared with 
the genomes of other B-cells malignancies like CLL or ALL (Schneider et al., 2011). 
Using next generation sequencing methods the genetic abnormalities in DLBCL, 
NOS can be classified in the context of the cell of origin theory in: i) those commonly 
affecting both GCB- and ABC-DLBCL e.g. genes involved in epigenetic mechanisms 
like acetylation/deacetylation and methylation/demethylation of histones and DNA, 
BCL6, changes affecting genes involved in immune surveillance mechanism or TP53; 
ii) the genetic lesions characteristic to GCB-DLBCL e.g. MYC and BCL2, PTEN and 
mir-17-92 micro RNA cluster and iii) genetic lesions to ABC-DLBC e.g. activation of 
NF-κβ or block in terminal B cell differentiation (Pasqualucci and Dalla-Favera, 2015). 
i) Genetic abnormalities affecting both GCB- and ABC-DLBCL. Up to 30% of 
DLBCL, NOS cases have mutations in acetyltransferase CREBBP and rarely in 
acetyltransferase EP300 (Goodman and Smolik, 2000). Both enzymes modify lysine 
residues by acetylation on both histone and non-histone nuclear proteins (Goodman and 
Smolik, 2000). This can result in both activation and deactivation of the modified 
protein. It has been postulated that acetylotransferases contribute to lymphomagenesis 
via impaired acetylation of BCL6 and p53, which leads to constitutive activation of the 
oncoprotein and inhibition of tumour suppressor (Bereshchenko et al., 2002). The 
changes affecting acetyltransferases are important as they can be targeted by a new 
group of drugs called inhibitors of deacetylases. 
Another group of affected proteins involved in epigenetic mechanisms are 
methyltransferases (Pasqualucci and Dalla-Favera, 2015). These enzymes transfer 
methyl groups on histones and other nuclear proteins. The most commonly affected 
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methyltransferase is MLL2. Mutations to the MLL2 gene can potentially lead to broad 
effects on chromatin regulations, which may contribute to lymphomagenesis. 
Importantly, the MLL2 mutations have been also found in FL cases (Morin et al., 2011). 
Alternations deregulating BCL6 are the main mechanism of transformation in 
DLBCL, NOS. The chromosomal translocations involving the BCL6 locus are present 
in approximately 35% of DLBCL cases, more frequently involving ABC-DLBCL (Iqbal 
et al., 2007). The BCL6 locus is also a target for point mutations observed in >70 cases 
(Shen et al., 1998). The mutations in the first noncoding exon are found exclusively in 
DLBCL and they deregulate BCL6 expression by disruption of the auto-regulatory loop 
by which BCL6 inhibits and regulates its own transcription (Wang et al., 2002) and by 
inhibition of binding of IRF4 and transcriptional repression (Saito et al., 2007). The 
activity of BCL6 can be also increased by mutation in the MEF2B transcription factor, a 
very potent BCL6 transcriptional activator (Ying et al., 2013). These mutations promote 
the function of MEF2B. In 5% of DLBCL cases the loss of function mutations of 
FBX011 inhibit proteosomal degradation of BCL6 (Duan et al., 2012). 
The loss of the immune surveillance mechanism is affecting a significant 
number of DLBCL cases (Pasqualucci and Dalla-Favera, 2015). The beta-2-
microglobuline (β2M) is a non-variable unit of the HLA class I complex and is not 
expressed on the tumour cells in approximately 60% of DLBCL cases. In 29% of 
DLBCL cases the β2M is lost because of mutation affecting directly its gene and in the 
remaining 30% due to another mechanism involving its expression (Challa-Malladi et 
al., 2011). The other gene involved in immune surveillance of DLBCL is CD58, a 
member of the immunoglobulin superfamily and a ligand of the CD2 receptor on T-cells 
participating in their adhesion and activation (Pasqualucci and Dalla-Favera, 2015). 
Among other lesions affecting DLBCL the mutations of the Tumour Protein 53 
(TP53) gene are important and common (found in approximately 20% of DLBCL cases) 
(Monti et al., 2012). Tumour Protein 53 is a protein which is crucial in preventing 
cancer formation in multicellular organisms and TP53 is classified as a tumour 
suppressor gene. The role of TP53 in prevention of oncogenesis is associated with its 
function in i) activation of DNA repair, ii) arresting the cells at the G1/S point due to 
DNA damage, iii) initiation of apoptosis and iv) response to short telomeres. Mutations 
of FOXO1 transcription factor are also of importance and are present in all subtypes of 
DLBCL (Trinh et al., 2013). 
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ii) Genetic abnormalities affecting GCB-DLBCL. The genetic lesions 
characteristic to GCB-DLBCL were very poorly characterized until recently. The 
majority of research focused on chromosomal translocations of MYC, BCL2, PTEN and 
mir-17-92 micro RNA cluster (Trinh et al., 2013) (Saito et al., 2009) (Lenz et al., 2008). 
As described above, in 35% of DLBCL the translocation (14;18) leads to ectopic 
expression of BCL2 (a key anti-apoptotic molecule) by juxtaposing the BCL2 in direct 
neighborhood of the Ig locus and disturbing negative suppression by BCL6 (Saito et al., 
2009). Additionally, 40% of DLBCL cases without (14;18) translocation co-express 
BCL2 and BCL6 as a result of i) deregulation of Miz1 (a molecule connecting BCL6 to 
BCL2), ii) aberant somatic hypermutation to BCL2 promotor side and iii) mutations to 
BCL2 coding sequence (Saito et al., 2009). 
Approximately 15% of DLBCL cases show a translocation t(8;14) involving the 
c-MYC transcription factor gene and the Ig gene locus (Kramer et al., 1998). 
Amplification of the MIGH1 region encoding the microRNA 17-92 cluster is present in 
around 12% of GCB-DLBCL (Lenz et al., 2008). The microRNAs from this cluster 
enhance the lymphomagenetic function of c-MYC (He et al., 2005). The cluster also 
promoted the oncogenesis by inhibition of tumour suppressor gene PTEN and the pro-
apoptotic protein BIM (He et al., 2005). The deletion of PTEN leads to the activation of 
AKT. The AKT can be also activated by phosphatidylinositol 3 kinase (PI3K) leading 
to inhibition of apoptosis, promotion of cell growth, cell motility and angiogenesis 
(Abubaker et al., 2007). 
The mutations involving the histone methyltransferase EZH2 gene have been 
reported in 22% of GCB DLBCL patients (Morin et al., 2010). These mutations usually 
cause the increased activity of the enzyme resulting in increased GCB hyperplasia and 
induction of DLBCL in cooperation with BCL2 (Béguelin et al., 2013). Importantly the 
EZH2 inhibitors just entered the clinical trials (Roschewski et al., 2014). 
Approximately 20% of GCB-DLBCL show structural damaging mutations in 
various components of G-proteins e.g. GNA12, SIPR2, ARHGEF1 and P2RY8 
resulting in increased GC B cells survival and dissemination (Muppidi et al., 2014). 
iii) Genetic abnormalities affecting ABC-DLBCL. Genetic lesions to ABC-
DLBCL are better characterized and they include two main groups: activation of NF-κβ 
and block in terminal B cell differentiation (Pasqualucci and Dalla-Favera, 2015). 
Additionally, the recurrent lesions involve the BCL2 locus as describe above and the 
CDKN2A/2B locus (Lenz et al., 2008). 
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Genetic lesions contributing to constitutive activation of NF-κβ are usually 
caused by mutations activating continuously the BCR (B-cell receptor) signaling 
pathway via Ig superfamily members CD79B and CD79A or CARD11, a BCR 
signalosom complex (Davis et al., 2010). BCR signaling is responsible for canonical 
activation of NF-κβ. Mutations of myeloid differentiation primary response gene 88 
(MYD88) gene, a universal activating protein responsible for NF-κβ activating in the 
TLR (toll like receptor) pathway, can lead to constitutive activation of NF-κβ and 
JAK/STAT transcriptional responses (Ngo et al., 2011). Finally the activation of NF-κβ 
can follow the mutation, inactivating negative regulators of NF-κβ like mutation to 
TNFAIP3 gene encoding A20 a dual function ubiquitin modification enzyme involved 
in the NF-κβ responses triggered by BCR and TLR stimulations (Ngo et al., 2011). The 
bi-allelic mutations of TNFAIP3 inhibit the function of A20 leading to inappropriately 
prolonged activation of NF-κβ. 
The second group of genetic aberrations characteristic to ABC-DLBCL are 
genetic lesions preventing terminal differentiation of B-cells into plasma cells. The B-
cell requires for this final step PRMD1, a sequence-specific transcriptional repressor 
(Shapiro-Shelef et al., 2003). The mutations to PRMD1 prevent this differentiation step. 
Approximately 25% of ABC-DLBCL have lost of PRDM1 gene owning to truncating 
mutations, missense mutations and / or genomic deletions (Pasqualucci et al., 2006). 
 
1.3.6 Prognostic factors in DLBCL 
 As DLBCL remains a very heterogeneous diagnosis with variable outcomes, a 
number of different studies have been performed in recent years in order to identify 
clinical and biological parameters, which could then be used to select patients with 
high-risk disease in order to assign the most efficient treatment to them. Furthermore, it 
is important to recognize that risk assessment is a moving target. The introduction of a 
more effective new therapy rituximab, cyclophosphamide, doxorubicine, vincristine, 
prednisolone (R-CHOP) has significantly altered the predictive power of the currently 
used prognostic indicators (Sehn et al., 2007). 
 
1.3.6.a Clinical prognostic factors 
 The treatment of patients with DLBCL is traditionally dictated by their Ann 
Arbor stage (Lossos and Morgensztern, 2006). This system was originally developed for 
patients with Hodgkin lymphoma (Carbone et al., 1971) and is based on the premise 
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that the disease spreads contiguously to adjacent lymph nodes (Rosenberg, 1977). This 
assumption is less accurate for NHL, particularly aggressive types, that are 
characterised by more unpredictable behaviour including early systemic dissemination 
and involvement of extranodal sites (Freeman et al., 1972). 
Currently the most widely accepted prognostic scoring system for patients with 
DLBCL is the International Prognostic Index (IPI) (Sehn, 2006). Originally the index 
was developed in patients with WF categories F, G and H (intermediate grade 
lymphoma) (Shipp, 1993). This cohort of patients was very heterogeneous and included 
not only lymphomas of B-cell origin other than DLBCL but also lymphomas with T-cell 
phenotypes which are characterised by a significantly worse outcome. Subsequently 
with the introduction of the pathological diagnosis of DLBCL the IPI was reassessed in 
patients with the specific diagnosis of DLBCL (Nicolaides et al., 1998) (Wilder et al., 
2002). The IPI is based on the number of negative prognostic clinical features present at 
the time of diagnosis (age >60 years, clinical stage (CS) III and IV, elevated serum 
lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group (ECOG) 
performance status ≥2 and involvement of more than one extranodal site); see table 1.6 
(Shipp, 1993). The IPI identifies four risk groups with predicted five-year survival rates 
of 73% - low risk group, 51% - low intermediate risk group, 43% - high intermediate 
risk group and 26% - high-risk group (Shipp, 1993). It was subsequently shown that 
patients ≤60 years had significantly different disease outcomes to patients >60years and 
an age-adjusted IPI (aaIPI) model for younger patients was developed (table 1.6) 
(Shipp, 1993). The aaIPI also identifies four risk groups with predicted five-years 
overall survival (OS) rates of 83% (low risk group), 69% (low intermediate risk group), 
46% (high intermediate risk group), and 32% (high-risk group) (Shipp, 1993). 
The development of the IPI and aaIPI was based on studies that included 
patients treated with CHOP or CHOP-like therapies. The recent addition of rituximab to 
CHOP has led to marked improvement in patient survival and has called into question 
the prognostic significance of the IPI. Recently a retrospective study on a homogeneous 
group of patients with DLBCL treated with R-CHOP has been performed to re-assess 
the predictive value of the IPI in the era of immunochemotherapy (Sehn et al., 2007).  
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IPI 
Variables 
• Age >60 years 
• Poor performance status (ECOG ≥2) 
• Advanced Ann Arbor status (III – IV) 
• Extranodal involvement (≥2 sites) 
• High serum LDH (>normal) 
Risk groups 
• Low: 0 - 1 variable 
• Low intermediate: 2 variables 
• High intermediate: 3 variables 
• High: 4 - 5 variables 
Age adjusted IPI (patients ≤60 years) 
Variables 
• Poor performance status (ECOG ≥2) 
• Advanced Ann Arbor status (III – IV) 
• High serum LDH (>normal) 
Risk groups 
• Low: 0 variable 
• Low intermediate: 1 variable 
• High intermediate: 2 variables 
• High: 3 variables 
Revised IPI (for rituximab treated patients) 
Variables 
• Age >60 years 
• Poor performance status (ECOG ≥2) 
• Advanced Ann Arbor status (III – IV) 
• Extranodal involvement (≥2 sites) 
• High serum LDH (>normal) 
Risk groups 
• Very good: 0 variable 
• Good: 1 - 2 variables 
• Poor: 3 - 5 variables 
Table 1.6 International prognostics index and its variants (Shipp, 1993). 
 
Initially the outcome of patients was predicted using the standard IPI. Although 
the IPI remained predictive, it now distinguished only two rather than four risk groups. 
The first group incorporated the “low” and “low-intermediate” risk groups and the 
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second the “high” and “high intermediate” risk groups. When outcome was plotted 
according to the number of individual IPI factors present at diagnosis three risk groups 
were identified: a “very good” group with zero risk factors, a “good” group with 1 – 2 
factors and a “poor” group with 3 – 5 factors (table 1.6). This gave rise to a new revised 
International Prognostic Index (R-IPI). If the two indices are compared the R-IPI is a 
better predictor of outcome for patients with DLBCL treated with R-CHOP. 
 Based on the information derived from clinical trials elevated β2M levels 
(>3mg/L) and the presence of more than one extranodal site of disease have been found 
to be negative prognostic indicators in terms of OS (Feugier et al., 2005). Bulky disease 
and the presence of at least one aaIPI factor were significant prognostic parameters for 
event-free survival (EFS) on a multivariate analysis in the MabThera International Trial 
Group (MInT) trial (Pfreundschuh et al., 2006). Table 1.7 represents the clinical 
prognostic models identified. 
 
Author Risk factor 
Shipp 1) 
Jagannath 2) 
Velasquez 3) 
Swan 4) 
Coiffier 5) 
Rodriguez 6) 
Shipp 7) 
Conconi 8) 
Performance status, bulky disease, extranodal sites 
LDH, tumour burden 
Age, tumour burden, LDH 
LDH, ß2-microglobulin 
LDH, stage, extranodal sites, tumour bulk 
ß2-microglobulin, LDH, stage, bulky disease, B-symptoms 
Age, stage, performance status, LDH, extranodal sites 
IPI, ß2-microglobulin 
Table 1.7 Additional clinical prognostic models in DLBCL. 
1) (Shipp et al., 1986) 2) (Jagannath et al., 1986) 3) (Velasquez et al., 1989) 4) (Swan et 
al., 1989) 5) (Coiffier, 1991) 6) (Rodríguez et al., 1992) 7) (Shipp et al., 2002) 8) 
(Conconi et al., 2000) 
 
 These indices have important limitations. They rely on a small number of 
dichotomised predictive variables, and patients are assigned to one of a small number of 
risk groups rather than giving a direct prediction, such as a predictive survival 
probability or a predictive median lifetime on a continuous scale for each patient. 
 
1.3.6.b Biological prognostic markers 
 The new high-throughput genomic technologies have yielded many potential 
biomarkers or biomarker models for prediction of survival in DLBCL. Their potential is 
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enormous and it is possible that in the near future they will become an integral part of 
our daily practice. Here the most important biomarkers and models will be described. 
 
Individual biomarkers for prediction of survival 
The heterogeneity of cancer including DLBCL is highlighted by the variable 
expression of molecular aberrations, which contribute to aggressive tumour behaviour 
namely: the capacity to sustain proliferation, evade apoptosis, inhibit differentiation and 
the ability to invade and promote angiogenesis (Lossos and Morgensztern, 2006). 
Multiple studies have assessed the relationship between patient survival and expression 
of specific biological markers by the malignant cells. These factors include: cell-cycle 
regulatory molecules (TP53, p27KIP1, Cyclin D, Ki-67), apoptosis-related proteins 
(survivin, BCL2, Caspases), proteins involved in B-cell differentiation (BCL6, HGAL, 
CD10, CD5, fork head box protein P1 [FOXP1], protein kinase ß [PKC-ß], CD21), cell 
adhesion molecules (intercellular adhesion molecule-1 [ICAM-1], CD44), angiogenesis 
factors (endostatin, vascular growth factor [VEGF], matrix metalloproteinase 2 and 6 
[MMP-2 and MMP-6]) and others factors (IL-10, hepatocyte growth factor, major 
histocompatibility complex [MHC] molecules) (Lossos and Morgensztern, 2006). Table 
1.8 provides an overview on selected molecular prognostic markers and their effect on 
patients outcome. 
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Prognostic marker 
Effect on 
outcome 
Mechanism 
BCL2 
BCL6 
CD10 
CD5 
HGAL 
FOXP1 
MUM1 
Mutation p53 
Cyclin D2/D3 
Skp2 
Survivin 
PKC-ß 
CD21 
ICAM-1 
Endostatin 
sVEGF 
MMP-9 
Caspase 8 inhibition 
Caspase 9 inhibition 
Nm23-H1 
sIL-10 
Loss MHC class II 
Unfavourable 
Favourable 
Favourable? 
Unfavourable? 
Favourable 
Unfavourable 
Unfavourable 
Unfavourable 
Unfavourable 
Unfavourable 
Unfavourable 
Unfavourable 
Favourable 
Unfavourable 
Unfavourable 
Unfavourable 
Unfavourable 
Favourable 
Unfavourable 
Unfavourable 
Unfavourable 
Unfavourable 
Anti-apoptosis 
Transcriptional repressor 
Neutral endopeptidase 
B-cell differentiation 
Germinal center phenotype 
Transcription factor 
Transcription factor 
Cell cycle regulation 
Cell cycle regulation 
Cell cycle progression 
Anti-apoptosis 
B-cell signalling 
B-cell differentiation 
Lymphocyte trafficking 
Angiogenesis 
Angiogenesis 
Promotes metastases 
Apoptosis signalling 
Apoptosis signalling 
B-cell differentiation 
Immune response regulator 
Immune surveillance 
Table 1.8 Molecular prognostic markers in DLBCL (Lossos and Morgensztern, 2006). 
 
BCL2, BCL6, CD10 and Ki-67 are the most studied molecular markers in 
patients with DLBCL treated with chemotherapy and immunochemotherapy. 
BCL2 is an anti-apoptotic protein that is important in normal B-cell 
development and differentiation (Hockenbery et al., 1990). Approximately 47% to 58% 
of DLBCL cells express BCL2 protein (Hill et al., 1996) (Gascoyne et al., 1997). The 
14;18 (q32;q21) translocation juxtaposes the BCL2 gene from position 18q21 to the 
immunoglobulin heavy chain locus, resulting in BCL2 overexpression (Bakhshi et al., 
1985) (Cleary and Sklar, 1985). However, this translocation is not the only mechanism 
that results in the overexpression of BCL2 protein as amplification of the BCL2 gene 
also induces its overexpression (Monni et al., 1997) (Rao et al., 1998). Several studies 
have shown that BCL2 translocation status does not correlate with patient survival 
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(Lossos and Morgensztern, 2006). By contrast a number of studies have reported that 
the overexpression of BCL2 protein in patients with DLBCL is significantly associated 
with poorer survival (Hill et al., 1996) (Gascoyne et al., 1997) (Kramer et al., 1996) 
(Hermine et al., 1996). The significance of BCL2 overexpression was re-evaluated in 
patients treated with CHOP and R-CHOP in the GELA trial (Mounier et al., 2003). In 
the group of patients treated with CHOP BCL2 protein overexpression was associated 
with poorer disease outcome. This was not the case in patients treated with R-CHOP. 
This finding was in concordance with other studies (Gutierrez-Garcia et al., 2011a) 
(Johnson et al., 2012). By contrast significant numbers of subsequent studies confirmed 
the prognostic value of BCL2 in patients treated with immunochemotherapy (Fu et al., 
2008) (Salles et al., 2011). As BCL2 staining is acceptably reproducible different cut-
off rates for reporting are the most likely reason for this phenomenon. Recently 
published studies propose that expression of BCL2 assessed with IHC may be a strong 
indicator of prognosis when assessed in conjunction with other molecules like Ki-67 
(Salles et al., 2011) or c-MYC (Johnson et al., 2012) (Green et al., 2012). 
BCL6 is a proto-oncogene involved in chromosomal translocations affecting 
band 3q27, the most common translocation detected in DLBCL (Chang et al., 1996) 
(Kerckaert et al., 1993) (Seyfert et al., 1996). BCL6 is necessary for GC formation (Ye 
et al., 1997) and it is almost exclusively expressed in GC lymphocytes or lymphomas 
originating at the GC differentiation stage (Cattoretti et al., 1995). The expression of 
BCL6 may be deregulated by translocations that affect the BCL6 locus, and also by 
mutations in the 5’ non-translated regulatory region of the gene (Pasqualucci et al., 
2003) (Wang et al., 2002). Although initial studies reported better disease outcomes for 
DLBCL patients with BCL6 gene rearrangements (Offit et al., 1994), this could not be 
confirmed in subsequent studies (Bastard et al., 1994) (Pescarmona et al., 1997) 
(Jerkeman et al., 2004). By contrast, mRNA or protein expression of BCL6 as a marker 
of GC origin of malignant cells predicted better survival in patients with DLBCL (Hans 
et al., 2004) (Lossos et al., 2001). The predictive power of BCL6 mRNA and protein 
expression  was independent of the IPI in a multivariate analysis in a study performed 
by Lossos et al. (Lossos et al., 2001). The US Intergroup Trial examined the prognostic 
value of BCL6 protein expression in patients treated with CHOP and R-CHOP (Winter 
et al., 2006). Whilst BCL6 positive patients receiving CHOP experienced better 
outcomes, BCL6 status did not influence the outcomes in R-CHOP treated patients. 
Further reports in patients treated with R-CHOP are inconclusive (Salles et al., 2011) 
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(Copie-Bergman et al., 2009) (Natkunam et al., 2008) (Seki et al., 2009) (Winter et al., 
2006). The reason for this may be due to the varying expression thresholds employed 
and the fact that IHC staining patterns are reported to be unstable with poor 
reproducibility, particularly when assessed using tissue microarrays (TMAs) (de Jong et 
al., 2007) (Linderoth et al., 2007). 
 Another molecular prognostic factor for DLBCL evaluated in a number of trials 
is the expression of the common acute lymphoblastic leukaemia antigen (CD10), a cell 
membrane-associated neutral endopeptidase. CD10 appears twice during lymphocyte 
differentiation, firstly on pro-B-cells, then it is lost during cell maturation to naïve B 
cells, and secondly it is re-expressed during antigen-dependent GC maturation. Twenty 
to thirty per cent of DLBCL tumours express CD10 protein (Colomo et al., 2003) 
(Fabiani et al., 2004). Expression of CD10 as a marker of GC origin has been assessed 
for prediction in patients with DLBCL and has revealed conflicting findings. While 
some authors reported increased OS in patients expressing CD10 protein (Ohshima et 
al., 2001), others were not able to confirm this correlation (Colomo et al., 2003) 
(Fabiani et al., 2004). The studies on prognostic impact of CD10 in patients treated with 
immunochemotherapy delivered controversial results (Salles et al., 2011) (Seki et al., 
2009). 
  Ki-67 is a nuclear antigen expressed by dividing cells. It is another molecule 
with controversial prognostic value in DLBCL (Lossos and Morgensztern, 2006). Miller 
et al reported in two separate studies a significant decrease in overall survival in patients 
with high expression of Ki-67 protein (Miller et al., 1994). By contrast the Nordic 
Lymphoma Study and other additional studies failed to confirm the prognostic value of 
Ki-67 protein expression (Colomo et al., 2003) (Jerkeman et al., 2004) (Zhang et al., 
1999) (Saez et al., 2004). These conflicting findings may partly be due to different cut 
off points of positivity / negativity used by the various groups (Lossos and 
Morgensztern, 2006). In two recent papers Ki-67 expression had significantly predictive 
power for survival estimations in patients treated with immunochemotherapy (Salles et 
al., 2011) (Culpin et al., 2013). In the study of Sales it was a basic part of the predictive 
model together with expression of BCL2 and the IPI (Salles et al., 2011). 
 
Gene expression profiling for prediction of survival 
 Although the studies on individual biomarkers in DLBCL provide additional 
prognostic information to the IPI and have enriched our knowledge on the 
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pathophysiology of DLBCL, their results were often conflicting and inconclusive. This 
was probably due to the retrospective nature of the various studies, small sample size 
and lack of uniformity in experimental design (Sehn, 2006). The role of individual 
biomarkers in clinical practice may be limited by the complexity of biological 
processes, the involvement of multiple genes, signalling pathways, and regulatory 
mechanisms (Lossos and Morgensztern, 2006). Genome-scale biomarker expression 
profiles assessed by DNA microarrays (Shipp et al., 2002) (Alizadeh et al., 2000) 
(Rosenwald et al., 2002) or real-time polymerase chain reaction (RT-PCR) (Lossos et 
al., 2004) have been used recently to assess the correlation between prognosis and 
molecular features of tumour cells in DLBCL. 
 The pivotal study of microarrays in DLBCL was performed by Alizadeh et al. 
using spotted DNA microarrays made by mechanical deposition of double-stranded 
cDNA fragments (approximately 500 base pairs) or long oligonucleotides (50-70 mer) 
on glass slides (Alizadeh et al., 2000). Among 42 patients with DLBCL treated with 
CHOP-like chemotherapy two molecularly distinct types of tumour were identified; one 
expressing genes characteristic of germinal centre B cells - “germinal centre B-cell-like 
DLBCL (GCB)”, and the second type expressing genes normally induced during in 
vitro activation of peripheral blood B-cells “activated B-cell like DLBCL (ABC)”. The 
5-year overall survival for patients with GCB was 76% and for those with ABC only 
16%. This difference was statistically significant (p<0.01). Rosenwald et al. confirmed 
these observations using the same methodology on 240 patients with DLBCL treated 
with CHOP-like chemotherapy (Rosenwald et al., 2002). This later study identified a 
third phenotype called “type 3 DLBCL”. Patients with GCB had a 5 –year survival rate 
of 60%, compared with a rate of 39% for patients with type 3 DLBCL and 35% for 
those with ABC (p<0.001) (Rosenwald et al., 2002). The subgroups differed in that the 
(14;18) translocation involving the BCL2 gene and the amplification of the c-rel locus 
on chromosome 2p occurred only in patients with GCB, suggesting the involvement of 
a different oncogenic mechanism in each subgroup. Shipp et al using oligonucleotide 
microarrays in tumour biopsies of 58 patients with DLBCL treated with CHOP (Shipp 
et al., 2002) analyzed the expression of 6,817 genes. In this study, two groups were 
identified: the group predicted to be cured and those predicted to have fatal/refractory 
disease. The 5-year overall survival was 70% and 12%, respectively (p=0.00004). 
 Additionally, Rosenwald et al and Shipp et al on the basis of a small number of 
previously identified predictive genes were able to construct survival models that could 
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be used routinely in the clinical assessment of patients with DLBCL (Shipp et al., 2002) 
(Rosenwald et al., 2002). The 13-gene IPI-independent model of Shipp et al included 
the following genes: dystrophin related protein 2, protein kinase C gamma, MINOR, 5-
hydroxytryptamine 2B receptor, H731, transducin-like enhancer protein 1, PDE4B, 
protein kinase C-beta-1, oviductal glycoprotein, zinc-finger protein C2H2-150, and 
three expressed sequence tags (Shipp et al., 2002). The model derived by Rosenwald et 
al. was based on the expression of 17 genes: BCL6, HGAL, clone 1334260, HLA-DPα, 
clone 1334260, HLA-DPα, HLA-DQα, HLA-DRα, HLA-DRβ, α-actin, collagen type III 
α1, connective-tissue growth factor, fibronectin 1, KIAA0233, urokinse plasminogen 
activator, c-MYC, E21G3, NPM3, and BMP6 (Rosenwald et al., 2002). Interestingly, 
there was no overlap of predictive genes between the two models. 
 Using the RT-PCR technique Lossos et al. performed a study on 36 genes whose 
expression had been previously reported to predict survival in patients with DLBCL. 
The strongest predictors were found to be LIM domain only 2 (LMO2), BCL6, 
fibronectin 1 (FN1), CCND2, SCYA3 and BCL2. In multivariate analysis the expression 
of these genes was independent of the IPI and increased its predictive power. This 
model identified three independent risk groups with 5-year OS rates of 65%, 49% and 
15% for the low, intermediate and high-risk groups respectively (p=0.004) (Lossos et 
al., 2004). 
 
Immunohistochemical models for prediction of survival 
Although gene expression profiling by DNA microarrays identified biologically 
distinct subtypes of DLBCL, this kind of profiling is not a practical tool for risk 
assessment in routine patient care. This is due to the lack of standardized, commercially 
available tests, to the requirement for fresh or fast frozen tissue specimens and to the 
high costs. The semi-quantitative assessment of protein expression in paraffin-
embedded tissue can be performed by IHC, which is used routinely for histological 
evaluation in lymphoma diagnostics. In several recent studies the information derived 
from gene-array investigations has been used to create immunohistochemical models 
that predict the cell of origin and / or survival. 
Barrans et al and Colomo et al assessed the prognostic value of the expression of 
proteins associated either with GCB phenotype or ABC phenotype. However these 
studies did not use hierarchical staining and never gained general acceptance (Barrans et 
al., 2002) (Colomo et al., 2003). 
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Subsequently models based on the assessment of expression of GC or ABC 
related proteins were developed (Hans et al., 2004) (Choi et al., 2009) (Muris et al., 
2006) (Nyman et al., 2009) (Meyer et al., 2011) (Visco et al., 2012). Some of these 
models were originally developed on patients treated with chemotherapy only (Hans et 
al., 2004) (Muris et al., 2006), whilst others included patients treated with 
immunochemotherapy (Choi et al., 2009) (Nyman et al., 2009) (Meyer et al., 2011) 
(Visco et al., 2012). All of them were recently reassessed on representative cohorts of 
patients treated with immunochemotherapy (Culpin et al., 2013) (Fu et al., 2008) 
(Meyer et al., 2011). Only the models of Hans and Choi used samples with completed 
GEP. Others investigators will not have this data until revalidation studies are 
completed (Hans et al., 2004) (Choi et al., 2009) (Muris et al., 2006) (Nyman et al., 
2009) (Meyer et al., 2011) (Visco et al., 2012). Table 1.9 provides a list of the most 
important IHC models for prediction of survival in DLBCL and subsequent studies 
which revaluated their predictive value. Figure 1.5 shows the design of the most 
important models. 
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Model 
Proved 
CHOP-era 
Prediction 
Proved 
R-CHOP-era 
Prediction 
Hans 1) 
 
 
 
 
 
 
 
 
 
Berglund 7) 
Sjo 8) 
Haarer 9) 
Chang 10) 
van Imhoff 11) 
Nyman 12) 
Amara 13) 
Natkunam 14) 
Veelken 15) 
Dupuis 16) 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
Meyer 5) 
Fu 17) 
Visco 6) 
Culpin 18) 
Nyman 4)  
Nyman 12) 
Natkunam 14) 
 
 
 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
 
 
 
Muris 2) 
 
 
Sjo LD 8) 
 
 
Yes 
 
 
Nyman 4) 
Meyer 5) 
Culpin 18) 
Yes PFS / No OS 
Yes 
No 
Choi 3) 
 
 
NA 
 
 
NA 
 
 
Meyer 5) 
Visco 6) 
Culpin 18) 
Yes 
Yes 
Yes PFS / No OS 
Nyman 4) 
 
NA 
 
NA 
 
Meyer 5) 
Culpin 18) 
Yes 
No 
Modified Hans 5) NA NA Culpin 18) Yes 
Modified Choi 5) NA NA Culpin 18) Yes PFS / No OS 
Tally 5) NA NA Visco 6) Yes 
Visco 6) NA NA Culpin 18) No 
Table 1.9 Immunohistochemical models for prediction of survival in DLBCL. 
1) (Hans et al., 2004); 2) (Muris et al., 2006); 3) (Choi et al., 2009); 4 (Nyman et al., 
2009); 5) (Meyer et al., 2011); 6) (Visco et al., 2012); 7) (Berglund et al., 2005); 8) (Sjo 
et al., 2007); 9) (Haarer et al., 2006); 10 (Chang et al., 2004); 11 (van Imhoff et al., 
2006); 12 (Nyman et al., 2007); 13) (Amara et al., 2008); 14) (Natkunam et al., 2008); 
15) (Veelken et al., 2007); 16) (Dupuis et al., 2007) 17) (Fu et al., 2008) and 18) 
(Culpin et al., 2013) 
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Figure 1.5 The design of the most important IHC algorithms in DLBCL. 
GCB, Germinal centre B-cell-like DLBCL; ABC, Activated B-cell-like DLBCL. (A) 
The Hans model (Hans et al., 2004); (B) The modified Hans model (Meyer et al., 2011); 
(C) The Muris model (Muris et al., 2006); (D) The Nyman model (Nyman et al., 2009); 
(E) The Choi model (Choi et al., 2009); (F) The modified Choi model (Meyer et al., 
2011); (G) The Viso-Young model (Visco et al., 2012) 
 
Hans et al developed a prognostic model based on the expression of three 
biomarkers; CD10, BCL6 and MUM1/IRF4 to assign patients to GCB and ABC 
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phenotype in patients with de novo DLBCL treated with CHOP (Hans et al., 2004). 
MUM1/IRF4 is a lymphoid-specific member of the interferon (IFN) regulatory factor 
family of transcription factors (Mamane et al., 1999) (Tsuboi et al., 2000) (Falini et al., 
2000), and it is a reliable marker of “late-stage GC” or “post-GC” B cells (Tsuboi et al., 
2000). There were statistically significant differences in overall survival between 
patients with GCB and ABC phenotype (p<0.001) (Hans et al., 2004). Additionally 
GEP analysis using cDNA microarrays were performed in all patients. Eight-seven per 
cent of patients assigned to GCB by the IHC model had the GCB signature in cDNA 
microarray. In patients with ABC 73% had the same signature in cDNA microarray. 
The Hans model was the first published IHC based model and was developed on a 
cohort of patients treated with chemotherapy only. It has subsequently been tested in 
several studies on patients treated with chemotherapy only (Berglund et al., 2005) (Sjo 
et al., 2007) (Haarer et al., 2006) (Chang et al., 2004) (van Imhoff et al., 2006) (Nyman 
et al., 2007) (Natkunam et al., 2008) (Veelken et al., 2007) (Dupuis et al., 2007) and 
later on patients treated with immunochemotherapy (Meyer et al., 2011) (Fu et al., 
2008) (Culpin et al., 2013) (Visco et al., 2012) (Nyman et al., 2007) (Natkunam et al., 
2008) (Nyman et al., 2009). Some of these studies confirmed its predictive power 
(Berglund et al., 2005) (Sjo et al., 2007) (Haarer et al., 2006) (Chang et al., 2004) (van 
Imhoff et al., 2006) (Nyman et al., 2007) (Meyer et al., 2011) (Fu et al., 2008) (Culpin 
et al., 2013) (Visco et al., 2012) whilst others did not (Natkunam et al., 2008) (Veelken 
et al., 2007) (Dupuis et al., 2007) (Nyman et al., 2007) (Nyman et al., 2009). These 
partially contradictory results prompted the researcher to investigate development of 
other models. 
Choi et all developed other IHC models based on the expression of GCET1, 
MUM1, CD10, BCL6 and FOXP1 in patients with DLBCL treated with 
immunochemotherapy (Choi et al., 2009). The GCET1 transcript is highly associated 
with the GCB subtype of DLBCL, and the GCET1 protein was later found to be 
restricted to B-cell neoplasms with a presumed GC B-cell origin (Choi et al., 2009). The 
FOXP1 gene on 3p14.1 encodes a member of the FOX family of transcription factors. 
Two alternatively spliced FOXP1 mRNA iso-forms are highly expressed in ABC-
DLBCL, and some studies showed that uniform high expression of FOXP1 protein is 
associated with an inferior survival in DLBCL patients (Choi et al., 2009). The 
algorithm closely approximated to the GEP classification with 93% concordance. The 
differences in OS for GCB and ABC were also significant (p<0.001). The predictive 
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value of the Choi algorithm was successfully confirmed by the work of Meyer et al, 
Visco et al and Culpin et al (for progression free survival [PFS] only) (Culpin et al., 
2013) (Meyer et al., 2011) (Visco et al., 2012). 
Recently, Meyer et al developed a simplified version of both models by the 
removal of BCL6 expression as a factor (Meyer et al., 2011). This step should improve 
the reproducibility of the models as anti-BCL6 staining is very sensitive and several 
laboratories reported difficulties in reproducibility. The modified version shows the 
same efficacy but a much simplified methodology (Meyer et al., 2011). This was 
confirmed by the study of Culpin et al. (Culpin et al., 2013). 
The models developed by Muris et al and Nylman et al deserve special attention 
as neither of them include the BCL6 protein and both are based on the expression of 
molecules associated with the activated B-cell phenotype (Muris et al., 2006) (Nyman et 
al., 2009). The Muris model based on expression of BCL2, CD10 and MUM1 was able 
to stratify patients into low and particularly high clinical risk groups (p=0.04 and 
p<0.0001; respectively) (Muris et al., 2006). The model was designed using a DLBCL 
cohort treated with chemotherapy only, but was subsequently reassessed in patients 
treated with immunochemotherapy with contradictory results (Culpin et al., 2013) 
(Meyer et al., 2011) (Nyman et al., 2009). In the study of Meyer et al the algorithm 
maintained its predictive power (Meyer et al., 2011) but in the study of Culpin et al it 
lost it (Culpin et al., 2013). In Nyman’s study prediction was retained for PFS and lost 
for OS. The Nyman model is based on the expression of MUM1 and FOXP1. Both 
proteins are associated with the ABC phenotype (Nyman et al., 2009). Tumours with 
high expression of MUM1 or FoxP1 were defined as ABC phenotype and they have a 
significantly shorter failure-free survival (FFS) (p=0.04) and OS (p=0.110) compared 
with other lymphomas. The model was developed on patients treated with 
immunochemotherapy and was subsequently re-evaluated by Meyer et al where it 
retained its predictive value (Meyer et al., 2011) and Culpin et al where it did not 
(Culpin et al., 2013). 
The most recent model based on sequential evaluation of immunohistochemical 
markers is the Visco-Young model, which is based on expression of CD10, FOXP1 and 
BCL6 (Visco et al., 2012). This model could distinguish between cases with GCB and 
non-GCB phenotype. The OS and PFS for GCB were significantly longer than for non-
GCB (p=0.003 and p=0.002; respectively). The algorithm was reported to have an 
extraordinary concordance with GEP results of 92.6%. 
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In addition to all the models described above Meyer et al designed the “Tally – 
model” which deserves particular attention. In contrast to other IHC models it does not 
rely on a particular sequence of applied staining but on the sum of two GC-markers 
(CD10 and GCET1), and two ABC-markers (Mum1 and FoxP1) with one “stratifying 
marker” – LMO2 (Meyer et al., 2011). Although the model was able to precisely assign 
the patient either to the GCB or ABC group with different OS and PFS, it also had some 
drawbacks. It uses antibodies which are not commonly used in the laboratories and 
which are difficult to use, and it predicts OS slightly less precisely compared with the 
Choi algorithm. 
There are only a few studies that compare all the important models on the same 
group of patients (Meyer et al., 2011) (Culpin et al., 2013) (Gutierrez-Garcia et al., 
2011a). Their results demonstrate that there is no consensus regarding the best 
immunohistochemical model for prediction of survival in DLBCL. Meyer et al 
reassessed most important IHC models (Hans, modified Hans, Choi, modified Choi, 
Muris, Nyman and Tally) using TMA in an unselected population of DLBCL patients 
treated with immunochemotherapy and with established GEP origin (Meyer et al., 
2011). The algorithms of Tally, Choi, modified Choi, Hans and modified Hans were the 
best at predicting cell of origin as defined by GEP. By contrast the Muris algorithm was 
the least accurate at predicting tumour cell origin being too specific for ABC-type 
DLBCL. All tested algorithms were able to separate the patients into two groups with 
significantly different survivals. All algorithms predicted EFS and OS independent of 
the IPI with the exception of the Nyman algorithm and OS. The Muris algorithm was 
the best at predicting OS and EFS. However the authors concluded that its application in 
everyday practice is limited because of its poor effectiveness at predicting cell of origin. 
The Choi, Hans and Tally algorithms were the others most accurate at predicting OS 
and PFS. Recently our group also published data on reassessment of IHC algorithms 
(Hans, modified Hans, Choi, modified Choi, Muris, Nyman and Visco-Young) in an 
unselected population of DLBCL patients treated with immunochemotherapy using 
whole IHC sections (Culpin et al., 2013). Unfortunately we were not in possession of 
GEP results, thus the data is limited to the assessment of prediction of survival only. 
The Hans, modified Hans and Muris were predictive for OS and PFS and Choi and 
modified Choi for PFS only. The Visco-Young and Nyman were not predictive. 
Gutiérrez-Garcia assessed the predictive value of the following algorithms: Colmo (was 
not described here in detail), Hans, Muris, Choi and Tally using TMA in patients with 
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DLBCL uniformly treated with immunochemotherapy (Gutierrez-Garcia et al., 2011a). 
The study revealed very low concordance of GCB / non GCB cases compared with the 
results of GEP and surprisingly none of the assessed algorithms was able to retain the 
prognostic impact of the GCB / non GCB groups. 
Despite the advantages of IHC models in diagnosis of DLBCL their value in 
stratification of the treatment of DLBCL is still limited. There are several issues, which 
could contribute to the disparity in results observed to date. Firstly, the cohort of 
patients employed in the study needs to be representative of the whole population and 
the patients need to be treated with identical treatments. In several studies on individual 
markers or IHC models the patients were recruited from highly preselected clinical 
trials, many received chemotherapy without the addition of rituximab and sometimes 
were not treated with uniform regimens. Secondly, different studies used different 
materials; TMA vs. whole tissue sections, or applied different antibodies with different 
fixation and staining procedures and used different cut-offs. Finally IHC is an examiner 
dependent, semi-quantitative method and thus will always have a certain degree of 
subjectivity. In the study on validation of immunohistochemical prognostic markers in 
DLBCL de Jong et al. concluded that IHC for subclassification of DLBCL is feasible 
and reproducible, but exhibits varying rates of concordance for different markers (de 
Jong et al., 2007). These findings may explain the wide variation of biomarker 
prognostic impact reported in the literature. Harmonization of techniques and 
centralized consensus review appears mandatory when using immunohistochemical 
biomarkers for treatment stratification. 
 
1.3.7 Treatment of DLBCL 
DLBCL has an aggressive natural history but most patients have a relatively 
good response to chemotherapy at least initially. It is maintenance of achieved 
remissions that is the bigger therapeutic problem. Although overall response rate (ORR) 
with modern therapeutic regimens vary between 75% and 80%, only 40% - 50% of 
patients achieve long-term remission (Coiffier, 2001). 
Chemotherapy with six – eight cycles of CHOP has been the mainstay of therapy 
since its development in the 1970s (McKelvey et al., 1976). The treatment outcome for 
patients with DLBCL varies considerably based on initial stage of disease. For patients 
with early-stage disease (stages I and II non-bulky), chemotherapy with “abbreviated 
CHOP”, 2 – 4 cycles plus involved field radiation therapy seems to be effective. 5-year 
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event free survival reaches 73% and overall survival is 84% (Horning et al., 2004). By 
contrast the outcome of patients with advanced disease treated with CHOP-like therapy 
is not satisfactory. This therapy can induce complete responses in only 44 % of patients, 
with three-year EFS and OS rates of 43% and 55%, respectively (Fisher et al., 1993). 
In order to try and improve treatment outcomes new and more complex 
regimens were developed in the 1970s and 1980s. Some are based on dosage escalation, 
others are multidrug chemotherapies that include additional drugs. Initial results from 
single-institution studies using new multidrug regimens were promising and suggested 
that the number of patients cured with those regimens might be doubled compared with 
results achieved with CHOP-like regimens. However, these findings were not 
confirmed by multicentre prospective randomised trials carried out by the Southwest 
Oncology Group (SWOG) and the ECOG (Fisher et al., 1993). Results showed that the 
new regimens were more toxic and the achieved remissions rates and OS were not 
improved compared with those achieved using CHOP alone (Fisher et al., 1993). 
The role of chemotherapy intensification was re-investigated in the late 1990s 
with the availability of granulocyte colony stimulating factors (G-CSF) or 
erythropoietin, which were supposed to reduce chemotherapy induced toxicities. The 
addition of etoposide to CHOP with or without time intensification improved complete 
remission (CR) and 5-year EFS for patients < 60 years but not for those > 60 years 
(Pfreundschuh et al., 2004a) (Pfreundschuh et al., 2004b). 
High-dose chemotherapy (HDCT) with up-front autologous stem-cell 
transplantation (ASCT), was another therapy option investigated in order to try and 
improve treatment responses in patients with poor-prognosis DLBCL. A variety of 
regimens were used but conflicting results were reported. A recent meta-analysis 
analysing efficacy of HDCT compared to conventional therapy in DLBCL patients 
found no evidence that HDCT improved OS and EFS in good risk DLBCL patients and 
the evidence for poor risk patients was inconclusive (Greb et al., 2007). Inadequate 
selection of patients and use of inappropriate induction regimens were postulated as 
possible reasons for the results. Therefore, the role of ASCT as initial therapy for 
patients judged to be at high-risk of treatment failure with conventional therapy remains 
to be assessed in prospective clinical trials. 
Further attempts to improve the outcome of CHOP treatment have been made by 
combining it with immune-factor-based therapy such as the infusion of B-cell specific 
monoclonal antibodies. The CD20 antigen is expressed on normal and malignant B-
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lymphocytes and it is known to regulate the cell cycle and cell differentiation (Maloney 
et al., 1994). Activation of CD20 by binding to its antibodies induces apoptosis of CD20 
expressing lymphocytes. Rituximab (MabThera, Rituxan Roche, Neuillyu-sur-Seine, 
France) is a chimeric human/murine immunoglobulin G1 monoclonal antibody that 
binds specifically to CD20. Activation of CD20 on lymphoma cells by rituximab results 
in complement mediated lysis of tumour cells, antibody dependent cell mediated 
cytotoxicity and induction of apoptosis (Golay et al., 2000) (Hofmeister et al., 2000) 
(Shan et al., 1998) (Cartron et al., 2004) (Eisenbeis et al., 2003). Recent clinical studies 
have shown that rituximab acts synergistically with chemotherapy in patients with B 
cell lymphoma. In phase II trials Rituximab demonstrated efficacy in patients with 
DLBCL either alone or in combination with CHOP (Sonkoly et al., 2007) (Vose et al., 
2001a). In a randomized study carried out by the GELA on elderly untreated patients 
with DLBCL, the addition of rituximab to CHOP significantly increased the CR rate 
(76% vs. 63%, p=0.005), and prolonged EFS and OS without a significant increase in 
toxicity (Coiffier et al., 2002). The five-year follow-up study showed that EFS, PFS, 
disease free survival (DFS), and OS remained statistically significant in favour of the 
combination R-CHOP (p=0.00002, p<0.00001, p<0.00031 and p<0.0073, respectively) 
(Feugier et al., 2005). Since the publication of the GELA Study R-CHOP has become 
the new standard in the treatment of elderly patients with DLBCL. Similarly, a 
retrospective study from British Columbia showed that the addition of rituximab to 
CHOP-like treatment improved EFS and OS in a group of previously untreated patients 
with DLBCL of all ages (Sehn et al., 2005). Additionally the MInT revealed that 
patients receiving CHOP or CHOP-like therapy with rituximab had a significantly 
higher 3-year EFS and OS compared with those who received chemotherapy alone 
(79% vs. 59%, p<0.0001 and 93% vs. 84%, p=0.0001; respectively). Importantly, there 
were no differences between the patients treated with R-CHOP and those given the 
more-intensified regimen cyclophosphamide, doxorubicine, vincristine, etoposide, 
prednisolone (CHOEP) (Pfreundschuh et al., 2006). Furthermore, data analysis showed 
that R-CHOP was an effective treatment for the younger patients with good-prognosis 
DLBCL. Although the results of prospective multicentre clinical trials appear to be very 
promising, the experience of clinicians working with unselected populations of patients 
with DLBCL seems to be less optimistic. In particular the treatment results for patients 
with poor-prognosis disease remain unsatisfactory. 
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More recent trials have focussed on improving the treatment of DLBCL on the 
basis of time intensification of the R-CHOP regimen with the support of growth factors 
(Halaas et al., 2005). Initial results are not promising nor are the results of the studies on 
the role of intermediate positron emission tomography (PET) scanning to aid treatment 
decisions.  
Another new approach in the therapy of DLBCL is the combination of R-CHOP 
with new less-toxic cytostatic agents, antibodies or small molecules (Zaja et al., 2006). 
To date findings of the first clinical trials which combine R-CHOP and antibodies to 
VEGF (bevacizumab), or anti-CD22 antibodies (epratuzumab) are very promising but 
require further study (Micallef et al., 2006) (Ganjoo et al., 2006). Targeting the affected 
pathways in GCB and ABC DLBCL with genasence and bortezomib is other new 
therapeutic option. 
In conclusion, the treatment of patients with DLBCL, particularly those of high-
risk, remains an important unresolved issue. New therapeutic concepts need to be 
developed particularly in the area of risk stratification. The above statements are of 
particularly high importance in view of the very disappointing results in 
relapsed/refractory patients with DLBCL. Patients with relapsed or progressive disease 
(PD) still have a very poor prognosis. High dose chemotherapy followed by ASCT is 
the treatment of choice for these patients (Verdonck et al., 1992) (Vose et al., 2001b) 
(Prince et al., 1996) (Saez et al., 1994) (Nademanee et al., 2000) (Kewalramani et al., 
2000) (Philip et al., 1995). The most compelling evidence for the superiority of HDCT 
compared with conventional-dose salvage therapy in relapsed and progressive NHL is 
based on the randomized “Parma trial” (Philip et al., 1995). In this study all patients 
received two cycles of conventional chemotherapy. Responders were randomized to 
receive either four cycles of conventional chemotherapy or HDCT followed by ASCT. 
Analysis at five years revealed that patients treated with HDCT had superior outcomes 
as measured by freedom from treatment failure (FFTF) (12% vs. 46%) and by OS (32% 
and 53%). However, in the “Parma trial” more than 50% of patients treated in the 
HDCT-arm relapsed and most of them died. Recent published results of second-line 
treatments based on high-dose (HD) protocols and ASCT are very limited (Vellenga et 
al., 2008) (Sieniawski et al., 2007) (Josting et al., 2005). 
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1.4 Peripheral T-cell lymphoma (PTCL) 
 
1.4.1 Definition of PTCL 
 PTCL is a heterogeneous group of malignancies derived from mature (post-
thymic) T-cells and NK-cells. PTCLs are characterised by a broad range of cellular 
composition. Some subtypes lack identified immunophenotypic profiles and defined 
cellular origin (de Leval and Gaulard, 2008). With the exception of ALCL, ALK 
positive tumours there are no known molecular markers in PTCL (de Leval and 
Gaulard, 2008). Although the current WHO 2008 Classification of Tumours of 
Haematopoietic and Lymphoid Tissues has included several new biological-genetic 
features, there is still a great emphasis on clinical features and anatomic location in the 
classification of PTCL (Swerdlow et al., 2008). There are approximately 23 defined 
types of lymphoid malignancies with T-cell origin, see table 1.2. 
 
1.4.2 Epidemiology of PTCL 
PTCLs are rare diseases, altogether accounting for less than 15% of NHL 
(Savage, 2007). In an evaluation of NHL performed worldwide on 1403 patients by the 
International T-cell Lymphoma Project (ITLP), PTCL was found in only 7% of cases, 
and anaplastic large T/null-cell lymphoma in 2.4% (Vose et al., 2008). The study 
revealed that the most common subtype is PTCL NOS with 25.9%, followed by AILT 
with 18.5% and natural killer/T-cell lymphoma with 10.4%,. 
Taking into consideration the fact that the total number of PTCLs is rather small 
then some of the lymphoma subtypes are extremely rare. The disease also shows a 
geographic variation; in Western countries it accounts for 5% - 10% of all NHL and 
15% - 20% of aggressive lymphomas. By contrast, PTCL is more common on the Asian 
continent accounting for 15% - 20% of all lymphomas, (21% in Hong-Kong). Subtypes 
of PTCL also show a geographic variation in incidence, (see table 1.10). In both North 
America and Europe PTCL NOS was the most common subtype with 34.4% and 
34.3%, respectively. Next in incidence were AITL and ALCL, ALK positive, both with 
16% in North America. In Europe AITL accounted for 28.7% and EATL (9.1%). In 
contrast ATLL was at 25% the most common subtype in Asia, followed by NK/T-cell 
lymphoma (22.4%), PTCL NOS (22.4%) and AITL (17.9%) (Vose et al., 2008). The 
presence or absence of pathogenetic factors in different regions may be at least partially 
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responsible for these differences e.g. HTLV-1 for ATLL, EBV for NK/T-cell 
lymphoma or coeliac disease for EATL (Vose et al., 2008). 
 
 
North 
America 
(%) 
Europe 
(%) 
Asia 
(%) 
PTCL – NOS 
Angioimmunoblastic 
Anaplastic large cell lymphoma, ALK positive 
Anaplastic large cell lymphoma, ALK negative 
Natural killer/T-cell lymphoma 
Adult T-cell leukaemia/lymphoma 
Entheropathy Associated T-cell Lymphoma 
Hepatosplenic T-cell lymphoma 
Primary cutaneous anaplastic large cell lymphoma 
Subcuteneos panniculitis-like 
Unclassifiable T-cell 
34.4 
16.0 
16.0 
7.8 
5.1 
2.0 
5.8 
3.0 
5.4 
1.3 
2.3 
34.3 
28.7 
6.4 
9.4 
4.3 
1.0 
9.1 
2.3 
0.8 
0.5 
3.3 
22.4 
17.9 
3.2 
2.6 
22.4 
25.0 
1.9 
0.2 
0.7 
1.3 
2.4 
Table 1.10 Major Lymphoma Subtypes by Geographic Region (Vose et al., 2008). 
 
1.4.3 Histopathology and classification of PTCL 
 The classification of T-cell lymphoma is based on both morphologic and clinical 
criteria. WHO 2008 classification includes approximately 22 entities (six of them 
provisional), which can be classified according to their presentation, see table 1.11. 
(Swerdlow et al., 2008). 
 More detailed characteristics of those subtypes included in our studies 
are provided here for: PTCL NOS; ALCL, ALK positive; ALCL, ALK negative, 
extranodal NK/T-cell lymphoma, nasal type, EATL and hepatosplenic T-cell 
lymphoma. 
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Leukaemic or disseminated 
• T-cell prolymphocytic leukaemia 
• T-cell large granular lyphocytic leukaemia 
• Chronic lymphoproliferative disordes of NK cells* 
• Aggressive NK-cell leukaemia 
• Adult T-cell lymphoma/leukaemia (HTLV1 – positive) 
• Systemic EBV-positive T-cell lyphoproliferative disorders of childhood 
Nodal 
• Angioimmunoblastic T-cell lymphoma (AILT) 
• Anaplastic large cell lymphoma, ALK-positive 
• Anaplastic large cell lymphoma, ALK-negative* 
• Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) 
Extranodal 
• Extranodal NK/T-cell lymphoma, nasal type 
• Enteropathy-associated T-cell lymphoma 
• Hepatosplenic T-cell lymphoma 
Extranodal – cutaneous 
• Mycosis fungoides 
• Sezary syndrome 
• Primary cutaneous CD30+ lymphoproliferative disorder 
• Primary cutaneous anaplastic large cell lymphoma 
• Lymphomatoid papulosis 
• Subcutaneous panniculitis-like T-cell lymphoma 
• Primary cutaneous gamma-delta T-cell lymphoma* 
• Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma* 
• Primary cutaneous small/medium CD4+ T-cell lymphoma* 
Table 1.11 Classification of mature T/NK-cell neoplasms according to 2008 WHO 
classification of lymphoid malignancies (Swerdlow et al., 2008). *) designates 
provisional entities 
 
1.4.3.a PTCL, not otherwise specified 
This is a heterogeneous category of nodal and extranodal mature T-cell 
lymphomas that do not correspond to any of the specifically defined subtypes of mature 
T-cell lymphoma in the current classification (Swerdlow et al., 2008). 
PTCL NOS accounts for approximately 30% of all mature T-cell neoplasms. 
Most patients are adults and predominantly male. The disease is rare in children (Rizvi 
et al., 2006). 
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The most common disease sites are peripheral lymph nodes. However any site 
may be affected and generalized disease with involvement of BM, liver, spleen and 
extranodal tissue is often seen. The involvement of PB can be seen but the leukemic 
variant is uncommon. Primary extranodal involvement may also occur with 
gastrointestinal tract being the most often involved (Rizvi et al., 2006). Most patients 
present with lymphadenopathy and have advanced stage disease with B-symptoms 
(Rizvi et al., 2006). Other paraneoplastic syndromes may be seen, for example, 
eosinophilia, pruritus or haemophagocytic syndrome (Rizvi et al., 2006). 
 In the lymph nodes PTCL NOS are characterised by paracortical or diffuse 
growth patterns with destruction of lymph node architecture (Swerdlow et al., 2008). 
The cytological spectrum is extremely broad. Most cases consist of numerous medium- 
or large-sized cells with irregular, pleomorphic, hyperchromatic or vesicular nuclei, 
prominent nucleoli and many mitotic figures (Harris et al., 1994) (Jaffe, 2006). Clear 
cells and Reed-Sternberg-like cells can also be seen. An inflammatory background is 
often present with small lymphocytes, eosinophils, plasma cells and large B-cells 
(Warnke et al., 2007). There are three defined morphological variants of PTCL NOS: 1) 
lymphoepithelioid (Lennert lymphoma), 2) follicular and 3) T-zone. Extranodal 
involvement has a diffuse infiltration pattern composed of similar cells. 
 PTCL NOS is characterized by an aberrant T-cell phenotype with frequent down 
regulation of CD5 and CD7 (Went et al., 2006). Most nodal cases are CD4+/CD8-, 
although double positivity and negativity is also seen, as is CD8, CD56 and cytotoxic 
granule expression (Went et al., 2006). T-cell receptor beta-chain is usually expressed 
and CD52 is absent in 60% (Chang et al., 2007) (Piccaluga et al., 2007b) (Rodig et al., 
2006). CD30 can be expressed, exceptionally with CD15 (Barry et al., 2003) (Went et 
al., 2006). PTCL NOS usually lacks a follicular T helper phenotype with the exception 
of the follicular variant (Attygalle et al., 2007) (Dorfman et al., 2006) (Went et al., 
2006). The proliferation index is usually high and Ki67 rates >70% are associated with 
a worse prognosis (Went et al., 2006). 
 TCR genes are clonally rearranged in most cases (Rizvi et al., 2006). PTCL NOS 
is a highly aberrant neoplasm and complex karyotypic changes are common (Rizvi et 
al., 2006). Recurrent chromosomal gains have been observed in chromosomes 7q, 8q, 
17q and 22q and recurrent losses in 4q, 5q, 6q, 9p, 10q, 12q and 13q (Zettl et al., 2004) 
(Thorns et al., 2007). Genetic imbalances and gene expression signatures differ from 
those of AILT or ALCL. 
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1.4.3.b Anaplastic large cell lymphoma, anaplastic lymphoma kinase positive 
 ALCL, ALK positive is a T-cell tumour consisting of large cells with abundant 
cytoplasm, pleomorphic, often horseshoe-shaped nuclei, with a translocation involving 
the ALK gene and expression of CD30 (Swerdlow et al., 2008). 
 The tumour is most frequent in the first 3 decades of life and accounts for 
approximately 10% - 20% of childhood lymphomas and 3% of adult NHL. It shows a 
male predominance (Stein et al., 2000) (Benharroch et al., 1998) (Falini et al., 1999a). 
ALCL, ALK positive can involve both nodal and extranodal sites. The most 
common extranodal sites are: skin, bone, soft tissue, lung and liver (Benharroch et al., 
1998) (Falini et al., 1999a). The involvement of gut or CNS is rare. The number of 
patients with BM involvement differs depending on the method of assessment (Fraga et 
al., 1995). The majority of patients present with advanced stage disease with peripheral 
or abdominal lymphadenopathy, often associated with extranodal involvement including 
BM. B-symptoms are common (Brugieres et al., 1998) (Falini et al., 1999a). 
 ALCL, ALK positive is characterised by a broad morphologic spectrum from 
small cell neoplasms to tumours composed of large cells (Benharroch et al., 1998) 
(Falini et al., 1998) (Harris et al., 1994). However, all cases contain so-called hallmark 
cells. These cells are mostly large, (small variants are also seen), and have eccentric 
horseshoe- or kidney-shaped nuclei (Benharroch et al., 1998). There are five 
morphologic patterns of ALCL, ALK positive: 1) common pattern (60%), 2) 
lymphohistiocytic pattern (10%), 3) small cell pattern (5-10%), 4) Hodgkin-like pattern 
(3%) and 5) “composite pattern” when more than one pattern is observed in the tissue 
sample (Swerdlow et al., 2008). 
 The tumour cells are positive for CD30 on the cell membrane and in the Golgi 
region. CD 30 immunostaining is dependent on cell size with the strongest staining on 
large cells (Benharroch et al., 1998) (Stein et al., 1985). The cells are positive for ALK 
staining with a nuclear and / or cytoplasmic pattern depending on the translocation 
partner (Benharroch et al., 1998) (Falini et al., 1998) (Pulford et al., 2004). The cells are 
positive for EMA (Benharroch et al., 1998). ALCL, ALK positive tumours are mostly 
negative for pan T cell antigens CD3 and CD8 but positive for CD2, CD5 and CD4 
(Benharroch et al., 1998) (Bonzheim et al., 2004). Most cases are also positive for 
cytotoxic associated antigens: TIA1, granzyme B and / or perforin (Foss et al., 1996) 
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(Krenacs et al., 1997). ALCL, ALK positive tumours are consistently negative for 
BCL2 and EBV (Costes-Martineau et al., 2002) (Brousset et al., 1993). 
 Clonal rearrangements of the TCR are present in approximately 90% of cases. 
The remaining 10% of tumours show no rearrangement of TCR or Ig genes (Foss et al., 
1996). The characteristic feature of ALCL, ALK positive tumours is a genetic mutation 
involving ALK, which lead to its expression. The ALK gene encodes a tyrosine kinase 
receptor belonging to the insulin receptor superfamily, normally absent in postnatal 
human tissue including lymphoid cells. It can be expressed in rare cells in the brain 
(Morris et al., 1994) (Pulford et al., 1997). The most frequently observed translocation 
is t(2;5)(p23;q35) between the ALK gene on chromosome 2 and the nucleophosmin 
gene on chromosome 5 (Lamant et al., 1996) (Mason et al., 1990). ALK can also have 
different translocation partner genes on chromosome 1, 2, 3, 17, 19, 22 and X (Cools et 
al., 2002) (Falini et al., 1999b) (Hernandez et al., 1999) (Lamant et al., 1999) (Lamant 
et al., 2003) (Mason et al., 1998) (Rosenwald et al., 1999) (Stein et al., 2000) (Tort et 
al., 2001) (Trinei et al., 2000) (Wlodarska et al., 1998). Additionally it has been shown 
that ALCL, ALK positive tumours carry secondary chromosomal imbalances: losses of 
chromosome 4, 11q and 13q and gains of 7, 17p and 17q (Salaverria et al., 2008). In 
gene expression analysis studies among 117 genes over-expressed in ALCL, ALK 
positive tumours as compared with ALCL,  tumours, the four most common were: 
BCL6, PTPN12, serpinA1 and C/EBP (Lamant et al., 1999). 
 
1.4.3.c Anaplastic large cell lymphoma, anaplastic lymphoma kinase negative 
 ALCL, ALK negative was introduced as a provisional entity in the current WHO 
lymphoma classification. It is a CD30 positive T-cell tumour, which is not reproducibly 
distinguishable morphologically from ALCL, ALK positive but lacks expression of the 
ALK protein (Swerdlow et al., 2008). Most cases express T-cell-associated markers and 
cytotoxic granule associated proteins. 
The tumour occurs mostly in adults aged 40 – 65 years, (unlike those that are 
ALCL, ALK positive), and has a slight male predominance (Falini, 2001) (Stein et al., 
2000). 
ALCL, ALK negative involves both lymph nodes and extranodal tissue, 
although not as often as ALCL, ALK positive. The commonest extranodal sites include 
bone, soft tissue and skin. Most patients present with advanced stage disease, with 
peripheral and abdominal lymphadenopathy and B symptoms (ten Berge et al., 2000). 
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 The usual morphological presentation is with solid cohesive sheets of neoplastic 
cells affecting the architecture of the lymph nodes or other involved tissue (Swerdlow et 
al., 2008). If the normal lymph node architecture is preserved the lymphocytes infiltrate 
the sinuses and mimic carcinoma metastases (Swerdlow et al., 2008). Generally the 
cells in ALCL, ALK negative are larger, more pleomorphic and with a higher nuclear: 
cytoplasmic ratio compared with conventional ALCL, ALK positive. “Hallmark” cells 
with eccentric horseshoe or kidney-shaped nuclei are seen to a variable degree (Falini et 
al., 1999a) (Nelson et al., 2008). 
 All tumour cells are strongly positive for CD30. The loss of T-cell markers can 
occur, however more than half of all cases express at least one or more T-cell markers. 
CD2 and CD3 are found more often than CD5, and CD43 is almost always expressed 
(Swerdlow et al., 2008). CD4 is positive in the majority of cases and CD8-positive cases 
are rare. Cytotoxic proteins are present in many cases. EMA is expressed in a minority 
of cases in contrast to ALCL, ALK positive where it is always seen. ALCL, ALK 
positive are consistently negative for EBV (Swerdlow et al., 2008). 
 TCR genes show clonal rearrangements despite the expression status of T-cell 
antigens. There are no characteristic, recurrent, primary cytogenetic abnormalities 
acknowledge in the recent 2008 WHO classification (Swerdlow et al., 2008), however 
the next generation sequencing characterised several translocation but they need re-
validation in larger cohort of cases. Several studies have reported differences between 
ALCL, ALK negative; PTCL NOS and ALCL, ALK positive in terms of genes gained 
and lost (Salaverria et al., 2008) (Zettl et al., 2004) and gene expression (Ballester et al., 
2006) (Lamant et al., 2007). 
 
1.4.3.d Extranodal NK/T-cell lymphoma, nasal type 
This entity is a predominantly extranodal lymphoma characterized by vascular 
damage and destruction, prominent necrosis, cytotoxic phenotype and association with 
EBV (Swerdlow et al., 2008). Most cases appear to be genuine NK-cell neoplasms. 
Some cases show a cytotoxic T-cell phenotype, thus are called NK/T-cell tumours. 
 The disease occurs mostly in Asians and in the Native American population of 
Mexico, Central and South America (Au et al., 2005) (Chan, 1998). Like other subtypes 
of PTCL, there is a predominance of male and adult patients (Swerdlow et al., 2008). 
 The aetiology of the disease is unknown but there is a very strong correlation 
with EBV infection irrespective of the ethnic origin of the patient (Arber et al., 1993) 
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(Chan et al., 1994). The circulating number of EBV-DNA copies correlates directly 
with the extent of disease, unfavourable response to therapy and poor survival (Au et 
al., 2004). Additionally the disease can occur in immunosuppressed patients including 
the post-transplant setting (Hoshida et al., 2001) (Kwong et al., 2000). 
 The nasal cavity, nasopharynx, paranasal sinuses and palate are the most 
frequently involved sites (Swerdlow et al., 2008). However, extranodal NK/T-cell 
lymphoma can also occur in extranasal sites such as skin, soft tissue, gastrointestinal 
tract and testis. Both secondary (Chan, 1998) (Chan et al., 1997) (Kern et al., 1992) and 
primary nodal involvement is also possible (Chim et al., 2005) (Kagami et al., 1999). 
Patients with nasal involvement usually present with symptoms of nasal obstruction and 
epistaxis, or with extensive midfacial destructive lesions (Swerdlow et al., 2008). The 
disease is primarily restricted to the upper aerodigestive tract but can spread rapidly to 
various sites: skin, gastrointestinal tract, testis or cervical nodes. BM involvement is 
uncommon (Wong et al., 2001) but some patients suffer from haemophagocytic 
syndrome (Cheung et al., 1998) (Kwong et al., 1997). Patients with extranodal NK/T-
cell lymphomas of non-nasal type usually present with advanced stage disease, with 
involvement of extranodal sites, lymph nodes and with B-symptoms (Chan et al., 1997) 
(Kern et al., 1992). Symptoms from the primary extranodal site will vary depending on 
localisation, for example skin ulcers or nodules or perforation in intestinal cases 
(Swerdlow et al., 2008). 
 The histopathological features of NK/T-cell lymphoma are similar despite the 
site of involvement. The mucosa often shows ulceration. Tumour cells infiltrate the 
mucosa in diffuse, angiodestructive and angiocentric patterns (Swerdlow et al., 2008). 
Coagulative necrosis and admixed apoptotic bodies are common findings (Swerdlow et 
al., 2008). The tumour cells are different sizes from small/ medium to large and 
anaplastic. The cells have irregular folded and elongated nuclei, which can be vesicular 
in large cells. The chromatin is granulated. The cytoplasm is moderate in amount and 
often pale or clear. The tumour can contain a large admixture of inflammatory cells 
(Chan, 1998) (Hasserjian and Harris, 2007). 
Typical cells are positive for CD2, CD56 and cytoplasmic CD3, and negative for 
surface CD3. CD56 is not specific for NK tumours and can be found in other PTCL 
(Chan, 1998) (Jaffe, 1995) (Tsang et al., 1996). Cytotoxic molecules e.g. perforin, 
granzyme B or TIA1 are positive (Elenitoba-Johnson et al., 1998). The common NK/T-
cell markers like CD4, CD5, CD8, TCRδ, CD16 and CD57 are usually negative, and 
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CD43, CD45RO, HLA-DR, CD25, FAS and FAS ligand are commonly expressed (Ng 
et al., 1997) (Ohshima et al., 1997). A diagnosis of extranodal NK/T-cell lymphoma is 
less likely if EBV is negative (Swerdlow et al., 2008). 
 TCR and Ig genes are in germline configuration in most cases (Swerdlow et al., 
2008). Although different cytogenetic aberrations have been reported, so far no specific 
abnormalities have been found. The commonest aberrations are: del(6)(q21q25) and 
i(6)(p10) (Siu et al., 2000) (Siu et al., 1999) (Tien et al., 1997) (Tien et al., 1997). 
Aberrant methylation of the promoter CpG regions of multiple genes is common (e.g. 
p73) (Siu et al., 2002). The studies also showed that the most affected genes are FAS, 
TP53, β-catenin, KRAS or KIT (Hongyo et al., 2005) (Quintanilla-Martinez et al., 2001) 
(Shen et al., 2002). 
 
1.4.3.e Enteropathy associated T-cell lymphoma (EATL) 
EATL is an intestinal tumour with origins in intraepithelial T lymphocytes. In 
the 2008 WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, two 
types of EATL were defined; type I EATL (tumour composed of large lymphoid cells) 
and type II EATL (tumour composed of monomorphic medium-size cells – 
monomorphic variant) (Swerdlow et al., 2008). The relationship between type I EATL 
and coeliac disease is well established (Diamanti et al., 2006) (Green and Cellier, 2007) 
(Cheung et al., 1998) (Isaacson, 1985) (Howdle et al., 2003) (Salmi et al., 2006). By 
contrast, any association of type II EATL with coeliac disease is not proven (Deleeuw et 
al., 2007). 
EATL occurs primarily in patients in the sixth or seventh decade of life. The 
disease is uncommon in most parts of the world. However type I EATL is more 
common in areas with a high prevalence of coeliac disease (Northern Europe). By 
contrast type II EATL has a broader geographic distribution and is also encountered in 
Asia and other regions where coeliac disease is rare (Swerdlow et al., 2008). 
In type I EATL the association with coeliac disease is characterised by positive 
serological tests, HLA-DQ2 and HLA-DQ8 expression, and other clinical findings 
associated with coeliac disease like dermatitis herpetiformis or hyposplenism (Diamanti 
et al., 2006) (Salmi et al., 2006) (Van Overbeke et al., 2005). In type II EATL an 
association with coeliac disease and other risk factors is yet not proven. 
The commonest presentation of type I EATL is reappearance of malabsorption, 
accompanied by abdominal pain, and frequently associated with intestinal perforation in 
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patients with a history of coeliac disease or refractory coeliac disease (Isaacson and Du, 
2005). In some patients the diagnosis of EATL and coeliac disease is made at the same 
time. The presentation of type II EATL is very similar except that patients usually do 
not have evidence of coeliac disease. 
EATL may occur in any part of the gastrointestinal tract but predominantly 
arises in the jejunum or ileum. Macroscopically, in most patients the tumour is 
multifocal (Diamanti et al., 2006), forming ulcers, nodules, plaques, strictures or less 
commonly large masses, often infiltrating the mesentery and mesenteric nodes (Isaacson 
and Du, 2005). Microscopically the picture of type I EATL is characterised by an 
infiltration of relatively monotonous medium-sized to large cells with round or 
angulated nuclei, prominent nucleoli and moderate to abundant, pale-staining cytoplasm 
(Swerdlow et al., 2008). In some cases the tumour cells exhibit marked pleomorphism 
with multinucleated anaplastic cells. Most of the tumours show an inflammatory 
infiltrate with abundant histiocytes and eosinophils, which may obscure the small 
numbers of tumour cells (Isaacson and Du, 2005). The intestinal mucosa adjacent to the 
tumour usually shows enteropathic features i.e. villous atrophy, crypt hyperplasia, 
increased lamina propria lymphocytes and plasma cells, and intraepithelial 
lymphocytosis (Chott et al., 1998) (Chott et al., 1999). In type II EATL the neoplastic 
cells are medium-sized and have round darkly staining nuclei with a rim of pale 
cytoplasm. Intestinal crypt epithelia show florid infiltration, and adjacent intestinal 
mucosa exhibit villous atrophy and crypt hyperplasia with intraepithelial lymphocytosis 
of crypt and surface epithelium. An inflammatory component is absent and necrosis is 
usually less evident than in type I (Swerdlow et al., 2008). 
In most type I EATL cases the tumour cells are positive for CD3, CD7, and 
CD103, negative for CD5 and positive / negative for CD8 and TCRß. A varying 
proportion of the tumour cells express CD30 (Spencer et al., 1985) (Wright, 1997). 
Intraepithelial lymphocytes in the adjacent enteropathic mucosa may show an abnormal 
immunophenotype, usually CD3+, CD5-, CD8- and CD4- (Spencer et al., 1988) 
(Wright, 1997). The immunophenotype of type II EATL is distinctive, and the tumour 
cells are CD3+, CD4-, CD8+, CD56+, TCRß+ (Swerdlow et al., 2008). Intraepithelial 
lymphocytes in the adjacent mucosa share the identical immunophenotype (Chott et al., 
1998). 
TCR beta and gamma chains genes are clonally rearranged in both types 
(Isaacson, 1985) (Murray et al., 1995). HLA-DQA1*0501 and HLA-DQB1*0201 
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genotypes characteristic for coeliac disease are also present in patients with type I 
EATL (Howell et al., 1995). Both types of EATL harbour complex segmental 
amplification of the 9q31.3 chromosome region, or show deletions in the 16q12.1 
chromosome region, in contrast to primary nodal PTCL (Swerdlow et al., 2008). Type I 
EATL frequently displays gains in chromosomes 1q and 5q. By contrast type II EATL 
is more often characterized by 8q24 (c-MYC) amplifications (Deleeuw et al., 2007) 
(Zettl et al., 2002). 
 
1.4.3.f Hepatosplenic T-cell lymphoma 
Hepatosplenic T-cell lymphoma is an extranodal and systemic neoplasm derived 
from cytotoxic T-cells, usually of γ/δ TCR type (Swerdlow et al., 2008). It usually 
involves spleen, liver and BM. 
 This is a very rare type of lymphoma. The reported incidence is <1% of all NHL. 
It usually presents in adolescents and young adults males.  
It is associated with chronic immunosuppression; most commonly after long-
term immunosuppressive therapy for organ transplant or prolonged antigenic 
stimulation (Belhadj et al., 2003) (Gaulard et al., 2003) (Vega et al., 2007) (Wu et al., 
2000). It is also seen in patients treated with azathioprine and infliximab for Crohn’s 
disease (Mackey et al., 2007) (Rosh et al., 2007). 
As its name suggests it commonly presents with involvement of spleen and liver. 
BM is almost always involved, (Belhadj et al., 2003) (Cooke et al., 1996) (Vega et al., 
2007), however patients have no lymphadenopathy (Farcet et al., 1990). Usually 
patients present with hepato-splenomegaly associated with B-symptoms. They can 
suffer from thrombocytopenia, anaemia and leukopenia. Peripheral blood involvement 
is uncommon at presentation but may appear during the course of the disease (Belhadj 
et al., 2003) (Cooke et al., 1996) (Vega et al., 2007). 
 The tumour cells are monotonous with medium-sized nuclei, loosely condensed 
chromatin and a rim of pale cytoplasm (Cooke et al., 1996). They diffusely infiltrate the 
cords and sinuses of the splenic red pulp with atrophy of the white pulp. The liver 
shows sinusoidal and BM intrasinusoidal infiltration (Swerdlow et al., 2008). 
 The cells are positive for CD3 and are usually TCRδ1+, TCRαβ-, CD56+/-, 
CD4-, CD8-/+ and CD5-. A minority of cases appear to be of α/β type (Macon et al., 
2001) (Suarez et al., 2000). They express cytotoxic granule-associated proteins TIA1 
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and granzyme M, but they are usually negative for granzyme B and perforin (Cooke et 
al., 1996) (Felgar et al., 1997) (Krenacs et al., 2003). 
TCR is rearranged in both γ/δ and α/β types. There is no characteristic single 
genetic mutation. The most common genetic mutations include: isochromosome 7q, 
ring chromosome 7, trisomy 8 and loss of a sex chromosome (Alonsozana et al., 1997) 
(Wlodarska et al., 2002) (Tamaska et al., 2006). 
 
1.4.4 Prognostic factors in PTCL 
Compared with other lymphomas e.g. DLBCL or FL prognostic factors are not 
as extensively studied in PTCL. This is most probably due to the heterogeneity, and 
consequent rarity of the individual entities. The definition and classification system of 
PTCL is also relatively new and has undergone several major changes in the last two 
decades. Another reason may be the generally poor outcome of patients diagnosed with 
PTCL, with only minimal differences in survival between subtypes. Thus it would be 
difficult to find a place for prognostic models in everyday clinical practice. Small 
patient numbers and differences in survival between individual patients also makes it 
very difficult from a research point of view. Despite these problems clinical prognostic 
indices have been used in several PTCL studies, and recently some novel models have 
been developed including some work on biomarkers. 
 
1.4.4.a Clinical prognostic factors 
The most frequently used prognostic index in PTCL is the IPI. This is despite 
the fact that the IPI was primarily developed in a cohort of patients with aggressive 
lymphomas including both B-cell and T-cell subtypes, with a significant majority of the 
former (Shipp, 1993). There are, however, different opinions on the usefulness of the 
IPI in PTCL. In some studies the IPI worked very well and could distinguish between 
group of patients with different outcomes (Suzumiya et al., 2009) (Lopez-Guillermo et 
al., 1998) (Chim et al., 2004); in others it could not (Savage et al., 2004) (Sieniawski et 
al., 2010). 
This confusion prompted the “Intergruppo Italiano Linfomi” to develop a new 
index called the PIT designed especially for patients with PTCL (Gallamini et al., 
2004). The index was developed in a cohort of 385 patients with PTCL NOS. Most 
patients had received chemotherapy with anthracyclines (78%), others were treated with 
high-dose chemotherapy and ASCT (12%) or with non-anthracycline regimens (8%), 
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and 2% of patients received no therapy. The score included the following factors: age 
(≤60 years vs. >60 years), performance status with ECOG (≤1 vs. >1), serum LDH 
(≤normal vs. >normal) and BM involvement (yes vs. no). Four separate groups with 
different risks were distinguished: group 1: no adverse factors – 5-year and 10-year OS 
of 62.3% and 54.9%, respectively; group 2: one factor – 52.9% and 38.8%, respectively; 
group 3: 2 factors – 32.9% and 18.0%, respectively and group 4: with 3 or 4 factors – 
18.3% and 12.6%. It should be noted however that the index was not developed in a 
group of uniformly treated patients. 
Subsequently, the index was modified (mPIT) by removing BM involvement 
and adding proliferation index as assessed by Ki-67 immunostaining in a cohort of 193 
patients: 148 PTCL NOS and 45 AILT (Went et al., 2006). Patients again received 
different treatments modalities: combination chemotherapy with anthracyclines (84%), 
single-agent chemotherapy (4%), combination chemotherapy without anthracyclines 
(3%) and 9% of patients received no chemotherapy. The mPIT could differentiate 3 
groups with different outcomes: group I (0 or 1 prognostic factor), median survival 37 
months; group II (2 prognostic factors), median survival 23 months and group III (3 or 4 
prognostic factors), median survival 12 months. However this index has several features 
which may lead to bias, namely: inclusion of two different histological entities with 
different prognoses: PTCL NOS and AILT, inclusion of patients receiving different 
treatment modalities and finally inclusion of approximately 50% of patients who were 
positive for HIV. 
The latest prognostic score (IPTCLP) was published by the ITLP using a cohort 
of patients with PTCL and AITL. It is based on the presence or absence of 3 factors: age 
(≤60 years vs. >60 years), ECOG performance status (≤1 vs. >1), and platelet count 
(≤150 x 109/l vs. >150 x 109/l) (Vose, 2005). The index identifies 4 different groups: 
group 1 (0 risk factor), 5 year FFS and OS of 21% and 42% (respectively), group 2 (1 
risk factor), 19% and 27%, respectively; group 3 (2 risk factors), 10% and 19%, 
respectively and group 4 (3 risk factors), 5% and 12%, respectively. Again however, the 
index was produced using a cohort of patients with different histological subtypes and 
treated with different regimens. 
Recently Gutierrez-Garcia evaluated these four indices in a cohort of 121 
patients (Gutierrez-Garcia et al., 2011b). The IPI and PIT allocated patients equally 
among 4 risk groups. The IPTCLP was characterised by higher numbers of low-
intermediate risk patients and the mPIT by higher numbers of low risk patients. Total 
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concordance across three scores was 52% for low-risk, 27% for low-intermediate-risk, 
20% for high-intermediate-risk and 14% only for high-risk groups. Three from four 
tested indices, (IPI, PIT, and IPTCLP) predicted statistically significantly differences in 
CR, with IPI being the best predictor in logistic regression. All four indices predicted 
statistically significantly differences in PFS and OS with PIT being the best predictor 
for PFS and IPTCLP for OS (Gutierrez-Garcia et al., 2011b). 
Generally all four published indices are characterised by similar limitations: 
inclusion of different histological subtypes, and use of different treatment modalities. 
They rely on a small number of dichotomised predictive variables. Additionally as all of 
them use cox-regression multivariate analysis patients are assigned to one of a small 
number of risk groups, rather than being given a direct prediction, such as predictive 
survival probability, or predictive median lifetime on a continuous scale. Table 1.12 
shows factors included in all the described clinical indices for PTCL. 
 
Factor IPI PIT mPIT IPTCLP 
Age (≤60 years vs. >60 years) 
ECOG (≤1 vs. >1) 
LDH (normal vs. high) 
CS by Ann Arbor (I/II vs. III/IV) 
Extranodal involvement (<2 vs. ≥2 sites) 
BM involvement (negative vs. positive) 
Platelet count (≤150 x 109 vs. >150 x 109) 
Ki 67 (%) (≤75 vs. >75) 
ü  
ü  
ü  
ü  
ü  
 
 
 
ü  
ü  
ü  
 
 
ü  
 
 
ü  
ü  
ü  
 
 
 
 
ü  
ü  
ü  
 
 
 
 
ü  
 
Table 1.12 Variables used for calculation of the different prognostic indicies for PTCL. 
 
1.4.4.b Biological and molecular prognostic factors 
Biological and molecular prognostic factors are less frequently studied in PTCL 
compared with other lymphomas. However, some interesting studies have been recently 
published. In particular, there are new studies evaluating selected subgroups of disease 
and these deliver more reliable results than older reports, which include cohorts of 
patients with different diagnoses. 
Taking into consideration the fact that the vast majority of PTCL are CD4+ / 
CD8- several studies assessed the impact of T-helper phenotype on patient outcome. 
This factor was proposed as a potential indicator of the better outcome characteristics of 
PTCL NOS. Tsuchiya et al assessed the expression of chemokine receptors associated 
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either with the Th1 phenotype: chemokine (C–X-C motif) receptor 3 and 5 (CXCR3 and 
CXCR5) or with the Th2 phenotype: ST2(L) and activated TCR OX40/CD134 in 
patients with PTCL (Tsuchiya et al., 2004). Specific subtypes of PTCL had different 
expression patterns. In AILT, almost all cases were immunoreactive for OX40/CD134 
(96%) and for CXCR3 (89%). By contrast, in ALCL, all cases were immunonegative 
for OX40/CD134, and only a few cases (24%) were immunoreactive for CXCR3. 
Almost all cases (94%) were positive for ST2(L). Importantly, when cases of PTCL 
NOS were divided into 2 groups; “positive activity group” with cases positive for at 
least one of the markers: CXCR3, CXCR5 or ST2(L), and “negative activity group” 
with cases negative for all markers, the patients from the first group had a statistically 
significant better OS. In a study by Ishida et al. the expression of chemokine receptors: 
CXCR3 (Th1 marker) and chemokine (C-C motif) receptor 4 (CCR4) (Th2 marker) 
have been assessed in samples of patients with PTCL (Ishida et al., 2004). The Th1 
phenotype was predominantly expressed in AITL and Th2 in mycosis fungoides in 
transformation and ALCL, ALK negative. As suspected PTCL NOS was characterised 
by a heterogeneous expression pattern. In an analysis of OS CXCR3 appeared to be a 
significantly favourable factor and CCR4 a significantly unfavourable factor. 
Several studies have assessed the role of apoptotic pathways and their inhibitors 
and outcomes of patients with PTCL, particularly ALCL. Ten Berge et al assessed the 
expression of caspase3 an apoptosis execution enzyme, BCL2 an inhibitor of the 
mitochondrial apoptotic pathway, and PI9 an inhibitor of granzyme B induced apoptosis 
in patients with ALCL (ten Berge, 2002). The expression of caspase3 in >5% of tumour 
cells was a negative prognostic factor. Expression of BCL2 in >50% of tumour cells and 
expression of PI9 were positive prognostic factors for PFS and OS in the evaluation of 
all patients and in ALK negative patients. Additionally, there were significant 
differences in expression between ALK positive and ALK negative cases – the latter 
was characterised by lower expression of caspase3 and higher expression of both 
inhibitors. 
Schlette et al assessed the expression and prognostic value of an anti-apoptotic 
molecule survivin in ALCL, ALK positive and negative (Schlette et al., 2004). Survivin 
was expressed in approximately half of the patients and was a negative prognostic factor 
for PFS and OS in both ALCL, ALK positive and negative. 
 Cytogenetic studies have revealed a high number of genetic aberrations in 
PTCL. Some could distinguish between the different subtypes of PTCL e.g. between 
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AILT and PTCL NOS (Thorns et al., 2007) or between AILT, PTCL NOS and ALCL, 
ALK negative (Nelson et al., 2008). Nelson’s study could find no association between 
specific chromosomal abnormalities and OS (Nelson et al., 2008). However, the cases 
with complex karyotypes, most frequently observed in ALCL, ALK negative and PTCL 
NOS had a significantly shorter OS. The only chromosomal abnormality in PTCL with 
a definite impact on treatment outcome and survival remains the translocation of ALK 
in ALCL. 
 Recently new studies on gene expression analysis in PTCL have been published 
following on from the success of the studies in DLBCL. Martinez-Delgado et al. 
(Martinez-Delgado et al., 2004) using the CNIO-OncoChip containing 6386 cancer-
related genes found significant differences between peripheral and lymphoblastic T-cell 
lymphomas, including deregulation and over-expression of nuclear factor kappa-light-
chain-enhancer of activated B-cells (NF-κβ1) signalling pathway in PTCL NOS. 
Additionally, two sets of genes, which differentiate between PTCL and normal T-cells 
as well as activated lymph nodes were found. 
In another study using cDNA microarray, the expression profiling could 
distinguish between AITL, ALCL and T-LBL (Ballester et al., 2006). By contrast, 
PTCL NOS had no common signature and three different molecular subgroups called 
U1, U2 and U3 could be distinguished. The U1 signature included genes associated with 
aggressive behaviour and poor outcome in several tumours like DLBCL (e.g. CCND2). 
The U2 genes were associated with translation, signal transduction and apoptosis (e.g. 
NF-κβ1 and BCL2) and the U3 genes with the IFN / Janus kinase (JAK) / signal 
transducer and activator of transcription (STAT) pathway. Importantly, patients with 
U2 and U3 signatures had similar outcomes that were better than patients with the U1 
signature. 
Recent gene expression profiling studies using Affymetrix arrays were published 
by ITLP (Iqbal et al., 2010). In an unsupervised analysis each major defined subtype of 
PTCL forms 2 – 3 main clusters. However PTCL NOS was characterised by strong 
heterogeneity and some minor PTCL subtypes formed distinct clusters, but because of 
low numbers of cases were not studied further. AITL was characterised by 3 distinctive 
signatures: (i) B-cell signature, (ii) follicular dendritic cell signature and (iii) cytokine 
signature. AITL cases had over-expression of a set of genes involved in TCR signalling 
/ activation, HTLV1 associated genes and a set of genes associated with melanoma. In 
ALCL, ALK positive the expression of Th17-associated molecules was noted. In PTCL 
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NOS, (despite its heterogeneity), a molecular subgroup with features of cytotoxic T 
lymphocytes and a poorer survival was identified. 
The recent developments in molecular biology and genetics have opened new 
perspectives in the assessment of pathobiology of PTCL. The studies on whole exon or 
whole genome sequencing revealed new prognostic markers and pathways (Iqbal et al., 
2016). 
Tet methylcytosine dioxygenase 2 (TET-2) is an enzyme converting 
methylcytosine to 5-hydroxymethylcytosine and is involved in epigenetic processes 
(Couronné et al., 2012). The enzyme is inhibited by 2-hydroxyglutarate an oncogenic 
metabolite by the mutated forms of isocitrate dehydrogenase isotype 1 and 2 (IDH1 and 
IDH2) (Couronné et al., 2012). The mutations involving TET-2 were first identified in 
myeloproliferative neoplasm and myelodysplastic syndromes (Delhommeau et al., 
2009). The mutations include deletions, missense, nonsense and frameshift mutations 
resulting in loss-of function and reduction in the level of intracellular 5-
hydroxymethylcytosine. Recently the TET2 mutations have been reported in T-cell 
lymphoid malignancies: AITL, “Th follicular like” PTCL-NOS and ATLL (Couronné et 
al., 2012). The concordant occurrence of TET2 mutations and mutations in DNMT3A 
was observed in a series of T-cell lymphomas. DNMT3A is a gene frequently showing 
mutations in myeloid cancers and its product is involved in cytosine methylation. The 
patients with mutations in TET2 and DNMT3A can be potentially treated with 
demethylating agents. 
IDH is an enzyme that catalyzes the oxidative of isocitrate producing alpha-
ketoglutatrate and CO2. In humans, the enzyme is naturally present in 3 isoforms: 
IDH1-3 (Cairns et al., 2012). The IDH3 isoform catalyzes the third step in the citric acid 
cycle. The IDH1 and IDH2 isoforms catalyze the same reaction but outside the citric 
acid cycle. The mutations of IDH1 and IDH2 have been described in grade 2 and 3 
gliomas, secondary glioblastomas and acute myeloid leukaemias. Mutations in IDH2 
have been described in two separate sets of AILT cases, in 20% and 45% of assessed 
cases respectively (Cairns et al., 2012). The mutations involved IDH2 only and were 
largely confined to alternations resulting in a R172 substitution. The mutated enzyme 
converts 2-oxoglutarate to D-2-hydroxyglutarate. D-2-hydroxyglutarate can play a role 
of oncometabolite by its interaction with numerous enzymes involved in hypoxia 
signaling, histones and DNA methylation and inhibits the activity of TET2 enzyme. 
There was no association found between the IDH2 mutation status and survival in 
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AILT. In the re-sequencing performed on a new series of AILT the frequency of IDH 
mutation was 32.8% and it was limited to the IDH2 at R172 locus. Interestingly, the 
IDH2R172 mutation defines a unique subgroup of PTCL with a distinct TFH gene 
expression and can induce DNA and histone methylation in AILT (Wang et al., 2015). 
Recurrent translocation t(6;7)(p25.3;q32.3) was recently described in ALCL 
ALK negative cases (Feldman et al., 2011). This translocation was associated with 
increased expression of DUSP22, a dual specificity phosphatase that inhibits T-cell 
antigen receptor signaling in reactive T-cells by inactivation of MAPK and ERK2. 
DUSP22 is a putative tumour repressor in T-cell malignancies. The translocation was 
also associated with increased expression of miR29A, a microRNA with potentially 
oncogenic function in T-cell lymphomas (Feldman et al., 2011). 
CD28 is the major TCR co-stimulatory receptor in T-cells. After binding its 
ligand and simultaneous activation of TCR, CD28 induces sustained T-cell activation 
and cytokine production. Recently the recurrent mutations in two residues of CD28 
have been identified in patients with AILT (Rohr et al., 2016). These mutations lead to 
increased affinity to ligand CD86 and intracellular adaptor proteins GRB2 and 
GADS/GRAP2. The over-expression of the CD28 responsive genes CD226 and TNFA 
was found in cells with T195 mutation and increased activation of NF-κβ in cells with 
both mutations. 
The changes to p53 pathway were not recognized in PTCL for a long time. The 
study on identification of rearrangements across the entire genome identified five 
mutations involving p53 pathway in TP53, TP63, CDKN2A, WWOX and ANKRD11 
(Vasmatzis et al., 2012). Mutations in TP63 were particularly interesting as the product 
of TP63 is known to have oncogenic properties and it inhibits the p53 pathway by a 
dominant-negative mechanism. Indeed the patient with TP63 mutations have worse 
outcome. TP63 mutations were seen in 12.5% ALCL ALK negative, 10.5% ALCL 
primary cutaneous and 9.4% PTCL NOS. 
Recent whole exon sequencing combined with RNAseq analysis and targeted 
deep sequencing identified known recurrent epigenetic factor mutations in TET2, 
DNMT3 and IDH2 but also identified a new highly prevalent RHOA p.Gly17Val 
mutation present in 67% AILT and 18% PTCL NOS (Palomero et al., 2014). RHOA is 
a small GTPase from the Rho family and it is responsible for linking of cell-surface 
receptors to different intracellular signaling proteins (Bar-Sagi and Hall, 2000). 
GTPases can be present in active (GDP bound) or inactive form (GTP-bound) (Bar-Sagi 
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and Hall, 2000). The active RHOA is responsible for the control of the structure and 
dynamics of the actin cytoskeleton and the formation of stress fiber. The gene encoding 
a p.Gly17Val alternation leads to inhibition of the signaling pathway (Palomero et al., 
2014). The subsequent study found that the RHOA was mutated in 14.6% of PTCL and 
34.2% of AITL (Palomero et al., 2014). Hence, the mutations of RHOA were associated 
with activation of several cellular pathways e.g. pathways related to CD4 T-cell and 
AILT signature, p38 mitogen-activated protein kinase, phosphatidylinositol 3-kinase 
and KRAS – the alternative NF-κβ pathway and RAC1 pathway. The RHOA status can 
be helpful in directing targeted therapies. The mutational status of RHOA had no 
prediction value for patient survival. 
Additionally, the whole exon sequencing identified mutations in FYN, ATM, 
β2M and CD58 implicating SCR signaling, an impaired DNA damage response and an 
escape from the immune surveillance mechanism (Palomero et al., 2014). The FYN 
tyrosine kinase is with LCK the predominant kinase found in T lymphocytes. It plays an 
important role in TCR signaling. The FYN mutations accounted in PTCL result in 
increased activation of the enzyme. This deserves more attention as it could be 
potentially targeted with SRC kinase inhibitors. 
 
1.4.5 Treatment of PTCL 
The standard therapy for PTCL remains CHOP and other anthracycline-based 
regimens despite modest outcomes (Vose et al., 2008). Reported OS rates at 5-years for 
PTCL treated with CHOP range between 25-35%. According to the data presented by 
the ITLP, the outcome varies between individual subgroups with 5-year PFS & OS from 
60% & 70% in ALCL, ALK positive; 36% & 49% in ALCL, ALK - negative to 20% & 
32% in PTCL NOS, 18% & 32% in AITL, 4% & 20% in EATL and 0% & 7% in 
hepatosplenic T-cell lymphoma. Interestingly the authors could find no advantage to 
anthracycline-based chemotherapy compared with non-anthracycline regimens in PTCL 
NOS and angioimmunoblastic lymphoma (Vose et al., 2008). The idea of using 
anthracycline-based regimens in the treatment of PTCL has its origins in the 
conventional inclusion of the majority of entities, currently known as PTCL, into the 
intermediate or high-grade lymphoma groups according to the WF (National Cancer 
Institute, 1982). Consequently, the recommendation to use an anthracycline-based 
regimen applied to the whole group irrespective of immunophenotype. The 
recommendation of CHOP as a specific standard anthracycline-based therapy comes 
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from the results of the large intergroup phase III trial which demonstrated non-
inferiority of CHOP compared with third generation combination regimens in 
intermediate subgroups of lymphoma according to the WF (Fisher et al., 1993). As 
previously discussed accepting the results of this study as a standard could be extremely 
misleading because it used the International WF, did not use immunophenotyping and 
included lymphomas with B-cell, T-cell and NK-cell phenotype. With current 
knowledge, it is accepted that all these tumours have different characteristics and 
outcomes and eventually will likely require different therapies (Vose, 2008). 
Several attempts have been made subsequently to try and improve the outcome 
of aggressive lymphomas including PTCL e.g. shortening of the chemotherapy intervals 
(CHOP-14 vs. 21), incorporation of additional drugs into the CHOP regimen (CHOEP-
21 and VACEP) (Karakas et al., 1996) or both approaches (CHOEP-14) (Pfreundschuh 
et al., 2004a) (Pfreundschuh et al., 2004b). The value of published results is limited 
mostly because of the fact that studies were performed in all aggressive lymphomas and 
subanalysis of PTCL was performed later. Importantly, the number of ALK positive 
cases included was unknown (Nickelsen et al., 2009). 
The prognostic impact of immunophenotype on the outcome of aggressive 
lymphomas was first evaluated by the GELA group who discovered that PTCL are 
characterised by a worse outcome than B-cell lymphomas treated with the same 
protocols for aggressive lymphomas: LNH84 and LNH87 (Gisselbrecht et al., 1998) 
(Coiffier et al., 1990). 
At the beginning of the 21st century the treatment of B-cell aggressive 
lymphomas moved towards the addition of anti-CD20 antibodies (Coiffier et al., 2002) 
and consequently the first studies separately designed for PTCL were introduced. The 
development of first-line treatment for PTCL moved in two different directions – the 
first was to try and find the analogue of “rituximab” in B-cell lymphomas, a monoclonal 
antibody (e.g. anti CD52) (Zinzani et al., 2005) (Enblad et al., 2004) or a cytostatic drug 
(e.g. gemcitabine or bleomycin) (Sung et al., 2006) (Kim et al., 2006), which could be 
added to the existing gold standard of CHOP. The second looked at the role of 
intensification of treatment by adding consolidation with ASCT. This approach was 
studied mostly in small cohorts of patients (Mercadal et al., 2008) (Rodriguez et al., 
2007) (Corradini et al., 2006) with only two big prospective trials assessing ASCT as 
consolidation after induction with CHOP or its derivatives (Reimer et al., 2009) 
(d'Amore et al., 2009). The preliminary results are promising, however the number of 
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patients with primary PD during induction remains high as expected using CHOP–like 
regimens (Reimer et al., 2009) (d'Amore et al., 2009) (Mercadal et al., 2008). 
Recently several phase I and II studies on new drugs in the treatment of PTCL 
have been published. The most advanced works have focused on a new antifolate – 
pralatrexate (O'Connor et al., 2009) (O'Connor et al., 2011), histone deacetylase 
inhibitors - romidepsin (Piekarz et al., 2008), an immunomodulatory drug – 
lenalidomide (Dueck et al., 2010) and a purine nucleoside phosphorylase inhibitor 
forodesine (Furman et al., 2006). Additionally, with the increasing knowledge of 
molecular pathology in PTCL, there is more hope of targeting individual aberrant 
pathways like the apoptotic pathway with drugs targeting BCL2 (ABT – 263), the NF-
κβ pathway with proteasome inhibitors (bortezomib) (Zinzani et al., 2007) or the 
platelet derived growth factor receptor (PDGRFα) and a tyrosine kinase receptor with 
the tyrosine kinase inhibitor (imatinib) (Piccaluga et al., 2007a). 
 
1.5 Aims of the thesis 
The aims of the thesis are: 
1. To describe patient characteristic at presentation, treatment and outcome of 
patients with DLBCL in a population-based setting in order to obtain the 
realistic picture of disease on unselected cohort patient in pre- and post-
rituximab era representative for the UK. 
2. To develop a prognostic model based on expression of molecular factors (c-MYC 
and HLA-DRβ – genes previously assessed in GEP studies) in FFPE tissue 
samples of nodal DLBCL using quantitative PCR (qPCR) in order to identify the 
high-risk patients suitable for more intense treatment on better base than 
standard clinical based IPI 
3. To assess whether version 2 of chromosome 13 open reading frame 25 transcript 
(v2-transcript) can be amplified by qPCR in lymphoma cell lines and FFPE 
tissue sections from lymph node biopsies of patients with DLBCL and 
eventually include it in prognostic model. 
4. Asses weather the microRNAs (miRNAs) encoded in v2-transcript can be 
amplified and measured by qPCR in lymphoma cell line and FFPE tissue section 
of nodal DLBCL and potentially be used as a biomarker. 
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5. To collect prospectively data in population-based setting on clinical 
presentation, treatment and outcome of patients with EATL, one of the subtypes 
of PTCL. 
6. To assess the role of a novel high-dose chemotherapy with ifosfamide, 
epirubicin, etoposide/methotrexate IVE/MTX and ASCT in first line treatment 
of EATL and subsequently in other subtypes of PTCL. 
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Chapter 2. Population-based studies on epidemiology, clinical 
presentation, treatment and outcome in DLBCL 
 
2.1 Introduction 
The published results of randomized clinical trials on the treatment of DLBCL, 
particularly since the advent of rituximab, give the impression that the disease outcome 
has improved and is now satisfactory. The monoclonal anti CD20 antibody, rituximab 
has been seen as a panacea for all difficulties in the treatment of DLBCL, but the reality 
is rather different. Regarding any drug as a panacea is dangerous as it turns off our 
vigilance. There is no doubt that rituximab significantly improves the outcome of 
patients with DLBCL but it is still not satisfactory in all groups of patients (Coiffier et 
al., 2002) (Pfreundschuh et al., 2006) (Pfreundschuh et al., 2008) (Habermann et al., 
2006). So it remains true that professionals involved in the everyday treatment of 
DLBCL have an impression that despite recent progress the optimal treatment of 
DLBCL remains an unsolved issue. 
There are several reasons for this. On the one hand based on recent studies 
DLBCL is now known to be a heterogeneous tumour (Swerdlow et al., 2008). This 
knowledge is already at least partially reflected in the new WHO classification of 
lymphoproliferative disorders, but has not yet been employed in clinical trials or 
everyday clinic practice (Swerdlow et al., 2008). The current impression is that there is 
an enormous gap between progress in pathobiology and clinical management of 
DLBCL. On the other hand there are outstanding treatment results coming from clinical 
trials performed on highly selected groups of patients (mostly in early stage disease who 
anyway have a more favourable prognosis) (Pfreundschuh et al., 2008). Additionally 
many studies do not include clearly defined risk groups of patients (Coiffier et al., 2002) 
(Pfreundschuh et al., 2004a) (Pfreundschuh et al., 2004b) (Habermann et al., 2006). The 
IPI and aaIPI seem to be universal keys for selection of patients entering clinical trials. 
However, unfortunately they are not applied uniformly in all studies, some of which use 
additional inclusion criteria e.g. the presence of bulky disease or increased LDH in 
addition to the IPI, making it then very difficult to compare results (Pfreundschuh et al., 
2008). Due to the lack of other sources of information the results of these trials are then 
applied to treatment algorithms for the whole population of patients where outcomes 
may be very different. This situation resembles very much that seen in pathology of 
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lymphoma before the introduction of the REAL classification. The best solution to these 
problems would be to gather a true picture of the disease from broad population-based 
studies and then subsequently design clinical trials to successfully target unsolved areas 
of disease management. 
In this chapter data on epidemiology, disease picture, treatment and outcome of 
population-based studies of patients with nodal origin DLBCL registered in the 
Scotland and Newcastle Lymphoma Group (SNLG) will be presented. Additionally the 
data from a recent population-based study on DLBCL treated with R-CHOP in the 
Northern region of England will be shown. This will allow to show a true picture of 
disease as it presents in the clinic. Furthermore, these data will be discussed in the 
context of other population-based studies and recent clinical trials performed in 
DLBCL. Particular attention will be paid to the feasibility of patients to receive curative 
treatment, the choice of appropriate age limits for studies on elderly and very elderly 
patients, the application of the IPI in population-based cohorts of patients, the role of 
the duration of first remission in survival of patients, and finally the impact of the 
inclusion of rituximab in the treatment of DLBCL on the population of the UK treated 
within the NHS. 
 
2.2 Material and methods 
 
2.2.1 Scotland and Newcastle Lymphoma Group (SNLG) 
 The SNLG was established in 1979 to create a forum for interested clinicians to 
design and conduct trials in the field of lymphoma and to maintain a database of 
patients diagnosed with lymphoma. Beginning in 1990, with the assistance of hospital 
pathology departments, the group aimed for total registration of all patients with 
lymphoma within the population of Scotland and the Northern Region of England. The 
project allowed accurate incidence and outcome measures for every patient with 
lymphoma and not just those entered into randomised clinical trials – a process known 
as population adjusted clinical epidemiology PACE (Proctor and Taylor, 2000). The 
SNLG worked with 27 regional hospitals and covered a population of circa 7.6 million, 
see figure 2.1. The creation of such a high quality clinical database had numerous other 
benefits, such as sub-group analysis and the possibility of studying rare disorders or 
interventions, which a single institution could not undertake alone. 
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Figure 2.1 Map of Scotland and Newcastle Lymphoma Group’s activity area. 
 
2.2.2 Data collection and response assessment in SNLG 
 Data was collected using standardised SNLG forms and subsequently checked 
for accuracy before being entered onto the SNLG computer database. The SNLG forms 
are presented in Appendix 1. At baseline evaluation patient demographics including 
date of birth, diagnosis, date of diagnosis of underlying malignancy, gender, and ECOG 
performance status were documented. The results of pathological examination and 
extent of disease as assessed by clinical examination, laboratory tests, biopsy, 
endoscopy and imaging were also recorded. Additionally the presence of general 
symptoms, calculated CS according to Ann Arbor criteria and IPI were entered. The 
first evaluation of patient treatment and outcome was performed at one year from 
diagnosis, or if patient was deceased at the time of death. Further follow-up was carried 
at one-year intervals or at the time of death. CR, partial remission (PR) and PD were 
defined according to the criteria reported by Cheson et al (Cheson et al., 2007). 
The following demographic and disease related data collected by the SNLG were used 
in this study. The format of the data is given in brackets. 
• Date of birth (dd/mm/yyyy) 
• Date of diagnosis (dd/mm/yyyy) 
• Gender (male or female) 
• CS according to Ann Arbor criteria (I - IV) 
• B – Symptoms (present or absent) 
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• Performance status measured by ECOG (0 - 5) 
• Extranodal involvement (yes or no) 
• Type of organ involved (name of organ) 
• Bulk (yes or no) 
• Haemoglobin (Hb) level (normal and abnormal and absolute level in g/dl) 
• White blood cells (WBC) (normal and abnormal and absolute level in g/dl) 
• LDH serum level (normal and abnormal and absolute level in U/l) 
• Albumin serum level (normal or abnormal) 
• Urea serum level (normal or abnormal) 
• Alkaline phosphatase (AP) serum level (normal or abnormal) 
• Treatment (chemotherapy, radiotherapy or combined modality) 
• Type of given chemotherapy (name of regimen) 
• The disease outcome at 12 months (remission / failure) 
• Date last seen / date of death (dd/mm/yyyy) 
• Remission status at date last seen or date of death (remission or relapse) 
• Cause of death 
 
2.2.3 Inclusion and exclusion criteria in SNLG 
In order to evaluate the clinical presentation, therapy and outcome of patients 
with DLBCL of primary nodal origin in a population-based setting; the SNLG database 
was searched for patients using the following inclusion and exclusion criteria. 
Inclusion criteria: 
• first diagnosis of DLBCL 
• primary nodal origin of disease 
• age at diagnosis ≥18 years 
• time of diagnosis between 1990 and 2003 
• known CS of disease 
• known outcome of disease 
Exclusion criteria: 
• unknown treatment 
• treatment with rituximab 
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2.2.4 Inclusion / exclusion criteria, data collection and response assessment in 
evaluation of patients treated with immunochemotherapy 
 In order to obtain a picture of current treatment and outcome of patients with 
DLBCL in the rituximab era records of patients diagnosed with the disease were 
retrospectively and prospectively searched in four NHS Trusts in the Northern Cancer 
Research Network. The selected patients had to fulfil the following inclusion criteria: 
• First diagnosis of DLBCL 
• No previous history of chemotherapy, immunotherapy or radiotherapy 
• Age at diagnosis ≥18 years 
• Started treatment with CHOP or CNOP (cyclophosphamide, mitoxantrone, 
vincristine and prednisolone) polychemotherapy in combination with rituximab 
(at least one cycle) 
• No previous or concurrent diagnosis of other malignant disorders including 
leukaemia and lymphoma 
• No extranodal origin of disease in CNS, testis or stomach 
• No known history of HIV positivity 
The data collected at baseline included the same parameters collected in the SNLG 
forms. Data on treatment and outcome was slightly modified as follows: 
• Treatment (chemotherapy, radiotherapy or combined modality) 
• Type of given chemotherapy (name of regimen) 
• Number of cycles given 
• Status of scheduled therapy (completed or not) 
• Reason for premature discontinuation of scheduled chemotherapy if applicable 
(progression, infection, organ failure, other) 
• Disease outcome after the end of first line treatment (CR, PR or failure) 
• Date last seen / date of death (dd/mm/yyyy) 
• Patients status at date last seen / date of death (alive or dead) 
• Remission status at date last seen or date of death (remission or relapse) 
The information was registered manually in a specially developed questionnaire (see 
Appendix 2) during an on-site visit and then transcribed into an electronic database, 
checked for accuracy and evaluated. This data was then compared with data of patients 
from an historical SNLG cohort treated with the same anthracycline-based regimen 
without the addition of rituximab. 
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2.2.5 Statistics 
 Demographics and disease characteristics were summarized using descriptive 
statistics. The χ2-test and Fisher’s exact test were used as appropriate to investigate 
differences on proportions and t-test, Mann-Whitney-test or Krushkai-Walis test on 
means. OS and PFS rates were estimated according to the method of Kaplan and Meier 
and comparison between the groups was with log-rank test. OS was calculated from 
date of diagnosis to the date of death, or if no death occurred, to the last documented 
follow up for the patient. PFS was calculated from date of diagnosis to the first 
documentation of progression during therapy, failure at the end of therapy, or further 
relapse or death from any cause during or after the end of treatment. Due to the method 
of data collection if disease progression occurred during first line therapy the date of the 
event was assigned as the date of pathological diagnosis. All tests were performed with 
a confidence interval of 95 % and statistical significance was defined as p≤0.05 using 
SPSS Version 13.0 for MAC OS X (SPSS Incorporated, Chicago, IL). 
 
2.3 Results 
 
2.3.1 Patient selection 
A total number of 2025 patients with a first diagnosis of DLBCL of primary 
nodal origin were registered on the SNLG database between 1990 and 2003. Forty-five 
patients were excluded after assessment of baseline data: nine were younger than 18 
years at diagnosis and 36 had no data on CS. A further 67 patients were excluded after 
assessment of treatment data: in 46 patients there was no data on treatment and 21 
patients received rituximab as part of their first line chemotherapy. Finally 50 patients 
were excluded because of missing outcome data; the remission status was not available 
in 49 patients and survival status in one patient. Thus 1863 patients fulfilled all criteria 
and proceed to further evaluation, see figure 2.2. 
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Figure 2.2 Flow diagram for patient with DLBCL of nodal origin registered with 
SNLG between 1990 and 2003. 
Drop out due base line data (n=45):
patient aged <18 years at diagnosis (n=36)
missing data on clinical stage (n=9)
Drop out due treatment data (n=67):
missing treatment data (n=46)
or treatment with rituximab (n=21)
Drop out due outcome data (n=50):
missing data on remission status (n=49)
missing data on survival status (n=1)
1863 evaluable patients
1913 patients
1980 patients
2025 included patients
 
Figure 2.2 Flow diagram for patient with DLBCL of nodal origin registered with SNLG 
between 1990 and 2003. 
 
2.3.2 Evaluation of all patients 
 
2.3.2.a Patient characteristics 
The median age of the 1863 evaluable patients at diagnosis was 66 years (range, 
18–98 years), 711/1863 (38.2%) patients were aged ≤60 years and 1152/1863 (61.8%) 
>60 years. Figure 2.3 shows the age histogram for all patients and demonstrates a 
maximum incidence between 60 and 80 years. Age distribution remains the same for 
patients in early CS (CS I and II) and advanced CS (CS III and IV), except for a slightly 
higher number of patients aged 20 – 40 years in the early stage group. However the 
difference was not statistically significant (p=0.297) figure 2.4. 
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Figure 2.3 Age histogram for all patients (n=1863). 
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Figure 2.4 Age histogram for patients with early and advanced stage disease, evaluation 
of all patients (n=1863). (A) patients in early stage (n=891) and (B) patients in advanced 
stage (n=972); (p=0.297, Mann-Whitney Test). 
 
The patients were equally distributed by sex with 953/1863 (51.2%) females and by CS 
with 891/1863 (47.8%) early stage cases and 972/1863 (52.2%) advanced stage cases 
see table 2.1. B-symptoms were assessed in 1834 patients and 41.7% had B-symptoms 
at diagnosis. Performance status measured by ECOG was recorded in 1673 patients and 
the majority of patients (73.9%) had ECOG equal to or less than one. Bulky disease was 
diagnosed in 895/1705 (52.5%) patients and 787/1635 (48.1%) patients had extranodal 
involvement. BM was the most frequently involved extranodal site in 242/1477 (16.4%) 
patients. 
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Clinical parameter N (%) 
Median age, range 
Patients aged 
≤ 60 years 
> 60 years 
Female gender 
ECOG >1 
CS 
I 
II 
III 
IV 
B-symptoms 
Bulk disease 
BM involvement 
Extra nodal involvement 
IPI Group 
Low 
Low intermediate 
High intermediate 
High 
Abnormal Hb 
Abnormal WBC 
Abnormal albumin 
Abnormal urea 
Abnormal AP 
Abnormal LDH 
66, 18 – 98 
 
711/1863 (38.2) 
1152/1863 (61.8) 
953/1863 (51.2) 
436/1673 (26.1) 
 
403/1863 (21.6) 
488/1863 (26.2) 
441/1863 (23.7) 
531/1863 (28.5) 
765/1834 (41.7) 
895/1705 (52.5) 
242/1477 (16.4) 
787/1635 (48.1) 
 
403/1057 (38.1) 
280/1057 (26.5) 
217/1057 (20.5) 
157/1057 (14.9)  
624/1787 (34.9) 
370/1794 (20.6) 
439/1707 (25.7) 
507/1763 (28.8) 
440/1729 (25.4) 
694/1166 (59.5) 
Table 2.1 Patient characteristics, all patients (n=1863). 
 
Hb, WBC, albumin, urea and AP were measured in more than 90% of patients at 
diagnosis and the majority of patients had normal results. LDH was measured in 1166 
patients and was elevated in 59.5% of patients. The IPI could be calculated for 1057 
patients. Most patients (38.1%) were in the low risk group, followed by 26.5% of 
patients in the low intermediate risk group, 20.5% of patients in the high intermediate 
risk group and 14.9% of patients in the high-risk group. 
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2.3.2.b Treatment 
The majority of patients 1391 (74.7%) were treated with anthracycline-based 
chemotherapy, followed by 142 (7.6%) patients who received no chemotherapy and no 
radiotherapy, and 132 (7.1%) patients who were treated with radiotherapy only. 
Chemotherapy not including anthracyclines was given to 107 (5.7%) patients and 91 
(4.9%) patients were treated with ASCT in first CR after successful treatment with 
anthracycline-based chemotherapy, see table 2. 
 
Clinical parameter 
Patients 
N (%) 
Treatment modality 
Ctx + anthracycline 
ASCT in 1st remission 
Ctx w/o anthracycline 
Rtx only 
No Ctx, no Rtx 
Treatment group 
Curative treatment 
Palliative treatment 
Anthracycline-based regimens 
CHOP 
CNOP 
VACOP-B 
Other 
Radiotherapy in anthracycline-based regimens 
Chemotherapy alone 
Combined modality 
 
1391/1863 (74.7) 
91/1863 (4.9) 
107/1863 (5.7) 
132/1863 (7.1) 
142/1863 (7.6) 
 
1482/1863 (79.6) 
381/1863 (20.4) 
 
963/1391 (69.2) 
155/1391 (11.1) 
98/1391 (7.0) 
175/1391 (12.6) 
 
936/1391 (967.3) 
455/1391 (32.7) 
Table 2.2 Patient treatment, all patients (n=1863). 
 
If any anthracycline-based regimen with or without consolidation with ASCT is 
considered as a curative treatment and other treatment modalities including alternative 
chemotherapy, radiotherapy alone, no chemotherapy and no radiotherapy are considered 
palliative treatments, then the vast majority of patients were treated with curative intent 
1482 (79.6%). The number of patients treated with palliative intention rose with 
increasing age of patients. Among the patients aged ≤60 years it was less than or about 
10% rising to 16.9% among patients aged 60 – 70 years, 28.8% among patients aged 70 
– 80 years and >50% for patients aged >80 years (figure 2.5). 
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Figure 2.5 Curative and palliative treatment over age-decade groups, evaluation of all 
patients (n=1863). 
 
For patients treated with anthracycline-based chemotherapy, CHOP was the 
most frequently given regimen in 963/1391 (69.2%) patients, followed by CNOP in 
155/1391 (11.1%) patients and etoposide, doxorubicin, cyclophosphamide, vincristine, 
prednisone and bleomycin (VACOP-B) in 98/1391 (7.0%) patients. The remaining 
patients received different regimens, table 2. In patients treated with anthracycline-
based regimes, chemotherapy was combined with radiotherapy in 455/1391 (32.7%) 
patients, and given alone in 936/1391 (67.3%) patients, table 2.2. 
 The treatment groups are statistically significantly different in terms of patient 
characteristics in all assessed factors except for serum albumin levels. In order to obtain 
more detailed results the individual treatment groups were compared with patients 
treated with standard anthracycline-based chemotherapy, see table 2.3 and 2.4. 
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Clinical parameter 
Ctx + 
anthracycline 
vs. 
ASCT in 1st 
remission 
Ctx + 
anthracycline 
vs. 
Ctx w/o 
anthracycline 
Ctx + 
anthracycline 
vs. 
Rtx only 
Ctx + 
anthracycline 
vs. 
No Ctx, no 
Rtx 
Median age, range 
Patient >60 years 
Female gender 
ECOG >1 
CS III / IV 
B symptoms 
Bulk disease 
BM involvement 
Extranodal involvement 
IPI Group 
Abnormal Hb 
Abnormal WBC 
Abnormal albumin 
Abnormal urea 
Abnormal AP 
Abnormal LDH 
<0.001** 
<0.001* 
0.423* 
0.892* 
0.002* 
0.105* 
<0.001* 
0.524* 
0.013* 
0.151* 
0.928* 
0.345* 
0.718* 
0.349* 
0.974* 
<0.001* 
<0.001** 
<0.001* 
0.008* 
<0.001* 
0.954* 
0.392* 
0.872* 
0.089* 
0.056* 
0.002* 
0.028* 
0.857* 
0.242* 
<0.001* 
0.024* 
0.443* 
<0.001** 
<0.001* 
0.194* 
0.154* 
<0.001* 
<0.001* 
<0.001* 
0.002* 
<0.001* 
<0.001* 
<0.001* 
0.095* 
<0.001* 
0.152* 
<0.001* 
<0.001* 
<0.001** 
<0.001* 
0.017* 
<0.001* 
0.233* 
0.009* 
0.637* 
0.001* 
<0.001* 
<0.001* 
<0.001* 
0.140* 
<0.001* 
<0.001* 
0.015* 
0.003* 
Table 2.4 Patient characteristics, comparison between different treatments modalities, 
all patients (n=1863).*) χ2 – test or Fisher exact test, **) Mann-Whitney-Test 
 
Patients treated with ASCT in first remission were characterised by a statistically 
significant lower median age, more advanced disease stage (fewer patients in CS I and 
more in CS IV), increased incidence of bulky disease, extranodal involvement and 
elevated LDH. By contrast patients treated with chemotherapy not including 
anthracyclines were statistically significantly older, were more likely to be female, have 
a higher ECOG status, higher IPI score, and abnormal values of Hb, urea and AP. 
Patients treated with radiotherapy alone had a higher median age and more localised 
disease with more patients in CS I. This group was also characterised by lower numbers 
of patients with B-symptoms, bulky disease, extranodal and BM involvement. There 
was predominance of the low risk IPI group and a low number of abnormal laboratory 
tests except for urea levels. Finally, the group of patients offered no anti-cancer 
treatment differed significantly statistically from those patients treated with standard 
anthracycline-based chemotherapy in all factors except for CS, bulky disease and 
abnormal WBC values (table 2.3 and 2.4). 
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A separate evaluation to compare patients treated with curative and palliative 
intent was performed, see table 2.5. In the group given palliative treatment there were 
more patients aged >60 years, more females, patients with ECOG >1, with early CS, 
extranodal involvement, low and intermediate low IPI and patients with abnormal 
values of albumin and urea. By contrast there were fewer patients with B-symptoms, 
bulky disease and elevated LDH. 
 
Clinical parameter 
Curative 
treatment 
N (%) 
Palliative 
treatment 
N (%) 
p-values 
Median age, range 
Patient aged > 60 years 
Female gender 
ECOG >1 
CS III / IV 
B symptoms 
Bulk disease 
BM involvement 
Extra nodal involvement 
IPI Group 
Low 
Low intermediate 
High intermediate 
High 
Abnormal Hb 
Abnormal WBC 
Abnormal albumin 
Abnormal urea 
Abnormal AP 
Abnormal LDH 
63, 18 – 92 
834/1482 (56.2) 
728/1482 (49.1) 
283/1327 (21.3) 
814/1482 (54.9) 
630/1468 (42.9) 
745/1366 (54.5) 
207/1281 (16.2) 
638/1364 (46.8) 
 
327/1122 (29.1) 
237/1122 (21.1) 
187/1122 (16.7) 
117/1122 (10.4) 
486/1429 (34.0) 
295/1435 (20.6) 
327/1380 (23.7) 
359/1426 (25.2) 
352/1400 (25.1) 
578/949 (60.9) 
75, 24 – 98 
318/381 (83.5) 
225/381 (59.1) 
153/346 (44.2) 
158/381 (41.5) 
135/366 (36.9) 
150/339 (44.2) 
35/196 (17.9) 
149/271 (55.0) 
 
76/189 (40.2) 
43/189 (22.8) 
30/189 (15.9) 
40/189 (21.2) 
138/358 (38.5) 
75/359 (20.9) 
112/327 (34.3) 
148/337 (43.9) 
88/329 (26.7) 
116/217 (53.5) 
<0.001** 
<0.001* 
0.001* 
<0.001* 
<0.001* 
0.038* 
0.001* 
0.535* 
0.014* 
 
0.021* 
 
 
 
0.108* 
0.884* 
<0.001* 
<0.001* 
0.574* 
0.046* 
Table 2.5 Patient characteristics, comparison of patients with curative and palliatives 
treatment, all patients (n=1863).*) χ2 – test or Fisher exact test and **) Mann-Whitney 
Test 
 
2.3.2.c Responses and outcome 
 At the evaluation of response to treatment 12 months after diagnosis 
920/1863 (49.4%) patients were in CR or PR. Remission rates were higher in patients 
with early disease stage (CS I and II) 556/1863 (62.4%) than those with advanced stage 
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(CS III and IV) 364/1863 (37.4%). This difference was statistically significant, p<0.001 
(table 2.6). The highest rate of remission was observed in patients treated with 
radiotherapy only with 77/132 (58.3%), followed by patients treated with anthracycline-
based chemotherapy with 759/1391 (54.6%) and ASCT in first remission with 48/91 
(52.7%). By contrast the remission rates among patients treated with other 
chemotherapy or with no anti-caner therapy were significantly lower with only 18/107 
(16.8%) and 18/142 (12.7%), respectively, the differences were statistically significant 
(p<0.001), see table 2.6. In the comparative evaluation of patients treated with curative 
and palliative intent, as expected, the highest response rates were observed in patients 
given curative treatment 807/1482 (54.5%) vs. 113/381(29.7%), see table 2.6. The 
difference was statistically significant with p<0.001. 
 
Patient group 
CR and PR 
N (%) 
Death 
N (%) 
All patients (n=1863) 920 (49.4) 1071 (57.5) 
CS I/II (n=891) 
CS III/IV (n=972) 
p-value 
556 (62.4) 
364 (37.4) 
<0.001* 
417 (46.8) 
654 (67.3) 
<0.001* 
Ctx + anthracycline (n=1391) 
ASCT in 1st remission (n=91) 
Ctx w/o anthracycline (n=107) 
Rtx only (n=132) 
No Ctx and no Rtx (n=142) 
p-value 
759 (54.6) 
48 (52.7) 
18 (16.8) 
77 (58.3) 
18 (12.7) 
<0.001* 
738 (53.1) 
37 (40.7) 
88 (82.2) 
81 (61.4) 
127 (89.4) 
<0.001* 
Curative treatment (n=1482) 
Palliative treatment (n=381) 
p-value 
807 (54.5) 
113 (29.7) 
<0.001* 
775 (52.3) 
296 (77.7) 
<0.001* 
Table 2.6 Patient outcome in all patients and according to disease stages, treatment 
modality and treatment group – all patients (n=1863). *) χ2 – test or Fisher exact test 
 
 During the study more than half the patients died 1071/1863 (57.5%). In the 
patients with early stage disease the number of deaths was statistically significantly 
lower compared with patients with advanced stage disease: 417/891 (46.8%) vs. 
654/972 (67.3%), p<0.001 (table 2.6). The highest mortality was observed in patients 
who did not receive any anti-neoplastic treatment – 127/142 (89.4%) and patients 
treated with other chemotherapy – 88/107 (82.2%), followed by patients treated with 
radiotherapy only – 81/132 (61.4%). The lowest death rates were observed among 
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patients treated with anthracycline-based chemotherapy – 738/1391 (53.1%) and ASCT 
in first remission – 37/91 (40.7%), see table 2.6. In the evaluation of patients treated 
with curative treatment compared with palliative treatment the death rate was lower in 
patients treated with curative treatment at 775/1482 (52.3%) versus patients treated with 
palliative intent 296/381 (77.7%). The difference was statistically significant with 
p<0.001 (table 2.6). 
The median PFS and OS were 11.0 and 32.8 months, respectively. The 5-years 
PFS and OS were 33% and 41% respectively (table 2.7). In the analysis of PFS and OS 
of patients in early and advanced stage disease, there were significant differences 
between both patients groups. The 5-years PFS in patients with early stages vs. patients 
with advanced stages were 43% vs. 22%, respectively (p<0.001) and 5-years OS 51% 
and 30%, respectively (p<0.001) – see table 2.7. 
 
Patient group 
5-years 
PFS 
5-years 
OS 
All patients (n=1863) 33% 42% 
CS I/II (n=891) 
CS III/IV (n=972) 
p-value* 
43% 
23% 
<0.001 
52% 
32% 
<0.001 
Ctx with anthracyclines (n=1391) 
ASCT in 1st remission (n=91) 
Ctx without anthracyclines (n=107) 
Rtx only (n=132) 
No Ctx and no Rtx (n=142) 
p-value* 
37% 
36% 
12% 
29% 
9% 
<0.001 
46% 
61% 
16% 
41% 
10% 
<0.001 
Curative treatment (n=1482) 
Palliative treatment (n=381) 
p-value* 
37% 
16% 
<0.001 
46% 
21% 
<0.001 
Table 2.7 5-years OS and PFS in all patients and according to disease stages, treatment 
modality and treatment group, all patients (n=1863),*) Log Rank test 
 
Regarding the 5-years PFS and OS rates in different treatment groups the highest 
rates were observed in patients treated with ASCT in first remission (36% and 61%, 
respectively), followed by anthracycline-based chemotherapy (37% and 46%, 
respectively), and radiotherapy alone (29% and 41%, respectively). Outcomes were 
significantly lower in patients treated with other chemotherapy (12% and 16%, 
respectively) and in the group not given any anti-neoplastic treatment (9% and 10%, 
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respectively). The differences were statistically significant with p values of p<0.001 and 
p<0.001, (table 2.7). In an evaluation of patients treated with curative intent versus 
palliative treatment, the 5-years PFS and OS in the curative treatment group was 36.8% 
and 45.9%, respectively and in the palliative treatment group 16.2% and 21.2%, 
respectively. The differences were statistically significant for both PFS and OS 
(p<0.001 and p<0.001, respectively), see table 2.7. 
 
2.3.3 Age in DLBCL 
Currently the majority of clinical trials for DLBCL are designed separately for 
young and elderly patients. Additionally, there are individual studies for patients with 
different disease stages in both age groups, particularly in younger patients. Thus age 
remains an important factor in the choice of therapy and subsequent outcome of patients 
with DLBCL. A separate evaluation was performed for young and elderly patients with 
additional stratification for early and advanced stages. In the evaluation we used the age 
limits ≤60 years for the younger group of patients and >60 years for elderly patients. 
We used the Ann Arbor classification to separate early and advanced stages. Early stage 
was defined as Ann Arbor stages I and II and advanced stage as stages III and IV. The 
reason for this was the fact that such separation is used in every day decisions in our 
centre. Additionally an age evaluation of patients decade by decade was performed in 
order to prove or dispute the correctness of currently used age limits for clinical trials. 
 
2.3.3.a Evaluation of young and elderly patients 
 
Patient characteristics 
A total number of 711 patients aged ≤60 years and 1152 aged >60 years were 
evaluated. In younger patients, median age was 50 years; range 18 – 60 years, 46.3% 
were female and 15.7% had ECOG >1. Patients were equally distributed over CS, 
41.9% of patients presented with B-symptoms and 55.5% had bulky disease. Extranodal 
involvement was found in 43.2% of patients with BM being infiltrated in 13.5%. Most 
patients were in low or low intermediate IPI risk groups (84.6%) and only 15.4% were 
in high intermediate and high IPI groups. Laboratory tests were normal in the majority 
of patients except for LDH. See table 2.8 for patient characteristics. 
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Clinical parameter 
≤ 60 years 
N (%) 
> 60 years 
N (%) 
p-
value* 
Median age, range 
Female gender 
ECOG >1 
CS 
I 
II 
III 
IV 
B-symptoms 
Bulk disease 
BM involvement 
Extra nodal involvement 
IPI Group 
Low 
Low intermediate 
High intermediate 
High 
Abnormal Hb 
Abnormal WBC 
Abnormal albumin 
Abnormal urea 
Abnormal AP 
Abnormal LDH 
50, 18 - 60 
329/711 (46.3) 
103/658 (15.7) 
 
157/711 (22.1) 
195/711 (27.4) 
165/711 (23.2) 
194/711 (27.3) 
295/704 (41.9) 
360/649 (55.5) 
85/628 (13.5) 
287/664 (43.2) 
 
252/442 (57.0) 
122/442 (27.6) 
50/442 (11.3) 
18/442 (4.1) 
196/680 (28.8) 
129/684 (18.9) 
114/659 (17.3) 
103/674 (15.3) 
164/671 (24.4) 
275/478 (57.5) 
72, 61 - 98 
624/1152 (54.2) 
333/1015 (32.8) 
 
246/1152 (21.4) 
293/1152 (25.4) 
276/1152 (24.0) 
337/1152 (29.3) 
470/1130 (41.6) 
535/1056 (50.7) 
157/849 (18.5) 
500/971 (51.5) 
 
151/615 (24.6) 
158/615 (25.7) 
167/615 (27.2) 
139/615 (22.6) 
428/1107 (38.7) 
241/1110 (21.7) 
325/1048 (31.0) 
404/1089 (37.1) 
276/1058 (26.1) 
419/688 (60.9) 
n.a. 
0.002 
<0.001 
 
0.688 
 
 
 
0.922 
0.058 
0.013 
<0.001 
 
<0.001 
 
 
 
<0.001 
0.150 
<0.001 
<0.001 
0.462 
0.250 
Table 2.8 Patient characteristics, comparison of younger and elderly patients - all 
patients (n=1863).*) χ2 – test or Fisher exact test. 
 
Among elderly patients the median age was 72 years (range 61 – 98 patients), 
there were more females than males (54.8% vs. 45.8%), 32.8% patients had ECOG >1 
and 41.6% B-symptoms. The patients were also equally distributed over CS. Bulky 
disease was diagnosed in 50.7% and 51.5% had extranodal involvement with 18.5% of 
patients with BM involvement. The elderly patients were equally distributed over IPI 
risk groups with 50.3% of patients in low and low intermediate risk groups and 49.7% 
in high intermediate and high-risk groups. The majority of patients had normal 
laboratory tests except for LDH but more patients had abnormal Hb levels, albumin and 
urea as compared to younger patients (table 2.8). 
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In the comparison of patients aged ≤60 years and those aged >60 years; in the 
younger group there were statistically significantly more male patients (p=0.001), 
patients with ECOG equal to or less than one (<0.001), and fewer patients with 
extranodal and BM involvement, p=0.001 and p=0.013, respectively. Significantly more 
younger patients were in IPI low risk and low intermediate risk groups (<0.001), and 
had normal Hb (p=0.001), albumin (p<0.001) and urea values (p<0.001), see table 2.8. 
 
Treatment 
 The majority of younger patients received anthracycline-based chemotherapy 
560 patients (74%), followed by a group treated with ASCT in 1st remission 88 patients 
(12.4%), radiotherapy only 32 patients (4.5%), no chemotherapy and no radiotherapy 18 
(2.5%) and other chemotherapy 13 (1.8%). In the comparison of early and advanced 
stage patients, there were more patients treated with ASCT in 1st remission in the 
advanced stage group (27/352 – 7.7% vs. 61/359 – 17%) and fewer patients treated with 
radiotherapy only (4/359 – 1.1% vs. 28/352 – 8.0%), see figure 2.6. 
In patients aged >60 years a majority were also treated with anthracycline-based 
chemotherapy 831/1152 (72.1%), followed by the group of patients given no 
chemotherapy or radiotherapy 124/1152 (10.8%), radiotherapy only 100/1152 (8.7%), 
and other chemotherapy 94/1152 (72.1%). Only 3 patients received ASCT in 1st 
remission. Also in this age group, there were statistically significant differences in the 
treatment given to patients in early and advanced stage disease. In patients with early 
stage disease more patients were treated with radiotherapy only, whereas the advanced 
stage patients received anthracycline-based chemotherapy (figure 2.6). 
In the comparison between young and elderly patients, there were more patients 
treated with anthracycline-based chemotherapy and ASCT in 1st remission among 
younger patients. By contrast among elderly patients, there were more patients treated 
with radiotherapy alone, no chemotherapy or radiotherapy or other chemotherapy. The 
difference was statistically significant, p<0.001, for details see figure 2.6. 
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Figure 2.6 Treatment in younger and elderly patients in early and advanced disease 
stages evaluation of all patients (n=1863). (A) treatment modality: ≤60 years vs >60 
years CS, (p=0.000)* and ≤60 years: CS I/II vs CS III/IV (p=0.000)* and >60 years CS 
I/II vs CS III/IV (p=0.000)* (B) Curative and palliative treatment: ≤60 years vs >60 
years CS, (p=0.000)* and ≤60 years: CS I/II vs CS III/IV (p=0.086)* and >60 years CS 
I/II vs CS III/IV (p=0.000)* (C) Different regimens of anthracycline-based 
chemotherapy: ≤60 years vs >60 years CS, (p=0.000)* and ≤60 years: CS I/II vs CS 
III/IV (p=0.752)* and >60 years CS I/II vs CS III/IV (p=0.030)* (D) Chemotherapy 
alone vs. combined modality in anthracycline-based chemotherapy ≤60 years vs >60 
years CS, (p=0.000)* and ≤60 years: CS I/II vs CS III/IV (p=0.000)* and >60 years CS 
I/II vs CS III/IV (p=0.000)*, *)Mann-Whitney test 
 
In the evaluation of groups treated with curative versus palliative intent, the vast 
majority of younger patients received the curative option: 648/711 (91.1%) and only 
63/711 patients (8.9%) received palliative treatment (figure 6). There were no 
significant differences in evaluation of early and advanced stages diseases (p=0.086). 
Among elderly patients the number of patients in the palliative group was statistically 
significantly higher as compared with younger patients: 318/1152 (27.6%), p=0.000. In 
the comparison of early vs. advanced stages there were more early stage patients in in 
the palliative treatment group (p=0.000). 
In the evaluation of patients treated with anthracycline-based chemotherapy 
CHOP was the most frequently given treatment to 398/560 (71%) of younger patients 
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and 565/831 (68%) of elderly patients. In younger patients this was followed by groups 
of patients treated with VACOP-B 56/560 (10%) and patients treated with CNOP 
16/560 (2.9%). In elderly patients CNOP 139/831 (16.7%) and VACOP-B 42/831 
(5.1%) were the next most commonly utilised regimens after CHOP. The difference was 
statistically significant (p=0.000). In an evaluation comparing early and advanced stages 
the difference was statistically significant in elderly patients, where patients in CS III 
and IV received significantly less CHOP and more CNOP (p=0.030). This finding was 
not seen in younger patients (p=0.752), figure 2.6. 
Among 560 patients aged ≤60 years treated with anthracycline-based 
chemotherapy, 232 (41.4%) received additional radiotherapy. In the group of elderly 
patients the figure was 223/831 (26.8%), a statistically significant lower number 
(p=0.000). In both age groups there were more early stage patients treated with 
combined modality treatment compared with patients with advanced stage disease. The 
differences were statistically significant for younger and for elderly patients, both 
p<0.001, for details see figure 2.6. 
 
Responses and outcome 
At the evaluation 12 months after the day of diagnosis 430/711 (60.5%) of 
younger patients and 490/1152 (42.5%) of elderly patients were in CR/PR, the 
difference was statistically significant, p=0.000 (table 2.9). In a comparison of early and 
advanced stage disease we observed a significantly higher number of CR/PR in patients 
with early stage disease in both age groups; 262/352 (74.4%) vs. 168/359 (46.8%); 
p=0.000 in younger patients, and 294/539 (54.5%) vs. 196/613 (32%); p=0.000 in 
elderly patients (table 2.10). 
As previously mentioned this study was not designed to assess the difference 
between treatment groups or reach a conclusion on superiority of one over another. 
Hence this is the only description of the outcomes in each group. In the group of 
younger patients remission rates were highest in patients treated with anthracycline-
based chemotherapy 356/560 (63.6%) followed by radiotherapy only 20/32 (71.4%) and 
ASCT in first remission 47/88 (55.6%) (table 2.9). By contrast among elderly patients 
the highest remission rates were observed in patients treated with radiotherapy only 
57/100 (57%), followed by patients receiving anthracycline-based chemotherapy 
403/831 (48.5). The number of patients treated with ASCT in first remission is too 
small to make any conclusions (table 2.9). The lowest remission rates were found in 
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both age groups in patients receiving chemotherapy without anthracyclines 3/13 
(23.1%) and 15/94 (16.0%) or no chemotherapy and no radiotherapy 4/18 (22.2%) and 
14/124 (11.3%) (table 2.9). 
 
Patient group 
CR / PR 
N (%) 
Death 
N (%) 
Younger 
(n=711) 
Elderly 
(n=1152) 
Younger 
(n=711) 
Elderly 
(n=1152) 
All patients (n=1863) 430 (60.5) 490 (42.5) 297 (41.8) 774 (67.2) 
p-value* <0.000 <0.000 
Ctx +anthracyclines (n=1391) 
ASCT in 1st remission (n=91) 
Ctx w/oanthracyclines (n=107) 
Rtx only (n=132) 
No Ctx and no Rtx (n=142) 
356 (63.6) 
47 (53.4) 
3 (23.1) 
20 (62.5) 
4 (22.2) 
403 (48.5) 
1 (33.3) 
15 (16.0) 
57 (57.0) 
14 (11.3) 
226 (41.0) 
36 (40.9) 
7 (53.8) 
14 (45.2) 
14 (82.4) 
512 (61.6) 
1 (33.3) 
81 (87.1) 
67 (67.0) 
113 (91.1) 
p-value* <0.000 <0.000 0.014 <0.000 
Curative treatment (n=1482) 
Palliative treatment (n=381) 
403 (62.2) 
27 (42.9) 
404 (48.4) 
86 (27.0) 
262 (40.4) 
35 (55.5) 
513 (61.5) 
261 (82.1) 
p-value* 0.004 <0.000 0.021 <0.000 
Table 2.9 Patient outcome in younger and elderly patients, all patients, in different 
treatment modality and treatment groups - all patients (n=1863).*) χ2 – test or Fisher 
exact test 
 
In the evaluation of early versus advanced stage disease in both age groups the 
standard treatment with anthracycline-based chemotherapy produced the highest and the 
second highest number of remissions in early stage disease: in younger patients 223/287 
(77.7%) and 216/354 (54.5%) in elderly patients. In younger patients it was followed 
and in elderly preceeded by the radiotherapy alone group with 20/28 (71.4%) and 54/88 
(61.4%), respectively. In advanced stage disease the highest remission rates were among 
the patients treated with ASCT in first remission in younger patients 32/61 (52.5%) 
followed by anthracycline-based chemotherapy 133/277 (48.7%); the latter regimen also 
gave the highest responses in elderly patients 187/377 (39.2%). The patients treated 
with chemotherapy without anthracyclines and with no chemotherapy or no 
radiotherapy had the lowest response rates in both age cohorts and disease stages (table 
2.10). 
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(A) 
Patient group 
CR / PR 
N (%) 
Death 
N (%) 
CS I/II 
(n=352) 
CS III/IV 
(n=359) 
CS I/II 
(N=352) 
CS III/IV 
(N=359) 
All patients (n=711) 262 (74.4) 168 (46.8) 
101 
(28.7) 
196 (54.6) 
p-value* <0.001 0.000 
Ctx + anthracyclines (n=560) 
ASCT in 1st remission (n=88) 
Ctx w/o anthracyclines (n=13) 
Rtx only (n=32) 
No Ctx and no Rtx (n=18) 
223 (77.7) 
15 (55.6) 
2 (50.0) 
20 (71.4) 
2 (33.3) 
133 (48.7) 
32 (52.5) 
1 (11.1) 
0 (0.0) 
2 (16.7) 
77 (26.8) 
10 (37.0) 
0 (0.0) 
10 (35.7) 
4 (66.6) 
149 (54.6) 
26 (42.6) 
7 (77.8) 
4 (100.0) 
10 (83.3) 
p-value* 0.008 0.006 0.237 0.011 
Curative treatment (n=648) 
Palliative treatment (n=63) 
238 (75.8) 
24 (63.2) 
165 (49.4) 
3 (12.0) 
87 (27.7) 
14 (36.8) 
175 (52.4) 
21 (84) 
p-value* 0.114 <0.001 0.251 0.001 
 
(B) 
Patient group 
CR / PR 
N (%) 
Death 
N (%) 
CS I/II 
(N=539) 
CS III/IV 
(N=613) 
CS I/II 
(N=539) 
CS III/IV 
(N=613) 
All patients (n=1152) 294 (54.5) 196 (32.0) 316 (58.6) 458 (74.7) 
p-value* <0.001 0.008 
Ctx + anthracyclines (n=831) 
ASCT in 1st remission (n=3) 
Ctx w/o anthracyclines (n=94) 
Rtx only (n=100) 
No Ctx and no Rtx (n=124) 
216 (61.0) 
0 (0.0) 
13 (28.9) 
54 (61.4) 
11 (21.2) 
187 (39.2) 
1 (33.3) 
2 (4.1) 
3 (25.0) 
3 (4.2) 
184 (52.0) 
0 (0.0) 
32 (71.1) 
57 (64.9) 
43 (82.7) 
328 (68.8) 
1 (33.3) 
49 (100.0) 
10 (83.3) 
70 (97.2) 
p-value* <0.001 <0.001 <0.001 <0.001 
Curative treatment (n=834) 
Palliative treatment (n=318) 
216 (61.0) 
78 (42.2) 
188 (39.2) 
8 (6.0) 
184 (52.0) 
132 (71.4) 
329 (68.5) 
129 (97.0) 
p-value* <0.001 <0.001 <0.001 <0.001 
Table 2.10 Patient outcome according to CS in younger and elderly patients, all patients 
and in different modality and treatment groups. (A) younger patients (n=711) and (B) 
elderly patients (n=1152). *) χ2 – test or Fisher exact test 
 
In the evaluation of patients treated with curative versus palliative intent we 
observed statistically significantly higher levels of CR/PR in patients treated with 
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curative intent: 403/648 (62.2%) vs. 27/63 (42.3%); p=0.004 in younger patients and 
404/834 (48.4%) vs. 86/318 (27.0%); p=0.000 in elderly patients (table 2.9). This trend 
was also seen in the evaluation of early and late stages of the disease among younger 
and elderly patients (table 2.10). 
The number of patients who died during the study was significantly higher 
among the elderly patients and patients with advanced disease, the latter was true for 
both age groups (table 2.9 and 2.10). The highest death rates were observed in patients 
receiving no chemotherapy or radiotherapy, followed by the group treated with 
chemotherapy without anthracyclines and the group treated with radiotherapy only. This 
was the case for both age groups and all stages except for early stage disease in younger 
patients (table 2.10). The death rates were statistically significantly higher in patients 
treated with palliative treatment in both age cohorts for all disease stages. In the group 
of elderly patients with advanced disease almost all patients died (97%). 
The 5-years PFS and OS were both significantly higher among younger patients 
compared with elderly patients: 44.6% vs. 57.7% and 24.7% vs. 29.8% respectively 
(p=0.000 for both), table 2.11. 
 
Patient group 
5-years PFS 
% 
5-years OS 
% 
Younger 
(N=711) 
Elderly 
(N=1152) 
Younger 
(N=711) 
Elderly 
(N=1152) 
All patients (n=1863) 44.6 24.7 57.7 29.8 
p-value* <0.001 <0.001 
Ctx + anthracyclines (n=1391) 
ASCT in 1st remission (n=91) 
Ctx w/o anthracyclines (n=107) 
Rtx only (n=132) 
No Ctx and no Rtx (n=142) 
47.4 
35.6 
0.0 
45.8 
0.0 
29.4 
33.3 
10.2 
23.1 
7.1 
58.7 
60.1 
49.5 
58.1 
15.7 
35.2 
50.0 
8.8 
33.2 
8.5 
p-value* <0.001 <0.001 <0.001 <0.001 
Curative treatment (n=1482) 
Palliative treatment (n=381) 
45.8 
31.9 
29.4 
12.9 
58.9 
44.5 
35.3 
16.3 
p-value* 0.017 <0.001 0.002 <0.001 
Table 2.11 5-years PFS and OS in younger and elderly patients, all patients, in different 
treatment modality and treatment groups - all patients (n=1863).*) Log Rank test 
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(A) 
 5-years PFS 
(%) 
5-years OS 
(%) 
CS I/II 
(N=352) 
CS III/IV 
(N=359) 
CS I/II 
(N=352) 
CS III/IV 
(N=359) 
All patients (n=711) 59.8 29.6 71.5 45.7 
p-value* <0.001 <0.001 
Ctx + anthracyclines (n=560) 
ASCT in 1st remission (n=88) 
Ctx w/o anthracyclines (n=13) 
Rtx only (n=32) 
No Ctx and no Rtx (n=18) 
63.9 
32.6 
50.0 
52.4 
33.3 
29.8 
36.8 
0.0 
0.0 
6.7 
73.0 
62.5 
ND 
67.2 
33.0 
44.9 
59.8 
27.8 
0.0 
16.7 
p-value* 0.004 0.003 <0.001 <0.001 
Curative treatment (n=648) 
Palliative treatment (n=63) 
61.2 
48.4 
31.3 
8.0 
71.8 
63.8 
46.9 
14.3 
p-value* 0.111 0.001 0.234 <0.001 
 
(B) 
Patient group 
5-years PFS 
(%) 
5-years OS 
(%) 
CS I/II 
(N=539) 
CS III/IV 
(N=613) 
CS I/II 
(N=539) 
CS III/IV 
(N=613) 
All patients (n=1152) 31.1 19.0 37.8 23.9 
p-value* <0.001 <0.001 
Ctx + anthracyclines (n=831) 
ASCT in 1st remission (n=3) 
Ctx w/o anthracyclines (n=94) 
Rtx only (n=100) 
No Ctx and no Rtx (n=124) 
37.6 
ND 
19.1 
23.6 
13.3 
23.2 
33.3 
20.0 
16.7 
28.0 
43.7 
ND 
16.6 
37.4 
17.6 
29.8 
50.0 
20.0 
16.7 
21.0 
p-value* <0.001 <0.001 <0.001 <0.001 
Curative treatment (n=834) 
Palliative treatment (n=318) 
37.6 
19.3 
23.2 
3.8 
43.3 
25.9 
29.3 
3.5 
p-value* <0.001 <0.001 <0.001 <0.001 
Table 2.12 5-years PFS and OS according to CS in younger and elderly patients, all 
patients and in different modality and treatment groups. (A) younger patients (n=711) 
and (B) elderly patients (n=1152). *) Log Rank test 
 
This was the case for all treatment groups. The highest 5-years PFS and OS rates 
were observed in patients treated with standard anthracycline-based chemotherapy with 
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or without consolidation with ASCT and in the group treated with radiotherapy only. By 
contrast the lowest rates were observed in patients treated with chemotherapy without 
anthracyclines, and those receiving no chemotherapy and no radiotherapy, table 2.11. In 
early stage patients the highest 5-years PFS and OS rates were observed in patients 
treated with anthracycline-based chemotherapy or radiotherapy alone in both age 
groups. In patients with advanced stage disease the best survival rates were achieved in 
the standard chemotherapy group and the group receiving ASCT in first remission 
(younger and elderly patients). In the evaluation of curative and palliative groups, as 
expected, the 5-years PFS and OS were significantly lower for palliative treatment 
compared with curative treatment in both age groups and for all disease stages (table 
2.11 and 2.12). 
 
2.3.3.b Evaluation of age limits 
In order to evaluate the influence of patient age on PFS and OS more accurately, 
the patients were assigned to eight different age groups: 
• <30 years 
• 30 – 40 years 
• 40 - 50 years 
• 50 - 60 years 
• 60 – 70 years 
• 70 - 80 years 
• >80 years 
All groups were evaluated for PFS and OS. This evaluation was performed for all 
patients treated with CHOP or CNOP and separately for patients in early and advanced 
stages. The large number of patients made it possible to perform such an analysis 
Figures 2.7 – 2.9 show Kaplan-Meyer plots and corresponding 5-years PFS and 
OS for all patients, patients with early, and patients with advanced stage disease. In the 
log-rank test calculated over all age groups, there were significant differences for both 
PFS and OS (p<0.001 for all tests). Tables in figures show the p-values for the log-rank 
test run pairwise between all age groups for PFS and OS in all patients, patients with 
early and patients with advanced stage disease. 
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(A)
 
(B) 
 
(C) 
Age group 5-years PFS 5-years OS 
≤30 years 58.7 60.5 
30 - 40 years 60.5 70.6 
40 - 50 years 54.1 64.9 
50 - 60 years 40.4 53.4 
60 - 70 years 36.7 43.4 
70 - 80 years 27.0 32.4 
>80 years 12.9 18.0 
(D) 
PFS 
years 30 – 40 40 – 50 50 – 60 60 – 70 70 – 80 >80 
≤30 0.992 0.502 0.111 0.030 >0.001 >0.001 
30 – 40  0.351 0.023 0.002 >0.001 >0.001 
40 – 50   0.073 0.002 >0.001 >0.001 
50 – 60    0.137 >0.001 >0.001 
60 – 70     0.002 >0.001 
70 – 80      0.075 
OS 
years 30 – 40 40 – 50 50 – 60 60 – 70 70 – 80 >80 
≤30 0.410 0.956 0.423 0.930 0.003 >0.001 
30 – 40  0.336 0.027 0.001 >0.001 >0.001 
 40 – 50   0.079 >0.001 >0.001 >0.001 
50 – 60    0.020 >0.001 >0.001 
60 – 70     >0.001 >0.001 
70 – 80      0.053 
 
Figure 2.7 Kaplan-Meier plots for PFS and OS in all CHOP/CNOP treated patients 
according to age decades (n=1118). (A) PFS (p<0.001)*, (B) OS (p<0.001)* (C) 5-
years PFS and OS (D) p-values* for pairwise comparison of PFS &OS in different 
age decades, all patients treated with CHOP/CNOP (n=1118). *) Log Rank Test 
 
(C) 
Age group 5-years PFS 5-years OS 
≤30 years 58.7 60.5 
30 - 40 years 60.5 70.6 
40 - 50 years 54.1 64.9 
50 - 60 years 40.4 53.4 
60 - 70 years 36.7 43.4 
70 - 80 years 27.0 32.4 
>80 years 12.9 18.0 
(D) 
PFS 
Years 30 – 40 40 – 50 50 – 60 60 – 70 70 – 8  >80 
≤30 0.992 0.502 0.111 0.030 <0.001 <0.001 
30 – 40  0.351 0.023 0.002 <0.001 <0.001 
40 – 50   0.073 0.002 <0.001 <0.001 
50 – 60    0.13  <0.001 <0.001 
60 – 70     0.002 <0.001 
70 – 80      0.075 
OS 
Years 30 – 40 40 – 50 50 – 60 60 – 70 70 – 80 >80 
≤30 0.410 0.956 0.423 0.930 0.003 <0.001 
30 – 40  0.336 0.027 0.001 <0.001 <0.001 
 40 – 50   0.079 <0.001 <0.001 <0.001 
50 – 60    0.020 <0.001 <0.001 
60 – 70     <0.001 <0.001 
70 – 80      0.053 
 
Figure 2.7 Kaplan-Meier plots for PFS and OS in all CHOP/CNOP treated patients 
according to age decades (n=1118). (A) PFS (p<0.001)*, (B) OS (p<0.001)* (C) 5-
years PFS and OS (D) p-values* for pairwise comparison of PFS &OS in different age 
decades, all patients treated with CHOP/CNOP (n=1118). *) Log Rank Test 
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(A) 
 
(B) 
 
(C) 
Age group 5-years PFS 5-years OS 
≤30 years 63.0 65.7 
30 - 40 years 72.5 84.6 
40 - 50 years 80.0 84.8 
50 - 60 years 54.6 68.3 
60 - 70 years 40.4 46.5 
70 - 80 years 36.0 43.4 
>80 years 19.9 24.5 
 (D) 
PFS 
years 30 – 40 40 – 50 50 – 60 60 – 70 70 – 80 >80 
≤30 0.575 0.385 0.622 0.050 0.014 0.004 
30 – 40  0.778 0.174 0.002 0.000 0.000 
40 – 50   0.053 0.000 0.000 0.000 
50 – 60    0.005 0.000 0.000 
60 – 70     0.200 0.033 
70 – 80      0.145 
OS 
years 30 – 40 40 – 50 50 – 60 60 – 70 70 – 80 >80 
≤30 0.103 0.152 0.984 0.146 0.023 0.005 
30 – 40  0.726 0.054 0.001 0.000 0.000 
40 – 50   0.05 0.000 0.000 0.000 
50 – 60    0.004 0.000 0.000 
60 – 70     0.030 0.008 
70 – 80      0.110 
 
Figure 2.8 Kaplan-Meier plots for PFS and OS in early clinical stage CHOP/CNOP 
treated patients according to age decades (n=524). (A) PFS (p<0.001)*, (B) OS 
(p<0.001)* (C) 5-years PFS and OS (D) p-values* for pairwise comparison of PFS 
&OS in different age decades. *) Log Rank Test 
 
(C) 
Age group 5-years PFS 5-years OS 
≤3 r  63.0 65.7 
30 - 40 years 72.5 84.6 
40 - 50 years 80.0 84.8 
50 - 60 years 54.6 68.3 
60 - 70 years 40.4 46.5 
70 - 80 years 36.0 43.4 
>80 years 19.9 24.5 
 (D) 
PFS 
Years 30 – 40 40 – 50 50 – 60 6  – 70 7  – 8  >80 
≤30 0.575 0.385 0.622 0.050 0.014 0.004 
30 – 40  0.778 0.174 0.002 <0.001 <0.001 
40 – 50   0.053 <0.001 <0.001 <0.001 
50 – 60    0. 05 < .001 <0.001 
60 – 70     0.200 0.033 
70 – 80      0.145 
OS 
Years 30 – 40 40 – 50 50 – 60 60 – 70 7  – 8  >80 
≤30 0.103 0.152 0.984 0.146 0.023 0.005 
30 – 40  0.726 0.054 0.001 <0.001 <0.001 
40 – 50   0.05 0.000 <0.001 <0.001 
50 – 60    0.004 <0.001 <0.001 
60 – 70     0.030 0.008 
70 – 80      0.110 
 
Figure 2.8 Kaplan-Meier plots for PFS and OS in early CS CHOP/CNOP treated 
patients according to age decades (n=524). (A) PFS (p<0.001)*, (B) OS (p<0.001)* (C) 
5-years PFS and OS (D) p-values* for pairwise comparison of PFS &OS in different 
age decades. *) Log Rank Test 
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(A) 
 
(B)  
(C) 
Age group 5-years PFS 5-years OS 
≤30 years 33.3 33.3 
30 - 40 years 42.9 50.0 
40 - 50 years 28.5 44.4 
50 - 60 years 27.8 41.1 
60 - 70 years 33.4 41.0 
70 - 80 years 20.1 25.0 
>80 years 9.1 17.9 
 (D) 
PFS 
years 30 – 40 40 – 50 50 – 60 60 – 70 70 – 80 >80 
≤30 0.588 0.603 0.785 0.768 0.890 0.666 
30 – 40  0.589 0.309 0.461 0.040 0.029 
40 – 50   0.552 0.887 0.020 0.004 
50 – 60    0.575 0.031 0.025 
60 – 70     0.005 0.010 
70 – 80      0.231 
OS 
years 30 – 40 40 – 50 50 – 60 60 – 70 70 – 80 >80 
≤30 0.380 0.197 0.439 0.568 0.827 0.939 
30 – 40  0.920 0.563 0.447 0.037 0.025 
40 – 50   0.529 0.220 0.001 0.001 
50 – 60    0.513 0.001 0.003 
60 – 70     0.006 0.008 
70 – 80      0.211 
 
Figure 2.9 Kaplan-Meier plots for PFS and OS in advanced clinical stage according 
to age decades (n=594). (A) PFS (p<0.001)*, (B) OS (p<0.001)*, (C) 5-years PFS 
and OS, (D) p-values* for pairwise comparison of PFS &OS in different age decades. 
*) Log Rank Test 
 
(C) 
Age group 5-years PFS 5-years OS 
≤30 years 33.3 33.3 
30 - 40 years 42.9 50.0 
40 - 50 years 28.5 44.4 
50 - 60 years 27.8 41.1 
6  - 70 years 33.4 41.0 
70 - 80 years 20.1 25.0 
>80 years 9.1 17.9 
 (D) 
PFS 
Years 30 – 40 40 – 50 50 – 60 60 – 70 70 – 80 >80 
≤30 0.588 0.603 0.785 0.768 0.890 0.666 
30 – 40  0.589 0.309 0.461 0.040 0.029 
40 – 50   0.552 0.887 0.020 0.004 
50 – 60    0.575 0.031 0.025 
60 – 70     0.005 0.010 
70 – 80      0.231 
OS 
Years 30 – 40 40 – 50 50 – 60 60 – 70 70 – 80 >80 
≤30 0.380 0.197 0.439 0.568 0.827 0.939 
30 – 40  0.920 0.563 0.447 0.037 0.025 
40 – 50   0.529 0.220 <0.001 <0.001 
50 – 60    .513 <0.001 0.003 
60 – 70     0.006 0.008 
70 – 80      0.211 
 
Figure 2.9 Kaplan-Meier plots for PFS and OS in advanced CS according to age 
decades (n=594). (A) PFS (p<0.001)*, (B) OS (p<0.001)*, (C) 5-years PFS and OS, (D) 
p-values* for pairwise comparison of PFS &OS in different age decades. *) Log Rank 
Test 
 
In the PFS evaluation of all patients and patients with advanced stage disease 
statistically significant differences were observed between “60 – 70 years” vs. “70 – 80 
years” groups. In patients with early stage disease the significance difference was 
observed between “50 - 60 years” vs. “60 – 70 years” groups. 
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In the OS evaluation of all patients and patients with early stage disease 
statistically significant differences were observed for OS between following groups: “50 
- 60 years” vs. “60 – 70 years” and “60 – 70 years” vs. “70 – 80 years”. By contrast 
significant differences for OS in patients with advanced stage disease were seen 
between: “60 – 70 years” vs. “70 – 80 years” only. Using these data the following new 
age groups could be built for evaluation of PFS: 
1) All patients and patients with advanced stages: 
• “18 – 70 years” 
• “>70 years”  
2) Patient with early stages: 
• “18 – 60 years” 
• “>60 years”. 
And for evaluation of OS: 
1) All patients and patient with early stage: 
• “18 – 60 years” 
• “60 – 70 years”  
• “>70 years”  
2) Patient with advanced stages: 
• “18 – 70 years” 
• “>70 years” 
 
2.3.4 Evaluation of International Prognostic Index 
 An additional separate analysis of the prognostic value of IPI and aaIPI were 
performed in patients treated with anthracycline-based chemotherapy. The IPI was 
calculated for all patients and the aaIPI additionally in younger patients. The IPI could 
be calculated in 803/1391 (57.7%) patients treated with anthracycline-based 
chemotherapy and the aaIPI was additionally calculated in 353/560 (63.0%) younger 
patients. In the evaluation of all patients according to IPI most patients belonged to the 
low risk group 305/803 (38.0%), followed by low intermediate group 212/803 (26.4%) 
and high intermediate group 174/803 (21.7%). Only 112/803 (13.9%) belonged to the 
high-risk group. By contrast the distribution of risk groups by aaIPI in younger patients 
was different with the low intermediate risk group being the most frequent 114/353 
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(32.3%), followed by high-intermediate risk group 109/353 (30.9%) and low risk group 
101/353 (28.6%). The high-risk group was the least frequent at 29/353 (8.2%). 
For all patients the 5-year PFS and OS were: 58.0% and 67.3% in the low risk 
group, 34.9% and 46.0% in the low intermediate group, 24.5% and 25.2% in the high 
intermediate group and 15.5% and 27.4% in the high risk group; p<0.001 (figure 2.10). 
In the pairwise evaluation, the IPI was able to distinguish between all risk groups for 
OS except for no difference between low risk and low-intermediate risk groups. For 
PFS there were also no differences between low risk and low intermediate groups or 
between low intermediate and high intermediate risk groups (figure 2.10). 
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Figure 2.10 Kaplan-Meier plots for PFS and OS according to IPI risk groups - 
population-based evaluation, all patients treated with anthracycline-based 
chemotherapy with calculated IPI (n=803). (A) 5-years PFS: low risk group 58.0%, 
low intermediate risk group 34.9%, high intermediate risk group 24.5% and high risk 
group 15.5%; (p=0.000)*, (B) 5-years OS: low risk group 67.3%, low intermediate 
risk group 46.0%, high intermediate risk group 25.2% and high risk group 27.4%; 
(p=0.000)* and (C) p-values for pairwise comparison of PFS & OS in different IPI 
groups. *) Log Rank Test 
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Figure 2.10 Kaplan-Meier plots for PFS and OS according to IPI risk groups, 
population-based evaluation, all patients treated with anthracycline-based chemotherapy 
with calculated IPI (n=803). (A) 5-years PFS: low risk group 58.0%, low intermediate 
risk group 34.9%, high intermediate risk group 24.5% and high risk group 15.5%; 
(p=0.000)*, (B) 5-years OS: low risk group 67.3%, low intermediate risk group 46.0%, 
high intermediate risk group 25.2% and high risk group 27.4%; (p=0.000)* and (C) p-
values for pairwise comparison of PFS & OS in different IPI groups. *) Log Rank Test 
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In younger patients the 5-year PFS and OS according to aaIPI were as follows: 
78.1% and 88.2% in the low risk group, 49.9% and 62.5% in the low intermediate 
group, 25.3% and 40.6% in the high intermediate group and 20.2% and 33.2% in the 
high risk group; p<0.001 (Figure 2.11). In contrast to the IPI the aaIPI was able to 
distinguish between all risk groups in a pairwise comparison for PFS and OS with the 
exception of high intermediate and high-risk groups, see figure 2.11. 
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Figure 2.11 Kaplan-Meier plots for PFS and OS according to aaIPI risk groups - 
population-based evaluation, patients aged ≤60 years treated with anthracycline-based 
chemotherapy with calculated aaIPI (n=353). (A) 5-years PFS: low risk group 78.1%, 
low intermediate risk group 49.9%, high intermediate risk group 25.3% and high risk 
group 20.2%; (p=0.000)*: (B) 5-years OS: low risk group 88.2%, low intermediate 
risk group 62.5%, high intermediate risk group 40.6% and high risk group 33.2%; 
(p=0.000)* and (C) p-values for pairwise comparison of PFS & OS in different aaIPI 
groups. *) Log Rank Test 
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Figure 2.11 Kaplan-Meier plots for PFS and OS according to aaIPI risk groups, 
population-based evaluation, patients aged ≤60 years treated with anthracycline-based 
chemotherapy with calculated aaIPI (n=353). (A) 5-years PFS: low risk group 78.1%, 
low intermediate risk group 49.9%, high intermediate risk group 25.3% and high risk 
group 20.2%; (p=0.000)*: (B) 5-years OS: low risk group 88.2%, low intermediate risk 
group 62.5%, high intermediate risk group 40.6% and high risk group 33.2%; 
(p=0.000)* and (C) p-v lues for pairwise compari on of PFS & OS in different aaIPI 
groups. *) Log Rank Test 
 
2.3.5 Prognostic value of duration of first remission on overall survival 
In order to assess the impact of duration of first remission on OS of patients 
treated with anthracycline-based chemotherapy, four groups were defined: “refractory 
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group” for patients who did not respond to first line treatment or relapsed within 9 
months from diagnosis, “early relapse group” for patients who relapsed within 9 – 18 
months from diagnosis, “late relapse group” for patients who relapsed after 18 months 
from diagnosis and “no relapse group” for patients who did not relapse. These groups 
were also assessed for possible differences between them in clinical features or IPI at 
presentation. 
Of 1391 patients treated with anthracycline-based chemotherapy 1375 patients 
were evaluable. 16 patients were excluded from analysis due to short follow-up. Most 
patients belonged to the “no relapse group” – 597/1375 (43%), followed by a 
comparable number 566/1375 (41%) in the “refractory group”, 120/1375 (9%) in the 
“late relapse group” and finally 92/1375 (7%) patients in the “early relapse group”, see 
figure 12 
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Figure 2.12 Different group according to duration of remission, all patients treated with 
anthracycline-based chemotherapy (n=1375), patients ≤60 years (n=557) and patients 
>60 years (n=818), p=0.001 - χ2 – test or Fisher exact test. 
 
557/1375 patients were aged ≤60 years and their distribution pattern was comparable 
with that described above and was as follows: 290/557 (52%) patients in the “no relapse 
group”, 185/557 (33%) patients in the “refractory group”, 46/557 (8%) patients in the 
“late relapse group” and 36/557 (7%) patients in the “early relapse group” (see figure 
2.12). By contrast for patients aged >60 years most patients 381/818 (46%) belonged to 
the “refractory group”, followed by 307/818 (38%) patients in the “no relapse group”, 
74/818 (9%) patients in the “late relapse group” and 56 patients (7%) in the “early 
relapse group” (figure 2.12). 
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Detailed patient characteristic for each group is provided in table 2.13. Generally 
the “refractory group” was characterised by the highest median age of patients and by 
contrast the “no relapse group” by the lowest. The female/male ratio varied about 1.0 
with the highest value in the “no relapse group” and the lowest in the “early relapse 
group”. The “refractory group” was characterised by the highest number of patients 
with advanced disease as measured by Ann Arbor CS, IPI, higher ECOG score values, 
B-symptoms, bulky disease, extranodal and BM involvement, and abnormal laboratory. 
By contrast fewer patients with the above features were in the “late relapse group” or in 
the “no relapse group”. 
 
Clinical parameter 
Refractory 
(n=566) 
Early 
Relapse 
(n=92) 
Late 
relapse 
(n=120) 
No relapse 
(n=597) 
N (%) N (%) N (%) N (%) 
Median age (range) 
Age >60 years 
Female gender 
CS III and IV 
B-symptoms 
ECOG >1 
Bulky disease 
BM involvement 
Extranodal involvement 
Low IPI 
low intermediate IPI 
High intermediate IPI 
High IPI 
Abnormal Hb 
Abnormal WBC 
Abnormal albumin 
Abnormal urea 
Abnormal AP 
Abnormal LDH 
68 (18 - 91) 
381/566 (67) 
272/566 (48) 
393/566 (69) 
318/556 (57) 
162/495 (33) 
330/517 (64) 
114/477 (24) 
249/566 (44) 
53/323 (16) 
93/323 (29) 
98/323 (30) 
79/323 (25) 
245/543 (45) 
148/542 (27) 
187/529 (35) 
190/545 (35) 
176/539 (33) 
287/362 (79) 
66 (26 – 85) 
56/92 (61) 
39/92 (42) 
61/92 (67) 
37/92 (40) 
15/80 (19) 
40/87 (46) 
17/84 (20) 
30/91 (33) 
16/47 (34) 
11/47 (23) 
15/47 (32) 
5/47 (11) 
33/88 (37) 
15/87 (17) 
15/85 (18) 
17/88 (19) 
20/87 (23) 
26/49 (53) 
63 (28 – 92) 
74/120 (62) 
60/120 (50) 
59/120 (50) 
46/119 (39) 
9/106 (8) 
50/118 (42) 
17/103 (17) 
29/120 (24) 
27/53 (51) 
15/53 (28) 
8/53 (15) 
3/53 (6) 
34/116 (29) 
24/116 (21) 
14/103 (14) 
19/112 (17) 
24/106 (23) 
25/56 (45) 
61 (18 – 92) 
307/597 (51) 
308/597 (52) 
129/597 (39) 
177/595 (30) 
75/549 (14) 
248/545 (45) 
41/518 (8) 
152/597 (25) 
205/369 (56) 
90/369 (24) 
52/369 (14) 
22/369 (6) 
138/577 (24) 
92/586 (16) 
89/561 (16) 
110/579 (19) 
109/565 (19) 
176/400 (44) 
Table 2.13 Patient characteristics, different group according to duration of remission, in 
patients treated with anthracycline-based chemotherapy (n=1375). 
 
 In an analysis of OS there were statistically significant differences between the 
groups. The 5-year OS was 8% in the “refractory group”, 16% in the “early relapse 
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group”, 50% in the “late relapse group” and 90% in the “no relapse group”; p<0.001 
(figure 2.13). These results were confirmed in patients aged ≤60 years: 5-years OS was 
13% in the “refractory group”, 31% in the “early relapse group”, 66% in the “late 
relapse group” and 94% in the “no relapse group”; p<0.001 (figure 2.13) and in the 
evaluation of patients aged >60 years: 4%, 6%, 40% and 85%, respectively, p<0.001 
(figure 2.13). Importantly the differences remained statistically significant, (all p-values 
<0.001), in a pairwise analysis of all patients, patients ≤60 years and >60 years, see 
figure 2.13. 
To assess potential differences in clinical features at presentation between 
patients in different groups, the groups were compared pair-wise: “refractory group” vs. 
“early relapse group”, “refractory group” vs. “late relapse group”, “refractory group” vs. 
“no relapse group”, “early relapse group” vs. “late relapse group”, “early relapse group” 
vs. “no relapse group” and “late relapse group” vs. “no relapse group” for all patients 
and then separately in young and elderly patients. The following 13 clinical factors were 
included in the evaluation: age, sex, CS, B-symptoms, ECOG, extranodal and BM 
involvement, bulky disease, Hb, leukocytes, albumin, urea and AP serum level. In the 
evaluation of all patients, the “refractory group” and “no relapse group” differed by the 
largest number of factors (12 of 13), the exception being gender. The “refractory group” 
and “late relapse” group varied by all factors (10 from 13 factors) except for gender, 
BM involvement and WBC The “refractory group” and “early relapse group” varied by 
8 from 13 factors. Age, gender, CS, BM involvement, abnormal Hb and AP serum 
levels were the exceptions. The “early relapse group” differed from “no relapse group” 
by age, CS, B-symptoms, IPI-group, BM involvement and Hb levels. The “early relapse 
group” differed from the “late relapse group” by one factor only, ECOG status, and the 
“late relapse group” varied from the “no relapse group” by two factors: CS and BM 
involvement, see table 2.14.A. A similar pattern of differences between the groups was 
observed in both age cohorts (see table 2.14.A and B). Importantley, the IPI could not 
distinguish between all individual groups in a pair-wise comparison of the remission 
groups. For all patients, younger and elderly patients there were no differences between 
the “early relapse group” vs. “late relapse group” and “late relapse group” vs. “no 
relapse group”. Additionally, in evaluations of younger and elderly patients there were 
no significant differences between “early relapse group” vs. “no relapse group” and for 
elderly patients only no significant differences between “refractory group vs. “early 
relapse group” (table 2.14). 
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(A) 
 
Patient group Early relapse Late relapse No relapse 
Refractory 
Early relapse 
Late relapse 
>0.000 
 
 
>0.000 
>0.000 
 
>0.000 
>0.000 
>0.000 
(B) 
 
Patient group Early relapse Late relapse No relapse 
Refractory 
Early relapse 
Late relapse 
>0.000 
 
 
>0.000 
>0.000 
 
>0.000 
>0.000 
>0.000 
(C) 
 
Patient group Early relapse Late relapse No relapse 
Refractory 
Early relapse 
Late relapse 
>0.000 
 
 
>0.000 
>0.000 
 
>0.000 
>0.000 
>0.000 
Figure 2.13 Kaplan-Meier plot for OS in different group according to duration of 
remission in patients treated with anthracycline-based chemotherapy. Refractory (blue 
line), early relapse (red line), late relapse (green line) and no relapse (purple line). (A) 
all patients (n=1391). 5-years OS for refractory 8%, early relapse 16%, late relapse 50% 
and no relapse 90%; (p=0.001)*, (B) patients ≤60 years (n=560): 5-years OS for 
refractory 13%, early relapse 31%, late relapse 66% and no relapse 94%; (p=0.001)* 
and (C) patients >60 years (n=831): 5-years OS refractory 4%, early relapse 6%, late 
relapse 40% and no relapse 85%; (p=0.001)* *)Log Rank Test 
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2.3.6 Evaluation of addition of rituximab to anthracycline-based chemotherapy 
 
2.3.6.a Patients characteristic 
The addition of rituximab to anthracycline-based chemotherapy (CHOP or 
CNOP) was introduced routinely in the Northern Region in 2004. The data of 214 
patients treated in 5 regional haematological departments were available for the present 
evaluation. 
Median age at diagnosis was 68 years (range, 18–91years) and the patients were 
equally distributed by sex with 105/214 (49.0%) females and by CS with 102/205 
(49.7%) early and 103/205 (50.3%) advanced CS (table 2.15). The majority of patients 
38/209 (18.2%) had ECOG ≤1 and B-symptoms were present at diagnosis in 72/197 
(36.5%) patients. Bulky disease was present in 93/193 (48.2%) patients and 92/206 
(44.7%) patients had extranodal disease with BM being involved in 12/173 (6.9%) 
patients. At diagnosis Hb, WBC, albumin, urea and AP were measured in more than 
90% of patients and the majority of patients had normal results. By contrast, LDH was 
elevated in most patients 108/152 (71.1%). The IPI and revised IPI could be calculated 
for 131 patients; most patients 40/131 (30.5%) were in the low risk group, followed by 
36/131 (27.5%) patients in the high intermediate risk group, 33/131 (25.2%) of patients 
in the low-intermediate risk group and 22/131 (16.8%) patients in the high-risk group, 
table 28. For the revised IPI, 10/131 (7.6%) patients were in the very low risk group, 
63/131 (48.1%) in the good risk group and 58/131 (44.3%) in the poor risk group. 
Patient characteristics at baseline were compared to those of 1118 patients treated with 
CHOP/CNOP from our population-based cohort and were generally comparable (table 
2.15). There were no statistically significant differences between the groups of patients 
according to age, sex, and features at presentation including IPI, except for a lower 
number of patients with BM involvement: 12/173 (6.9%) vs. 132/956 (13.8%); p=0.013. 
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Clinical parameter 
Chemotherapy 
with rituximab 
n (%) 
Chemotherapy 
without 
rituximab 
n (%) 
p-value 
Median age, range 
Age group 
≤ 60 years 
> 60 years 
Female gender 
ECOG >1 
CS 
I 
II 
III 
IV 
B symptoms 
Bulk disease 
BM involvement 
Extranodal involvement 
IPI Group 
Low 
Low intermediate 
High intermediate 
High 
Abnormal Hb 
Abnormal WBC 
Abnormal albumin 
Abnormal urea 
Abnormal AP 
Abnormal LDH 
68, 18 – 91 
 
61/214 (28.5) 
153/214 (71.5) 
105/214 (49.0) 
38/209 (18.2) 
 
40/205 (19.5) 
62/205 (30.2) 
56/205 (27.3) 
47/205 (22.9) 
72/197 (36.5) 
93/193 (48.2) 
12/173 (6.9) 
92/206 (44.7) 
 
40/131 (30.5) 
33/131 (25.2) 
36/131 (27.5) 
22/131 (16.8) 
79/210 (62.4) 
49/210 (23.3) 
46/197 (23.4) 
69/199 (34.7) 
54/197 (27.4) 
108/152 (71.1) 
66, 18 – 92 
 
414/1118 (37.0) 
704/1118 (63.0) 
557/1118 (49.8) 
222/997 (22.3) 
 
216/1118 (19.3) 
308/1118 (27.5) 
296/1118 (26.5) 
298/1118 (26.7) 
452/1108 (1108) 
533/1023 (52.1) 
132/956 (13.8) 
451/1024 (44.0) 
 
238/640 (37.2) 
181/640 (28.3) 
131/640 (20.5) 
90/640 (14.1) 
353/1080 (32.7) 
226/1081 (20.9) 
244/1037 (23.5) 
292/1079 (27.1) 
254/1054 (24.1) 
411/702 (58.5) 
0.614** 
 
0.017* 
 
n.s.* 
n.s.* 
 
n.s.* 
 
 
 
n.s.* 
n.s.* 
0.013* 
n.s.* 
 
n.s.* 
 
 
 
n.s.* 
n.s.* 
n.s.* 
n.s.* 
n.s.* 
n.s.* 
Table 2.15 Characteristics of patients treated with immunochemotherapy (n=214) and 
chemotherapy only (n=1118).*) χ2 – test or Fisher exact test and **) Mann-Whitney 
Test 
 
2.3.6.b Treatment 
Of the 214 patients in the immunochemotherapy group the majority 190 (88.8%) 
received CHOP and 24 (11.2%) patients CNOP with substitution of mitoxantrone for 
doxorubicin. All except one patient given CNOP were aged >60 years. When patients 
from the immunochemotherapy group were compared with patients treated with 
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CHOP/CNOP there were no statistical differences in the number of patients treated with 
both regimens in the evaluation of all patients, patients aged ≤60 years and >60 years, 
see figure 2.14. 
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Figure 2.14 Type of anthracycline-based chemotherapy and combined modality in 
patients treated with immunochemotherapy vs. chemotherapy only, in all patients, 
younger and elderly patients. (A) CHOP and CNOP regimens in immunochemotherapy 
(n=214) vs chemotherapy only group (n=1118) – all patients (p = n.s.*), patients ≤60 
years (p=n.s.*) and >60 years (p=n.s.*) (B) Chemotherapy alone vs combined modality 
in immunochemotherapy (n=214) vs chemotherapy only group (n=1118) – all patients 
(p=0.003*), patients ≤60 years (p=n.s.*) and >60 years (p=0.001*); *) χ2 – test or Fisher 
exact test 
 
Data on additional radiotherapy was available in 210 patients from the 
immunochemotherapy group, 116 (55.2%) received chemotherapy alone and 94 
(44.8%) combined modality treatment. There were more patients treated with combined 
modality aged ≤60 years than patients aged >60 years; 32/61 (52.5%) vs. 62/149 
(41.6%). When compared with the control group of patients treated with CHOP/CNOP, 
the number of patients treated with combined modality increased significantly in the 
evaluation of all patients (44.8% vs. 34.2%, respectively; p=0.003) and patients aged 
>60 years (41.6& vs. 28.3%, respectively; p=0.001). There was no significant difference 
for patients aged ≤60 years (52.5% vs. 44.2%, respectively), see figure 2.14. 
 
3.3.6.c Responses and outcome 
 All patients were evaluable at 12 months for treatment response. In order to 
assess the impact of the addition of rituximab the response rates were compared with 
the control group treated with the same regimens (CHOP/CNOP) without rituximab. 
The majority of patients in immunochemotherapy group were in CR or PR at 12 
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months, 160/214 (74.8%). For patients with early stage disease CR/PR response rates 
were 85/102 (83.3%) versus 69/103 (67.0%) for advanced stage patients. When 
compared with patients treated with CHOP/CNOP, there were significant advantages 
for immunochemotherapy for all groups, see table 2.16. 
 
Patient group 
CR / PR 
N (%) 
p-value* 
Death 
N (%) 
p-value* 
All 
patients 
R-CHOP / R-CNOP (n=214) 
CHOP / CNOP (n=1118) 
160 (74.8) 
615 (55) 
<0.001 75 (35) 
575 (51.8) 
<0.001 
R-CHOP (n=190) 
CHOP (n=963) 
146 (76.8) 
557 (57.8) 
<0.001 62 (32.6) 
462 (48.0) 
<0.001 
Early 
stages 
R-CHOP / R-CNOP (n=102) 
CHOP / CNOP (n=524) 
85 (83.3) 
357 (68.1) 
0.002 26 (25.5) 
209 (40.3) 
0.005 
R-CHOP (n=90) 
CHOP (n=459) 
75 (83.3) 
330 (71.9) 
<0.026 23 (25.6) 
163 (35.5) 
0.068 
Late 
stages 
R-CHOP / R-CNOP (n=103) 
CHOP / CNOP (n=594) 
69 (67.0) 
258 (43.4) 
<0.001 45 (43.7) 
36.6 (62.0) 
<0.001 
R-CHOP (n=91) 
CHOP (n=504) 
65 (71.4) 
227 (45.0) 
<0.001 35 (38.5) 
299 (59.3) 
<0.001 
Table 2.16 Patient outcome in all patients treated with immunochemotherapy vs. 
chemotherapy only. R-CHOP/R-CNOP (n=214) vs. CHOP/CNOP (n=1118) and R-
CHOP (n=190) vs CHOP (n=963).*) χ2 – test or Fisher exact test 
 
The same comparisons were performed for patients aged ≤ 60 years and > 60 
years treated with immunochemotherapy and chemotherapy alone. In younger patients 
overall CR/PR rates were 56/61 (86.9%); early stage 30/33 (90.9%) and advanced stage 
21/25 (84%). Compared with patients treated with CHOP/CNOP, the statistically 
significant differences were for all and advanced stage patients, but not early stage 
patients, see table 2.17. In contrast response rates for elderly patients were lower at 
69.9% (55/69) overall; 79.7% (48/78) for early stage patients and 61.5% (48/78) for 
advanced stage patients. However, the response rates for all rituximab treated patient 
groups were statistically significant higher compared with the no rituximab groups 
(table 2.17). 
 In evaluation of patients treated with CHOP chemotherapy with and without 
addition of rituximab the outcome reminded same with the exemption that the 
differences in death rates in patients with early stage disease lost their significance in 
evaluation of all patient and younger and elderly patients. 
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(A) 
Patient group 
CR / PR 
N (%) 
p-value* 
Death 
N (%) 
p-value* 
All 
patients 
R-CHOP / R-CNOP (n=61) 
CHOP / CNOP (n=414) 
53 (86.9) 
267 (64.5) 
<0.001 9 (14.8) 
158 (38.4) 
<0.001 
R-CHOP (n=60) 
CHOP (n=398) 
52 (86.7) 
259 (65.1) 
<0.001 9 (15.0) 
149 (37.4) 
<0.001 
Early 
stages 
R-CHOP / R-CNOP (n=33) 
CHOP / CNOP (n=210) 
30 (90.9) 
167 (79.5) 
n.s 2 (6.4) 
48 (23.1) 
0.025 
R-CHOP (n=33) 
CHOP (n=203) 
30 (90.9) 
164 (80.8) 
n.s 2 (6.1) 
43 (21.2) 
n.s. 
Late 
stages 
R-CHOP / R-CNOP (n=25) 
CHOP / CNOP (n=204) 
21 (84.0) 
100 (49.0) 
<0.001 6 (24.0) 
110 (54.2) 
0.004 
R-CHOP (n=24) 
CHOP (n=195) 
20 (83.3) 
95 (48.7) 
0.002 6 (25.0) 
106 (54.6) 
0.008 
 
(B) 
Patient group 
CR / PR 
N (%) 
p-value* Death p-value* 
All 
patients 
R-CHOP / R-CNOP (n=153) 
CHOP / CNOP (n=704) 
107 (69.9) 
348 (49.4) 
<0.001 66 (43.1) 
41.7 (59.7) 
<0.001 
R-CHOP (n=130) 
CHOP (n=565) 
94 (72.3) 
298 (52.7) 
<0.001 53 (40.8) 
313 (55.4) 
0.002 
Early 
stages 
R-CHOP / R-CNOP (n=69) 
CHOP / CNOP (n=314) 
55 (79.7) 
190 (60.5) 
0.003 24 (34.8) 
161 (51.8) 
0.011 
R-CHOP (n=57) 
CHOP (n=256) 
45 (78.9) 
166 (64.8) 
0.043 21 (36.8) 
120 (46.9) 
n.s. 
Late 
stages 
R-CHOP / R-CNOP (n=78) 
CHOP / CNOP (n=390) 
48 (61.5) 
158 (40.5) 
<0.001 39 (50.0) 
256 (66.1) 
0.007 
R-CHOP (n=67) 
CHOP (n=309) 
45 (67.2) 
132 (42.7) 
<0.001 29 (43.3) 
193 (62.5) 
0.004 
Table 2.17 Patient outcome in younger and elderly patients treated with 
immunochemotherapy and chemotherapy only. (A) patients aged ≤60 years treated with 
R-CHOP/R-CNOP (n=61) vs. CHOP/CNOP (n=414) and R-CHOP (n=60) vs CHOP 
(n=398) and (B) patients aged >60 years treated with R-CHOP/R-CNOP (n=153) vs. 
CHOP/CNOP (n=704) and R-CHOP (n=130) vs CHOP (n=565) *) χ2 – test or Fisher 
exact test 
 
 The median observation time of all patients treated with CHOP-R/CNOP-R was 
24.3 months and for living patients 34.5 months. For patients from the control group 
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treated with CHOP/CNOP it was 21.8 months and 48.15 months, respectively. For all 
CHOP-R/CNOP-R patients the 3-years PFS and OS were 57.6% and 64.6% and this 
was statistically significantly higher than the 43.1% and 54.3%, for CHOP/CNOP 
patients, (p=0.000 and 0.014, respectively). However in a sub-evaluation of patients 
with early stage disease the 3-years PFS and OS were 67.7% and 74.2% in the 
immunochemotherapy group and 57.0% and 66.1% in the chemotherapy group with no 
statistically significant differences. For advanced stage disease patients the 3-years PFS 
and OS were lower at 47.7% and 56.0% in the immunochemotherapy group and 30.3% 
and 43.8% in the chemotherapy group with statistically significant difference for PFS 
but not for OS (table 2.18). 
 
Patient group 
3-years 
PFS 
(%) 
p-value* 
3-years 
OS 
(%) 
p-value* 
All 
patients 
R-CHOP / R-CNOP (n=214) 
CHOP / CNOP (n=1118) 
57.6 
43.1 
<0.001 64.6 
54.3 
0.014 
R-CHOP (n=190) 
CHOP (n=963) 
59.2 
45.8 
<0.001 66.8 
57.7 
0.031 
Early 
stages 
R-CHOP / R-CNOP (n=102) 
CHOP / CNOP (n=524) 
67.7 
57.0 
0.064 74.2 
66.1 
0.159 
R-CHOP (n=90) 
CHOP (n=459) 
66.6 
60.5 
0.187 73.1 
70.1 
0.512 
Late 
stages 
R-CHOP / R-CNOP (n=103) 
CHOP / CNOP (n=594) 
47.7 
30.3 
<0.001 56.0 
43.8 
0.054 
R-CHOP (n=91) 
CHOP (n=504) 
52.3 
31.8 
<0.001 61.9 
46.3 
0.022 
Table 2.18 3-years PFS and OS in all patients treated with immunochemotherapy vs. 
chemotherapy only. R-CHOP/R-CNOP (n=214) vs. CHOP/CNOP (n=1118) and R-
CHOP (n=190) vs CHOP (n=963).*) Log Rank test 
 
 Subsequently, separate evaluations were performed for younger patients (aged 
≤60 years) and elderly patients (aged >60 years); table 2.19. As suspected, generally the 
PFS and OS rates were higher among younger patients. For all patients, the 3-years PFS 
and OS were 78.7% and 87.6%, for CHOP-R/CNOP-R and 54.9% and 67.4%, for 
CHOP/CNOP; p=0.002 and p=0.005, respectively. 
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(A) 
Patient group 
3-years 
PFS 
% 
p-value* 
3-years 
OS 
% 
p-value* 
All 
patients 
R-CHOP / R-CNOP (n=61) 
CHOP / CNOP (n=414) 
78.7 
54.9 
0.002 
87.6 
67.4 
0.005 
R-CHOP (n=60) 
CHOP (n=398) 
78.4 
55.2 
0.002 
87.4 
67.8 
0.006 
Early 
stages 
R-CHOP / R-CNOP (n=33) 
CHOP / CNOP (n=210) 
90.8 
72.8 
0.062 
93.8 
80.9 
0.082 
R-CHOP (n=33) 
CHOP (n=203) 
90.8 
73.5 
0.071 
93.8 
81.9 
0.097 
Late 
stages 
R-CHOP / R-CNOP (n=25) 
CHOP / CNOP (n=204) 
63.5 
36.2 
0.013 
81.0 
53.4 
0.025 
R-CHOP (n=24) 
CHOP (n=195) 
62.3 
35.7 
0.016 
80.7 
52.8 
0.029 
 
(B) 
Patient group 
3-years 
PFS 
% 
p-value* 
3-years 
OS 
% 
p-value* 
All 
patients 
R-CHOP / R-CNOP (n=153) 
CHOP / CNOP (n=704) 
48.5 
35.6 
0.001 54.9 
46.3 
0.081 
R-CHOP (n=130) 
CHOP (n=565) 
49.4 
38.5 
0.003 56.7 
50.2 
0.183 
Early 
stages 
R-CHOP / R-CNOP (n=69) 
CHOP / CNOP (n=314) 
55.7 
46.0 
0.114 64.1 
55.8 
0.234 
R-CHOP (n=57) 
CHOP (n=256) 
50.7 
49.6 
0.415 60.0 
60.1 
0.815 
Late 
stages 
R-CHOP / R-CNOP (n=78) 
CHOP / CNOP (n=390) 
42.4 
27.2 
0.002 47.8 
38.6 
0.236 
R-CHOP (n=67) 
CHOP (n=309) 
48.6 
29.2 
0.001 55.0 
42.1 
0.122 
Table 2.19 3-years PFS and OS in younger and elderly patients treated with 
immunochemotherapy vs. chemotherapy only. (A) patients ≤60 years treated with R-
CHOP/R-CNOP (n=61) vs. CHOP/CNOP (n=414) and R-CHOP (n=60) vs CHOP 
(n=398) (B) patients >60 years treated with R-CHOP/R-CNOP (n=153) vs. 
CHOP/CNOP (n=704) and R-CHOP (n=130) vs CHOP (n=565) *) Log Rank test 
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In younger patients, in a sub-analysis of early stage patients, the 3-years PFS and OS 
were 90.8% and 93.8%, respectively in the immunochemotherapy group and 72.8% and 
80.9%, respectively in the chemotherapy group with no statistically significant 
differences between them. For patients with advanced stage disease, the 3-years PFS 
and OS were 63.5% and 81.0%, respectively for CHOP-R/CNOP-R and 36.2% and 
53.4% for CHOP/CNOP; p=0.013 and p=0.025, respectively (table 2.19). In elderly 
patients the 3-years PFS and OS in all patients were 48.5% and 54.9% in the 
immunochemotherapy group and 35.6% and 46.3% in the chemotherapy group 
(p=0.001 and p=0.081; respectively), see table 32. The 3-years PFS and OS were higher 
in patients with early stage disease at 55.7% and 64.1% in the immunochemotherapy 
group and 46.0% and 55.8% in the chemotherapy group, with no statistically significant 
differences for both PFS and OS. In patients with advanced stage disease PFS and OS 
were lower at 42.4% and 47.8% in the immunochemotherapy group and 27.2% and 
38.6% in the chemotherapy alone group with significant differences for PFS but not for 
OS (table 2.19). 
 An additional evaluation of patients treated with CHOP, with or without the 
addition of rituximab revealed similar results with one difference; in evaluation of all 
patients with advanced stage disease, where the previously not statistically significant 
difference became significant (table 2.18). 
 
2.3.6.d Clinical prognostic indices in patients treated with anthracycline-based 
chemotherapy with rituximab 
 The 3-year PFS and OS for IPI risk groups were as follows: 78.95 and 85.8% in 
the low risk group, 63.5% and 75.7% in the low intermediate risk group, 56.1% and 
59.5% in the high intermediate risk group and 18.2% and 22.5% in the high risk group 
with p=0.000 for both PFS and OS (figure 2.15). In the more detailed pairwise 
evaluation, the IPI was able to distinguish for PFS between all groups except between 
“low risk group” vs. “low intermediate risk group” and “low risk group” vs. “high 
intermediate risk group”, see figure 2.15. For OS the IPI was additionally able to 
distinguish between “low intermediate risk group” and “high intermediate risk group” 
but failed to differentiate between “low risk group” vs. “low intermediate risk group”. 
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Figure 2.15 Kaplan-Meier plots for PFS and OS according to IPI in population-based 
evaluation of all patients treated with R-CHOP/R-CNOP (n=131). (A) 3-years PFS: 
low risk group 78.9%, low intermediate risk group 63.5%, high intermediate risk 
group 56.1% and high risk group 18.2% (p=0.000)*, (B) 3-years OS: low risk group 
85.8%, low intermediate risk group 75.7%, high intermediate risk group 59.5% and 
high risk group 22.5% (p=0.000)* and (C) p-values* of pairwise comparison of PFS 
& OS in different IPI group. *)Log Rank Test. 
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Figure 2.15 Kaplan-Meier plots for PFS and OS according to IPI in population-based 
evaluation of all patients treated with R-CHOP/R-CNOP (n=131). (A) 3-years PFS: low 
risk group 78.9%, low intermediate risk group 63.5%, high intermediate risk group 
56.1% and high risk group 18.2% (p=0.000)*, (B) 3-years OS: low risk group 85.8%, 
low intermediate risk group 75.7%, high intermediate risk group 59.5% and high risk 
group 22.5% ( =0.000)* and (C) p-values* of pairwise comparison of PFS & OS in 
different IPI group. *)Log Rank Test. 
 
 The 3 year PFS and OS for revised IPI (R-IPI) risk groups were as follows: 90% 
and 100% for the very good risk group, 68.9% and 77.7% for the good risk group and 
40.3% and 44.6% for the poor risk group. Differences between the groups were 
statistically significant for both PFS and OS (figure 2.16). However, in the more 
detailed pairwise comparison for both PFS and OS, the differences were statistically 
significant between all groups except for “very good risk group” vs. “good risk group”, 
see figure 2.16. 
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Figure 2.16 Kaplan-Meier plots for PFS and OS according to R-IPI in population-
based evaluation of all patients treated with R-CHOP/R-CNOP (n=131). (A) 3 years 
PFS: very good risk group 90%, good risk group 68.9%, poor risk group 40.3% 
(p=0.000)*, (B) 3-years OS: very good risk group 100%, good risk group 77.7% and 
poor risk group 44.6% - (p=0.000)* and (C) p-values* of pairwise comparison of PFS 
& OS in different R-IPI groups. *)Log Rank Test. 
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Figure 2.16 Kaplan-Meier plots for PFS and OS according to R-IPI in population-based 
evaluation of all patients treated with R-CHOP/R-CNOP (n=131). (A) 3 years PFS: very 
good risk group 90%, good risk group 68.9%, poor risk r up 40.3% ( =0.000)*, (B) 3-
years OS: very good risk group 100%, good risk group 77.7% and poor risk group 
44.6% - (p=0.000)* and (C) p-values* of pairwise comparison of PFS & OS in different 
R-IPI groups. *)Log Rank Test. 
 
2.4. Discussi n 
 
Evaluation of all patients 
The majority of data on DLBCL comes from clinical trials performed mostly on 
highly selected patients. Clinical trials are obviously useful, however it should always 
be kept in mind that they are not representative of all patients but only those fulfilling 
the inclusion criteria. Thus the conclusions may be biased and not always representative 
for patients presenting in every day practice. In contrast the epidemiology, clinical 
features, treatment and outcome of DLBCL have not yet been studied extensively in a 
population-based setting. Ideally the general picture of the disease should be assessed in 
population-based studies and then selected, specific problems should be further assessed 
in clinical trials. 
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There are few available publications on population-based studies in DLBCL. 
Unfortunately most of them are based on the results of regional / national cancer 
registries and are not specifically designed studies. Also most evaluate the entire group 
of lymphomas and the data on DLBCL are presented as a sub-analysis only. Some of 
the reports focus on aspects of DLBCL e.g. treatment of elderly patients. The vast 
majority of these data come from the pre-rituximab era and thus their value in the 
rituximab era is limited. 
Among the currently published general population-based studies on DLBCL the 
studies of Hasselblom et al and Krol et al are the most important and the results of our 
study will be discussed in their context (Hasselblom et al., 2007) (Krol et al., 2003). 
Hasselblom et al conducted a retrospective study on adult patients with a de novo 
diagnosis of DLBCL registered with the population-based Regional Lymphoma 
Registry of the Western Sweden Health Care Region (Hasselblom et al., 2007). The 
evaluation included epidemiology, clinical presentation, treatment and outcome 
including prognostic factors. In the Netherlands, Krol et al. performed a population-
based study on epidemiology of NHL using the resources of the population-based 
registry of the Comprehensive Cancer Centre West (Krol et al., 2003). The registry 
covered the west region of the Netherlands and was based on pathological data; only 
patients with a confirmed diagnosis of lymphoma could enter the registry. The study 
was similar to that of Hasselblom et al., however all cases with NHL were included, 
with additional evaluations of DLBCL and FL (Hasselblom et al., 2007). Recently the 
data on lymphoma incidence, survival and prevelance were published by 
Haematological Malignancy Network from the UK {Smith et al., 2015, #30493}. The 
studies of Møller et al. and Luminari et al. are two other studies frequently citied in the 
literature. Both of them however suffered from major limitations (Moller et al., 2004) 
(Luminari et al., 2007). Møller et al. assessed the clinical implications of an extranodal 
vs. nodal presentation of DLBCL in a population-based study using the capacity of the 
LYFO registry of the Danish Lymphoma Group covering western Denmark (Moller et 
al., 2004). The study compared both groups of patients in terms of clinical presentation, 
treatment, prognosis and survival. Unfortunately since it included patients with 
complete IPI staging only its relevance as a population-based study is nearly lost. 
Luminari et al performed a population-based study on incidence, clinical characteristics, 
treatment and survival of all lymphoma in the province of Modena in northern Italy 
(Luminari et al., 2007). This study suffers from two issues, which limit its value. The 
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presented data on treatment are rather sparse and surprisingly BL and DLBCL were 
evaluated as a one group. Thus any detailed discussion of results solely relating to 
DLBCL is difficult. 
The Scotland and Newcastle Lymphoma Group operated in Scotland and the 
Northern region of England, which can be regarded as a representative population not 
only for the UK but also for Western Europe and North America. The group collected 
information on all patients diagnosed with DLBCL of nodal origin in the geographical 
area without using any pre-selection.  
In our cohort the median age of 1863 evaluable patients was 66 years with a 
slight female majority at 51.2%. The median age of patients with DLBCL reported in 
the study by Krol et al. was comparable at 67 years (Krol et al., 2003) and in the study 
of Hasselblom et al. was higher at 73 years (Hasselblom et al., 2007). Smith et al in his 
evaluation of the british cohort reports the median age of 70 years. Kroll et al reported 
equal numbers of male and female patients (Krol et al., 2003) and in the study of 
Hasselblom et al. and in the study of Smith et al there was a slight dominance of male 
patients with 52% in both studies (Hasselblom et al., 2007) {Smith et al., 2015, 
#30493}. There is no explanation for these small differences. 
In our cohort of patients a performance status with ECOG >1was reported in 
26.1% of patients, a comparable number to the study of Hasselblom et al. (29%) 
(Hasselblom et al., 2007). By contrast in the study of Krol et al. (Krol et al., 2003) this 
number was significantly higher at 39%. There is no known explanation for this 
difference. Patients in our study presented almost equally with early and advanced stage 
disease with only a minimal predominance of advanced stage at 52.2%. By contrast in 
the study of Krol et al. more patients presented with early stage disease: 56% (Krol et 
al., 2003) and in the study of Hasselblom et al. there was the same number of patients 
with early and advanced disease (Hasselblom et al., 2007). B symptoms were present in 
41.7% and were comparable with data from Hasselblom et al. (45%) (Hasselblom et al., 
2007). Krol et al. (Krol et al., 2003) did not assess the presence of B-symptoms. 
Comparison of patients with bulky disease is difficult because of different definitions 
used in the studies and thus it will not be further discussed. Extranodal involvement in 
our cohort was seen in 48.1% of patients versus 59% in the study of Hasselblom et al. 
(Hasselblom et al., 2007). Krol et al. did not report on extranodal involvement, except 
for BM involvement, which was 20% followed by 16.4% in our cohort and 13% in the 
study of Hasselblom (Hasselblom et al., 2007) (Krol et al., 2003). Importantly BM 
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assessment and serum LDH levels were missing in significant numbers of patients in all 
studies. Elevated LDH serum levels were observed in 59.5%, 49.5% and 53.5% of 
tested patients in our study, Hasselblom et al. and Kroll et al.; respectively (Hasselblom 
et al., 2007) (Krol et al., 2003). The laboratory values were reported only in our study. 
Regarding therapy, individual studies used different definitions for their 
treatment modalities thus direct comparisons are difficult. However, it was possible to 
observe some common trends. Approximately 75% of our patients were treated with 
anthracycline-based systemic chemotherapy and 4.9% of patients received 
anthracycline-based chemotherapy with ASCT in first remission. Only 5.7% received 
systemic chemotherapy without anthracyclines, 7.1% were treated with radiotherapy 
only and 7.6% received no chemotherapy or radiotherapy. During the time period of 
patient recruitment curative standard of care for patients with localised disease was 
radiotherapy alone. In fact the vast majority of patients in this group are patients with 
stage I disease. This is not common practice anymore, and has caused problems in 
classification of patients. In order to stay uniform with other studies we could not 
classify radiotherapy alone as curative treatment. Thus curative treatment was given to 
79.6% of patients and palliative treatment to 20.4%. In the study of Hasselblom et al., 
70% of patients received curative treatment and the remaining 30% palliative treatment 
(Hasselblom et al., 2007). By contrast in the study of Krol et al. only 40.5% of patients 
received an anthracycline-based systemic chemotherapy, 31.5% a localised treatment 
(mostly radiotherapy), 21.5% received systemic chemotherapy without anthracyclines 
and 6.8% no treatment at all (Krol et al., 2003). Mitoxantrone containing regimens were 
considered as a palliative treatment in contrast to our and other studies, which defined 
this treatment as curative. The standard treatment for patient with localised lymphoma 
in CS I was radiotherapy only. And indeed, the majority of patients treated with 
localised treatment had CS I. According to these numbers 40.5% of patients only were 
treated with curative treatment, increasing for patients in CS II – IV to 55%. The 
number of patients treated with palliative treatment is actually the lowest in our study, 
which was recruiting patients during the most recent period of time between 1990 and 
2003, and it was highest in the study of Krol et al which recruited between 1985-1989 
(Krol et al., 2003). Looking closer at the chemotherapy regimens CHOP, CNOP and 
VACOP-B were the three most often used in our group and by Hasselblom et al 
(Hasselblom et al., 2007). 
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We could observe differences in patient characteristics between the different 
treatment groups in our cohort. Patients treated with consolidation with ASCT in first 
remission were significantly different from the group of patients treated with standard 
anthracycline-based chemotherapy with more advanced/aggressive disease; statistically 
significant differences in CS, bulky disease, extranodal involvement and high LDH. 
This makes it obvious that the main reason for ASCT was more advanced disease at 
presentation in young, healthy patients. The group of patients treated with 
chemotherapy without anthracyclines as compared to patients treated with standard 
chemotherapy had significantly more elderly patients, female, patients with ECOG >1 
and with higher IPI score, abnormal Hb, urea and AP. The patients treated without 
anthracyclines were older, with worse general condition and more or less the same 
incidence of advanced disease. This suggests that anthracyclines were usually omitted 
due to advanced age and comorbidities. The higher number of female patients may be 
associated with the higher average age of patients treated without anthracyclines and the 
number of females is higher among an elderly population. The differences were even 
more significant in comparison to patients not receiving any treatment. Both groups 
differ in all aspects except CS, bulky disease and abnormal WBC. 
Looking at the patients in the curative and palliative groups in our study they 
differ significantly in all aspects except for the number of patient with BM involvement, 
abnormal HB, WBC and AP. Generally patients in the palliative chemotherapy group 
had similar pictures of disease but were older and more fragile as compered with the 
patients from the curative group. In the evaluation of the patients given palliative versus 
curative treatment by age decade, the number of palliatively treated patients remained 
constant until the beginning of the 7th decade and then it started to increase reaching 
more than 50% by the 9th decade. In all other studies age remained the main reason for 
not administering curative treatment. In the study of Krol et al. patients in the palliative 
treatment group were older, there were more females in this group, patients with normal 
LDH, CS I/ II and low risk IPI (Krol et al., 2003). Hassleblom et al has not compared 
directly both groups but collected information on the reasons for not giving curative 
treatment. The most common were high age and concomitant disease, followed by high 
age (18%), concomitant disease (17%), poor performance status (17%), and other 9% or 
not specified 12% (Hasselblom et al., 2007). Taking into consideration all the above 
factors the reasons for the relatively high number of patients treated with palliative 
therapies could be either related to the evaluation method or to patient characteristics. In 
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the older studies the recommendations for using anthracycline-based treatment were less 
strong, and patients with localised disease were receiving radiotherapy alone. This could 
contribute to the increased number of “palliatively treated patients” particularly if 
localised disease was more common in the study; e.g. Krol et al as compared to our 
cohort (Krol et al., 2003). Additionally, in the past supportive therapies were not so 
successful as they are currently and this obviously contributed to a reduced number of 
patients treated with anthracyclines. On top of this some studies classified mitoxantrone 
containing protocols as not anthracycline-based and this increased the number of 
patients in palliative groups e.g. Krol et al and  (Krol et al., 2003). In conclusion a 
significant group of patients with DLBCL did not receive appropriate curative treatment 
with anthracycline-based chemotherapy. However, this number may have been affected 
by several subjective reasons such as treatment recommendation, supportive therapies 
or the definition of cohorts studied. Age seems to be the most important patient related 
objective factor. 
The ORR for all patients in our study was 49.4% and as expected patients with 
early stage disease had higher response rates than those with advanced stage. Direct 
comparison between the treatment groups can be difficult particularly if looking at 
patients treated with radiotherapy alone as this group includes mostly patients with CS I 
without B-symptoms. Excluding this group from the comparison the best results were 
achieved in the group treated with the anthracycline-based chemotherapy and patients 
with ASCT in first remission. The slightly inferior results in the latter group may be 
associated with patients with more advanced disease. The lowest ORR was observed as 
expected among patients treated with chemotherapy without anthracyclines and patients 
not receiving any treatment. The ORR in the curative treatment group was 54.5% and 
was comparable with the results described by Hasselblom et al. and Krol et al. (Krol et 
al., 2003) (Hasselblom et al., 2007). The response to treatment in the curative group 
from Hasselblom’s study was CR/CRu/PR in 65% of patients (CR 44%, CRu 17% and 
PR 14%), 20% of patients failed to respond and 5% were not assessed because of death 
or were not assessed properly (Hasselblom et al., 2007). In Krol et al’s report the ORR 
was calculated for all patient receiving treatment at 55% (Krol et al., 2003). 
The 5-year PFS and OS for the whole group was 33% and 42%, respectively and 
was comparable with the results of Hasselblom et al who estimated 5 years OS and PFS 
for all patients of 37% and 36%; respectively (Hasselblom et al., 2007). In Krol et al. 
the 5-year OS was 34% and the median OS 20 months, both calculated for all patients 
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receiving treatment (Krol et al., 2003). In terms of survival results for individual 
treatment groups the best were as expected in the groups treated with anthracycline-
based chemotherapy, ASCT in first remission or radiotherapy only and worst among 
patients treated with no anthracycline-based chemotherapy, and patients treated with no 
chemo and no radiotherapy. The 5 year PFS and OS for the curative group was 37% and 
46%, respectively and in the palliative group 16% and 21%, respectively: directly 
comparable to the results of Hasselblom et al. In the curative group he estimated 5-year 
PFS and OS of 48% and 46%; respectively and in the palliative group 5-years OS was 
9% only (Hasselblom et al., 2007). 
 
Role of age in the choice of therapy and outcome in DLBCL 
Next to disease stage age is the most important predictive factor, which stratifies 
studies for DLBCL. Therefore we had a closer look at the population of younger and 
elderly patients in our cohort. This was done in two different ways; firstly by comparing 
the group of patients aged ≤60 years and >60 years using the age limit used by the IPI 
and most clinical trials, and secondly using age decades, in order to achieve a more 
detailed picture. 
The issue of age in patients presenting with DLBCL was assessed in the two 
bigger population-based studies of Maartense et al. (Maartense et al., 1998) (Maartense 
et al., 2000). Both studies used the capacity of the Dutch Comprehensive Cancer Centre 
West population-based registry previously described in detail by Krol et al (Krol et al., 
2003). One of the studies focused on comparing younger and elderly patients 
(Maartense et al., 1998) and the other on a detailed analysis of influence of the age as 
continuous variable for outcome of aggressive and indolent NHL (Maartense et al., 
2000). Unfortunately both studies based their evaluation on the WF classification and 
the first one analyzes patients with all subtypes of NHL together. On the positive side 
they include a representative population-based cohort of patients. In addition, two other 
single centre studies focus on the aging population of patients with DLBCL or NHL, in 
terms of presentation, possible treatment and outcome. The first one by Varga et al. 
comes from the Jewish General Hospital in Montreal, Canada (Varga et al., 2014) and 
the other from Thieblemont et al. in Lyon, France (Thieblemont et al., 2008). 
Unfortunately the results of both evaluations are influenced and biased by the small 
populations they cover. In addition the latter evaluated cumulatively all patients with 
Non-Hodgkin lymphoma. Hasselblom et al. also included age as an independent 
 161 
prognostic factor in their study, which delivered some interesting results (Hasselblom et 
al., 2007). 
In our cohort, in terms of patient characteristics, the younger and older groups 
differed significantly in the number of female patients, patients with ECOG >1, BM and 
other extranodal involvement, abnormal Hb, albumin and urea – all more frequently 
present in the elderly group. Varga et all reported that elderly patients aged more than 
80 were more likely to have ECOG >2 and higher IPI scores (Varga et al., 2014). In the 
study of Maartense, a majority of patients aged 70 or more were female and there were 
a higher number of patients with ECOG >2; these findings were significantly different 
from patients aged 70 years or less (Maartense et al., 1998). The significantly higher 
number of female patients among elderly patients can be explained by the larger 
proportion of female in aging population due to longer life expentancies of female as 
compare with male. The higher number of patients with higher ECOG scores in elderly 
groups can be associated with increased incidence of co-morbidities in an aging 
population. The higher number of patients with high IPI can be explained by age and 
ECOG score that is used in calculation of the IPI. Low albumin status and abnormal Hb 
is also associated with the aging population. 
Anthracycline-based chemotherapy with or without consolidation with ASCT 
was by far the most commonly used regimen in younger patients. By contrast in elderly 
patients there were almost none treated with ASCT, but significant numbers of patients 
treated with less powerful regimens like no anthracycline-based chemotherapy, 
radiotherapy alone, or no treatment at all. All three options were equally distributed. 
Interestingly, among these less intense modalities radiotherapy alone was the most 
common one used in early stage disease in elderly and in younger patients. The 
treatment was efficient and without generalised side effects. As expected in the 
evaluation of curative and palliative treatment groups, a higher number of patients 
treated with palliative regimens were observed in elderly patients and in patients with 
early stages. In the latter group it was most likely due to frequent application of 
radiotherapy only for stage I disease. It is likely that clinicians treating patients with 
limited disease opted for less intense treatments. In advanced stage disease the choice of 
a less powerful treatment was most probably associated with the increasing age of 
patients and performance status. By contrast a young age encourages clinicians to 
choose more intensive regimens. In Varga et al standard anthracycline-based 
chemotherapy was successfully administered to 32.5% of patients aged 80 or more as 
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compared with 86.6% of the younger group (Varga et al., 2014). Suboptimal therapy 
was given to 25% vs. 6% and no therapy to 40% versus 5.2%. Patients, who did not 
receive standard chemotherapy were characterized by significantly higher ECOG 
scores, more advanced stage disease and lower albumin levels as compared with those 
who received standard treatment. Importantly, there were no differences in the Charlson 
comorbidity index (Varga et al., 2014). The data of Maartense et al. shows that the 
cohort of elderly patients was characterised by significantly lower numbers treated with 
anthracycline-based chemotherapy and higher numbers of patients treated with 
chemotherapy not including anthracyclines. Also significantly more elderly patients 
received no treatment (Maartense et al., 1998). The number of patients treated with 
surgery only or radiotherapy only was comparable in both groups. Obviously it needs to 
be noted that these numbers refer to all types of NHL. Thieblemont et al, studied very 
elderly patients aged 80 or more. The majority of those with an aggressive lymphoma 
were treated with anthracycline-based chemotherapy (47.1%), followed by 22.5% 
administered a single agent, 21.6% administered multidrug chemotherapy not including 
anthracyclines and 8.8% who received no treatment (Thieblemont et al., 2008). This 
data indicates that 47.1% of this cohort was treated with curative intent and 52.9% 
palliatively. This approach is in keeping with our results. The study by Boslooper et al 
confirmed these results in the rituximab era (Boslooper et al., 2014). A regional cancer 
registry was employed to analyse patients aged 75 and over in terms of treatment and 
outcome (Boslooper et al., 2014). The majority of patients - 80 (78%) received 
immunochemotherapy, 9 (9%) radiotherapy only, and 12 patients (11%) supportive 
treatment only. This means that approximately 22% of patients received palliative 
treatment (Boslooper et al., 2014). 
Within anthracycline-based regimens we observed some variation. CNOP differs 
from standard CHOP by using mitoxantrone instead of doxorubicin and was used 
mostly in elderly patients. Mitoxantrone is an antineoplastic agent belonging to the 
anthracenediones group. It is thought to be less cardiotoxic than anthracyclines e.g. 
doxorubicin and thus is commonly used in patients vulnerable to cardiac side effects 
e.g. elderly. Unfortunately it is not as efficient as anthracyclines. VACOP-B, a third 
generation regimen, in our cohort was used more often in younger patients, particularly 
in those with early stage disease. This regimen is more time intense and thus probably 
more often used in younger individuals. 
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Combined modality treatment was more often used in younger patients, and in 
patients with early stage disease in both age groups. Although the data on radiotherapy 
in aggressive lymphomas is very poor, the treatment is associated with relatively small 
numbers of side effects and patients may still benefit, particularly those with limited or 
bulky disease. Clinicians were possibly motivated by the latter to employ this modality 
in patients with high-risk tumours. 
Although this study was not designed as a direct comparison of the outcome of 
different treatment modalities we will briefly discuss the results. The ORR, PFS and OS 
as expected were statistically significantly higher in younger patients, and in patients 
with early stage disease in both age groups. This was also true for all treatment 
modalities and groups and the evaluation of curative and palliative treatment groups. An 
ORR above 50% was observed in younger and elderly patients with early stage disease. 
In patients with advanced disease it was 46.8% in younger patients and 32% in the 
elderly. The results of different modalities suggest that patients with DLBCL have poor 
response rates unless they receive anthracycline-based chemotherapy. The ORR for 
chemotherapy without anthracyclines or groups receiving no chemotherapy and no 
radiotherapy was as low as 20% in both groups. The radiotherapy only group deserves 
special mention. As the only treatment group, which did not use anthracyclines, it was 
characterized by an ORR comparable with that from anthracycline-based chemotherapy 
group. This was however the case for early-stage disease only, the results for advanced 
stage were poor. Because the radiotherapy only group was classified as palliative 
treatment for the purpose of this evaluation it contributes to the relatively high ORR in 
this group in younger patients. Varga et al. also reports significantly lower CR rates in 
elderly patients, aged 80 years or over (Varga et al., 2014). Hasselblom et al divided 
patients into two age groups ≤68 years and >68 years; the CR and CRu rates did not 
significantly differ between the two groups (61% and 60%; p=0.86) (Hasselblom et al., 
2007). However in the group aged >80 years the CR / CRu rate was significantly lower 
at 44%. Maartense et al. reports a significantly higher CR rate in patients aged 70 or less 
in an evaluation of all patients and for all assessed treatment modalities in patients with 
NHL (Maartense et al., 1998). The differences between both age groups were 
significant for intermediate grade lymphoma and DLBCL. In Thieblemont et al the CR 
rate in very elderly patients with aggressive lymphoma aged > 80 years was 36% only 
(Thieblemont et al., 2008). 
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The results of PFS and OS follow those of the ORR. Despite all the limitations 
of this study, we see that the PFS and OS in patients treated with anthracycline-based 
chemotherapy were significantly lower than those reported in clinical trials, only being 
over 50% in early stage disease in younger patients. By contrast PFS and OS for 
palliative groups in elderly patients were only 10-20% or lower depending on the PS of 
patients. It should be emphasized that a direct comparison between treatment groups is 
not appropriate for this evaluation, as the design of the study did not allow for this. This 
is particularly important for patients with or without ASCT as consolidation, as those 
undergoing ASCT were preselected for this treatment at diagnosis due to high-risk 
disease. Interestingly, the relatively high ORR achieved in patients with early stage 
disease treated with radiotherapy alone were not reflected by the results of PFS and OS 
when compared with patients treated with standard anthracycline-based chemotherapy. 
In Varga et al, OS at 12 months calculated for all patients was significantly higher in 
younger patients. In the elderly group, patients who completed standard chemotherapy 
achieved the best survival rates. The worst survival data came from the group given no 
treatment. Patients with sub-optimal treatment were between these two groups. Elderly 
patients who completed standard treatment and obtained a CR had comparable OS to 
the younger patients. The data on event-free survival confirms these observations 
(Varga et al., 2014). The group of patients with NHL aged 70 or more in Maartense et 
al. was characterised by a significantly lower 5-year OS when compared with the 
younger patients (Maartense et al., 1998). This was confirmed in patients with 
intermediated grade lymphoma by WF and in DLBCL. By contrast there were no 
differences in disease free survival for all the above named groups. Thieblemont et al 
reports a median OS of 1.2 years only in very elderly patients aged > 80 years 
(Thieblemont et al., 2008). Hasselblom et al reports that age ≤60 years and >60 years 
was a statistically significant factor in univariate and multivariate analysis for OS in 
curatively treated patients and in all patients (Hasselblom et al., 2007). In the evaluation 
of PFS it was a significant factor in multivariate analysis for all patients but not for 
curatively treated patients. In conclusion the outcome of elderly patients was worse in 
all these publications. 
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Evaluation of impact of age as continuous variable on progression free survival and 
overall survival 
The analysis of patients according to age decades delivered interesting results. In 
the evaluation of all patients, three separate groups were defined on the basis of 
differences in the OS rates between patients in different age decades: patients aged 60 
years or less, patients between 60 – 70 years and those above 70. By contrast, based on 
PFS we could separate only two groups; 70 years or less and more than 70. In early 
stage disease in patients analysed by OS the same three groups were defined and 
according to the PFS we could still separate two groups. However the age limit was 60 
years. In advanced stage disease we could distinguish between patients aged 70 years or 
less and more than 70 by both OS and PFS. This data corresponds with the observation 
that patients with advanced disease in their 60s should be treated with regimens 
designed for younger patients rather than with those for elderly patients. In patients with 
early stage disease the situation is not so obvious with the age limit of 60 years. This 
should be taken into consideration when new trials for patients with DLBCL are 
designed. The Dutch group of Maartense et al also studied the significance of age limits 
for patients with DLBCL (Maartense et al., 2000). They found that patients aged 65 or 
more had rapidly decreasing rates of CR and OS. This data is the opposite of ours, 
confirming the use of an age limit of 60 – 65 years for distinguishing younger and older 
patients. Importantly, the study of Maartense et al. included patients treated with 
different modalities whereas ours included only those receiving anthracycline-based 
chemotherapy. It is likely that patients receiving other treatment modalities were less fit 
and thus their response to treatment were worse confounding the age limits.  
 
Evaluation of International Prognostic Index 
The IPI is the most commonly used prognostic index for patients with DLBCL. 
It was developed in the late 1980’s and published in the early 1990’s as a response to 
increasing demand to supplement the Ann Arbor staging system in patients with 
DLBCL. The latter was primarily developed for HL and emphasises the distribution of 
nodal disease, because HL commonly spreads through continuous groups of lymph 
nodes (Carbone et al., 1971). Since the pattern of disease spread is different in NHL it is 
obvious that the Ann Arbor system is less accurate in DLBCL (Rosenberg, 1977). The 
IPI was developed based on a cohort of 3273 patients coming from different centres in 
Northern America and Western Europe. Complete data was available for 1872 patients 
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and 1385 were randomly selected for the dataset. Patients had a de novo diagnosis of 
diffused mixed, diffuse large-cell, or large-cell immunoblastic lymphoma (WF 
categories F, G, and H); diffuse centroblastic-centrocytic, centroblastic, immunoblastic 
or unclassified high-grade lymphoma (Kiel classification); or diffuse mixed 
lymphocytic-hystiocytic or diffuse histiocytic lymphoma (Rappaport classification). 
Unfortunately, at this time several different classification systems for lymphomas were 
in use in participating countries, which could lead to significant heterogeneity of the 
cohort. All patients were treated with a combination-chemotherapy regimen containing 
doxorubicin. The IPI and aaIPI for patients younger than 60 years were developed. 
Our cohort includes only patients with a diagnosis of DLBCL and only patients 
from Northern England and Scotland. Like the original paper all our patients received 
anthracycline-based chemotherapy. The IPI was previously evaluated in other cohorts of 
patients however ours is the most representative as it has the highest number of patients 
and is population-based. Comparing both cohorts the distribution of patients in each risk 
group was very similar; for low and intermediate low risk groups with 35% vs. 38% and 
27% vs. 26%; original vs. SNLG cohort respectively. For high intermediate and high 
risk groups the values were 16% vs. 22% and 22% vs. 14%; original vs. SNLG cohort 
respectively. For the aaIPI in the cohort of patients aged <60 years the comparisons 
were very similar with 22% vs. 29% in low risk group, 32% vs. 32% in low 
intermediate risk group, 32% vs. 31% in high intermediate risk group and 14% vs. 8% 
in high risk group; original vs. SNLG. 
The 5-years OS in IPI groups was comparable for low, low intermediate and 
high-risk groups with 73% vs. 67%, 51% vs. 46% and 26% vs. 27%. For the high 
intermediate group the 5-year OS of our cohort was surprisingly low 43% vs. 25%, 
original vs. SNLG cohort. We cannot find any explanation for this phenomenon. For the 
aaIPI the 5-years OS was comparable for all risk groups: 83% vs. 88% (low); 69% vs. 
62.5% (low intermediate); 46% vs. 41% (high intermediate) and 32% vs. 33% (high); 
original vs. SNLG cohort respectively. In the original IPI cohort and also in our cohort 
group the differences in OS between the individual risk groups were statistically 
significant in over all evaluation. The pair-wise evaluation was not presented in the 
original paper, however in our cohort we found significant differences except for low 
risk group and low intermediate risk group. Additionally, an evaluation of PFS was 
performed in our cohort and statistically significant differences were recorded in over 
all evaluation. In pairwise evaluation there were no statistically significant differences 
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between low risk group and low intermediate risk group and between low intermediate 
risk group and high intermediate risk group. For aaIPI, in an overall evaluation, the 
differences in OS were statistically significant for all risk group in the original 
evaluation and in our cohort, also for PFS. In pairwise evaluation in our cohort, we were 
not able to show significant differences between the high intermediate risk group and 
high risk group. 
Armitage et al presented similar results on IPI in a study, which collected newly 
diagnosed NHL cases from 8 centres. The first 200 eligible cases from each centre were 
included (Armitage and Weisenburger, 1998). However both intermediate groups low 
and high were merged for the purposes of the evaluation. The IPI was also re-valuated 
in population-based studies on DLBCL by Hasselblom and Krol (Hasselblom et al., 
2007) (Krol et al., 2003). In the study of Hasselblom the IPI and aaIPI strongly 
predicted OS but the differences between the low intermediate and high intermediate 
groups were rather small though still significant in the aaIPI model but not in the IPI 
(Hasselblom et al., 2007). The IPI and aaIPI were strongly predictive factors in the 
multivariate analysis of the curative group and all patients in this study. In Krol et al 
population-based registry study the IPI was available in 376 of 470 patients and 143 
patients were in the low risk group, 96 in the low intermediate risk group, 66 in the high 
intermediate risk group and 71 in the high risk group (Krol et al., 2003). Median 
survival for the four groups was 80, 20, 7 and 5 months respectively (p<0.001). 
In conclusion, the IPI is a robust and stable tool for prediction of survival in 
patients with DLBCL. However it has its limitations in certain groups of patients. 
Unfortunately the IPI is not universally used for patients with DLBCL. Thus 
comparison of results between individual studies still remains difficult. 
 
Prognostic value of duration of first remission on overall survival 
Some recent publications emphasize the influence of duration of first remission 
on the OS of patients with DLBCL. The GELA assessed the role of duration of first 
remission in DLBCL patients included in its trials. They found significantly shorter OS 
in patients who did not achieve remission, and those with shorter remission duration 
compared with those with PR, longer remission duration and patients with CR (Coiffier 
et al., 2008). 
One of our aims was to assess the influence of duration of first remission in a 
population-based setting in patients with DLBCL treated with standard anthracycline-
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based chemotherapy, and to further assess the possible differences in clinical features, 
(including IPI), between patients with different durations of first remission. 
Unfortunately it was not possible to obtain a precise remission status (CR vs. PR) for 
the majority of our patients. Thus the duration of remission was used as the main factor 
to select patients for the purposes of the evaluation. Patients were assigned to one of the 
following groups: 1) “refractory group” - patients who did not respond to first line 
treatment or relapsed within nine months from diagnosis (566 patients – 41%), 2) “early 
relapse group” - patients who relapsed within 9 – 18 months from diagnosis (92 patients 
– 7%), 3) “late relapse group” - patients who relapsed later than 18 months from 
diagnosis (120 patients – 9%) and 4) “no relapse group” - patients who did not relapse 
(597 patients – 43%). In younger patients, aged ≤60 years, the proportions were 33%, 
7%, 8% and 52% respectively, and in elderly patients aged >60 years 46%, 7%, 9% and 
38%. The increased number of patients in the “refractory group” in elderly patients 
could be explained by the generally worse prognosis of the disease in this group of 
patients. 
Our results confirm the significant role of duration of first remission on OS of 
patients with DLBCL. The statistically significant highest 5-years OS was in the group 
with the longest remission time; the “no relapse group” (90%), followed by the group 
with the second longest, remission time; the “late relapse group” (50%), the “early 
relapse group” (16%) and the group with the shortest remission, the “refractory group” 
(8%). These results were confirmed both in younger patients aged ≤60 years – where 5 
year. OS was 94%, 66%, 31% and 13% respectively (p<0.001) and in elderly patients 
aged >60 years, 85%, 40%, 65 and 4% respectively, p<0.001. 
The GELA study assigned 7198 participating patients into five groups 
depending on quality and duration of remission (Coiffier et al., 2008). The 7 year OS 
was as follows: 1) patients with CR – above 90%, 2) patients with PR and 3) patients 
with early relapse (within first year) – both 38%, 4) patients with late relapse and 5) 
patients non-responding / refractory – both 12%. The data for patients treated with 
immunochemotherapy were similar to these except that OS for all groups tended to be 
higher. If we compare the GELA and SNLG results: we can conclude that the results are 
similar indicating that obtaining a remission and sustaining it for the longest possible 
period is crucial for long-term survival. Unfortunately the GELA PR group has no 
counterpart in our evaluation as our “no relapse group” does not distinguish between 
CR and PR. 
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To assess potential differences in clinical features of patients at presentation the 
individual groups were compared pair-wise: “refractory group” vs. “early relapse 
group”, “early relapse group” vs. “late relapse group” and “late relapse group” vs. “no 
relapse group”. The groups were compared for the following 13 clinical factors: age, 
sex, CS, B-symptoms, ECOG, extranodal and BM involvement, bulky disease, Hb, 
leukocytes, LDH, albumin, urea, and serum AP level. As suspected, the groups with the 
largest differences in OS were characterised by the largest differences in clinical 
characteristics at diagnosis – “the refractory group” vs. “early relapse group” and “late 
relapse group” and “no relapse group” followed by the “early relapse group” vs. “no 
relapse group”. By contrast, the groups with the smallest differences in OS, varied only 
by a single factor, e.g. “early relapse group” vs. “late relapse group” and “late relapse 
group” vs. “no relapse group”. CS, B-symptoms and ECOG were the most frequently 
variable factors. All are included in the IPI. CS and BM involvement were the only 
factors, which statistically distinguished between groups with small differences in OS, 
for example the “early relapse” and “late relapse group” and more importantly the “late 
relapse ” vs. “no relapse group”. The IPI, has the power to distinguish between the 
groups with the largest differences, but was not enough strong to distinguish between 
the groups with similar survival e.g. “early relapse group” vs “late relapse group” and 
“no relapse group” vs “late relapse group”. Additionally it lost power in individual 
evaluations between younger and elderly patients, probably due to decreasing patient 
numbers in the groups. In the GELA study the IPI also could not distinguish between 
individual groups (Coiffier et al., 2008). It is difficult to discuss these results further, as 
the IPI was not developed for this purpose. 
Interestingly, the data on remission quality in patients with FL treated in GELA 
studies also confirms statistically significant longer OS for patients with CR as 
compared to those with PR (Bachy et al., 2010). 
In conclusion, the data from both clinical trials and population-based studies on 
the duration and depth of remission in patients with DLBCL shows that better quality 
and longer duration of the achieved remission are associated with longer OS. This 
possibly indicates that regimens that result in achievement of the best possible, and 
longest remissions should be favoured at diagnosis. Additionally, it is impossible to 
entirely distinguish between the individual remission groups by clinical features or IPI 
at diagnosis. We conclude that the current prognostic indices based on clinical factors 
need to be enhanced using biological features of the tumour. 
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Evaluation of addition of rituximab to anthracycline-based chemotherapy 
The advent of rituximab in the treatment of DLBCL was a break through event. 
It has contributed to the creation of new terms like pre-rituximab and post-rituximab 
era. The first results of the addition of rituximab come from randomized trials (Coiffier 
et al., 2002) (Feugier et al., 2005) (Habermann et al., 2006) (Pfreundschuh et al., 2006) 
(Pfreundschuh et al., 2008), and represent generally better results than expected in the 
patient population, mostly due to patient pre-selection. More recently, several 
population-based analyses of patients with DLBCL in the post-rituximab era were 
published (Sehn et al., 2005) (Krause et al., 2012) (Keegan et al., 2013) (Lee et al., 
2012). The first population-based study to assess the impact of rituximab on outcomes 
of patients with DLBCL comes from the province of British Columbia in Canada. This 
retrospective study was carried out between September 1999 and August 2002, a 3-
years period representing 18 months pre-rituximab (140 patients) and 18 months post 
the introduction of rituximab (152 patients) (Sehn et al., 2005). Lee et al performed a 
population-based analysis of all patients in the province of Ontario between Jan 1997 
and Dec 2007 (Lee et al., 2012). All patients had a new diagnosis of DLBCL and 
received at least one cycle of CHOP-based chemotherapy, with or without the addition 
of rituximab (Lee et al., 2012). Patients from the CHOP group were then matched 
according to the clinical data at presentation, and the OS was calculated for both groups, 
and for individual age groups. Keegan et al evaluated the impact of adding rituximab to 
chemotherapy in DLBCL patients based on the National Cancer Institute’s Patterns of 
Care studies (Keegan et al., 2013). Krause et al performed a population-based study 
based on the data of a single tumour centre cancer registry comparing the outcome of 
patients with de novo aggressive lymphomas (Krause et al., 2012). 
In our study we assessed for the first time in a population-based setting the 
influence of the addition of rituximab to anthracycline-based chemotherapy for patients 
with DLBCL, treated in the NHS. The new data was compared to an historical cohort of 
patients treated with CHOP in the same service. Both cohorts were comparable with the 
exception for a smaller number of patients with BM involvement in the 
immunochemotherapy group and more elderly patients. In the study of Lee et al. all 
patients in the CHOP-R group were significantly older, and had higher comorbidity 
scores (Lee et al., 2012). By contrast in Krause et al there were no differences between 
the treatment groups in terms of age and sex (Krause et al., 2012). In the British 
Columbia study by Sehn et al no differences were described between the patients from 
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the pre-rituximab and post-rituximab eras according to sex, age, performance status, 
LDH, extranodal site numbers, CS, bulky disease and IPI. 
In our cohort of patients doxorubicin was changed to mitoxantrone in the same 
number of patients treated with chemotherapy only and immunochemotherapy. 
However, we observed an increase in the use of additional radiotherapy in the patients 
treated with immunochemotherapy, particularly in the patients aged ≤60 years. This 
may be due either to improvement of results with the new regimen or new data 
supporting the use of combined modality treatment, plus general motivation to sustain 
remissions in younger patients. Krause et al. reported the same number of patients 
receiving additional radiotherapy in the chemotherapy only and chemotherapy with 
addition of rituximab groups (Krause et al., 2012). By contrast Sehn et al described 
more patients receiving post-chemotherapy radiation in the post-rituximab era compared 
with patients from the pre-rituximab era (24% vs. 14%, respectively; p=0.04) (Sehn et 
al., 2005). 
Statistically significant differences in ORR were observed in the evaluations of 
all patients, younger and elderly patients, and in all stages with the exception of early 
stage in younger patients. Anthracycline-based chemotherapy boosted by radiotherapy, 
(combined modality treatment), which was commonly used in the region in the pre-
rituximab era was probably sufficient for this group of patients. 
As suspected in the evaluation of all patients there was a statistically significant 
increase in the duration of PFS and OS. However the differences were significant only 
in patients with advanced stage disease and not early stage disease. This was also 
observed in the evaluation of younger patient. By contrast in the evaluation of elderly 
patients the difference remained for PFS but not for OS. Importantly, there were no 
statistically significant differences in OS for any of the stage groups in elderly patients. 
The study of Sehn et al, which was characterised by short follow-up described 
differences in OS at 2 years between patients treated with and without rituximab. In the 
evaluation of all patients there were significant differences in PFS and OS between both 
groups (PFS: 51% vs. 69%, p=0.002 and OS: 52% vs. 78%, p<0.0001), and in elderly 
patients (PFS: 44% vs. 68%, p=0.007 and OS: 42% vs. 73%, p=0.0003). However, in 
younger patients there were significant differences in OS but not in PFS; PFS: 60% vs. 
70%, p=0.13 and OS: 67% vs. 85%, p=0.02). Lee et al reported a similar 5-year OS of 
57% in the group of all patients treated with R-CHOP. By contrast, in an evaluation of a 
matched group of patients the difference in 5-year OS was significant for all patients, 
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patients aged 60 or more, and patients aged 60 – 80, but not for very elderly patients 
aged 80 or over. In Keegan et al. patients who received chemotherapy with the addition 
of rituximab had better OS, but patients with impaired performance status, elevated 
LDH and advanced stage disease had worse OS (Keegan et al., 2013). In Krause et al. 5-
year survival in the chemotherapy plus rituximab group was significantly better than the 
chemotherapy only group, 69.6% vs. 56.8% (Krause et al., 2012). 
In conclusion data from clinical trials and population-based studies confirms the 
positive influence of the addition of rituximab on the outcome of patients with DLBCL. 
However this influence varies in different patient groups. 
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Chapter 3. Studies on new prognostic molecular markers for DLBCL 
 
3.1 Introduction 
 Better risk stratification and prediction of response to standard therapy and 
selection of the high-risk groups suitable for more intensive and novel therapy 
approaches are essential in order to target the treatment of DLBCL more effectively. All 
previously described prognostic markers including: individual biomarkers, GEP studies 
or IHC models are currently not used in routine practice due to different reasons 
including costs, requirement of fresh material or reliability. The limited amount of 
diagnostic tissue in the era of small biopsies is another currently arising issue (Rimsza 
et al., 2008). 
In recent years the qPCR became a very reliable and efficient tool in 
investigating gene expression. Originally the method required use of fresh or snap-
frozen material in order to achieve true and reproducible results. Thus, it was mostly 
used in the diagnosis of leukaemias and other conditions with easy access to fresh 
material. The measurement of BCR-ABL fusion gene in diagnostic and treatment 
monitoring of chronic myeloid leukaemia (CML) is one of the best known examples of 
employment of qPCR in routine diagnostics. The introduction of modern highly 
efficient RNA extraction methods and enzymes for reverse transcription (RT) and qPCR 
changed the situation. Now qPCR can be successfully applied in the genetic material 
extracted from FFPE tissue. This opened entirely new opportunities for qPCR 
application in routine diagnosis of solid tumours. However, the degradation of RNA 
still remains one of the main unsolved issues. The selection of primer sets for possibly 
short amplicon and housekeeper genes for control are crucial conditions of success. 
In the following studies, we aim to investigate the application of qPCR in 
assessment of gene expression for survival prognosis in patients with DLBCL. We 
selected two genes: c-MYC and HLA-DRβ. Both were previously described as 
prognostic in single biomarker studies and GEP studies (Rosenwald et al., 2002) 
(Rimsza et al., 2004) (Rimsza et al., 2007) (Veelken et al., 2007) (Chang et al., 2000). 
The overexpression of c-MYC protein is associated with increased tumour proliferation 
and the loss of expression of HLA-DRβ protein with absence or reduction in 
immunosurveillance. Importantly, Rimsza et al. re-analyzed the expression of 36 genes 
with significant impact on patient survival in previous GEP studies in RNA extracted 
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from FFPE tissue samples of DLBCL patients treated with R-CHOP (Rimsza et al., 
2008). The applied quantitative S1 nuclease protection assay is suitable for analysis of 
gene expression in the material extracted form FFPE samples. The expression of the 
only two genes: c-MYC and HLA-DRβ was significantly associated with patient 
survival, and they together with IPI were included in a new prognostic model. The 
model was based on high expression of one of the major proto-oncogenes responsible 
for cell proliferation and low expression of an MHC gene playing a key role in 
immunosurveillance. The abundance in expression of these two genes is also a defining 
attribute of BL, suggesting that lack of immunosurveillance and high proliferation are 
the key features defining the most aggressive lymphomas (Rosenwald et al., 2002) 
(Dave et al., 2006) (Hummel et al., 2006) (Rimsza et al., 2007). Bearing in mind 
significant improvement of outcome in patients with BL with introduction of more 
intensive chemotherapy regimens (R-CODOX-M/IVAC or GMAIL), there could be a 
hope that the patients selected with this predictive model would benefit from these 
regimens despite toxicity. 
We also studied the prognostic role of a non-coding transcript: version 2 of the 
gene chromosome 13 open reading frame 25 (C13orf25), called also v2-transcript. The 
v2-transcript is encoded within the 13q31-32 chromosomal region and a high degree of 
amplification of this region was identified in haematological malignancies including 
DLBCL (Rao et al., 1998) (Ota et al., 2004). v2-transcript plays potential role in 
oncogenesis of haematological malignancies (Ota et al., 2004). It encodes a miRNA 
cluster (miR-17-92), consisting of seven mature miRNAs: miR-17-5p, miR-17-3p, miR-
18, miR-19a, miR-19b, miR-20, and miR-92 (Ota et al., 2004) (He et al., 2005), which 
have been shown to act in an oncogenic capacity (He et al., 2005). Thus, additionally 
we aim to address the question of application of qPCR in assessment of v2-transcript 
and miRNAs encoded in v2-transcript as new prognostic biomarkers in DLBCL. The 
techniques used for miRNA assessment are novel and required completely new 
approach including new extraction methods of RNA and qPCR. 
 
3.1.1 c-MYC 
 c-MYC oncogene was originally identified in the avian myelocytomatosis virus 
and subsequently its oncogenic potential was described in several cancer types (Adams 
et al., 1985). The normal cellular proto-oncogene, c-MYC, encodes the protein c-MYC, 
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a transcription factor. The c-MYC is located in chromosome 8 and consists of 3 exons 
separated by 2 introns. The first exon codes for an untranslated leader; see figure 3.1.a. 
 
(A) 
RESEARCH ARTICLE
Differential Expression of the
Translocated and the Untranslocated
c-myc Oncogene in Burkitt Lymphoma
Abbas ar-Rushdi, Kazuko Nishikura, Jan Erikson
Rosemary Watt, Giovanni Rovera, Carlo M. Croce
In approximately 90 percent of Burkitt
lymphomas the malignant 'cells show a
reciprocal translocation between chro-
mosomes 8 and 14 [t(8;14)], whereas in
the remaining 10 percent the cells show
4). The human cellular homolog, c-myc,
of the transforming gene of the avian
myelocytomatosis virus, v-myc, is nor-
mally located on human chromosome 8
(5-6). In Burkitt lymphoma cells, howev-
Abstract. Burkitt lymphoma cells carrying either a rearranged or unrearranged c-
myc oncogene were examined with the use ofprobes from the 5' exon and for the
second and third exon of the oncogene. The results indicate that the normal c-myc
gene on chromosome 8 and the 5' noncoding and 3' coding segments of the c-myc
oncogene separated by the chromosomal translocation are under different transcrip-
tional control in the lymphoma cells. Burkitt lymphoma cells carrying a translocated
but unrearranged c-myc oncogene express normal c-myc transcripts. In contrast,
lymphoma cells carrying a c-myc gene rearranged head to head with the immuno-
globulin constant ,u region gene express c-myc transcripts lacking the normal
untranslated leader.
either a t(2;8) or a t(8;22) chromosome
translocation, the breakpoint on chromo-
some 8 being consistently on band q24
(1). By examining somatic cell hybrids
between mouse cells and Burkitt lym-
phoma cells we have found that the
breakpoint on chromosome 14 in Burkitt
lymphoma cells with the t(8;14) translo-
cation is within the immunoglobulin
heavy chain locus (2) and that genes for
the heavy chain variable region (VH)
translocate from c romo ome 14, wher
they normally reside (3), to the deleted
chromosome 8 in the lymphoma cells (2,
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er, c-myc translocates to the heavy chain
locus (5). In some cases, the translocated
c-myc gene is not rearranged within a
large DNA restriction (Bam HI) frag-
ment, in others it rearranges 5' to 5'
(head to head) with the immunoglobulin
constant ,u region gene (C,, gene) (5, 7).
The cell lines JD38 IV and ST486
contain a rearranged and a normal c-
myc gene. Recently, we sh wed that
high levels of c-myc transcripts are de-
tectable in Burkit lymphoma c ll l nes
(4, 8). We also showed that hybrids
between mouse myeloma and Burkitt
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Fig. 1. A simplified map of the human c-myc gene in pBR322 (pMyc4l * HE) (10) and the
restriction sites relevant to the studies in this article. Genomic and cDNA probes used in
Southern and Northern hybridizations are: (a) an Xho I-Pvu II leader fragment of449 base pairs
within exon-I (probe A); (b) a 1029-base pair fragment obtained from the Pst I digest of cDNA
clone (pRyc7.4) which includes 221 base pairs of the 3' end of exon-II and all of exon-IIl (8).
Shaded areas indicate exons; unshaded areas, intron and flanking regions.
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lymphoma cells carrying the translocat-
ed human c-myc oncogene express high
levels of human c-myc transcripts,
whereas hybrids carrying the untranslo-
cated c-myc oncogene on the normal
chromosome 8 do not (8). These results
indicate that the translocated and un-
translocated c-myc oncogene are under
different control in B cells (8). In the
present study we investigated the ex-
pression of human c-myc transcripts in
three lymphoma cell lines. One of these
cell lines, Daudi, carries an unrearranged
c-myc oncogene translocated to human
chromosome 14 (5, 7). The other two,
JD38 IV and ST486, carry a c-myc onco-
gene rearranged head to head with an
immunoglobulin C,, gene (5, 7). We dem-
onstrated recently that the human c-myc
oncogene has'three exons separated by
two introns (9, 10), and that the first
exon codes for an untranslated leader (9)
which is normally expressed in lympho-
blastoid cell lines and in other human cell
lines (10).
Using the Southern blotting technique,
we examined Bam HI, Hind III, and Xba
I digests of the DNA from three indepen-
dent lymphoma cell lines with a comple-
mentary DNA (cDNA) probe (Ryc7.4)
specific for the second and third exon of
the c-myc gene (Fig. 1, probe B) and with
a genomic probe specific for the first c-
myc exon (Fig. 1, probe A). As shown in
Fig. 2, while Daudi cells contain both c-
myc genes unrearranged, the other two
lymphoma cell lines (JD38 IV and
ST486) contain a rearranged and a nor-
mal c-myc gene. Hybridization of the
DNA from these cell lines with a probe
specific for the 5' exon (Figs. 3 and 4),
however, indicated that the first noncod-
ing exon is separated from the two cod-
ing exons in JD38 IV and ST486 lympho-
ma cells that contain one rearranged c-
myc gene (Figs. 3 and 4). Thus, in JD38
IV and ST486 cells the break occurred
between the first and the second exon.
The two segments of the rearranged c-
myc gene are on two different chromo-
somes: the 5' noncoding exon remains of
the long arm of chromosome 8 (8q-) and
the two coding exons translocate to the
long arm of chromosome 14 (14q+). Pre-
vious studies have shown that the 5'
exon is proximal and the 3' exon distal
on band q24 of chromosome 8 (5, 7-8).
Only the translocated myc gene is
transcribed in Burkitt lymphoma. The c-
Abbas ar-Rushdi is a visiting scientist, Kazuko
Nishikura is assistant professor, and Jan Erikson
and Rosemary Watt are graduate students in the
Molecular Biology graduate group of the University
of Pennsylvania. Giovanni Rovera is professor and
Carlo M. Croce is professor and associate director of
the Wistar Institute, Philadelphia, Pennsylvania
19104.
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Figure 3.1. c-MYC structure. (A) A simplified map of then human c-MYC gene (ar-
Rushdi et al., 1983) (B) Functional domains of human c-MYC protein (Pelengaris and 
Khan, 2006). 
 
The physiological role of c-MYC protein is very versatile in healthy cell; it 
promotes cell cycle progression and is involved in cell differentiation, cell growth, 
apoptosis and angiogenesis (Coller et al., 2000). In order to become transcriptionally 
active c-MYC requires dimerization with another protein called c-myc-associated factor 
X (MAX). c-MYC possesses three functional domains: 1) the C-terminal domain (CTD) 
including helix-loop-helix leucine zipper motif for dimerization with MAX, 2) the N-
terminal domain (NTD) containing conserved c-MYC boxes I and II (MB I and II) 
domain essential for transactivation of c-MYC target genes and 3) the central region 
including MB III which negatively influences apoptosis (see figure 3.1.b) (Pelengaris 
and Khan, 2006) (Nilsson and Cleveland, 2004) (Herbst et al., 2005). In health, c-MYC 
is not expressed in all cells. The cells possessing high proliferative capacity (e.g. 
epidermis) are characterized by high expression whereas it is undetected in cells which 
have exited the cell cycle (Pelengaris and Khan, 2006). 
c-MYC has a very important role in cell growth and proliferation. c-MYC genes 
belongs to the early-response genes induced within 15 minutes from the binding of 
growth factor to the receptor and allowing cells to exit G0 and enter the cell cycle. By 
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contrast, in non-proliferating cells, c-MYC is inactive. During oncogenic activation of c-
MYC the cell is a subject of constant stimulation. The regulation of cell proliferation 
happens via induction of cyclin dependent kinase E-CKD2 (major factor in G1 – S 
progression) by c-MYC protein. Additionally c-MYC protein influences the cell-cycle 
by repression of genes encoding cyclin-dependent kinase inhibitor (CKIs) p15INK4b and 
p21CIP1, factors involved in cell cycle arrest (Pelengaris and Khan, 2006). Finally, c-
MYC potein has an ability to remodel chromatin by methylation (Brenner et al., 2005). 
The mechanism of the influence of c-MYC protein on cell growth is not entirely 
understood but it happens via the activation of RNA polymerase III, however the recent 
studies indicate that all three nuclear RNA polymerases are activated by c-MYC protein 
(Gomez-Roman et al., 2003). 
The terminal differentiation of proliferating cells requires their exit from the cell 
cycle and as the c-MYC protein keeps cells in the cell cycle it prevents their 
differentiation. Thus, unregulated levels of c-MYC protein can lead to excessive 
proliferation of cells and maturation arrest. By contrast, the differentiation of cells 
requires down regulation of c-MYC protein. The important molecule playing a role in c-
MYC suppression is Max-interacting transcriptional repressor protein (MAD) MXII, 
which polymerizes with the MAX protein preventing the synthesis of active c-MYC-
MAX dimers (Ayer et al., 1995). Some recent studies indicate that the onset of 
differentiation does not necessary involve cell cycle arrest (e.g. haematopoietic 
differentiation). Other recent studies emphasise the role of c-MYC in maintaining stem 
cell pluripotency and self-renewal (Pelengaris and Khan, 2006). 
 The pro-apoptotic features of c-MYC were discovered in the 1990’s and were 
breakthrough news (Evan et al., 1992). There is not a single mechanism of c-MYC 
induced apoptosis activation (Evan et al., 1992). One described pathway runs through 
indirect activation of tumour suppressor gene tumor protein p53 (p53) via activation of 
other tumour suppressor p19ARF (Zindy et al., 1998). c-MYC can also promote apoptosis 
by interactions with BCL2 family (repression of anti-apoptotic molecules BCL2 and 
BCLxL and induction of pro-apoptotic molecule BIM) (Pelengaris and Khan, 2006). 
Lately, it has been postulated that highly conserved c-MYC box III region is involved in 
the pro-apoptotic activity of c-MYC (Herbst et al., 2005). 
Bearing in mind the enormous importance of c-MYC in cell life and 
homeostasis, cells have evolved several control mechanism of c-MYC activity and 
accumulation (Pelengaris and Khan, 2006) (Amati, 2004). The activity of c-MYC is 
 179 
controlled by a repertoire of promoting factors: growth factors, mitogens and β-catenin 
and inhibiting factors such as TGF-β (Amati, 2004). Mature c-MYC is also a very 
unstable protein, being a subject of ubiquitin-dependent degradation (Amati, 2004) and 
protein acetylation (Patel et al., 2004). Interestingly, not all c-MYC molecules undergo 
degradation at the same time leaving preserved pools of molecules. 
Regarding the expression of c-MYC protein in human cancer, the most 
characteristic example is BL with c-MYC translocation (Swerdlow et al., 2008). In 
addition the elevated or deregulated expression of c-MYC has been detected in 
numerous other cancer types e.g. breast, colon, cervical, small-cell lung carcinomas, 
osteosarcomas, glioblastomas, melanoma, and myeloid leukaemia (Pelengaris et al., 
2002). Usually, the overexpression of c-MYC is an adverse prognostic factor and is 
associated with aggressive, poorly differentiated tumours. The mechanism of 
overexpression of c-MYC varies from translocation, through gene amplification, 
stabilization of c-MYC mRNA, enhanced initialization of translation due to mutations or 
activation of upstream signalling pathways to affected stability of the c-MYC molecule 
(Pelengaris and Khan, 2006). 
c-MYC plays an important role in lymphomagenesis. The c-MYC, human 
sequence related to the transforming gene (v-MYC) of avian myelocytomatosis virus 
(MC29), was found for the first time in the translocated region of chromosome 8q24 in 
BL cell lines (Dalla-Favera et al., 1982). The reciprocal translocation involves portions 
of chromosome 8 and chromosome 14 t(8;14)(q24;q32), or less frequently 
chromosomes 2 t(2;8)(p11;q24) and 22 t(8;22)(q11;q24). In the chromosomes 14, 2 and 
22, the breakpoints occur within the regions carrying Ig genes: on chromosome 14 
(heavy chains) or chromosome 2 and 22 (kappa and lambda light chains respectively). 
Regarding the breakpoints in chromosome 8, three different classes of translocation 
were described: class I with the breakpoint within the first exon or intron, class II with 
the breakpoints immediately upstream of the gene and class III with distant breakpoints. 
Class I and II translocation are predominant in sporadic BL and class III with the 
breakpoints up to 300 kb upstream of the gene are more frequent in endemic BL (Joos 
et al., 1992) (Siebert et al., 1998). 
The cytogenetic changes in DLBCL are complex, and the rearrangements of c-
MYC, BCL2 and BCL6 are the most common and the best characterized (Johnson et al., 
2009). According to the data of population-based NHL Registry of the Comprehensive 
Cancer Centre West (CCCW), the c-MYC rearrangements were found in 7% of samples 
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(10/151) among this group two patients had additional BCL6 rearrangements. 
Importantly, the c-MYC translocation was found predominantly in patients with primary 
extranodal disease, mostly involving the gastrointestinal tract and surprisingly was 
associated with favourable DFS (Kramer et al., 1998). In the data of Niitsu et al, the 
frequency of c-MYC rearrangements was estimated at 5.7% (28/489 and eight patients 
had concurrent t(14;18) (q32;q21) translocation. The patients with c-MYC 
rearrangements were characterised by more advanced disease, worse response and 
reduced survival. This was particularly evident in patients with concurrent BCL2 
rearrangements (Niitsu et al., 2009). The negative predictive value of c-MYC 
translocation was also confirmed in patients treated with CHOP-R (Barrans et al., 2010) 
(Savage et al., 2009). Moreover, it was confirmed that the c-MYC translocation usually 
occurs with concurrent BCL2 and BCL6 translocations and that patients carrying these 
complex karyotypes have very poor outcome. In addition, Barrans et al were able to 
create a new prognostic index based on age, IPI and c-MYC translocation status. 
Interestingly, the GELA group could not confirm the predictive value of c-MYC 
rearrangement status in their cohort of patients treated with CHOP-R. By contrast, they 
were able to develop an immune-fluorescence index predicting survival in DLBCL 
patients treated with CHOP-R. The index is based on expression of MUM1/IRF4 and 
FOXP1 and BCL6 rearrangement status (Copie-Bergman et al., 2009). The issue of 
concurrent translocation of c-MYC, BCL2 and BCL6 in B-cell lymphomas, so called 
“double or triple-hit” was addressed by several groups confirming their poor prognosis 
(Johnson et al., 2009) (Snuderl et al., 2010). This lymphoma has not benefitted from 
addition of rituximab to the anthracycline-based chemotherapy and furthermore they are 
usually resistant to standard salvage chemotherapy with R-ICE and R-DHAP (Cuccuini 
et al., 2012). 
Despite the interesting data on prognostic value of c-MYC rearrangements there 
are only few data available on the predictive value of c-MYC protein expression in 
DLBCL. This is possibly due to difficulties in IHC staining for c-MYC. However, since 
the introduction of new antibodies the situation has changed (Gurel et al., 2008). The 
pilot study of Ruzinova et al. confirmed the association between the presence of 
primarily nuclear or mixed nuclear / cytoplasmic staining pattern and c-MYC 
translocation in aggressive lymphoma (Ruzinova et al., 2010). Green et al in their study 
on 219 DLBCLs and BLs could confirm positive correlation between presence of c-
MYC translocation and expression of c-MYC protein (Green et al., 2012a). The recent 
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study from DSHNHL assessed the predictive impact of c-MYC, BCL2 and BCL6 
rearrangement status and c-MYC, BCL2 and BCL6 protein expression in patients aged 
>60 years treated with CHOP-R (Horn et al., 2013). The expression status c-MYC 
(high), BCL2 (high) and BCL6 (low) and c-MYC rearrangement status were predictive 
independently from IPI for inferior outcome. However, it is still not clear if the c-MYC 
rearrangements itself or overexpression of c-MYC protein has a conclusive impact on 
patient survival. Additionally, there is still little known about the regulation of 
expression of c-MYC in DLBCL. There is very limited information available on data on 
predictive value of increased expression of c-MYC mRNA. Some results come from a 
GEP study of Rosenwald et al and this was confirmed by the study of Rimsza et al 
(Rosenwald et al., 2002) (Rimsza et al., 2008). Hummel et al in his GEP study on BL 
proved that the presence of c-MYC rearrangements is not necessarily associated with an 
increased in c-MYC mRNA expression (Hummel et al., 2006). 
 
3.1.2 HLA-DRβ 
 HLA-DRβ is one of the genes encoding the β chain of the MHC class II 
molecule. MHC class II molecules are dimers of one α and one β transmembrane chain. 
Each chain consists of two domains α1 and α2 and β1 and β2 respectively (figure 3.2.a) 
(Janeway et al., 1999). The MHC II class molecules are present on macrophages and B-
lymphocytes and are responsible for presentation of intra-vesicular antigens to the 
CD4+ cells (Th1 and Th2) cells (Janeway et al., 1999). There are three pairs of MHC 
class II α and β chain genes: HLA-DP, HLA-DR and HLA-DQ; see figure 3.2.b. In some 
haplotypes the HLA-DR cluster contains an additional β–chain gene, which can pair 
with the HLA-DR α chain gene. Thus these three sets of genes can build four types of 
MHC class II molecules. The MHC class II genes are highly polymorphic (e.g. there are 
>200 alleles of HLA-DRβ chain) and they are characterized by co-dominant expression. 
Together with polygeny, this contributes to the diversity of MHC molecules expressed 
by an individual (Janeway et al., 1999). 
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(A) 
 
(B) 
 
Figure 3.2 HLA-DRβ structure. (A) The structure of an MHC class II molecule and (B) 
the genetic organization of the MHC in humans (Janeway et al., 1999). 
 
The expression of MHC class I and II molecules, or more precisely the lack of 
expression, in DLBCL was described as a negative prognostic factor for patients with 
DLBCL (Rimsza et al., 2004) (Rimsza et al., 2007) (Veelken et al., 2007). The 
predictive value of HLA-DRβ increases with its low expression, significantly higher 
with cut-off of 20% as compared to median cut off (Rimsza et al., 2008). The 
importance of lost MHC class II appears to be related to a loss of tumour 
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immunosurveillance as evidenced by decreased numbers of tumour-infiltrating T-cells 
(Rimsza et al., 2004) (Chang et al., 2007) (Lippman et al., 1990) (List et al., 1993). 
Bernd et al described the loss of expression of HLA-DRβ molecule together with 
immunoblastic tumour phenotype to predict adverse outcome in patients with DLBCL 
(Bernd et al., 2009). This was also confirmed by others (Rimsza et al., 2004) (Veelken 
et al., 2007). Additionally, the loss expression of MHC class II molecule genes was 
reported as related with poor patient survival. Rosenwald et al in his GEP study 
described lack of expression of HLA-DRβ, HLA-DRα, HLA-DPα and HLA-DQα as a 
prognostic factor (Rosenwald et al., 2002). Rimsza et al confirmed this results in the 
study on the FFEP tissue samples of DLBCL patients treated with R-CHOP, where 
HLA-DRβ and c-MYC were the only significant prognostic factors (Rimsza et al., 2008). 
 
3.1.3 v2-transcript and microRNAs (miRNAs) of miR-17-92 cluster 
 The miRNAs are small (~ 22 nucleotides [nt]) endogenous RNAs that are 
diverse in sequence and expression pattern and are evolutionarily widespread (Lagos-
Quintana et al., 2001) (Lau et al., 2001). MiRNAs are involved in sequence-specific, 
posttranscriptional regulatory mechanisms of gene expression. Together with short 
interfering RNAs (siRNAs), the miRNAs form a part of the RNA interference process. 
RNA interference is an RNA-dependent gene-silencing process that is mediated by the 
RNA-induced silencing complex (RISC) and is initiated by short double-stranded RNA 
molecules in the cytoplasm. The short RNA fragments are known as siRNA when they 
derive from exogenous sources such as viruses and miRNA when they are produced 
from RNA-coding genes in the cell's own genome. 
The history of miRNAs begun in the early 1990’s, when two groups, one led by 
Amros and the other by Ruvkun, found independently that larval development of the 
nematode Caenorhabditis elegans required a tiny RNA (mir lin-4) to inhibit the 
expression of the lin-14 gene (Ruvkun et al., 2004) (Lee et al., 2004). The further 
studies on miRNAs expanded the work on RNA interference and posttranscriptional 
gene silencing. At the moment it is known that miRNA genes are encoded in the 
genome of most eukaryotic organisms, and thousands of miRNAs have been identified 
to date (Griffiths-Jones, 2004). 
The miRNA are coded by miRNA genes, which are transcribed by RNA 
polymerase II into primary miRNAs (pri-miRNA). The longer pri-miRNAs are then 
processed into 60 to 70 nt long stem loop miRNA precursors miRNAs (pre-miRNA) by 
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the complex of nuclear RNase III Drosha and the DiGeorge syndrome critical region 8 
(DGRC8) protein (Denli et al., 2004) (Gregory et al., 2004) (Landthaler et al., 2004). 
The pre-miRNAs are transported from the nucleus to the cytoplasm by Exportin-5, a 
guanosine triphosphate (GTP) dependent transporter (Bohnsack et al., 2004) 
(Brownawell and Macara, 2002) (Lund et al., 2004) (Yi et al., 2003). In the cytoplasm, 
the pre-miRNAs are cleaved at the base of the loop by a second RNase II enzyme, 
Dicer, to generate an imperfect miRNA : miRNA duplex of about 21 to 24 nt (Ouellet et 
al., 2006) (Bernstein and Whitington, 1988). Dicer has been recently reported to act in 
association with the trans-activating response RNA-binding protein (TRBP) within a 
pre-miRNA processing complex (Gregory et al., 2005). After the strand 
selection/separation, mature miRNAs of about 22 nts in length in combination with 
Argonaute 2 (Ago2), Dicer and TRBP form the RISC. RISC is then guided within the 
cytoplasm towards specific mRNA. RISC can then mediate the cleavage or repression 
of target mRNA, depending whether the miRNA : mRNA pairing is perfect or not 
(Bartel, 2004). The miRNAs pathway is shown in figure 3.3. 
 
Figure 3.3 miRNA pathways (Ouellet et al., 2006). 
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 miRNAs are involved in different biological processes including the regulation 
of developmental processes (Wightman et al., 1991) (Lee et al., 1993) (Kloosterman et 
al., 2004), genome rearrangement (Mochizuki et al., 2002), gene inhibition (Volpe et al., 
2002) (Provost et al., 2002) (Savage et al., 2006) and chromosome segregation (Provost 
et al., 2002). MiRNAs are also known to regulate normal haematopoiesis (Kluiver et al., 
2006), the immune response (Rodriguez et al., 2007) and are involved in macrophage 
inflammatory responses (Taganov et al., 2007). It has also been reported that miRNAs 
play a vital role in cell growth and apoptosis (Brennecke et al., 2003) (Cheng et al., 
2005) (Chan et al., 2005) (Cimmino et al., 2005) (Calin et al., 2002). However the 
greatest interest is focused on the role of miRNAs in oncogenesis. 
The role of miRNA in disease pathogenesis was primarily assessed in 
leukaemia, because of the easy access to genetic material in this condition. The original 
data arrives from studies on involvement of miRNAs in the pathogenesis of CLL. They 
reported loss of expression of miR-15 and miR-16 in CLL cells (Calin et al., 2002) 
(Calin et al., 2004) or presence of different miRNA signatures in CLL cells and normal 
lymphocytes (Calin et al., 2004) (Calin et al., 2005). Venturini et al. assessed the role of 
miRNAs in pathogenesis of CML indicating increased expression of miRNAs from the 
miR-17-92 cluster (Venturini et al., 2007). Interesting data come also from studies on 
the oncogenic role of miRNAs in solid tumours. The studies of Volinia et al indicate 
overexpression of miRNAs in tumour tissue of lung, breast, stomach, prostate, colon 
and pancreas (Volinia et al., 2006). Takamizawa confirmed this in studies on lung and 
colon cancers (Takamizawa et al., 2004). By contrast the reduced expression of miR-
143 and miR-145 was associated with oncogenesis of colon cancer (Michael et al., 
2003). The work of Kulshreshtha focused on the role of miRNAs in mechanisms of 
hypoxia in oncogenesis indicating several miRNAs being involved (Kulshreshtha et al., 
2007). 
 Research on the involvement of miRNAs in the pathogenesis of lymphoma 
focused on the expression of miR-155 and its pri-miRNA called B-cell integration 
cluster (BIC) as well on the role of the miRNAs encoded by the miR-17-92 polycistron 
of the c13orf25 transcript variant 2. BIC was originally identified as a target for pro-
viral insertions in the avian leucosis virus (AVL) – induced lymphomas (Clurman and 
Hayward, 1989). Tuschl et al. demonstrated that BIC is the pri-miRNA of the mir-155 
(Tuschl and Borkhardt, 2002). The expression of mir155 and BIC was analysed in HL- 
and NHL-derived cell lines and patient tissue samples by both Northern blotting and in 
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situ hybridisation (ISH) (Kluiver et al., 2005). BIC was expressed in 90% of the HL 
cases, in 67% of DLBCL and in 100% of PMLBL cases. However, other cases of NHL 
revealed no expression of BIC. The expression of BIC was higher in ABC-like DLBCL 
cases compared with that observed in GC-like DLBCL, implying involvement of BIC in 
aggressiveness of the disease. These results were confirmed by qPCR in both DLBCL 
and PMLBL cases. In addition Northern blot analysis showed the expression of miR155 
in all HL, DLBCL and PMLBL cell lines and in some patient samples (Tuschl and 
Borkhardt, 2002). Recently, using semi-quantitative RT-PCR and Northern-blotting, Eis 
et al also investigated the expression of BIC and miR155 in a number of lymphoma cell 
lines (Eis et al., 2005). The expression of BIC was in concordance with the expression 
of mir155 and, as reported before by Kluiver et al (Kluiver et al., 2005). The highest 
expression was observed in ABC-like DLBCL-cells followed by HL-cells and GC-like 
DLBCL-cells. In contrast the cell lines of CML, myeloma and acute promyelocytic 
lymphoma were negative. Transfection of the HEK-293T cell line, which is negative for 
BIC and miR-155 expression, with miR-155-coding sequence (BIC) or with miR-155 
negative sequence (control) resulted in the overexpression of mature miR-155 in the 
BIC transfected cells. These findings confirmed the association between BIC and miR-
155. Quantification of BIC and miR-155 expression using the Invader RNA assay 
revealed higher expression of BIC and miR-155 in the ABC-like DLCBL samples than 
in GC-like DLBCL samples. As the ABC-like DLCBL phenotype is a more aggressive 
disease, the above findings may imply that miR-155 expression could be used for 
assessing prognosis in patients with DLBCL. These results were in concordance with 
those obtained using semi-quantitative RT-PCR and Northern blotting. Examination of 
the correlation between BIC and miR-155 revealed a weak correlation implying that the 
amount of BIC-RNA should not be taken as an accurate measure of the amount of miR-
155. Eis et al evaluated as well the expression of other miRNAs such miR-15a and miR-
16 and let70 in the DLBCL cells (Eis et al., 2005). Reduced expression of miR-15a and 
miR-16 was observed in 30-70% and in 25% of samples respectively, while a 
heterogeneous level of expression was reported with let 70. 
Amplification of the 13q31 locus is frequently observed in various subtypes of 
NHL including DLBCL, FL, MCL and primary cutaneous lymphoma (Neat et al., 2001) 
(Mao et al., 2002) (Ota et al., 2004). The candidate target gene at 13q31 is c13orf25. 
There are two major transcripts in the C13orf25 – variant 1 and 2 (Ota et al., 2004). The 
C13orf25 transcript variant 1 (V1-trancript) has been reported as bA121J7.2 (Ota et al., 
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2004). The c13orf25 transcript variant 2 (V2-trancript) encodes a miRNA cluster (miR-
17-92) consisting of seven mature miRNAs: miR-17-5p, miR-17-3p, miR-18, miR-19a, 
miR-19b, miR-20 and miR-92, see figure 3.4 (O'Donnell et al., 2005). 
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Supp 1. The miR-17-92 cluster. A. The C13orf25 (v2) gene is located on chromosome 
13q31.3 and encodes a polycistronic cluster of 7 mature microRNAs. The cluster is located 
within the 3rd intron of the C13orf25 transcript (1). B. The sequences of the mature 
microRNAs are shown and the ‘seed sequences’ indicated in bold and red (2). 
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Figure 3.4 Structure of v2-transcript and miR-17-92 cluster. (A) The C13orf25 (v2-
transcript) gene is located on chromosome 13q31.3 and encodes a polycistronic cluster 
of 7 mature miRNAs (Ota et al., 2004). (B) The sequences of the mature miRNAs are 
shown and the ‘seed sequences’ indicated in bold and red (Griffiths-Jones et al., 2006). 
 
The miR-17-92 mature miRNAs have been shown to act in an oncogenic capacity via 
targeting genes with roles in apoptosis (Olive et al., 2009) (Mu et al., 2009) (Xiao et al., 
2008) (Ventura et al., 2008) and cell proliferation (Inomata et al., 2009) (Cloonan et al., 
2008). He et al reported that the mir-17-92 cluster co-operates with c-MYC to induce 
lymphom ge esis, thus identifying the firs  ncogenic miRNA, termed oncomir-1 (He 
et al., 2005). Tagawa et al. investi ated the expression v2-tr nscript and of its 7 
miRNAs in 12 malignant lymphoma cell lines and 21 cases of DLBCL (Tagawa and 
Seto, 2005). The expression of v2-transcript measured with RT-PCR was significantly 
higher in the cell lines and tumour samples with a 13q31 gain. Northern blot analysis of 
the seven mature miRNAs revealed that these were significantly more highly-expressed 
in the cell lines with a 13q31 gain/amplification when compared with those without the 
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gain. The abundance of 191 mature miRNAs was assessed using microarray technology 
in four lymphoma cell lines that expressed the v2-transcript and such expression was 
compared to six cell lines lacking the amplicon (Ota et al., 2004). Six miRNAs were 
identified for which high-level expression correlated with the expression level of v2-
transcript. Five of them belong to the mir-17-92 polycistron. Further, the expression of 
the v2-transcript measured with RT-PCR was performed on series of human lymphoma 
and colorectal carcinomas. A significant overexpression of v2-transcript was observed 
in 65% of lymphoma cases and only in 15% of colorectal carcinoma samples. Ota et al 
assessed the oncogenic potential of the mir-17-92 cluster of c13orf25 locus using a 
mouse model, which confirmed its oncogenic role in the development of lymphoma 
(Ota et al., 2004). Transplantation of hematopoietic stem cells (HSC) from Eµ-MYC/+ 
mice to lethally irradiated recipient mice resulted in the development of B-cell 
lymphoma after 4-6 months post transplantation. Co-expression of the mir-17-92 cluster 
in HSC from Eµ-MYC/+ mice and transplantation of these cells to lethally irradiated 
recipients resulted in the development of lymphoma at a significant shorter time 
interval. Additionally, in the work of Rinaldi et al. the expression of the c-MYC gene 
and of the mir-17-92 cluster was measured by FISH in a human MCL cell line and the 
concomitant expression of v2-transcript was defined (Rinaldi et al., 2007). The 
overexpression of 9 mature miRNAs (4 of which were encoded within the polycistronic 
mir-17-92 cluster) was found by RNA microarray and RT-PCR in the 3 BCR-ABL-
positive CML cell-lines (Venturini et al., 2007). The expression could be down 
regulated by both imatinib and anti-BCR-ABL-RNA interference. The expression of 
mir-17-92 was also reduced by anti-cMYC-RNA interference and enhanced by c-MYC 
transfection, indicating that the expression of mir-17-92 c-Myc is possibly regulated by 
c-MYC. Additionally, the expression of v2-transcript, c-MYC and mature miRNAs was 
investigated in patients with chronic phase and in those with blast-crisis of CML. v2-
transcript was overexpressed in 86% of patients in chronic phase and in a lower level in 
all blast crisis patients. c-MYC was overexpressed in 79% of patients in chronic phase 
and had a heterogeneous expression pattern in patients with blast crisis. By contrast, the 
mature miRNAs were overexpressed in patients in chronic phase but not in blast crisis 
patients. The overexpression of mature miRNAs in patients with chronic phase could be 
reduced by treatment with imatinib. Interesting data on miR-17-92 cluster from 
C13orf25 gene come from the study of Hayashita et al on lung cancer (Hayashita et al., 
2005). The miR-17-92 cluster was overexpressed in lung cancer cell lines, especially of 
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small-cell lung cancer origin and was predominately localized in the cell nucleus. The 
authors reported that the growth of lung cancer cell was enhanced by the introduction of 
the expression construct of the miR-17-92 cluster, but not by introduction of the 
putative open reading frame of C13orf25; implying the involvement of the miR-17-92 
in oncogenesis. 
The above studies confirm that miRNAs play an important role in oncogenesis. 
Although, the expression of miRNAs was assessed not only in cell lines but also in 
clinical samples, investigation into the relationship with disease outcome is less well 
documented. Because of their small size miRNA are supposed to be resistant to fixation 
and storage-induced degradation in FFPE blocks. Thus they have potential to represent 
an important new potential source of biomarkers. Numerous studies showed that the 
miRNAs from the miR-17-92 cluster and their pri-miRNA v2-transcript are involved in 
the oncogenesis of different tumours, including lymphomas and DLBCL. Particularly, 
the expression of miRNAs and v2-transcript was associated with the aggressive course 
of the disease in studies on clinical samples and also successfully proven experimentally 
in an in vitro mice model. Thus, the v2-transcript and miRNAs of miR-17-92 cluster 
were selected for further assessment and will be assessed as potential biomarkers. 
 
3.1.4 Quantitative polymerase chain reaction (qPCR) 
 Discovery of the polymerase chain reaction (PCR) entirely revolutionized 
studies on nucleic acids. The introduction of quantitative PCR (qPCR) was the next 
development step in molecular biology (figure 3.5.A). Briefly, the conventional PCR is 
a qualitative method allowing the confirmation of presence or absence of the assessed 
gene or its mRNA. By contrast the qPCR allows additionally the quantitative analysis of 
expression of the studied amplicon. 
 190 
(A) 
Real-Time PCR Vs. Traditional PCR 
Description 
This tutorial will discuss the evolution of traditional PCR methods towards the use of 
Real-Time chemistry and instrumentation for accurate quantitation. 
Objectives 
This tutorial will provide an understanding of the following: 
• Limitations of traditional PCR 
• Introduction to Real-Time PCR 
• Advantages of Real-Time chemistries over traditional PCR methods 
The Evolution of PCR to Real-Time 
PCR has completely revolutionized the detection of RNA and DNA.  Traditional PCR has 
advanced from detection at the end-point of the reaction to detection while the reaction 
is occurring.   
Figure 1: Real-Time PCR Evolution 
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3
Chemistry Overview
TaqMan® Gene Expression Master Mix Protocol
Figure 1 Two-step RT-PCR
About TaqMan
Gene Expression
Master Mix
TaqMan Gene Expression Master Mix reagents provide a PCR mix 
that may be used with any appropriately designed primer and probe to 
detect any DNA target (including cDNA, genomic, or plasmid DNA). 
The mix is optimized for TaqMan assays, and it contains AmpliTaq 
Gold® DNA Polymerase, UP (Ultra Pure), Uracil-DNA Glycosylase 
(UDG), deoxyribonucleotide triphosphates (dNTPs) with 
deoxyuridine triphosphate (dUTP), ROX™ Passive Reference, and 
buffer components optimized for sensitivity, precision, specificity, 
and duplexing.
AmpliTaq Gold
DNA Polymerase,
(UP) Ultra Pure
AmpliTaq Gold® DNA Polymerase, UP, a chemically modified form 
of AmpliTaq® DNA Polymerase, is a key ingredient in an automated, 
convenient, and efficient Hot Start PCR. The thermal incubation step 
required for activation ensures that active enzyme is generated only 
at temperatures where the DNA is fully denatured.
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(C) 
As you can see from the figure, the samples in the gel contain 10 copies and 50 copies, 
respectively.  It is hard to differentiate between the 5-fold change on the Agarose gel.  
Real-Time PCR is able detect a two-fold change (i.e. 10 Vs. 20 copies). 
PCR Phases: 
To understand why end-point PCR is limiting, it is important to understand what happens 
during a PCR reaction. 
A basic PCR run can be broken up into three phases: 
• Exponential: Exact doubling of product is accumulating at every cycle (assuming 
100% reaction efficiency). The re ction is very specific and precise. 
• Linear (High Variability): The reaction components are being consumed, the 
reaction is slowing, and products are starting to degrade. 
• Plateau (End-Point: Gel detection for traditional methods): The reaction has 
stopped, no more products are being made and if left long enough, the PCR 
products will begin to degrade. 
Figure 3: PCR Phases 
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Figure 3 shows three replicates of a sample. The replicates have the same starting 
quantity.  As the PCR reaction progresses, the samples begin to amplify in a very 
precise manner.  Amplification occurs exponentially, that is a doubling of product 
(amplicon) occurs every cycle. This type of amplification occurs in the exponential 
phase.  Exponential amplification occurs because all of the reagents are fresh and 
available, the kinetics of the reaction push the reaction to favor doubling of amplicon. 
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(D) 
Chapter 1 Introduction
About AQ Experiments
4 Absolute Quantitation Using Standard Curve Getting Started Guide for 7300/7500/7500 Fast Systems
Notes
Terms Used in
Quantitation
Analysis
The figure below shows a representative amplification plot and includes some of the 
t rms defined above.
Term Definition
Baseline The initial cycles of PCR in which there is little change in 
fluorescence signal.
Threshold A level of delta Rn—automatically determined by the software or 
manually set—used for CT determination in real-time assays. The 
level is set to be above the baseline and sufficiently low to be within 
the exponent al g ow h region of the amplification curve. The 
threshold is the line whose intersection with the Amplification plot 
defines the CT.
Threshold cycle (CT) The fractional cycle number at which the fluorescence passes the 
threshold.
No t mplate control 
(NTC)
A sample that does not contain template. It is used to verify 
amplification quality.
Nucleic acid target 
(also called “template”)
Nucleotide sequence that you want to detect and quantitate.
Passive reference A dye that provides an internal fluorescence reference to which the 
reporter dye signal can be normalized during data analysis. 
Normalization is necessary to correct for fluorescence fluctuations 
caused by changes in concentration or in volume.
Reporter dye The dye attached to the 5′ e  of a TaqMan® probe. The dye 
provides a fluorescence signal that indicates specific amplification.
Normalized reporter 
(Rn)
The ratio of the fluorescence emission intensity of the reporter dye 
to the fluorescence emission intensity of the passive reference dye.
D lta Rn (∆Rn) The magnitude of th signal generated by the specified set of PCR 
conditions. (∆Rn = Rn − ba eline)
Standard A sample of known quantity used to construct a standard curve.
Unknown sample A sample containing an unknown quantity of template that you want 
to characterize.
R
n
CT
Sample
Threshold
Baseline
Cycle Number
No Template Control
0 5 10 15 20 25 30 35 40
Rn
 
Figure 3.5 Introduction to PCR and qPCR. (A) PCR vs. qPCR (B) PCR principal 
reactions (C) PCR phazes and (D) amplification plot and qPCR terms (Biosystems, 
2006b). 
 
Principals of PCR and qPCR 
The PCR synthesises of a copy of the target amplicon via a DNA polymerase, 
usually a Taq DNA polymerase. The selectivity of the reaction is guaranteed by specific 
primers, which are also necessary for initiation of the reaction. The basic required 
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components of each PCR reaction are: a nucleic acid sample, a DNA polymerase, a set 
of primers and nucleotides. For the assays detecting the DNA sequence, the DNA 
sample is simply used in the reaction. By contrast, the assays detecting mRNA require 
RT of the mRNA into cDNA see figure 3.5.B. Usually the whole mRNA is transcribed 
into a cDNA library using the random hexamer primers set or oligo-dT or sequence 
specific primers. The PCR reaction runs in a particular pattern accompanied by changes 
in the reaction temperature. In the first phase of the single reaction cycle, the 
temperature is increased up to above 90°C and the double strands of nucleic acids 
separate. In the next phase the temperature decreases, the primers bind to specific 
fragments of single strand nucleic acid and DNA polymerase starts to build a copy of 
the desired fragment of nucleic acid using nucleotides. After the competition of 
synthesis the temperature of reaction is increased again and the cycle starts from 
beginning. The whole PCR run is composed of about 20 – 40 such cycles. 
In order to understand the principals and differences of conventional PCR and 
qPCR, the knowledge of the kinetics of a PCR run is required. Below, the short 
introduction to the method based on the materials of ABI is summarized (Biosystems, 
2006b) (Biosystems, 2006a) (Biosystems, 2004). The basic single PCR run can be 
divided into three phases (see figure 3.5.C): 1) exponential phase: exact doubling is 
accumulating at every cycle (assuming 100% reaction efficiency). At this phase the 
reaction is very specific and precise. 2) linear phase: as the reaction components are 
being consumed, the reaction is slowing and products are starting to degrade. This phase 
of the reaction is characterized by high variability. 3) Plateau (end-point) phase: the 
reaction has stopped, no more products are being made and if left long enough, the PCR 
products will begin to degrade. Assuming the replicates have the same starting quantity 
of the amplicon (shown in figure 3.5.C), with the progress of the reaction, the samples 
begin to amplify in a very precise manner. A doubling of product occurs every cycle 
during the exponential phase. During the course of the reaction some of the reagents are 
being consumed as a result of amplification. This will occur at different rates for each 
reaction. The reaction starts to slow down and the PCR product is no longer being 
doubled at each cycle. The linear amplification can be seen on the product diagram and 
the reaction enters the linear phase. The three example samples in figure 3.5.C begin to 
diverge in their course during the linear phase as the reaction efficacy will be different 
in each sample and depends on multiple factors. In further course, the reaction slows 
down more and stops altogether reaching the plateau. Each reaction will plateau at a 
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different point due to the different kinetics for each sample. The plateau phase is where 
conventional PCR takes its measurement and thus it can say nothing on the initial 
quantity of the product. Usually the PCR product is separated in gel electrophoresis and 
consequently marked by an intercalating agent binding to double strand nucleic acid. By 
contrast the qPCR takes measurements of the amount of the reaction product, by 
measuring the fluorescence level, during the whole reaction as it occurs and particularly 
during exponential phase, where the replicate samples are amplifying exponentially. 
The data is therefore collected through the PCR process, rather than at the end of the 
PCR like in conventional PCR. qPCR is characterized by the point in time during 
cycling, when amplification of a target is first detected by measured fluorescence. In 
other words, the fluorescence level reached the set up limit (threshold) in the certain 
qPCR cycle so called cycle threshold (Ct), see figure 3.5.D. The higher the starting copy 
number of the target amplicon, the sooner detection occurs in an earlier cycle. Thus 
amplicons with high expression levels are associated with lower Ct value and those with 
low expression levels with higher Ct value. 
 
qPCR chemistry 
Currently there are two different technologies to detect PCR products during 
qPCR: i) SYBR Green dye chemistry and ii) TaqMan® chemistry, both using 
fluorescence (figure 3.6). 
i) The SYBR Green chemistry uses in addition to the primer set the SYBR 
Green I dye to detect PCR products by binding to the minor groove of double-strand 
DNA synthesized during PCR reaction. The bound SYBR Green dyes have higher 
fluorescence emission as compared with unbound ones. The increase in fluorescence is 
detected during the PCR reaction, see figure 3.6.A. 
ii) The TaqMan® chemistry uses in addition to the set of primers a specific 
probe. The probe is a nucleic acid strand that has incorporated a reporter dye at the 5’ 
end and a quencher dye at the 3’end. When the probe is intact and the reporter and 
quencher dye lie close to each other, the fluorescence energy of the reporter dye is 
absorbed by the quencher dye. During the reaction, if the target sequence is present, the 
probe binds to the specific target nucleic acid fragment downstream one of the primers. 
The Taq DNA polymerase works from 3’to 5’direction on the leading DNA strand, 
synthesising the copy from its 3’ to its 5’ end and cleaving the probe from the leading 
DNA strand by its 5’ nuclease activity. First the reporter dye and subsequently the 
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quencher dye are released. As the distance between the both dyes increases, the energy 
of the reporter dye is no longer absorbed and can be sent free and detected. The cleaved 
probes do not interfere with the Taq DNA polymerase function which continues the 
synthesis of the target amplicon. Additional reporter dye molecules are cleaved from 
their respective probes with each cycle, resulting in an increase in fluorescence intensity 
proportional to the amount of amplicon produced see figure 3.6.B. 
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Chemistries
Applied Biosystems offers two types of chemistries that you can use to detect PCR 
products on real-time instruments, as explained in the following table. Both TaqMan® 
probe-based and SYBR® Green I dye chemistries can be used for either one- or two-step 
RT-PCR. For more information about these chemistries, refer to the Real-Time PCR 
Systems Chemistry Guide.
Chemistry Process
TaqMan® reagents or kits
Description
TaqMan® reagent-based chemistry uses a 
fluorogenic probe to enable detection of a specific 
PCR product as it accumulates during PCR cycles.
Advantages
• Increases specificity with a probe. Specific 
hybridization between probe and target 
generates fluorescence signal.
• Provides multiplex capability.
• Optimized assays available.
• Allows 5′ -nuclease assay to be carried out 
during PCR.
SYBR® Green I reagents
Description
Uses SYBR Green I dye, a double-stranded DNA 
binding dye, to detect PCR products as they 
accumulate during PCR cycles.
Advantages
• Reduces cost (no probe needed).
• Amplifies all double-stranded DNA.
• Yields a melting profile of distinct PCR runs.
• Increases sensitivity for detecting amplification 
products relative to product length.
Limitations
Binds nonspecifically to all double-stranded DNA 
sequences. To avoid false positive signals, check 
for nonspecific product formation using dissociation 
curve or gel analysis.
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Step 1: A reporter (R) and a 
quencher (Q) are attached to the
5' and 3' ends of a TaqMan
probe.
Step 1 (continued): When both dyes
are attached to the probe, reporter 
dye mission is quenched.
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Step 2: During each extension 
cycle, the AmpliTaq Gold® DNA
polymerase cleaves the reporter
dye from the probe.
Step 3: After being separated from 
the quencher, the reporter dye 
emits its characteristic 
fluorescence.
FORWARD
PRIMER
REVERSE
PRIMER
Step 1: Reaction setup
The SYBR® Green I dye 
fluoresces when bound to 
double-stranded DNA.
Step 2: Denaturation
When the DNA is denatured, 
the SYBR® Green I dye is 
released and the fluorescence 
is drastically reduced.
Step 3: Polymerization
During extension, primers 
anneal and  PCR product 
is generated.
Step 4: Polymerization completed
SYBR® Green I dye binds to the 
double-stranded product, 
resulting in  a net increase in 
fluorescence detected by the 
instrument.
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About
Chemistries
Applied Biosystems offers two types of chemistries that you can use to detect PCR 
products on real-time instruments, as explained in the following table. Both TaqMan® 
probe-based and SYBR® Green I dye chemistries can be used for either one- or two-step 
RT-PCR. For more information about these chemistries, refer to the Real-Time PCR 
Systems Chemistry Guide.
Chemistry Process
TaqMan® reagents or kits
Description
TaqMan® reagent-based chemistry uses a 
fluorogenic probe to enable detection of a specific 
PCR product as it accumulates during PCR cycles.
Advantages
• Increases specificity with a probe. Specific 
hybridization between probe and target 
generates fluorescence signal.
• Provides multiplex capability.
• Optimized assays available.
• Allows 5′ -nuclease assay to be carried out 
during PCR.
SYBR® Green I reagents
Description
Uses SYBR Green I dye, a double-stranded DNA 
binding dye, to detect PCR products as they 
accumulate during PCR cycles.
Advantages
• Reduces cost (no probe needed).
• Amplifies all double-stranded DNA.
• Yields a melting profile of distinct PCR runs.
• Increases sensitivity for detecting amplification 
products relative to product length.
Limitations
Binds nonspecifically to all double-stranded DNA 
sequences. To avoid false positive signals, check 
for nonspecific product formation using dissociation 
curve or gel analysis.
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Step 1: A reporter (R) and a 
quencher (Q) are attached to the
5' and 3' ends of a TaqMan
probe.
Step 1 (continued): When both dyes
are attached to the probe, reporter 
dye emission is quenched.
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Step 2: During each extension 
cycle, the AmpliTaq Gold® DNA
polymerase cleaves the reporter
dye from the probe.
Step 3: After being separated from 
the quencher, the reporter dye 
emits its characteristic 
fluorescence.
FORWARD
PRIMER
REVERSE
PRIMER
Step 1: Reaction setup
The SYBR® Green I dye 
fluoresces when bound to 
double-stranded DNA.
Step 2: Denaturation
When the DNA is denatured, 
the SYBR® Green I dye is 
released and the fluorescence 
is drastically reduced.
Step 3: Polymerization
During extension, primers 
anneal and  PCR product 
is generated.
Step 4: Polymerization completed
SYBR® Green I dye binds to the 
double-stranded product, 
resulting in  a net increase in 
fluorescence detected by the 
instrument.
 
Figure 3.6 qPCR chemistry. (A) SYBR® Green and (B) Taqman (Biosystems, 2006a). 
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The most important difference between the TaqMan® and SYBR green 
chemistry is that the SYBR Green I dye will detect all double stranded DNA, including 
non specific reaction products. A well-optimized reaction is therefore essential for 
accurate results. By contrast the TaqMan® chemistry will detect only one specific PCR 
product. The primary disadvantage of the TaqMan® chemistry is that the synthesis of 
different probes is required for different sequences. 
 
Absolute and relative qPCR 
 There are two different ways to calculate the results of qPCR assays: absolute 
and relative quantitation. The absolute quantitation assay is used to quantitate unknown 
samples by interpolating their quantity from a standard curve with known concentration 
of the target (in mass unit or copies number). This method might be used to correlate 
exact viral copy number with a disease state when it is of interest to the researcher to 
know the exact copy number of the target in a given biological sample in order to 
monitor the progress of disease. 
A relative quantitation assay does not give the result of expression as a definite 
number but as the ratio of the expression of target gene in a given sample (sample 
obtained from treated patient or sick patient) to the expression in reference sample (such 
as untreated or healthy control sample). The relative quantitation maybe used to 
measure gene expression in response to a drug or in a tumour sample. The level of gene 
expression of a particular gene of interest in a treated sample or cancer sample would be 
compared relative to the level of gene expression in an untreated sample or healthy 
sample, so called calibrator. There are two different methods used for relative 
quantitation: i) standard curve method and ii) comparative Ct method (2-ΔΔCt method). 
In both methods, it is recommended to obtain the ratio of the target gene to the 
endogenous control (reference) in a tested sample and in a calibrator for control and 
normalization purposes (for differences in amount of cDNA added to each reaction, 
imprecise RNA measurement after extraction, RNA integrity or inaccurate pipetting). 
The endogenous control is usually constitutively expressed gene or so called 
‘housekeeper gene’. 
i) The standard curve method is based on interpolating quantity of target and 
endogenous control in tested sample and in calibrator sample from a relevant standard 
curve. As the tested sample quantity is divided by target quantity, the unit of the 
standard is cancelled out. Thus, only the relative dilution of samples in standard curve is 
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required. For relative standard curve method any stock of cDNA containing the 
appropriate target can be used. 
ii) The comparative Ct method is similar to the standard curve method, except it 
uses the arithmetic formula to achieve the same result for relative quantitation. It is 
possible to eliminate the use of standard curves and to use comparative Ct method 2-ΔΔCt 
method as long the PCR efficiencies of target and endogenous control(s) are relatively 
equivalent and close to one. The following formula can be used: 
2-ΔΔCt 
The ΔCt in tested sample and in calibrator sample can be calculated by: 
ΔCt = Ct (target) – Ct (reference) 
The ΔΔCt is calculated by: 
ΔΔCt = ΔCt (tested sample) – ΔCt (calibrator sample) 
 
Conditions for successful and precise qPCR 
In order to achieve precise and correct results in all different types of qPCR 
several conditions need to be met. As comparative Ct method 2-ΔΔCt will be used in this 
study, we focus on conditions relevant for this method. 
i) The input of high quality RNA is required for successful quantitation of gene 
expression. Protein contamination, including RNAses, can inhibit the PCR reaction or 
cause degradation of RNA. Carry-over chemicals e.g. phenol can cause PCR inhibition. 
Degraded RNA sample (samples with low RNA integrity) can contribute to loss of 
detection of rare transcripts. Co-extracted genomic DNA can serve as a PCR template 
and can cofound RNA detection results. The latter can be avoided by use of exon-exon 
spanning primers or use of DNAse before the RT. It is recommended to assess the RNA 
quality by spectrophotometr: A260/280 ≥2.0 is the recommended quality indicating a 
protein free RNA isolate. 
ii) The efficacy of qPCR needs to be close to one for target genes and reference 
gene(s). This particularly important if the comparative Ct method 2-ΔΔCt is used and the 
custom designed primers and probes are used. The efficacy of reaction for all assessed 
targets needs to be checked in a validation experiment. When standard curves for the 
targets are produced and the efficacy of the reaction calculated, it is expected to achieve 
the correlation coefficient (R2 value >0.99). All TaqMan® Gene Expression Assays are 
tested for efficacy of reaction equal one and do not require a validation experiment. 
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iii) All reactions should be performed in triplicates and the mean Ct value used 
with SD <0.3. This is particularly important for samples with high Ct values (34-40) 
when due to statistical distribution there is always a high level of Ct variation. In the 
case that one Ct value from a triplicate is outstanding, the duplicate can be used if SD 
<0.3. 
iv) Regarding the reference genes, it is recommended to use at least two genes, 
with different range of Ct. Geometric mean of average Ct of both genes is used for 
calculation purposes. The Ct of reference gene should be ≤34 and equal distribution 
over all samples is required; fold change in distribution should not excide 1.3. 
 
Summary 
There are several advantages of using qPCR over the conventional PCR. The 
most important is the quantitative character of the method. The qPCR requires no-post 
PCR processing and detection is capable down to a 2-fold change. Beyond the 
competition with conventional PCR, the qPCR using the TaqMan® chemistry is 
currently the most sensitive and specific method in analysis of gene expression. Its 
capabilities surpass those of e.g. Northern blotting, microarray and other assays. 
Particularly, the real-time PCR is method of choice for confirmation of results of studies 
using microarrays. Thus, in our studies we have chosen qPCR with TaqMan® chemistry 
for prognostic assessment of gene and mature miRNA expression. 
 
3.2 Materials 
 
3.2.1 Selection and culture of lymphoma cell lines 
Sixteen different cell lines of lymphoid origin: 10 DLBCL, 2 FL, 2 MCL and 2 
lymphoblastic lymphomas, were selected for this study. All cell lines were obtained 
from The German Collection of Microorganisms and Cell Cultures (DSMZ). Table 3.1 
provides a list and characteristics of origin of the cell lines. 
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Cell line Origin 
NU-DHL-1 DLBCL (lymph node) 
SU-DHL-4 DLBCL (peritoneal effusion) 
SU-DHL-5 DLBCL (lymph node) 
SU-DHL-6 DLBCL (peritoneal effusion) 
SU-DHL-8 DLBCL (pleural effusion) 
SU-DHL-10 DLBCL (pleural effusion) 
HT DLBCL (peritoneal effusion) 
DB DLBCL (peritoneal effusion) 
KARPAS-422 DLBCL (pleural effusion) 
OCI-LY-19 DLBCL (bone marrow) 
SC-1 Follicular lymphoma (peritoneal effusion) 
WSU-FSCLL Follicular lymphoma (peripheral blood) 
GRANTA-519 Mantle cell lymphoma (peripheral blood) 
REC-1 Mantle cell lymphoma (lymph node & peripheral blood) 
CI-1 Lymphoblastic lymphoma (peritoneal effusion) 
U-698-M Lymphoblastic lymphoma (tonsil) 
Table 3.1 Cell lines and cell line origin. 
 
Cell lines were cultured according to the supplier’s instruction: WSU-FSCLL, 
REC-1, U-698-M, NU-DHL-1, SU-DHL-4, SU-DHL-5, SU-DHL-6, SU-DHL-10, HT 
and KARPAS-422 in Roswell Park Memorial Institute Medium (RPMI) 1640 [Gibco 
UK] supplemented with 10% v/v heat inactivated foetal calf serum [Sera Lab LTD, 
UK]; CI-1, SU-DHL-8 and DB in RPMI 1640 supplemented with 20% v/v heat 
inactivated foetal calf serum; GRANTA-519 in Dulbecco’s minimal essential medium 
(DMEM) (4.5g/L glucose) [Gibco UK] supplemented with 10% v/v heat inactivated 
foetal calf serum and OCI-LY-1 in 80% alpha minimal essential medium (MEM) 
[Gibco UK] supplemented with 20% v/v heat inactivated foetal calf serum. All media 
contained 100IU/ml penicillin [Gibco UK], 100µg/ml streptomycin [Gibco UK] and 
2mM L-glutamine [Gibco UK]. All cultures were incubated at 37°C in a humidified 
atmosphere of 5% CO2 in air incubator Galaxy B [Scientific Laboratory Supplies LTD, 
UK]. 
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3.2.2 Selection of formalin fixed paraffin embedded (FFPE) with corresponding 
frozen tissue 
 A cohort of 11 patients with diagnosis of DLBCL lymphoma with available 
FFPE tissue blocks with corresponding snap frozen tissue blocks was randomly selected 
from the Tissue Bio-bank, Department of Cellular Pathology, Newcastle upon Tyne 
Hospital NHS Foundation Trust for the study. 
 
3.2.3 Selection of RNA samples isolated from FFPE of patients with DLBCL for 
confirmation studies 
 A series of RNA samples isolated from the FFPE of patients with DLBCL were 
kindly provided by Dr R Crossland for confirmation work. Those samples were isolated 
from FFFP blocks using the High Pure FFPET RNA Isolation Kit [Roche®, UK]. All 
RNA samples were treated with the DNAse TURBO DNA-free™ [Ambion®, UK]. 
 
3.2.4 Selection of FFPE tissue of population-based cohort of DLBCL patients 
 A cohort of 92 patients with DLBCL and available FFPE tissue blocks was 
selected from the Lymphoma Bio-bank, Northern Institute of Cancer Research, 
Newcastle University. The patients had to fulfil all following inclusion criteria and to 
fulfil none of the following exclusion criteria: 
Inclusion criteria: 
- First diagnosis of DLBCL NOS 
- No previous history of chemotherapy, immunotherapy and radiotherapy 
- Age at diagnosis ≥18 years 
- Started treatment with CHOP or CNOP polychemotherapy in combination with 
rituximab (at least one cycle) 
- Available actual information at least on patients survival 
Exclusion criteria: 
- Previous or concurrent diagnosis of other malignant disorder including 
leukaemia and lymphoma 
- Origin of disease in CNS, testicle or stomach 
- HIV infection 
The clinical information available for included patients incorporates the detailed 
demographic and clinical data at presentation (gender, age at diagnosis, performance 
status by ECOG, CS, B-symptoms, BM and other extranodal involvement, bulky 
 199 
disease, laboratory data and IPI), data on treatment (kind of chemotherapy, number of 
administered cycles, eventual reason for discontinuation of chemotherapy and 
information on radiotherapy if given) and finally outcome data (response, date of 
eventual progression if occurred and date of last seen or date of death). All samples 
were additionally reviewed by expert haematopathologists and the detailed 
immunohistochemical staining allowing assignment of the patients to GC or ABC 
phenotype by Hans classification were also performed. 
 The patient characteristics of the cohort are provided in table 3.2. The median 
age of the group was 66 years, majority of patients were male and had ECOG <1. 
 
Clinical parameter 
Patients 
n (%) 
Univariate 
analysis 
for PFS 
Univariate 
analysis 
for OS 
Median age, range 
Female gender 
ECOG >1 
CS I / II 
B symptoms 
Bulk disease 
BM involvement 
Extra nodal involvement 
IPI Group 
Low 
Low intermediate 
High intermediate 
High 
Abnormal Hb 
Abnormal WBC 
Abnormal albumin 
Abnormal urea 
Abnormal AP 
Abnormal LDH 
Hans phenotype 
Activated B-cell 
Germinal centre 
66, 27 – 91 
44/92 (47.8) 
12/83 (14.5) 
34/68 (50.0) 
24/77 (31.2) 
33/77 (42.8) 
3/65 (4.6) 
28/76 (36.8) 
 
19/42 (45.2) 
8/42 (19.0) 
9/42 (21.4) 
6/42 (14.3) 
27/84 (32.1) 
18/84 (21.4) 
18/79 (22.8) 
23/81 (28.4) 
17/80 (21.3) 
41/58 (70.7) 
 
24/80 (30.0) 
56/80 (70.0) 
0.001 
0.032 
0.004 
0.001 
0.025 
0.669 
<0.001 
0.002 
 
<0.001 
 
 
 
0.566 
0.654 
0.011 
<0.001 
0.671 
0.063 
 
0.059 
 
0.002 
0.104 
0.001 
0.003 
0.023 
0.563 
<0.001 
0.01 
 
<0.001 
 
 
 
0.478 
0.887 
0.001 
<0.001 
0.816 
0.044 
 
0.082 
 
Table 3.2 Patient characteristics of the cohort with v2-transcript, c-MYC and HLA-DRβ 
evaluation and significance of clinical factors on PFS and OS in univariate analysis Cox 
regression (n=92). 
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 Among the patients with established CS exactly the half of patients were in 
advance stage disease and one third had B-symptoms at the diagnosis. The IPI could be 
calculated for 42 only. The major reason so few patients had an IPI was lack of BM 
biopsy and LDH level. The majority of patients had low and intermediate low IPI index 
(64.3%). The Hans phenotype was established for 80 patients and 30% had ABC 
phenotype and 70% GC. The remaining clinical data are provided in table 3.2. 
The vast majority of patients received the combined immunochemotherapy of 
CHOP with rituximab and approximately 10.9% of patients received CNOP in 
combination with rituximab; see table 3.3. 
 
Clinical parameter 
Patients 
n (%) 
Chemotherapy regimen 
CHOP 
CNOP 
NK 
Combined modality 
Yes 
No 
NK 
Scheduled chemotherapy discontinued 
No 
Yes 
NK / ND 
Reason for discontinuation 
Progression 
Infection 
Organ failure 
Other 
Overall responce 
CR 
PR 
Failure 
NK / ND 
3 years PFS 
3 years OS 
 
74 / 92 (80.4) 
10 / 92 (10.9) 
8 / 92 (8.7) 
 
31 / 92 (33.9) 
52 / 92 (56.5) 
9 / 92 (9.8) 
 
70 / 92 (76.1) 
14 / 92 (15.2) 
8 / 92 (8.7) 
 
3 / 14 (21.4) 
2 / 14 (14.3) 
2 / 14 (14.3) 
7 / 14 (50%) 
 
74 / 92 (68.5) 
10 / 92 (7.6) 
14 / 92 (15.2) 
8 /92 (8.7) 
62.9% 
68.3% 
Table 3.3 Treatment and treatment outcome of the cohort with v2-transcript, c-MYC 
and HLA-DRβ evaluation (n=92). 
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Approximately one third of patients received additional radiotherapy. The vast 
majority of patients completed the scheduled chemotherapy and the most common 
reason for the discontinuation were: progression, infection and organ failure. The ORR 
was 76% with 68.5% CR and 7.6% PR. The 3-year PFS and OS were 62.9% and 68.3% 
respectively; see table 3.3. 
 All clinical factors were included in univariate analysis of risk factors for PFS 
and OS. For PFS age, gender, CS, presence of B-symptoms, BM involvement, abnormal 
urea and albumin were statistically significant and for OS additionally the LDH serum 
level was statistically significant but not patient gender. For the results with 
corresponding p-values see table 3.2. 
 
3.2.5 Selection of control tissue 
The pooled RNA of normal CD19+ B-cells isolated from peripheral blood of 
three healthy individuals was used as control tissue for the studies on cell lines, on 
corresponding frozen and FFPE tissue and confirmation studies. The isolation of 
CD19+ B-cells was performed using positive selection of CD19+ cells directly from 
anti-coagulated whole blood using Whole Blood CD19 MicroBeads [Miltenyi Biotec, 
UK] in an autoMACSTM Separator [Miltenyi Biotec, UK]. 
For the patient cohort study pooled RNA extracted from 2 FFPE tissue blocks of 
reactive lymph nodes and no evidence of any malignancy was used as control tissue. 
The two independent patients were randomly selected from the collection of the Tissue 
Bio-bank, Department of Cellular Pathology, Newcastle upon Tyne Hospital NHS 
Foundation Trust for the study. 
 
3.3 Methods 
 
3.3.1 Extraction of RNA 
For studies on gene expression, the RNA was isolated from cell lines and 
CD19+ lymphocytes using mirVanaTM miRNA Isolation Kit [Ambion®, UK] with the 
protocol for a total RNA isolation. This protocol was also employed for isolation of 
RNA from frozen DLBCL tissues. Extraction of RNA from FFPE tissues was 
performed with the RecoverAll™ Total Nucleic Acid Isolation Kit [Ambion®, UK]. 
For the studies on expression of miRNAs, the mirVanaTM miRNA Isolation Kit 
provides a possibility of extracting RNA by two different protocols: i) the protocol for a 
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total RNA isolation (called mirVanaTM total) and ii) the protocol for an enrichment 
isolation of small RNAs (called mirVanaTM micro). Both methods of the mirVanaTM 
miRNA Isolation Kit were employed in the preliminary study on expression of miRNAs 
in cell lines. Subsequently for all future studies on miRNAs, the protocol for isolation of 
total RNA only was employed on cell lines and frozen samples and the RecoverAll™ 
Total Nucleic Acid Isolation Kit [Ambion®, UK] was used for extraction of the RNA 
from FFPE. 
The residual DNA contamination in samples provided for assessment of gene 
expression was removed using the TURBO DNA-free™ [Ambion®, UK] DNAse 
treatment and removal reagents. 
The concentration and purity of all isolated RNA samples was determined 
spectrophotometrically using ND-1000 spectrophotometer [NanoDrop Technologies. 
Inc]. 
 
3.3.2 Assessment of gene expression 
 Expression of V2-transcript, c-MYC and HLD-DRβ was determined with qPCR 
with TaqMan® chemistry by [Applied Biosystem®, UK] and was normalized using the 
2-∆∆CT method relative to selection of housekeeper genes (GAPDH, PGK1 and TBP). 
The expression of target genes in lymphoma cell lines, frozen tissue blocs and 
corresponding FFPE tissue blocks and confirmation samples was normalized to their 
expression in pooled RNA of normal CD19+ B-cells isolated from peripheral blood of 3 
healthy individuals. By contrast in cohort study, the expression of the target genes was 
normalized to their expression in pooled RNA extracted from 2 FFPE tissue blocks of 
lymph nodes with no evidence of any malignancy. 
The RT reaction was performed using the High Capacity RNA-to-cDNA Kit 
[Applied Biosystem®, UK] in 2720 Thermal Cycler [Applied Biosystem®, UK]. The 
reaction conditions are summarized in table 3.4. 
 
Step Step Type Time Temperature 
1. Hold 60 min 37°C 
2. Hold 5 min 95°C 
3. Hold ∞ 4°C 
Table 3.4 Parameter values for RT of total cDNA library. 
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The real time PCR step was performed using TaqMan® Universal Maser Mix I 
and II in ABI Prism® 7900HT Sequence Detection System [Applied Biosystem®, UK]. 
The thermal cycling parameters are provided in table 3.5. 
 
Step 
Step 
Type 
PCR Phase Time Temperature 
Activation Hold  10 min 95°C 
PCR Cycle 
Denaturation 15 sec 95°C 
Annealing / extension 60 sec 60°C 
Table 3.5 Parameter values for qPCR for assessment of expression of the genes and 
miRNAs. 
 
All qPCR reactions were performed in triplicate and the reported Ct value is an 
average from those three, further it is defined as Ct only. All used primers and probes 
were supplied by Applied Biosystem®, UK: 
1) For c-MYC expression the ready to use probe and primers set was used: 
MYC - v-myc avian myelocytomatosis viral oncogene homolog 
Amplicon size: 107 
Assay ID: Hs00153408_m1 
NM: NM_002467.4 
Cat No: 4453320 
2) For HLA-DRβ expression the ready to use probe and primers set was used: 
HLA-DRB1 - major histocompatibility complex, class II, DR beta 1 
Amplicon size: 75 
Assay ID: Hs99999917_m1 
NM: NM_001243965.1 
Cat. No: 4453320 
3) For V2-transcript of c13orf25 the primers and probe described by Venturini et 
al. were used (Venturini et al., 2007). These primers and probe bind to the latter 
sequence of the V2-transcript beyond the region encoding mature miRNAs and 
the length of the amplicon is approximately 170 nb. The screening of the V2-
transcript for alternative primers and probe binding sites, preferably within the 
region encoding the miRNA and shorter amplicon remained unsuccessful. 
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V2-transcript forward primer:  
CAGTAAAGGTAAGGAGAGCTCAATCTG 
V2-transcript reverse primer: 
CATACAACCACTAAGCTAAAGAATAATCTGA 
V2-transcript FAM-TAMRA probe: 
TGGAAATAAGATCATCATGCCCACTTGAGAC 
 
4) For GAPDH expression a ready to use endogenous control assay including 
primers and probe were used: 
GAPDH - glyceraldehyde-3-phosphate dehydrogenase 
Amplicon size: 122 
Assay name: Human GAPD (GAPDH) 
Endogenous Control (FAM™/MGB probe, non-primer limited) 
NM: NM_002046.3 
Cat No: 4333764 
5) For PGK1 expression a ready to use endogenous control assay including primers 
and probe were used: 
PGK1 - Human PGK1 - Phosphoglycerate Kinase 1 
Amplicon size: 75 
Assay name: Human PGK1 (Phosphoglycerate Kinase 1) Endogenous Control 
(FAM™/MGB Probe, non-primer limited) 
NM: NM_000291.2 
Cat No: 4333765 
6) For TBP expression a ready to use endogenous control assay including primers 
and probe were used: 
TBP – Human TBP (Tata-box binding Protein) 
Amplicon size: NK 
Assay name: Human TBP (TATA-box binding Protein) Endogenous Control 
(FAM™/MGB probe, non-primer limited) 
NM: NK 
Cat No: 4333769 
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3.3.3 Assessment of expression of mature miRNAs 
 TaqMan® MicroRNA Assay [Applied Biosystem®, UK] is a novel tool in 
assessment of expression of miRNAs. It is based on the principles of TaqMan® gene 
expression assays with several differences such as transcript specific RT. It specifically 
detects the miRNA and does not react with genomic DNA. 
 Expression of mature miRNAs (miR155, miR17-5p, miR20 and miR92) was 
determined using the TaqMan® MicroRNA Assay [Applied Biosystem®, UK] and was 
normalized using the 2-∆∆CT method relative to expression of miR24, “house keeping 
miRNA”. The expression of target miRNAs in lymphoma cell lines, frozen tissue 
blocks and corresponding FFPE tissue blocks and in the confirmation FFPE tissue 
cohort was normalized to their expression in pooled RNA of normal CD19+ B-cells 
isolated as described in the materials section. 
The RT step with specific primers from TaqMan® MicroRNA Assay was 
performed in a 2720 Thermal Cycler [Applied Biosystem®, UK]. The reaction 
conditions are summarized in table 3.6. 
 
Step Step Type Time Temperature 
1. Hold 30 min 16°C 
2. Hold 30 min 42°C 
3. Hold 5 min 85°C 
4. Hold ∞ 4°C 
Table 3.6 Parameter values for RT of miRNAs. 
 
The qPCR step was performed using TaqMan® Universal Maser Mix, UDG 
Free in ABI Prism® 7900HT Sequence Detection System [Applied Biosystem®, UK]. 
The thermal cycling parameters are provided in table 5. Likewise in the assessment of 
gene expression all qPCR reactions for miRNA were performed in triplicate and the 
reported Ct value is an average from those three, further it is defined as Ct only. 
Following TaqMan® MicroRNA Assay [Applied Biosystem®, UK] were 
employed in this study for assessment of individual miRNAs: 
1) For miR-155 TaqMan® MicroRNA Assay: 
sequence: UUAAUGCUAAUCGUGAUAGGGGU 
Assay Name: hsa-miR-155 
Assay ID: 002623 
Cat No: 4427975 
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2) For miR-17-5p TaqMan® MicroRNA Assay: 
sequence: CAAAGUGCUUACAGUGCAGGUAGU 
Assay Name: hsa-miR-17-5p 
Assay ID: 000393 
Cat No: 4427975 
3) For miR-20 TaqMan® MicroRNA Assay: 
sequence: UAAAGUGCUUAUAGUGCAGGUAG 
Assay name: hsa-miR-20a 
Assay ID: 000580 
Cat No: 4427975 
4) For miR-92 TaqMan® MicroRNA Assay: 
sequence: UAUUGCACUUGUCCCGGCCUGU 
Assay name: hsa-miR-92a 
Assay ID: 000431 
Cat No: 4427975 
5) For miR-24 TaqMan® MicroRNA Assay: 
sequence: UGGCUCAGUUCAGCAGGAACAG 
Assay Name: hsa-miR-24 
Assay ID: 000402 
Cat No: 4427975 
 
3.3.4 Statistics 
 Demographics and disease characteristics were summarized using descriptive 
statistics. The Mann-Whitney-U-test was used to investigate differences between 
means. Spearman’s R correlation was used to assess the correlation between 
distributions of factors. Bland-Altman plots were used to assess the level of agreement. 
In brief, for Bland-Altman analysis the two methods agreed if the bias between them 
was equal to or less than one as this equated to less than one qRT-PCR cycle difference. 
For correlation, significance was set at p<0.05 and trend to significant set at p<0.10. 
The PFS and OS times were calculated from date of diagnosis to the first documentation 
of progression during therapy, failure at the end of therapy, or further relapse or death 
from any cause during or after the end of treatment. OS was calculated from date of 
diagnosis to the date of death, or if no death occurred, to the last documented follow up 
for the patient. The rates of PFS and OS were estimated according to the method of 
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Kaplan and Meier and comparison between the groups was with the log-rank test. Cox-
regression analysis was used for assessment of PFS and OS and gene expression as a 
continuous variable. The limits for dichotomizing the gene expression were defined 
using receiver operating characteristic (ROC) curve analysis and the assessment of PFS 
and OS and gene expression as dichotomous variables. All tests were performed with a 
confidence interval of 95 % and statistical significance was defined as p ≤0.05. 
Statistical analysis was performed with SPSS Version 13.0 for MAC OS X (SPSS 
Incorporated, Chicago, IL), Prism Version 6 for MAC OS X and SIGMA Plot Version. 
 
3.4 Results - studies on expression of v2-transcript, c-MYC and HLA-DRβ 
 
3.4.1 Validation of qPCR for v2-transcript 
 As the primers for v2-transcript of c13orf25 were custom designed they had to 
be checked to ensure they are specific to mRNA and do not react with genomic DNA 
during qPCR. The “standard” and “NO RT” (without reverse transcriptase) RT 
reactions were performed on RNA samples treated and not treated with DNAse. The 
cDNA from each reaction has been then used in qPCR for v2-transcript and, for control 
purposes, for GAPDH. 
In samples using RNA not treated with DNAse, the qPCR for v2-transcript was 
strongly positive in cDNA samples from both “standard” and “NO RT” RT reactions. 
By contrast the qPCR for GAPDH was significantly positive in “standard” RT reactions 
with no signal in “NO RT” RT reactions. In samples using RNA treated with DNAse, 
the qPCR for both v2-transcript and GAPDH was positive in “standard” RT reactions 
and negative in “NO RT” RT reactions. These results indicate that primers for v2-
transcript react with both mRNA and genomic DNA. Thus RNA treatment with DNAse 
is a necessary step before RT and qPCR. 
Additionally, in order to prove the efficiency and dynamic range of qPCR for 
v2-transcript and GAPDH, a validation experiment was performed. The cDNA library 
was created from RNA extracted from GRANTA19 cell line. Subsequently the qPCR 
was perfrmed in the reactions in samples with six consequent dilutions of cDNA: 1:1, 
1:5, 1:25, 1:125, 1:625 and 1:3125. The RNA input in RT reaction was 10 ng/µl of RT 
reaction giving the final input of cDNA in qPCR reaction as follows: 1.0ng/µl of qPCR 
reaction, 0.2ng/µl, 0.04ng/µl, 0.008ng/µl, 0.0016ng/µl, 0.00032ng/µl and 0.000064ng/µl 
(making assumption that the evfficiency of the RT was 1.0). The standard curves have 
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been established. For v2-transcript the slope was -3.1390402 and R2 0.99107 and for 
GAPDH -3.2888095 and 0.99829805. These results allow using 2-ΔΔCt method for 
normalization of expression of v2-transcript (figure 3.7). 
 
(A) 
 
(B) 
 
Figure 3.7 qPCR standard curve for v2–transcript and GAPDH, total RNA extracted 
from GRANTA 519 cell line. (A) v2–transcript and (B) GAPDH. 
 
3.4.2 Expression of v2-transcript, c-MYC and HLA-DRΒ in lymphoma cell lines 
 
Validation of endogenous control (GAPDH) for qPCR 
 In preliminary experiments for genes expression using qPCR in lymphoma cell 
lines, GAPDH was proposed as housekeeping gene for normalization purposes of 2-ΔΔCt 
method. In order to validate the expression of GAPDH as a reference gene the qPCR for 
GAPDH was performed in RNA extracted from all studied cell lines. The RT and qPCR 
were performed according to the standard conditions on DNAse treated, total RNA 
extracted from each cell line. The concentration of RNA in the RT reaction was 10ng/µl 
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of RT reaction and cDNA in the qPCR reaction 1ng/µl of qPCR reaction. These 
conditions were maintained through all experiments on gene expression in cell lines. In 
order to avoid changes in condition of reaction, RT and qPCR were performed 
simultaneously in all samples. GAPDH was expressed nearly equally in all tested cell 
lines with fold change of 1.23 in all cell lines. This met the conditions for a housekeeper 
gene. The mean Ct value for all cell lines was 17.05, range from 14.98 to 18.42 (figure 
3.8). According to these results GAPDH fulfilled the criteria for a housekeeping gene in 
2-ΔΔCt method. 
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Figure 3.8 Expression of GAPDH (Ct value) in individual cell lines. 
 
Expression of v2-transcript, c-MYC and HLA-DRΒ in lymphoma cell lines 
 The RT and qPCR of all assessed genes in the lymphoma cell lines were 
performed to the standard conditions described above. The expression was evaluated 
according to 2-ΔΔCt using GAPDH as endogenous control and RNA extracted from 
normal CD19+ B-cell from 3 healthy donors as calibrator. 
 v2-transcript was expressed in all analyzed cell lines (see figure 3.9.A). As 
compared with the normal calibrator the v2-transcript was under-expressed in all cell 
lines except from SC1 (FL cell line) and REC1 (MCL cell line). In comparison between 
DLBCL cell lines and other lymphoma cell lines, v2-transcript had significantly lower 
expression in DLBCL cell lines (log2 RQ range from -1.72 to -6.35; average -3.56) than 
in other lymphoma cell lines (log2 RQ range from -4.18 to 0.83; average -1.46); 
(p=0.042, Mann-Whitney U Test), figure 3.9.B. 
 c-MYC and HLA-DRβ were also under-expressed in all cell lines as compared to 
the normal calibrator (figure 3.9.C and 3.9.E). There were no significant difference 
between the DLBCL cell lines and other cell lines in expression of c-MYC: log2 RQ 
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range from -0.44 to -7.41; average -2.88 in DLBCL cell lines vs. log2 RQ range from -
1.01 to -5.57; average -2.58 in other cell lines (p=0.713) and HLA-DRβ: log2 RQ range 
from -1.77 to -29.90; average -14.64 in DLBCL cell lines vs. log2 RQ range from -3.36 
to -29.90; average -12.49 in other cell lines (p=0.792); (figure 3.9.D and 3.9.F). 
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Figure 3.9 Expression of v2-transcript, c-MYC and HLA-DRβ in lymphoma cell lines. 
Expression (log2 RQ) in individual lymphoma cell lines (A) v2-transcript, (C) c-MYC, 
(E) HLA-DRβ and a comparison of expression (log2 RQ) in DLBCL vs. other lymphoma 
cell lines (Mann-Whitney U test). (B) v2-transcript, (D) c-MYC, (F) HLA-DRβ 
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3.4.3 Expression of v2-transcript, c-MYC and HLA-DRΒ in FFPE and frozen 
lymphoma tissue samples 
 As the proposed study material should be FFPE tissue and qPCR on nucleic acid 
extracted from FFPE usually encountered significant difficulties due to loss of their 
integrity the qPCR was performed on the RNA extracted from both FFPE and 
corresponding frozen tissue from the series eleven patients with lymphoma. The RNA 
input in RT was 10ng/µl of RT reaction and cDNA input in qPCR was 0.5ng/µl of 
qPCR reaction throughout this study. The calibrator was RNA extracted from normal B-
cells. 
 
Validation of endogenous control (GAPDH) for qPCR in FFPE and frozen 
lymphoma tissue samples 
 The expression of GAPDH was assessed in RNA extracted from eleven FFPE 
tissue blocks and from corresponding eleven frozen tissue blocks. GAPDH was 
expressed in all assessed samples; see figure 3.10.A. The expression in frozen tissue 
was characterized by lower Ct values with min Ct of 19.87 and max Ct of 24.46 (mean 
Ct 21.64) as compared to FFPE tissue (min Ct of 26.36 and max Ct of 32.14; mean Ct 
29.29). This difference was statistically significant (p=0.000), figure 13.10.B. The fold 
of difference among both frozen tissue samples and FFPE tissue samples was lower 
<1.3 with respectively: 1.23 and 1.22. According to this data the GAPDH can be used as 
endogenous control for normalization purposes of 2-ΔΔCt method. 
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Figure 3.10 Expression of GAPDH in FFPE tissue and corresponding frozen tissue. (A) 
expression of GAPDH (Ct value) in all samples (B) comparison of GAPDH expression 
(Ct value) in FFPE tissue and frozen tissue samples (Mann-Whitney U test). 
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Expression of v2-transcript, c-MYC and HLA-DRΒ in FFPE and frozen lymphoma 
tissue samples 
All assessed genes were expressed in the frozen tissue and corresponding FFPE 
blocks. There were significant differences in Ct values between both types of material, 
see figure 3.11. The mean Ct of v2-transcript in frozen tissue was 30.25 (range from 
26.59 to 32.90) and in FFPE was 35.00 (range from 30.23 to 36.54); p<0.001 (see figure 
3.11.A). Regarding the expression of c-MYC, the mean Ct value in frozen tissue was 
26.14 (range from 23.33 to 28.77) and in FFPE 33.31 (range from 30.61 to 36.38); 
p<0.001 (see 3.11.C). The same pattern of expression was observed in HLA-DRβ, the 
mean Ct value in frozen tissue was 31.12 (range from 21.79 to 40.00) and in FFPE was 
34.60 (range from 27.65 to 40.00), however the difference was not significant; p=0.243 
(figure 3.11.E). 
Additionally, correlation between gene expression measured in FFPE tissue 
blocks and in corresponding frozen tissue was evaluated using Spearman’s correlation. 
The expression of c-MYC and HLA-DRβ showed significant correlation; for c-MYC 
Rs=0.7727 and p=0.0074 (figure 3.11.B) and for HLA-DRβ Rs=1.00 and p<0.0001 
(figure 3.11.D). But there was no significant correlation for expression of v2-transcript 
Rs=0.2273 and p=0.5034 (figure 3.11.F). 
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Figure 3.11 Expression of v2-transcript, c-MYC and HLA-DRβ in FFPE tissue and 
corresponding frozen tissue. Comparison of expression (Ct-values) in FFPE tissue and 
corresponding frozen tissue samples (Mann-Whitney U test). (A) v2-transcript, (C) c-
MYC and (E) HLA-DRβ. Correlation of expression (log2 RQ) in FFPE tissue and 
corresponding frozen tissue samples (r Spearman). (B) v2-transcript, (D) c-MYC and 
(F) HLA-DRβ. 
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3.4.4 Validation of repeated qPCR for V2-transcript, c-MYC and HLA-DRΒ in series 
of DLBCL FFPE clinical tissue samples 
 In order to assess the precision and repeatability of the applied assays, the 
expression of the studied genes was assessed twice using two different concentrations of 
the mRNA extracted from the FFPE of a cohort patients with DLBCL for the RT and 
subsequently qPCR. In the first series of experiments the concentration of RNA used for 
RT was 10ng/µl of RT reaction and in subsequent series this was reduced to 5ng/µl of 
RT reaction. The concentration of cDNA in qPCR was 0.5ng/µl of qPCR reaction in the 
first series of experiments and 0.25ng/µl of qPCR reaction in the next series. 
 Concordance between the expressions of the genes in both series of experiments 
was evaluated using Bland-Altman method to measure agreement and Spearman’s 
correlation to assess correlation. Ad described above for Bland-Altman analysis the two 
methods agreed if the bias between them was equal to or less than one as this equated to 
less than one qPCR cycle difference. For correlation, significance was set at p<0.05. 
The evaluation showed that the expression of all assessed genes: v2-transcript, c-MYC 
and HLA-DRβ agreed between the two series of experiments with bias of -0.2559, -
0.1046 and -0.2038 respectively (figure 3.12A, C and E). There was a significant 
correlation between the expression of all genes from two series of experiments with 
Rs=0.791 and p<0.001 for v2-transcript, 0.761 and p<0.001 for c-MYC and Rs=0.998 
and p<0.001 for HLA-DRβ (figure 3.12.B, D and F). 
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Figure 3.12 Expression of v2-transcript, c-MYC and HLA-DRβ in two repeated series of 
FFPE tissue samples. Bland-Altman plots for agreement of expression (log2 RQ). (A) 
v2-transcript, (C) c-MYC and (E) HLA-DRβ. Correlation of expression (log2 RQ), r 
Spearman. (B) v2-transcript, (D) c-MYC and (F) HLA-DRβ. 
 
 216 
3.4.5 Expression of v2-transcript, c-MYC and HLA-DRβ in a population-based cohort 
of DLBCL patients 
 
Validation of endogenous controls for qPCR in a cohort of patients with DLBCL 
For the purposes of the 2-ΔΔCt three individual housekeeper genes with estimated 
different Ct values were evaluated: GAPDH, PGK1 and TBP. In order to fulfil the 
criteria of a valid housekeeper the Ct value should be <34 and SD of triplicate 
expression ≤0.3. The GAPDH was evaluable in 80 samples. In remaining 12 samples, it 
was not detected in one sample, Ct was ≥34 in 8 samples, SD was >0.3 in one sample 
and Ct was ≥34 and SD >0.3 in two samples. The mean Ct value of GAPDH was 29.29 
(range from 24.71 to 33.61) and the ratio between the lowest and highest Ct value was 
1.36, being just above the conventional limit of 1.3 (figure 3.13.A). The PGK1 was 
evaluable in 87 samples. Among 5 non-evaluable samples the Ct was ≥34 in four 
samples and SD >0.3 in one sample. The mean Ct value of PGK1 was 28.05 (range 
from 24.64 to 32.69) and the ratio between the lowest and highest Ct value was 1.32, 
being just above the conventional limit of 1.3 (figure 3.13.B). By contrast the TBP was 
evaluable in two samples only. In remaining 90 samples the gene was not expressed in 
37 samples, in 32 samples the Ct was ≥34 and in 21 Ct was ≥34 and the SD was >0.3. 
Following these results the GAPDH and PGK1 were used as housekeeper genes for the 
purposes of the 2-ΔΔCt evaluation. 
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Figure 3.13 Expression of GAPDH and PGK1 (Ct value) in FFPE tissue samples of 
patient cohort with DLBCL. (A) GAPDH and (B) PGK1. 
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Expression of v2-transcript, c-MYC and HLA-DRβ in a cohort of patients with 
DLBCL 
The expression of all assessed target genes was performed in 92 samples. The 
expression of target genes was evaluable if the gene was expressed with SD ≤0.3. For 
the evaluation purposes both housekeeper genes: GAPDH and PGK1 had to be 
measurable in the tested samples. 
The v2-transcript was expressed with SD ≤0.3 in 74 samples. In 9 samples there 
was no expression of the gene and in remaining 9 samples the SD was >0.3. Among 74 
patients with evaluable expression, the housekeeper genes were not evaluable in 3 
samples, thus the v2-transcript was assessed with a 2-ΔΔCt method in 71 samples. The 
total efficacy of the method was 77%. The mean log2 RQ was -0.44 (range from -3.89 to 
1.94, SD 1.16); (Figure 3.14.A). 
c-MYC was expressed with SD ≤0.3 in 71 samples. In 6 samples there was no 
measured expression and in further 15 samples the SD was >0.3. Among 71 samples 
with evaluable c-MYC expression, the housekeeper genes were not evaluable in 3 
samples, thus the expression of c-MYC assessed with a 2-ΔΔCt method was performed in 
68 samples, giving the total efficacy of method of 74%. The mean log2 RQ was -0.82 
(range from -3.03 to 1.81, SD 0.92); (Figure 3.14.B). 
HLA-DRβ was expressed in 89 samples with SD ≤0.3. In the remaining 3 
samples, the gene was expressed, however the SD was >0.3. Among 89 samples with 
evaluable HLA-DRβ expression, the housekeeper genes were not evaluable in 9, thus the 
expression of HLA-DRβ by 2-ΔΔCt method was performed in 80 samples with a total 
efficacy of the method of 87%. The mean log2 RQ was -17.81 (range from -29.90 to 
1.85, SD 14.19); (Figure 3.14.C). 
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Figure 3.14 Expression of v2-transcript, c-MYC and HLA-DRβ (log2 RQ) in samples of 
patient cohort with DLBCL. (A) v2-transcript, (B) c-MYC and (C) HLA-DRβ. 
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Association of expression of v2-transcript, c-MYC and HLA-DRβ with clinical 
characteristics in a cohort of patients with DLBCL 
 The expression of all measured genes was correlated with the patient 
characteristic parameters in all evaluable patients, see table 3.7. The v2-transcript was 
significantly more highly-expressed in patients with BM involvement and with higher 
ECOG (p=0.015 and p=0.049; respectively). By contrast c-MYC was significantly more 
expressed in patients with bulky disease (p=0.027), higher serum LDH levels (p=0.030) 
and lower albumin levels (p=0.046). The expression of HLA-DRβ was not associated 
with any parameter. 
 
Factor v2-transcript c-MYC HLA-Drβ 
Sex 
Age 
CS 
ECOG 
B-symptoms 
Extranodal involvement 
Bulk 
BM involvement 
LDH 
Β2-microglobulin 
Hb 
WBC 
Albumin 
Urea 
AP 
IPI 
Hans phenotype 
n.s. 
n.s. 
n.s. 
0.049 
n.s. 
n.s. 
n.s. 
0.015 
n.s 
n.s 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
0.027 
n.s. 
0.030 
n.s 
n.s. 
n.s. 
0.046 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
Table 3.7 Expression of v2-transcript, c-MYC and HLA-DRβ and their relation to 
patient characteristics by Mann-Whitney-Test. 
 
Association of expression of v2-transcript, c-MYC and HLA-DRβ with response to 
treatment and survival in a cohort of patients with DLBCL 
The expression of v2-transcript, c-MYC and HLA-DRβ was tested in patients 
with different response to treatment rates and different survival status (alive or death at 
the end of the treatment). There were no statistical differences. 
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The predictive value of expression of v2-transcript, c-MYC and HLA-DRβ on 
PFS and OS was assessed as a continuous variable using the Cox-regression model. The 
expression of none of assessed genes (v2-transcript, c-MYC and HLA-DRβ) was 
predictive as a continuous variable for PFS or OS (see table 3.8). 
 
PFS 
Target H.R.; (C.I.); p-value 
v2-transcript 0.864; (0.618 – 1.207); 0.391 
c-MYC 1.030; (0.662 – 1.604); 0.895 
HLA-DRβ 0.988; (0.964 – 1.013); 0.348 
OS 
Target H.R.; (C.I.); p-value 
v2-transcript 0.879; (0.621 – 1.244); 0.467 
cMYC 0.911; (0.564 – 1.470); 0.702 
HLA-DRB 0.986; (0.960 – 1.013); 0.292 
Table 3.8 Survival analysis (PFS and OS) and expression of v2-transcript, c-MYC and 
HLA-DRβ as continuous variables by Cox regression. 
 
In order to assess the predictive value of v2-transcript, c-MYC and HLA-DRβ 
expression as a dichotomous variable and the limits for dichotomizing expression values 
were set up using the ROC curves methods. The mean PFS and OS should be compared 
for both values (high and low expression) using Log-rank test. 
The ROC curves analysis could calculate the limits for dichotomized evaluation of v2-
transcript and c-MYC for PFS and OS and no valid limits for HLA-DRΒ for both PFS 
and OS, see table 3.9. However, the calculated limits for v2-transcript and c-MYC had 
restricted predictive value and could not be used for appropriate evaluation. 
 
PFS 
 Direction Cutoff Sensitivity Specificity ROC p-value 
v2-transcript Low -0.8350 0.4815 0.7619 0.5573 0.4242 
c-MYC high -3.000 1.0000 0.0000 0.5188 0.8001 
OS 
 Direction Cutoff Sensitivity Specificity ROC p-value 
v2-transcript low 1.9340 1.0000 0.0222 0.5308 0.6674 
c-MYC low 0.3877 0.9545 0.1087 0.5326 0.6653 
Table 3.9 ROC curve analysis for limits of expression of v2-transcript and c-MYC; PFS 
(pre-test probability = 0.58) and OS (pre-test probability = 0.65). 
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3.5 Results - studies on expression of miRNAs 
 
3.5.1 Influence of different RNA extraction methods on qPCR of mature miRNAs 
 As the practical knowledge of molecular techniques in assessment of miRNAs is 
very limited, there is a need for novel laboratory methods including the extraction, 
processing and storage of nucleic acids and expression assays. In order to choose the 
best method for extraction of RNA from cell lines for expression studies of miRNAs 
two different protocols of the mirVanaTM miRNA Isolation Kit were compared: the 
protocol for a total RNA isolation (called mirVanaTM total) and the protocol for an 
enrichment isolation of small RNAs (called mirVanaTM micro). The amplification of 
two miRNAs was performed: miR-24, which is used as a housekeeping miRNA in the 
studies on lymphoma and miR-155 a miRNA, which is known to be expressed in 
lymphoid tissue. Three lymphoma cell lines were used: NU-DHL-1 a DLBCL cell line, 
U-698-M a lymphoblastic lymphoma cell line and SC-1 a FL cell line. The 
amplification was performed in two separate series of RNA; one with storage time of 2 
weeks or shorter and the second series with preservation time of approximately 12 
months. Both sets of samples were stored in -70°C. 
 Both miRNAs could be amplified successfully in all samples. The differences in 
the mean Ct value were statistically significant between the samples with RNA 
extracted with two different protocols in amplification of miR24 (p=0.004) and also 
present but not significant in amplification of miR155 (p=0.548), figure 3.15. 
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Figure 3.15 Expression of miRNAs in total and enriched RNA extracted from 
GRANTA519. Comparison of expression (Ct values) in total and enriched RNA (Mann-
Whitney U test). (A) miR-24 and (B) miR-155. 
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Hence the amplification of miRNAs was possible in RNA samples extracted both 
protocols but the mirVanaTM micro can bias the results of amplification of the regular 
amplicons and it would be of importance to amplify both miRNAs and regular genes in 
one sample it was decide to use the mirVanaTM total in future analysis. This will be 
additionally assessed in the samples with RNA with shorter and longer storage. 
 
3.5.2 Influence of the storage time of RNA on qPCR of mature miRNAs 
 Just as two different extraction methods were compared in the preliminary 
studies, a similar experiment was designed in order to assesse the potential degradation 
of miRNAs during the storage of RNA samples. The amplification of two mature 
miRNAs miR-24 and miR-155 was performed on the RNA samples with shorter storage 
(less than 2 weeks) and longer storage time (approximately 12 months). All samples 
were stored at temperature of approximately -70°C. The RNA was extracted from 3 
different lymphoma cell lines: NU-DHL-1, U-698-M and SC-1 with mirVanaTM micro 
and total. 
 Both of the miRNA could be amplified in all samples and there were no 
significant differences in the sample pairs with different storage times. This pattern was 
seen in samples extracted with both extraction methods: mirVanaTM micro and total. 
Figure 3.16.A and B show the average Ct values for miR24 and miR155 respectively in 
all RNA samples with shorter and longer storage time. The differences were not 
statistically significant (p>0.999 for both). 
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Figure 3.16 Expression of miRNAs in RNA with shorter and longer storage time, 
extracted from GRANTA519. Comparison of expression (Ct values) in samples with 
shorter and longer storage time (Mann-Whitney U test). (A) miR-24 and (B) miR-155. 
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 The results of this study confirmed that the RNA for studies on miRNA can be 
stored at least up to a year and there were no advantages in using the enrichment 
extraction method. 
 
3.5.3 Validation of qPCR for mature miRNAs 
 In order to prove the efficiency of RT and qPCR of mature miRNAs and to 
select the optimal amount of RNA the reactions for two different miRNAs: miR-24 and 
miR-155 were performed with three different total amounts of RNA used in each RT 
reaction: 25ng, 125ng and 250ng in each RT reaction. These amounts correspond with 
the following concentrations of RNA in RT reactions: 1.66ng/µl, 8.33ng/µl and 
16.66ng/µl of RT reaction and qPCR reactions: 0.074ng/µl, 037ng/µl and 0.74ng/µl of 
qPCR reaction. The RNA was extracted with mirVanaTM total from a DLBCL cell line 
(NU-DHL-1). For both miR-24 and miR-155 the lowest Ct values were measured in 
samples with the highest amount of RNA used, see figure 3.17. 
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Figure 3.17 Expression of miR-24 and miR-155 (Ct value) in samples with different 
RNA amount (25ng, 125ng, 250ng of total RNA extracted from GRANTA519 per RT 
reaction). 
 
To assess the correlation between the Ct values and amount of RNA used the 
Pearson Correlation test has been performed. There was a linear correlation between the 
Ct values and amount of RNA used for both miRNAs (for miR-24 R=0.999, p<0.001 
and for miR-155 R=0.973, p<0.0001). These results allow the usage of 2-∆∆CT method 
for normalization of expression of mature miRNAs. It was decided that in the future 
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experiments the total amount of RNA will be 200ng per one miRNA RT (13.33ng/µl of 
RT reaction). 
 
3.5.4 Expression of mature miRNAs in lymphoma cell lines 
 
Validation of miR-24 as a reference miRNA for qPCR for mature miRNAs 
 miR-24 was reported in several studies as an appropriate candidate for the 
studies on lymphomas. To validate the expression of miR-24 as a reference miRNA its 
expression was assessed in the samples of RNA extracted from all cell lines. The RNA 
was extracted with mirVanaTM total from each cell line and was used in a concentration 
of 13.33ng/µl of RT reaction and concentration of RT-product in qPCR was 0.059ng/µl 
of qPCR reaction. The RT and qPCR were performed as per standard conditions. In 
order to stay with homogenous conditions the RT and qPCR of all samples were 
performed simultaneously in all samples. miR-24 was expressed nearly equally in all 
samples (i.e. <1.3-fold of change in all cell lines). The median Ct value for all cell lines 
was 28.72, range from 24.11 in KARPAS-422 to 29.86 in DB (figure 3.18). According 
to these results the expression of mature miRNAs in tested cell lines can be normalized 
to expression of miR-24 using 2-∆∆CT method. 
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Figure 3.18 Expression of miR-24 (Ct value) in different cell lines. 
 
Expression of mature miRNAs in lymphoma cell lines 
The RT and qPCR was performed according to the standard conditions on RNA 
isolated with mirVanaTM total from each cell line used in RT in concentration of 
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13.33ng/µl of RT reaction and concentration of RT-product in qPCR was 0.059ng/µl of 
qPCR reaction. The expression of each miRNA was compared to endogenous control 
miR-24. The ratio of target miRNA and endogenous control in each cell line was 
compared to the ratio of target miRNA and endogenous control in calibrator (RNA from 
normal CD19+ B-cells from 3 healthy donors). Fold change was calculated using 2-∆∆CT 
method. 
Four miRNAs were chosen for these experiment: miR-155 as an internal control 
as this miRNA is known to be expressed in lymphoid malignancies and 3 miRNAs from 
miR-17-92 cluster: miR-17-5p, miR-20 and miR-92. miR-17-5p is encoded in the 
beginning of the cluster, miR-20 in the middle and miR-92 at its end. All analysed 
miRNAs were expressed in the tested cell lines. The expression pattern of miR-155 over 
different cell lines was the most heterogeneous. It was mostly under-expressed in the 
DLBCL cell line, highly under-expressed in FL cell lines SC-1 and WSU-FSCLL, 
slightly over-expressed in both MCL (GRANTA-519 and REC-1) and had mixed 
pattern in lymphoblastic lymphoma cell lines (CI-1 and U-698-M); figure 3.19.A. miR-
155 was slightly more highly-expressed among lymphoma cell lines as compared with 
DLBCL cell lines (figure 3.19.B), p>0.999. By contrast, the expression of miRNAs 
from miR-17-92 cluster had a more homogenous pattern. miR-17-5p was overexpressed 
in all cell lines (figure 3.19.C), like miR20 which was slightly under expressed only in 
two cell lines – one DLBCL cell line (NU-DHL-1) and one MCL line (GRANTA-519); 
figure 3.20.E. miR-92 was also overexpressed in all cell lines with an exception of NU-
DHL-1 and GRANTA-519 and additionally KARPAS-422 (figure 3.19.G). All three 
miRNA were significantly more highly-expressed among other lymphoma cell lines as 
compared with DLBCL cell lines (figure 3.19 D, F and H). 
 
 225 
HT
SU
-D
HL
-5
SU
-D
HL
-8 DB
KA
RP
AS
-42
2
OC
I-L
Y-
19
NU
-D
HL
-1
SU
-D
HL
-10
SU
-D
HL
-4
SU
-D
HL
-6
SC
-1
WS
U-
FS
CL
L
GR
AN
TA
-51
9
RE
C-
1
CI
-1
U-
69
8-M
-15
-10
-5
0
5
lo
g2
 R
Q
 m
iR
-1
55
log2 RQ miR-155
(A) Expression of miR-155 in different cell lines
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(C) Expression of miR-17-5p in different cell lines
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(E) Expression of miR-20 in different cell lines
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Figure 3.19 Expression of miR-155, miR-17-5p, miR-20 and miR-92 in lymphoma cell 
lines. Expression (log2 RQ) in individual lymphoma cell lines (A) miR-155, (C) miR-
17-5p, (E) miR-20 and (G) miR-92 and a comparison of expression (log2 RQ) in 
DLBCL vs. other lymphoma cell lines (Mann-Whitney U test). (B) miR-155, (D) miR-
17-5p, (F) miR-20 and (H) miR-92. 
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3.5.5 Expression of mature miRNAs in FFPE and frozen lymphoma tissue samples 
 As previously mentioned in the section on studies on gene expression, the 
proposed study material should be FFPE tissue. One of the common limitations of 
qPCR is its efficacy in nucleic acid extracted from FFPE tissue, particularly for 
amplicons >150nt. It usually encounters significant difficulties due to loss of their 
integrity. The small size of miRNAs could suggest they could be better targets for 
qPCR. In order to prove this hypothesis the qPCR for mature miRNAs was performed 
on the RNA extracted from both FFPE and corresponding frozen tissue from the series 
of eleven patients with lymphoma. The concentration of RNA in RT reaction was 
13.3ng/µl of RT reaction and the concentration of RT product in qPCR reaction was  
0.059ng/µl of qPCR reaction through out this study. 
 
Validation of endogenous control (miR-24) for qPCR in FFPE and frozen lymphoma 
tissue samples 
 The expression of miR-24 was assessed in RNA extracted from eleven FFPE 
tissue blocks and from corresponding eleven frozen tissue blocks. miR-24 was 
expressed in all assessed samples; see figure 3.20.A. Importantly, by contrast to the 
studies on GAPDH, there was no statistical difference in measured Ct values of miR-24 
between the FFPE tissue and frozen samples, p=0.898. Ct values in frozen tissue 
samples ranged from 22.79 to 25.64 (mean 24.30) and in FFPE tissue samples from 
22.58 to 26.20 (mean 24.51); figure 3.20.B. The fold of difference among both frozen 
tissue samples and FFPE tissue samples was lower <1.3 with respectively: 1.13 and 
1.16. According to this data miR-24 can be used as endogenous control for 
normalization purposes of 2-ΔΔCt method. 
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Figure 3.20 Expression of miR-24 in FFPE tissue and corresponding frozen tissue. (A) 
expression (Ct value) of miR-24 in all samples and (B) comparison of miR-24 
expression (Ct value) in FFPE tissue and frozen tissue samples (Mann-Whitney U test). 
 
Expression of mature micro RNAs in FFPE and frozen lymphoma tissue samples 
All assessed miRNAs were expressed in the frozen tissue and corresponding 
FFPE blocks. By contrast to the results of the similar experiments in expression of the 
genes, there were no significant differences in Ct values between both types of material. 
The mean Ct of miR-155 in frozen tissue was 24.69 (range from 20.91 to 27.63) and in 
FFPE was 24.46 (range from 21.69 to 28.37); p=0.699; figure 3.21.A. The same pattern 
of expression was observed in expression of miRNAs from the miR-17-92 cluster: the 
mean Ct value of miR-17-5p in frozen tissue was 25.82 (range from 24.23 to 27.48) and 
in FFPE 25.91 (range from 23.50 to 27.73); p=0.699, figure 3.21.C. The mean Ct of 
miR-20 in frozen tissue was 22.59 (range from 21.25 to 23.83) and in FFPE 22.63 
(range from 21.06 to 24.55); p=0.949 (figure 3.21.E) and regarding miR-92, the mean 
Ct value in frozen tissue was 22.03 (range from 20.23 to 22.89) and in FFPE was 22.35 
(range from 20.90 to 23.44), p=0.332; figure 3.21.G. 
Additionally, correlation between miRNA expression measured in FFPE tissue 
blocks and in corresponding frozen tissue was evaluated using Spearman’s correlation. 
All assessed miRNAs showed significant correlation; for miR-155 Rs=0.6818 and 
p=0.0251 (figure 3.21.B), for miR-17-5p Rs=0.6636 and p=0.030 (figure 3.21.D), for 
miR-20 Rs=0.5545 and p=0.0818 (figure 3.21.F) and for miR-92 Rs=0.6091 and 
p=0.0519; see figure 3.21.H. 
 228 
FFPE tissue frozen tissue
18
20
22
24
26
28
30
C
t m
iR
-1
55
(A) Expression of miR-155
in FFPE and frozen tissue samples
p=0.699  (Mann - Whitney U Test)
FFPE tissue frozen tissue
22
24
26
28
30
C
t m
iR
-1
7-
5p
(C) Expression of miR-17-5p
in FFPE and frozen tissue samples
p=0.699  (Mann - Whitney U Test)
FFPE tissue frozen tissue
20
22
24
26
C
t m
iR
-2
0
(E) Expression of miR-20
in FFPE and frozen tissue samples
p=0.949  (Mann - Whitney U Test)
FFPE tissue frozen tissue
18
20
22
24
26
C
t m
iR
-9
2
(G) Expression of miR-92
in FFPE and frozen tissue samples
p=0.332  (Mann - Whitney U Test)
-6 -4 -2 2
-6
-4
-2
2
4
(B) Correlation of miR-155
in FFPE and frozen tissue samples
log2 RQ miR-155 FFPF tissue
lo
g2
 R
Q
 m
iR
-1
55
 fr
oz
en
 ti
ss
ue
r=0.6818 & p=0.0251
-1.0 -0.5 0.5 1.0 1.5
-2
-1
1
2
(D) Correlation of miR-17-5p 
in FFPE and frozen tissue samples
log2 RQ miR-17-5p FFPF tissuel
og
2  R
Q
 m
iR
-1
7-
5p
 fr
oz
en
 ti
ss
ue
r=0.6636 & p=0.0306
-2 -1 1 2
-4
-2
2
4
(F) Correlation of miR-20
in FFPE and frozen tissue samples
log2 RQ miR-20 FFPF tissue
lo
g2
 R
Q
 m
iR
-2
0 
fr
oz
en
 ti
ss
ue
r=0.5545 & p=0.0818
-3 -2 -1 0
-4
-3
-2
-1
0
1
2
(H) Correlation of miR-92
in FFPE and frozen tissue samples
log2 RQ miR-92 FFPF tissue
r=0.6091 & p=0.0519
 
Figure 3.21 Expression of mature miRNAs in FFPE tissue and corresponding frozen 
tissue. Comparison of expression (Ct-values) in FFPE tissue and corresponding frozen 
tissue samples (Mann-Whitney U test): (A) miR-155, (C) miR-17-5p, (E) miR-20 and 
(G) miR-92. Correlation of expression (log2 RQ) in FFPE tissue and corresponding 
frozen tissue samples (r Spearman): (B) miR-155, (D) miR-17-5p, (F) miR-20 and (H) 
miR-92. 
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3.5.6 Validation of repeated qPCR for mature miRNA in series of DLBCL FFPE 
clinical tissue samples 
 In order to assess the precision and repeatability of the applied assays, the 
expression of the studied miRNAs was assessed in two series of experiments using two 
different concentrations of the RNA extracted from the FFPE tissue of a cohort of 
patients with DLBCL. In the first series the concentration of RNA used for RT reaction 
was 1.38ng/µl of RT reaction and subsequently in the second series of experiments it 
was reduced to 0.66ng/µl of RT reaction. The concentration of the miRNA RT product 
in qPCR reaction was 0.006147ng/µl of qPCR reaction in the first series and 
0.00325ng/µl of qPCR reaction in the second series. 
The evaluation showed that the expression of all assessed miRNAs: miR-155 
and miR-17-5p agreed between the two series of experiments with bias of 0.2905 and 
0.6856, retrospectively (figure 3.22.A and C). By contrast there was no agreement in 
expression of miR-20 with bias of 1.1194 (figure 3.22.E). There was a significant 
correlation between the expression of all miRNAs from two series of experiments with 
Rs of 0.601, p=0.043 for miR-155 (figure 3.22B), Rs of 0.717 and p=0.037 for miR-17-
5 (figure 3.22.D) and Rs of 0.839 and p=0.001 for miR-20 (figure 3.22.D). 
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Figure 3.22 Expression of mature miR-155, miR-17-5p and miR-20 in two repeated 
series of FFPE tissue samples. Bland-Altman plots for agreement of expression (log2 
RQ) (A) miR-155, (C) miR-17-5p and (E) miR-20. Correlation of expression (log2 RQ), 
r Spearman: (B) miR-155, (D) miR-17-5p and (F) miR-20. 
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3.6 Discussion 
 
The research in this chapter focused on assessment of expression of c-MYC, 
HLA-DRβ and v2-transcript at the RNA level using qPCR on the material extracted 
from FFPE tissue samples as predictive factors for DLBCL. Additionally, we assessed 
the potential role of mature miRNAs encoded in the v2-transcript as predictive 
biomarkers in DLBCL. All these genes have been reported to play important roles in 
oncogenesis and also have prognostic value in DLBCL. c-MYC is a known oncogene 
and chromosomal aberrations involving its locus are well defined in lymphomagenesis, 
as are alterations its expression at the protein level. HLA-DRβ is one of the MHC class 
II genes and its under-expression plays important role in limiting immune-surveillance. 
Finally, v2-transcript is a new candidate for a new class of proto-oncogenes encoding 
miRNAs involved in RNA interference processes. 
The expression of c-MYC and HLA-DRβ was assessed using ready-to-use 
commercial TaqMan® Gene Expression Assays including sets of primers and probes 
and they do not require any additional testing. By contrast, there were no commercially 
available ready-to-use assays for assessment of v2-transcript. We used the set of 
primers and probes previously described by Venturini et al (Venturini et al., 2007). 
Hence, these primers and probe are characterized by some limitations e.g. they bind to 
the amplicon beyond the region encoding mature microRNAs and the transcribed 
amplicon has significant length of 172nt. The amplicon was re-scanned using Applied 
Biosystem software in order to find a more optimal set of primers and probes. 
Unfortunately, no further candidates were found. The chosen v2-transcript primers and 
probes passed successfully the standard curve experiment. It was also proven that 
primers and probes can react with genomic DNA thus treatment with DNAse is 
necessary. 
In preliminary experiments the expression of c-MYC, HLA-DRβ and v2-
transcript was successfully measured in RNA extracted from a collection of lymphoma 
cell lines. Generally, the mean Ct values fluctuated around 15-25. The c-MYC and HLA-
DRβ were under-expressed in all cell lines as compared with the expression in reference 
healthy B-cells. There were no differences in the expression of both genes between the 
DLBCL cell lines and other lymphoma cell lines. The v2-transcript was under-
expressed in all cell lines with an exception of two cell lines with a random origin. It 
showed lower expression in DLBCL cell lines as compared with other lymphoma cell 
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lines. The results of expression in cell line studies should be taken with big reserve, as 
all cell lines are in vitro models, which do not necessary show any association with 
natural disease picture. Most of the cell lines were developed from cells isolated from 
pleural effusions or ascites from patients with advanced, usually chemotherapy-resistant 
tumours. It also difficult to compare the results of our experiment with other cell line 
studies because the cell lines tent to change their characteristics the culture. In our 
studies they were used for the purposes of establishing a reaction condition only. 
Additionally, in case of c-MYC the expression of the gene in control sample (B-cell 
collection) was higher than in cell line samples and thus could bias the results. 
Hence the aim of the study was to assess expression of the genes in RNA 
extracted form FFPE tissue samples. As quantity and quality (particularly integrity) of 
nucleic acid is often affected by the process of formalin fixation, paraffin embedding 
and sample storage, we moved experiments to materials extracted from FFPE and 
corresponding frozen tissue. A selection of eleven pairs of FFPE tissue and 
corresponding frozen samples with diagnosis of lymphoma was established. 
Unfortunately, there was no guarantee that both samples came from same region of the 
tumours and the individual samples can obviously differ in the amount of tumour cells 
and connective tissue. This obviously can affect the results of the studies and limited the 
predication of number of performed statistical tests. Generally, all assessed genes were 
expressed in both materials; however there was a significant difference in measured Ct 
values between them. Importantly, the Ct values of a reference gene GAPDH in FFPE 
tissue samples ranged between 26.36 and 32.14 with mean Ct of 29.29 and the fold of 
difference between the lowest and the highest value was 1.22. In the material extracted 
from frozen tissue samples the Ct values for GAPDH ranged from 19.87 to 24.46 (mean 
Ct 21.64) with fold change of 1.23. This confirmed the suitability of GAPDH as a 
reference gene. The mean Ct value of v2-transcript in frozen tissue and FFPE tissue 
samples was 30.25 and 35.00, respectively, for c-MYC 26.14 and 33.31 and for HLA-
DRΒ 23.33 and 34.60. With the mean Ct value measured in RNA extracted from FFPE 
tissue varied from 33.31 for c-MYC, through 34.60 for HLA-DRΒ to 35.00 for v2-
transcript, the qPCR is reaching its limits of dynamic range and requires very careful 
controls e.g. only samples with SD <0.3 in triplicates could be used. Despite applying 
theses special conditions, significant variation of results is possible, as the expression of 
genes is measured at the single copy level and can be easily affected by number of 
factors including RNA quality, technical problems or inhibition of reaction. 
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Additionally, we performed the correlation studies on the gene expression in frozen and 
FFPE tissue samples. We found the significant correlation for c-MYC and HLA-DRβ 
(r=0.7727 & p=0.0074 and r=1.0 & p=0.0028; respectively) but not for v2-transcript 
(r=0.2273 & 0.5034). 
Subsequently, in order to check the precision and reproducibility of assays the 
expression of studied genes was assessed in two series of RNA samples with different 
concentrations extracted from the FFPE tissue samples in a cohort of patients with 
DLBCL. The Bland-Altman assessment confirmed the agreement in expression in both 
experiments with bias of -0.2559 (SD=0.4980) for v2-transcript, -0.1046 (SD=0.5811) 
for c-Myc and -0.4546 (SD=0.4226) for HLA-DRβ. Spearman’s correlation tests also 
showed significant correlation for all assessed genes with r=0.7905 & p<0.001 for v2-
transcript, r=0.7613 & p<0.001 for c-Myc and r=0.967 & p<0.001 for HLA-DRβ. 
 Although reaching the technical limits of qPCR we were able to perform the 
assessment of the genes in FFPE samples collected from a population-based cohort of 
patients with DLBCL. In order to deliver the most precise result we applied strict 
criteria for assessment of the genes with low abundance, as recommended by Applied 
Biosystem. Additionally, following the recent recommendation, two control genes were 
used for evaluation purposes: PGK1 and GAPDH. The GAPDH was evaluable in 80 
samples (87%), the mean Ct value was 29.29 (range from 24.71 to 33.61) with the fold 
of difference between the lowest and the highest value of 1.36 and PGK1 was evaluable 
in 87 samples (95%) with a mean Ct value of 28.05 (range from 24.64 to 32.69) with 
the fold of difference between the lowest and the highest value of 1.33. Both genes 
passed successfully the criteria for control genes in the material extracted from FFPE 
tissue. 
The efficacy of qPCR for individual genes varied from 74% for c-MYC, through 
to 77% for v2-transcript to 87% for HLA-DRβ. All tested genes had a mean RQ lower 
than in control tissue with mean RQ for v2-transcript of -0.44 (range -3.89 – 1.94, SD 
1.16), for c-MYC -0.82 (range -3.03 – 1.81, SD 0.92) and for HLA-DRβ -17.81 (range -
29.90 – 1.85, SD 14.19). The expression of v2-transcript was significantly higher in 
patients with lower ECOG status and BM involvement. This could be explained by 
higher aggressiveness of tumours with higher expression of v2-transcript. The c-MYC 
showed higher expression in patients with bulky disease, increased LDH serum levels 
and lower albumin levels. All these factors can be also associated with more aggressive 
tumours with higher expression of c-MYC. In our evaluation there was no association of 
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the expression of v2-transcript, c-MYC or HLA-DRβ measured as continuous or 
dichotomized variables and patient survival. 
 The role of c-MYC in lymphomagenesis of DLBCL was firstly associated with 
the presence of the chromosomal translocation involving its locus (Johnson et al., 2009) 
(Kramer et al., 1998). It was usually described together with the presence of 
chromosomal translocations involving BCL2 and BCL6. The tumours harbouring both 
translocations are called “double hit lymphomas” and those with all translocation “triple 
hit lymphomas”. The outcome of patients with c-MYC translocation, particularly those 
with additional translocations of BCL2 or BCL6, was very dismal when treated with 
standard anthracycline-based chemotherapy with or without addition of rituximab 
(Niitsu et al., 2009) (Barrans et al., 2010) (Savage et al., 2009) (Johnson et al., 2012). 
They often are classified as B-cell lymphoma unclassifiable, with features between 
DLBCL and BL (Snuderl et al., 2010) (Swerdlow, 2014). The “double and triple hit 
lymphomas” are also usually resistant to salvage chemotherapy with r-DHAP or R-ICE 
(Cuccuini et al., 2012). Due to lack of reliable monoclonal antibodies against c-MYC, 
immunohistochemical studies on c-MYC expression were scarce until the advent of new 
type of antibodies in 2008 (Gurel et al., 2008) (Ruzinova et al., 2010). The recent 
studies described the adverse predictive value of c-MYC expression alone or in 
association with expression of BCL2 and BCL6, so called “double and triple 
expressors” usually with the rearrangement status of assessed genes (Horn et al., 2013) 
(Green et al., 2012b) (Valera et al., 2013) (Hu et al., 2013). However there are also 
some reports, which could not support a predictive role of c-MYC rearrangement status 
(Kramer et al., 1998) (Visco et al., 2013). Despite these encouraging results on c-MYC 
rearrangements and protein expression, there is still little known about the role of 
expression of c-MYC at mRNA level, although it would be logical to focus the research 
in this direction. The data from GEP studies of Rosenwald and confirming studies of 
Rimsza were suggesting negative predictive value of c-MYC RNA expression in 
DLBCL (Rosenwald et al., 2002) (Rimsza et al., 2008). In our studies we could not 
confirmed these results. There are several possible explanations for this. With 
increasing knowledge of c-MYC it can be confirmed that its role in oncogenesis is 
multidirectional. Particularly the complex regulation of c-MYC expression on all levels 
(DNA, mRNA and protein) and c-MYC pro-proliferative and pro-apoptotic properties 
contribute towards it (Pelengaris and Khan, 2006). Recently it was postulated that in 
order to assess the c-MYC equilibrium in the cell it is necessary to measure the 
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expression of c-MYC on all expression levels. The c-MYC rearrangements seem to have 
more predictive value as compared with c-MYC mRNA expression or c-MYC protein 
expression. The c-MYC rearrangements usually lead to constant overflow of a cell with 
the amount of c-MYC protein overcoming the regulation mechanism. Other 
mechanisms leading to increased c-MYC overexpression preserve the complex 
regulatory machinery. Additionally, the factors associated with selection of the patients 
and technical limitation of qPCR could interfere with our results, as discussed below. 
 Regarding the expression of MHC class I and II protein, the low or absent 
expression of these molecules was associated with worse survival of patients with 
DLBCL, most likely due to loss of immunosurveillance (Rimsza et al., 2004) (Rimsza 
et al., 2007) (Veelken et al., 2007). The loss of expression of HLA-DRβ molecule 
together with immunoblastic tumour phenotype was predictive for adverse outcome of 
patients with DLBCL in the study of Bernd et al (Bernd et al., 2009). The loss of 
expression of MHC class II genes at the mRNA level was a negative prognostic factor 
in the GEP studies of Rosenwald. Subsequently this was confirmed by the study of 
Rimsza et al (Rosenwald et al., 2002) (Rimsza et al., 2008). Unfortunately, we could not 
confirm these results. As the association between reduced expressions of HLA-DRβ 
seems to be established, the possible explanation of our results should be more likely 
found in the applied technology or patient selection. 
 The v2-transcript is a new candidate for an oncogene acting through miRNAs 
encoded within it. Its increased amplification was observed in various subtypes of 
lymphoma including DLBCL (Neat et al., 2001) (Ota et al., 2004) (Mao et al., 2002). Its 
oncogenic capacity has been described in several pre-clinical studies. It was also 
assessed in a cohort of patients with CML via qPCR with TaqMan technology, showing 
not only a predictive value but also positive answer to the treatment with tyrosine kinase 
inhibitor (Venturini et al., 2007). Data on expression of v2-transcript in patients with 
DLBCL were lacking. We aimed to address this in the population-based cohort of 
patients with DLBCL. We could not find any predictive value of the v2-transcript 
expression in our cohort. However it is worth mentioning that the set of primers and 
probes was suboptimal for assessment in the material extracted from FFPE tissue with 
the length of amplicon of 170nt and high G-C content. Further limitations of the method 
and cohort described below also apply. 
In terms of the selection of patients, our cohort was based on an unselected 
group of patients with characteristics that did not differ from those presented by others. 
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Solely the general health condition of our patients could be different as we evaluated 
samples from unselected cohort of patients. By contrast, in the majority of other studies, 
the samples of patients included in clinical trials were evaluated. There is known bias in 
patient selection in clinical trials that usually favours more healthy patients. This can 
obviously differ depending on used inclusion criteria. In this case the response and 
survival data are usually better. 
Also, looking from the perspective of applied methodology, there can be a 
different explanation of our results. Regarding the technical limitation of qPCR, the 
expression of all genes was characterized by high Ct values reaching the dynamic range 
of the method. In this situation, the expression of single copies of the genes is detected 
and it can be easily affected by several factors including quality of RNA, inhibition of 
reaction or technical failures. Despite promising preliminary results, the use of qPCR in 
material extracted from FFPE tissue appears to be complex and not reliable. Probably 
the use of a non-enzymatic method would have more advantages, particularly that 
several new technologies have been recently introduced e.g. NanoString. 
Additionally, in all studies the RNA was extracted from curls obtained from 
whole tumour blocks. It is obvious that in some cases not a whole block was infiltrated 
by tumour cells. Thus, the extracted RNA could be easily contaminated by RNA 
coming from non- malignant cells e.g. connective tissue cells. In the situation when the 
Ct values are very high and we measure single copies of the amplicon, this can affect 
easily the results. The optimal solution to this problem would be to work on RNA 
extracted from tissue microarrays. However, the amount of extracted RNA can be an 
issue when using TMA. 
Regarding the pilot studies on the expression of miRNA as potential biomarkers, 
firstly we assessed the most appropriate way of extracting RNA. At that time, 
experiments on miRNAs were novel and little was known about the optimal techniques. 
As we aimed to work on the same material for gene and miRNA expression analysis we 
opted for the normal protocol of RNA extraction rather than the one which involved 
enriching extracted miRNAs. The both methods delivered comparable Ct values of 
assessed miRNAs. In order to assess the potential influence of storage time of extracted 
RNA, we compare the expression of miRNA in the RNA extracted from the same cell 
lines but with different storage time. We could not find any significant difference in 
expression rates, confirming the stability of miRNA over a one year in appropriate 
conditions. 
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One of the main conditions for successful relative qPCR is finding an 
appropriate candidate for reference gene (amplicon). In our studies we aimed for miR-
24, which was previously successfully used in the studies on DLBCL. The expression of 
miR-24 was equally distributed over the selected cell lines, with mean Ct value of 28.72 
(range 24.11 – 29.86) and the fold difference in the expression between the lowest and 
highest Ct value of 1.24. For our studies we choose 4 different miRNAs: miR-155m (it 
has already an established role in the lymphomagenesis) and three miRNAs encoded in 
different loci of v2-transcript: miR-17-5p (at the beginning), miR-20 (in the middle) 
and miR-92 (at the end). We were able to detect and measure the expression signal for 
all assessed miRNAs in the RNA extracted from the selection of lymphoma cell lines. 
MiR-155 showed the most heterogeneous expression pattern, being under-expressed in 
DLBCL cell lines, highly under-expressed in FL cell lines, slightly over-expressed in 
both MCL cell lines and variably expressed in lymphoblastic lymphoma cell lines. MiR-
155 showed higher expression in non-DLBCL cell lines as compared with DLBCL cell 
lines. The miRNAs from the v2-transcript had a more homogenous expression pattern, 
being overexpressed in almost all assessed lymphoma cell lines. Expression was slightly 
higher in non-DLBCL cell lines than DLBCL cell lines. As the aim of this study was 
not to focus on expression in the cell line model we used these results as a preliminary 
model. 
Similar to the studies on gene expression, we moved to the studies on the 
material extracted from FFPE tissue. The first studies compared the expression of 
mature miRNAs in the material extracted from FFPE tissue samples and corresponding 
frozen tissue samples. The expression of miR-24 met the criteria for a reference gene 
with mean Ct value in FFPE tissue and corresponding frozen tissue samples of 24.51 
(range 22.58 – 26.20) with the fold of difference between the lowest and the highest 
value of 1.16 and 24.30 (range 22.79 – 25.64) with the fold of difference between the 
lowest and the highest value of 1.13, respectively. By contrast to the studies on gene 
expression, the difference between Ct levels in frozen tissue and FFPE tissue was not 
significant. This indicates better resistance of miRNAs for material fixation and 
embedding and storage associated degradation, as it was assumed. This was also 
confirmed for the all assessed miRNAs. The mean Ct value of miR-155 in frozen tissue 
and FFPE tissue was 24.69 and 24.46, respectively, for miR-17-5p 25.82 and 25.91, for 
miR-20 22.59 and 22.63 and for miR-92 22.03 and 22.35. There were no statistically 
significant differences between the expression in both materials, confirming the 
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hypothesis of better preservation of miRNAs in FFPE tissue. By contrast to the gene 
expression the qPCR method was within its dynamic range for expression of miRNA in 
FFPE tissue. There was a significant correlation between the expression of miR-155 and 
miR-17-5p in the frozen tissue and FFPE tissue (r=0.6818 & p=0.0251 and 0.6636 & 
0.0306) but no correlation was found in expression of miR-20 and miR-92 (r=0.5545 & 
0.082 and 0.6091 & p=0.0519). Notably, the R-values were smaller as compared with 
the gene expression studies, indicating worse correlation. Taking into consideration the 
tumour homogeneity in the corresponding FFPE and frozen tissue samples this could 
reflect potentially greater sensitivity of qPCR for miRNAs as compared with genes 
assessments. 
Subsequently, in order to check the precision and repeatability of the assays the 
expression of studied miRNAs was assessed in two different concentrations of RNA 
extracted from the FFPE tissue samples from a cohort of patients with DLBCL. The 
Bland-Altman assessment confirmed the agreement in expression in both experiments 
for miR-155 (bias 0.2905 & SD=0.7358) and miR-17-5p (0.6856 & 0.7627) but not for 
miR-20 (bias 1.194 & SD=1.004). Spearman’s correlation tests showed significant 
correlation for all assessed miRNAs with r=0.014 & p=0.043 for miR-155, r=0.7167 & 
p=0.0369 for miR-17-5p and r=0.8392 & p=0.0011 for miR-20. However, the statistical 
values were worse than those obtained in the gene expression studies. Additionally, 
looking closer at the results, surprisingly the measured Ct values were higher than those 
measured in FFPE tissue samples from studies on comparison of expression in FFPE 
tissue samples and corresponding frozen tissue samples. The differences were 
statistically significant: for miR-24 24.05 vs. 31.38 (p=0.000), for miR-155 24.64 vs. 
31.73 (p=0.000), for miR-17-5p 25.91 vs. 33.06 (p=0.000) and for miR-20 22.63 vs. 
31.31 (p=0.000). Importantly, the differences for the same comparison performed on 
gene expression were not significant: for GAPDH 29.81 vs. 28.27 (p=0.196), for v2-
transcript 35.00 vs. 34.80 (p=0.869), for c-MYC 33.31 vs. 33.32 (p=0.924) and for 
HLA-DRβ 30.11 vs. 30.50 (p=1.000). Importantly, the Ct values for miRNAs from these 
studies lie again at the limits of the dynamic range of the method and can be easily 
interfered with by several factors, as discussed above. One of the potential explanations 
could be differences in processing the extracted RNA in both studies. In these studies, 
the RNA samples were uniformly treated with DNAse, for both miRNAs and gene 
assessment. By contrast, in studies on comparison of expression in FFPE tissue samples 
and corresponding frozen tissue samples, the RNA samples for gene assessment were 
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treated with DNAse but those for miRNAs assessment were not. The treatment with 
DNAse could potentially reduce amount of the miRNAs in the samples. Importantly, 
the DNAse protocol incorporates a step of inhibition and deactivation of DNAse using 
absorbing micro particles. Most likely the micro particles could absorb the microRNAs. 
This observation shows how sensitive techniques used in qPCR can be and how fragile 
the material used for assessment of miRNAs is. Despite this, we could confirm that 
assessment of miRNA expression in FFPE tissue samples on an unselected cohort of 
patients with DLBCL is possible and can be evaluated further. The technical limitation 
of used materials and methods discussed above apply here as well. During this work, 
several studies have successfully assessed miRNAs as biomarkers in DLBCL in 
material extracted from FFPE tissue (Lawrie et al., 2007) (Alencar et al., 2011) (Iqbal et 
al., 2015) (Fassina et al., 2012). 
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Chapter 4. Epidemiology, clinical presentation, traditional and novel 
treatment modalities in EATL 
 
4.1 Introduction 
Primary gastrointestinal lymphomas comprise 4% - 12% of all NHL and 1 - 4% 
of all gastrointestinal tumours (Gale et al., 2000). Intestinal lymphomas account for 20 – 
40% of all lymphomas of the gastrointestinal tract (Domizio et al., 1993). Primary T-
cell gastrointestinal lymphomas are rare. The only defined clinicopathological entity is 
EATL (Isaacson and Du, 2005). The current 2008 WHO Classification of Tumours of 
Hematopoietic and Lymphoid Tissues defines two types of EATL: type I and type II 
EATL. The detailed histopathological picture of the tumour has been presented in the 
Chapter 1. 
EATL is an uncommon type of aggressive lymphoma in most parts of the world, 
with an estimated annual incidence rate of 0.5 -1 per million people in Western 
countries (Catassi et al., 2002). Type I EATL is seen with greater frequency in areas 
with a high prevalence of coeliac disease (particularly Northern Europe), by contrast, 
type II EATL has a broader geographic distribution and is also seen in regions where 
coeliac disease is rare (Swerdlow et al., 2008). 
Typically EATL occurs primarily in patients in the sixth or seventh decade of 
life. Usually, patients present with abdominal pain frequently associated with intestinal 
perforation. The published data on the clinical features of the disease are restricted to 
small retrospective series of patients, single centre studies (Gale et al., 2000) or 
subanalysis (Daum et al., 2003). In type I EATL, a small proportion of patients have a 
history of childhood onset of coeliac disease but most have a history of adult onset 
coeliac disease with or without a disease free period. In some patients type I EATL is 
diagnosed simultaneously with coeliac disease. Others do not have a diagnosis of 
coeliac disease at all. The clinical presentation of type II EATL is similar, with the 
exception that most patients do not demonstrate evidence of previous or co-existing 
coeliac disease (Swerdlow et al., 2008). 
The relationship between type I EATL and coeliac disease is well established 
and characterised by positive serological tests, HLA-DQ2 or HLA-DQ8 expression and 
associated clinical findings such as dermatitis herpetiformis and hyposplenism 
(Diamanti et al., 2006) (Green and Cellier, 2007) (Cheung et al., 1998) (Isaacson, 1985) 
 247 
(Howdle et al., 2003) (Salmi et al., 2006). By contrast, type II EATL, may be diagnosed 
in patients without a history of coeliac disease and thus an association with coeliac 
disease and other risk factors is not proven (Deleeuw et al., 2007). 
Coeliac disease is the commonest food intolerance disorder in Western 
populations with a prevalence estimated at 0.5% – 1.0% (Dube et al., 2005) (Fasano et 
al., 2003) (Verbeek et al., 2008). In patients with coeliac disease the ingestion of gluten 
leads to chronic inflammation of the small intestinal mucosa, resulting in villous 
atrophy, crypt hyperplasia, plasmacytosis of the lamina propria and increased 
intraepithelial lymphocytes (Isaacson and Du, 2005). Previously, coeliac disease was 
considered a gastrointestinal disorder of childhood with classical symptoms (Green and 
Cellier, 2007). Currently, it is regarded as a chronic systemic autoimmune disease with 
a complex clinical picture (Green and Cellier, 2007), more commonly diagnosed in 
adults (Verbeek et al., 2008). The clinical picture includes such symptoms as: diarrhoea 
with abdominal pain or discomfort, gastroesophageal reflux, constipation or a more 
subtle presentation with iron-deficiency anaemia, osteoporosis or neurological 
symptoms (Green and Cellier, 2007). The only accepted treatment for coeliac disease is 
lifelong elimination of gluten from the diet (Green and Cellier, 2007). A small number 
of patients (2% – 5%) fail to improve on a gluten-free diet and are considered to have 
refractory coeliac disease (Daum et al., 2005). Refractory coeliac disease is defined as 
persisting villous atrophy with crypt hyperplasia and increased intraepithelial T 
lymphocytes in spite of a strict gluten-free diet for more than 12 months, or severe 
symptoms necessitating intervention independent of the duration of the diet (Cheung et 
al., 1998) (Al-Toma et al., 2007a). Refractory coeliac disease is classified as type 1, 
with intraepithelial lymphocytes of normal phenotype, or type 2 with clonal expansion 
of intraepithelial lymphocytes with aberrant phenotype (Green and Cellier, 2007). 
Patients with type 2 refractory coeliac disease have a limited life expectancy with a 5-
year OS rate of 50% - 58% (Cheung et al., 1998) (Al-Toma et al., 2007a). The main 
cause of death in these patients is EATL (88.4%) (Al-Toma et al., 2007a). 
The treatment options have historically included surgical resection with or 
without anthracycline-based chemotherapy (Daum et al., 2003) (Gale et al., 2000) or 
less commonly HDCT with ASCT (Al-Toma et al., 2007b) (Okuda et al., 2002) 
(Rongey et al., 2006). The results of treatment with surgery or conventional 
chemotherapy are poor and the reported prognosis of EATL is dismal with 5-year PFS 
and OS of approximately 3.2% and 19.7%, respectively (Gale et al., 2000). The results 
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of HDCT with ASCT are available only as case reports (Okuda et al., 2002) (Rongey et 
al., 2006) or small series of patients (Al-Toma et al., 2007b). 
 In the following two studies, we approached the problem of the treatment of 
EATL. In the first one, data on clinical presentation, treatment and outcome of patients 
with EATL were collected prospectively in a population-based setting in order to obtain 
a more accurate picture of the disease. In the second study, a novel treatment regimen, 
HDCT with IVE/MTX and ASCT was evaluated prospectively in a cohort of patients 
with EATL. As most research on EATL was performed before the introduction of the 
new WHO classification for purposes of clarity where the generic term EATL is used in 
this article it will refer to both forms of the disease. 
 
4.2 Population-based study on epidemiology, clinical presentation and treatments 
modalities in EATL 
 
4.2.1 Materials and methods 
 
4.2.1.a Patient selection 
 The SNLG prospectively collected data on all patients with a diagnosis of 
lymphoproliferative disease in Scotland and the Northern region of England 
(population, circa 7.6 million) beginning in 1979. Total registration of all new cases was 
achieved during 1994 to 1998. The data collection was performed with a help of a 
specially designed questionnaire, see Appendix III. Records of patients with a new 
diagnosis of EATL made between 1994 and 1998 were selected for further evaluation 
and case records were reviewed. Original histopathological material was re-valuated by 
haematopathology experts. 
 
4.2.1.b Data collection and response assessment 
Data obtained included patient demographics, details of baseline evaluations, 
treatment and patient outcomes. 
At baseline evaluation the collected data included: the results of clinical 
examination, laboratory tests, BM biopsy, endoscopy and imaging, including X-ray, 
ultrasound and computed tomography. Where appropriate, detailed operation notes were 
available to further inform definitive staging of disease. The extent of disease was 
recorded using published staging systems for primary gastrointestinal lymphomas: 
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Lugano and Manchester scores (table 4.1). 
 
Stage Definition 
Lugano score for gastrointestinal lymphomas 
I 
 
II1* 
II2* 
IIE 
IV 
 
Confined to GI-tract (single primary or multiple non-contiguous sites of 
disease) 
Local abdominal nodal involvement 
Distant abdominal nodal involvement 
Serosal penetration to involve adjacent organ or tissues 
Disseminated extranodal involvement or supradiaphragmatic nodal 
involvement 
Manchester score for gastrointestinal lymphomas 
Ia 
 
Ib 
 
IIa 
IIb 
IIc 
III 
 
IV 
 
Tumour confined to one area of the gastrointestinal tract without penetration 
of the serosa 
Multiple tumours confined to the gastrointestinal tract without penetration of 
the serosa 
Tumour with local nodes histologically involved (gastric or mesenteric) 
Tumour with perforation and / or adherence to adjacent structures 
Tumour with perforation and peritonitis 
Tumour with widespread nodal involvement (paraaortic or more distant 
nodes) 
Disseminated disease involving extra-lymphatic tissues not adjacent to the 
tumour (eg. liver, bone marrow, bone, lung etc.) 
Table 4.1 Lugano and Manchester scores for gastrointestinal lymphomas. *) 
combinations like II1 E and II2 E are also possible 
 
The available data on treatment included the treatment modality (surgery or 
chemotherapy), type of surgical procedure and chemotherapy type and number of cycles 
given. 
Evaluation of the final response was performed three months after the end of 
treatment (day of operation or last day of chemotherapy, whichever was appropriate). 
Further follow-up was carried once a year when the patient records were re-valuated for 
possible relapse, treatment given and survival status. CR, PR and PD were defined 
according to the criteria reported by Cheson et al (Cheson et al., 2007). 
 
4.2.1.c Statistics 
 Demographics and disease characteristics were summarized using descriptive 
statistics. The χ²-test, Fisher’s exact test, and t-test were used as appropriate to 
 250 
investigate differences on proportions and means, respectively. PFS and OS rates were 
estimated according to the method of Kaplan and Meier and comparison between the 
groups was with log-rank test. PFS was calculated from date of diagnosis to the first 
documentation of progression during therapy, failure at the end of therapy, or further 
relapse or death from any cause during or after the end of treatment. OS was calculated 
from date of diagnosis to the date of death, or if no death occurred, to the last 
documented follow up for the patient. All tests were performed with a confidence 
interval of 95 % and statistical significance was defined as p ≤0.05. Statistical analysis 
was performed with SPSS Version 13.0 for MAC OS X (SPSS Incorporated, Chicago, 
IL). 
 
4.2.2 Results 
 
4.2.2.a Epidemiology of EATL in SNLG 
 Between 1994 and 1998, in the population of approximately 7.6 million people 
in Scotland and the Northern Region of England, 4542 patients were diagnosed with 
NHL. Fifty-four had features of EATL, giving an overall incidence of 0.14/100 000 per 
year. The distribution of the registered EATL cases remained constant over the study 
period. 
 
4.2.2.b Clinical presentation of the patients 
The detailed patient characteristics are summarised in table 4.2. Median age at 
diagnosis was 57 years (range 28 – 82 years) and 21/54 (39%) patients were female. 
The majority of patients 37/54 (70%) had extensive disease (defined as Lugano stages 
II2, IIE and IV and Manchester stages IIb, IIc, III and IV). Tumour was arising from the 
jejunum and ileum in 52/54 (96%) patients; in the duodenum in one patient and the 
iliocaecal region in the remaining patient. BM was assessed in 33 patients at diagnosis 
with two patients having BM involvement 2/33 (6%). The majority of patients 46/52 
(88%) presented with a reduced performance status (ECOG >1). 
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Clinical parameter N (%) 
Median age (range) 
Female sex 
Lugano stage 
I 
II 1 
II 2 
II E 
II 1E 
II 2E 
IV 
Manchester stage 
Ia 
Ib 
IIa 
IIb 
IIc 
III 
IV 
Site of disease in GT 
Jejunum / ileum 
Stomach / duodenum 
Duodeno-jejunal flexure 
Ileocaecal 
Bone marrow involvement 
ECOG > 1 
Presenting features 
Pain 
Lump 
Nausea / vomiting 
Weight loss 
Bowel upset 
Perforation 
Subacute obstruction 
57 (28 – 82) 
21/54 (39) 
 
8/53 (15) 
8/53 (15) 
6/53 (11) 
0/53 (0) 
0/53 (0) 
21/53 (40) 
10/53 (19) 
 
5/53 (9) 
3/53 (6) 
8/53 (15) 
4/53 (8) 
17/53 (32) 
6/53 (11) 
10/53 (19) 
 
52/54 (96) 
0/54 (0) 
1/54 (2) 
1/54 (2) 
2/33 (6) 
46/52 (88) 
 
43/53 (81) 
3/53 (6) 
2/53 (38) 
30/53(57) 
17/53 (32) 
21/53 (40) 
16/53 (30) 
Table 4.2.A Population-based evaluation of EATL patient characteristics (n=54). 
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Clinical parameter N (%) 
Duration of symptoms pre-diagnosis 
0 – 1 months 
1 – 3 months 
3 – 6 months 
> 6 months 
Presence of coeliac disease 
Prior to diagnosis 
At diagnosis 
Diagnosis at 
Surgery 
Endoscopy 
Post mortem 
Abnormal chest X ray at diagnosis 
Abnormal abdomen ultrasound at diagnosis 
Abnormal chest CT at diagnosis 
Abnormal abdomen CT at diagnosis 
Abnormal Hb 
Abnormal WBC 
Abnormal kidney function 
Abnormal liver function 
Abnormal LDH 
 
17/51 (33) 
13/51 (26) 
15/51 (29) 
6/51 (12) 
48/52 (92) 
18/52 (34) 
30/52 (58) 
 
49/54 (91) 
4/54 (7) 
1/54 (2) 
3/45 (7) 
8/24 (33) 
2/28 (7) 
25/35 (71) 
27/50 (54) 
18/50 (36) 
16/50 (32) 
39/51 (76) 
11/26 (42) 
Table 4.2.B Population-based evaluation of EATL patient characteristics (n=54). 
 
Presenting symptoms were assessed in 53 patients. Pain was the most commonly 
observed symptom in 43/53 (81%) of patients, followed by weight loss 30/53 (57%), 
visceral perforation 21/53 (40%), nausea/vomiting 20/53 (38%), change in bowel habit 
17/53 (32%), subacute obstruction 16/53 (30%) and palpable mass 3/53 (6%). Details of 
the duration of symptoms before the diagnosis of EATL were assessed in 51 patients. In 
30/51 patients (59%) symptoms were present for less than 3 months before diagnosis 
and in 21/51 patients (41%) for more than 3 months. The coeliac disease status was 
available in 52 patients. The majority of patients 48/52 (92%) had co-existing coeliac 
disease; 18/52 (35%) were known coeliac patients and 30/52 (58%) had coeliac disease 
diagnosed co-incidentally with their lymphoma. Diagnosis of EATL was made at 
laparotomy in 49/54 patients (91%), in four patients at endoscopy and in one patient at 
post mortem. 
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Various imaging techniques were used for diagnostic and staging purposes 
including computed tomography of the abdomen in 35/54 (65%) patients. Seventy-one 
per cent of studies (25/35) were abnormal. Abdominal ultrasound was performed in 
25/54 (46%) patients with abnormal results in 8/25 (32%). Additional staging 
procedures included chest X-ray in 45/54 (83%) patients with only 3 patients having 
abnormal results (7%) and computed tomography of the chest in 28/54 (52%) patients, 
with pathological findings in only 2/28 (7%) patients. 
 At diagnosis the majority of patients 39/51 (76%) had abnormal liver function 
tests mainly due to low albumin levels. Hb was abnormal in 27/50 (54%) and LDH 
level in 11/26 (42%) patients. WBC and kidney function tests were abnormal in 
approximately one third of patients. 
 
4.2.2.c Treatment modalities 
Forty-nine patients (91%) presented with acute abdominal symptoms, 
necessitating emergency surgical procedures performed with diagnostic and therapeutic 
intent. Thirty of those patients (56%) were treated with additional systemic 
chemotherapy. Five patients (9%) received systemic chemotherapy only and no surgery. 
Thus, 35 patients were treated with chemotherapy with or without surgery, and 19 
patients were treated with surgery alone. 
The majority of patients treated with chemotherapy 31/35 (89%) received 
anthracycline-based chemotherapy: 17 patients received CHOP, 7 patients CNOP, 7 
vincristine, doxorubicin, etoposide, prednisolone, cyclophosphamide, bleomycin 
(VAPEC-B) and one patient cyclophosphamide, vincristine and prednisolone (CVP). 
Three patients were treated up-front with the HD regimen IVE/MTX, one went on to 
receive BEAM and ASCT. Twenty-three patients (66%) completed their scheduled 
chemotherapy regimen. The remaining 12 patients (34%) discontinued the scheduled 
treatment due to PD or side effects. Importantly, there were no statistically significant 
differences between patients treated with systemic chemotherapy with or without 
surgery and those with surgery alone, with the exception of a higher number of elderly 
patients in the latter group. 
 
4.2.2.d Responses and outcome 
Seventeen patients (32%) achieved CR at the end of their treatment: 2/19 (11%) 
patients treated with surgery alone and 15/35 (43%) patients treated with chemotherapy 
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with or without surgery. The difference between groups was statistically significant, 
p=0.02; see table 4.3. Forty-four patients (81%) died; more in the surgery alone group - 
18/19 (95%) than in the chemotherapy with or without surgery group - 26/35 (74%); 
though the difference was not statistically significant, p=0.08. The majority of patients 
died due to disease progression or complications of treatment. 
 
 
all patients 
No (%) 
surgery alone 
No (%) 
chemotherapy 
+/- surgery 
No (%) 
p-value* 
Response 
CR/PR 
Failure 
 
Death 
 
17/54 (32) 
37/54 (69) 
 
44/54 (81) 
 
2/19 (11) 
17/19 (89) 
 
18/19 (95) 
 
15/35 (43) 
20/35 (57) 
 
26/35 (74) 
 
0.02 
 
 
0.08 
Table 4.3 Patient outcome in population-based evaluation, all patients (n=54), patients 
treated with surgery alone (n=19) vs patients treated with chemotherapy +/- surgery 
(n=35). *) patients treated with surgery alone vs patients treated with chemotherapy  
+/- surgery. 
 
For all patients median PFS was 3.4 months and median OS 7.1 months (figure 
4.1). 5-year PFS and OS for all patients were 18% and 20%, respectively (figure 4.1). 
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Figure 4.1 Kaplan-Meier plots for PFS and OS in population-based evaluation of 
patients with EATL, all patients (n=54). (A) PFS and (B) OS. 
 
Figure 4.1 Kaplan-Meier plots for PFS and OS in population-based evaluation of 
patients with E , ll atients (n=54). (A) PFS and (B) OS. 
 
There were statistically significant differences for both PFS and OS between 
patients treated with chemotherapy with or without surgery and those treated with 
surgery alone (p<0.001). Five-year PFS and OS for patients from the chemotherapy 
with or without surgery group were 26% and 28%, respectively whereas none of 
patients treated with surgery alone survived at this time. 
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4.2.3 Discussion 
 The epidemiology, clinical features, treatment and outcome of EATL have not 
been studied extensively particularly in a population-based setting. Most currently 
available information comes from sub-analyses of bigger trials (Daum et al., 2003), 
retrospective evaluations of single centre experiences (Gale et al., 2000) or evaluation of 
national registries (Verbeek et al., 2008). Verbeek et al, conducted a nation-wide study 
of incidence of EATL in the Netherlands (Verbeek et al., 2008). This study utilised the 
resources of the nation-wide network and registry of histo- and cytopathology reports 
available in the Netherlands (PALGA). The study covered the entire population of the 
country, however the data evaluated were rather sparse and restricted to age, gender, site 
of disease and coeliac disease status. Daum et al, performed a non-randomized 
prospective trial of CHOP in intestinal lymphoma, however EATL was evaluated 
together with other subtypes of T-cell lymphoma (Daum et al., 2003). Al-Toma, 
assessed the survival in refractory coeliac disease and EATL (Al-Toma et al., 2007a). 
This was a single-centre retrospective evaluation and delivered some very interesting 
information on EATL that developed from refractory coeliac disease type II. The most 
comprehensive data was presented in a retrospective evaluation of a lymphoma database 
from the Wessex Regional Medical Oncology Unit in Southampton by Gale et al (Gale 
et al., 2000). The cases were carefully evaluated for presenting features, treatment and 
outcome. 
The incidence of EATL in our population study was 0.14/100.000/year and 
EATL accounted for only 1.4% of all registered NHL cases. The median age of patients 
was 57 years and the majority of patients were male (61%). The results of another 
population-based study by Verbeek et al are comparable with ours, showing an 
incidence of EATL of 0.10/100.000/year, a median age of 64 years and 64% of patients 
were male (Verbeek et al., 2008). The predominance of male gender with 74% male 
patients was also reported by Gale et al (Gale et al., 2000), but by contrast in the study 
of Daum et al the majority of patients were female (Daum et al., 2003). Al-Toma 
reported predominance of male patients in de-novo EATLs but of females in EATLs 
that developed on a background of refractory coeliac disease type 2 (Al-Toma et al., 
2007a). The median age of patients was lower than in our group in the other British 
study by Gale et al (50 years) (Gale et al., 2000) whereas in the remaining studies the 
median age of patients was greater than 60 years (Daum et al., 2003) (Verbeek et al., 
2008). 
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The majority of our patients presented with a reduced performance status, with 
an ECOG score of >1 in 88% of patients, mainly due to high numbers of patients with 
acute abdominal symptoms and poor nutritional status. This observation was confirmed 
in the studies of Gale et al and Daum et al (Gale et al., 2000) (Daum et al., 2003). In our 
study, as in the studies published by Gale et al, Daum et al and Verbeek et al the 
diagnosis was predominantly made at laparotomy (Gale et al., 2000) (Daum et al., 2003) 
(Verbeek et al., 2008). Daum et al additionally distinguish between an elective and 
emergency procedure, both being equal in the T-cell lymphoma group. In our cohort of 
patients the majority underwent an emergency procedure as they presented with an 
acute abdomen. The pattern of presenting symptoms in our evaluation and those 
presented by Gale et al and Daum et al was comparable with pain, nausea/vomiting and 
weight loss being the most common (Gale et al., 2000) (Daum et al., 2003). 
The majority of patients (70%) in our study presented with advanced stage 
disease. This was confirmed by Daum et al and Gale et al, however both these studies 
used the Ann Arbor staging system, which presents significant limitations for the 
assessment of intestinal lymphomas (Gale et al., 2000) (Daum et al., 2003). Although, 
both the surgical and pathological reports were reviewed, it was very difficult to 
determine the tumour localisation in the small intestine. Thus all the tumours of jejunum 
and ileum were assigned to one common group. However, other studies have confirmed 
the jejunum as the most common site (Gale et al., 2000) (Daum et al., 2003). As in other 
studies, infiltration of the colon was continuous with the iliocaecal region. We did not 
observe any patients with secondary involvement of the colon. 
Coeliac disease was diagnosed in 92% of patients, 34% had previous records of 
coeliac disease and in 58% of patients the diagnosis of coeliac disease and of EATL 
were made simultaneously. In the Dutch population-base registry study, coeliac disease 
was reported in 47% of patients, however this was not a mandatory field in the register 
questionnaire (Verbeek et al., 2008). In the study of Gale et al, a third of patients had a 
previous history of coeliac disease but there is no information on the presence or 
absence of coeliac disease in the patient’s histopathological samples (Gale et al., 2000). 
The recent WHO 2008 classification of EATL distinguishes between EATL with and 
without a diagnosis of coeliac disease. However, we should bear in mind that due to 
changes in diagnostic criteria for coeliac disease and the current availability of more 
advanced laboratory tests any more valid conclusions from previous studies are 
difficult. 
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Sixty-five per cent of our population study patients were treated with systemic 
chemotherapy, mostly anthracycline-based, with or without a surgical procedure and 
35% were treated with surgery alone. These results are similar to those previously 
published by Gale et al and Daum et al (Gale et al., 2000) (Daum et al., 2003). The 
study of Al-Toma, which includes more recent patients, additionally registered several 
patients treated with ASCT (Al-Toma et al., 2007a). One reason for withholding 
chemotherapy was the poor condition of patients after surgery. In addition, the median 
age of patients treated with surgery alone was statistically significantly higher than 
patients treated with systemic chemotherapy with or without surgery. As in other 
published studies, only around half of our population study patients completed their 
scheduled chemotherapy; the main reasons for discontinuation being refractory disease 
and toxicity (Gale et al., 2000) (Daum et al., 2003).  
The outcome of the whole population study group was very poor; 81% died and 
the median PFS and OS were 3.4 months and 7 months, respectively. 5-year PFS and 
OS for the whole group were 20% and 18%, respectively. Gale et al in their study 
reported 5-year PFS and OS of 3.2% and 19.7%, (Gale et al., 2000) respectively and 
Daum et al 2 year OS of 28% (Daum et al., 2003). Patients treated with chemotherapy 
with or without surgery had a significantly better outcome than those treated with 
surgery alone. Because of the lack of published data on survival of patients treated with 
surgery alone, further comparison is impossible. However, the outcome in our study for 
patients treated with chemotherapy with and without surgery was comparable with that 
previously reported (Gale et al., 2000) (Daum et al., 2003). 
 In conclusion, EATL is a rare lymphoma, which mostly presents in male patients 
aged more than 50 years. Approximately one third of patients have a previous history of 
coeliac disease and other 50% are diagnosed with coeliac disease at the same time as 
their diagnosis of EATL. Most patients undergo emergency surgical procedures at 
presentation due to acute abdominal symptoms and are treated with conservative 
treatment procedures including surgery and chemotherapy with anthracycline-based 
regimens. The outcome of patients treated with surgery alone is dismal but results can 
be improved by the addition of systemic chemotherapy. 
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4.3 Study on novel treatment approach: ifosfamide, etoposide, epirubicin / 
methotrexate (IVE/MTX) followed by autologous stem cell transplant (ASCT) in 
EATL 
 
4.3.1 Materials and methods 
 
4.3.1.a Patient selection 
In view of the dismal outcomes obtained with conventional anthracycline-based 
chemotherapy, from 1998 onwards the SNLG introduced a novel treatment regimen for 
patients with a diagnosis of EATL. The treatment decision was made by a panel of 
specialist haematologists. The eligibility criteria for the IVE/MTX regimen were: de 
novo EATL, age ≥18 years and ability to tolerate HD treatment. Patients were discussed 
at multidisciplinary unit meetings, and all patients who were assigned to receive the 
new treatment were evaluated. The data collection was performed with a help of a 
specially designed questionnaire, see Appendix III. 
 
4.3.1.b Study design and treatment 
 The IVE/MTX regimen begins with one course of CHOP chemotherapy 
(cycloposphamide 750mg/m2 - day 1, doxorubicin 50mg/m2 - day 1, vincristine 2mg - 
day1 and prednisone 100mg - days 1-5); followed by three courses IVE (ifosfamide 
3000mg/m2 on days 1 – 3, epirubicine 50mg/m2 on day 1 and etoposide 200mg/m2 on 
days 1 – 3) alternating with intermediate dose methotrexate 1500mg/m2 in a 24 hr 
infusion (table 4.4). 
 
Drug Dose Route Day of cycle 
IVE 
Epirubicin 
Etoposide 
Ifosfamide 
Intermediate MTX 
Methotrexate 
 
50mg/m2 
200mg/m2 
3000mg/m2 
 
1500mg/m2 
 
IV 
IV 
IV 
 
IV 
 
1 
1 - 3 
1 - 3 
 
1 
Table 4.4 Chemotherapy dosage for a novel IVE/MTX regimen. 
 
ASCT was performed 4 – 6 weeks after the last course of IVE/MTX if the patient was 
in remission and sufficient numbers of PBSC had been collected. Stem cell harvesting 
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was performed after the second or third course of IVE. The treatment schedule is shown 
in figure 4.2. 
Conditioning for ASCT was either HD melphalan/total body irradiation (TBI): 
melphalan, 140mg/m2 on day 1; TBI, 1200 cGy in 6 fractions over 3 days or BEAM: 
carmustine, 300mg/m2 on day 1, etoposide: 200mg/m2, cytarabine: 200mg/m2 bd on 
days 2–5, and melphalan: 140 mg/m2 on day 6. 
 
1 –2 cycles CHOP* (optional) 
⇓  
Day 0 – 1st IVE** 
⇓  
Day 21 – 1st intermediate dose Methotrexate 
⇓  
Day 28 – 2nd IVE (PBSC harvest) 
⇓  
Day 49 – 2nd intermediate dose Methotrexate 
⇓  
Day 56 – 3rd IVE (PBSC harvest) 
⇓  
Day 77 – 3rd intermediate dose Methotrexate 
⇓  
final myeloablative course + ASCT	
Figure 4.2 Treatment flowchart for IVE/MTX. *) CHOP: cyclophosphamide, 
doxorubicin, vincristine, prednisone **) IVE: ifosfamide, epirubicin, etoposide 
 
4.3.1.c Response assessment 
At baseline evaluation the extent of disease was assessed by clinical 
examination, laboratory tests, BM biopsy and imaging, including X-ray, ultrasound and 
computed tomography. Where appropriate endoscopy and emergency surgery were 
performed. Detailed operation notes were available to further inform definitive staging 
of disease. The extent of disease was recorded using Lugano and Manchester scores 
(table 4.1). 
Evaluation of the final response was performed 3 months after the end of 
treatment. Further follow-up was carried out at 3 monthly intervals during the first year 
and thereafter at 6 monthly intervals. All sites of initial disease were reassessed using 
appropriate techniques. 
CR, PR and PD were defined according to the criteria reported by Cheson et al 
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(Cheson et al., 2007). Safety was assessed continuously during the study on the basis of 
reports, laboratory tests and vital sign measurements. Adverse events were categorized 
according to the Common Toxicity Criteria of WHO. 
 
4.2.1.d Statistics 
Demographics and disease characteristics were summarized using descriptive 
statistics. The χ²-test, Fisher’s exact test, and t-test were used as appropriate to 
investigate differences on proportions and means, respectively. PFS and OS rates were 
estimated according to the method of Kaplan and Meier and comparison between the 
groups was with log-rank test. PFS was calculated from date of diagnosis to the first 
documentation of progression during therapy, failure at the end of therapy, or further 
relapse or death from any cause during or after the end of treatment. OS was calculated 
from date of diagnosis to the date of death, or if no death occurred, to the last 
documented follow up for the patient. All tests were performed with a confidence 
interval of 95 % and statistical significance was defined as p ≤0.05. Statistical analysis 
was performed with SPSS Version 13.0 for MAC OS X (SPSS Incorporated, Chicago, 
IL). 
 
4.3.2 Results 
 
4.3.2.a Patient characteristics 
From 1998 onwards 26 patients with de novo EATL were treated with 
IVE/MTX in 7 centres around the UK (Newcastle upon Tyne, Stoke on Trent, 
Edinburgh, Inverness, Poole and Stafford). In our experience, the novel treatment can be 
tolerated by most patients presenting with EATL. During the study time 17 patients 
presented with a diagnosis of EATL to the Newcastle Hospitals Lymphoma 
Multidisciplinary Team, the primary site where the protocol was initiated, and 12 
patients (71%) were enrolled. The remaining 5 patients were excluded from the new 
protocol because of advanced age in 3 cases and poor general condition in 2 (failure to 
recover from primary surgery). 
Generally, patient characteristics at baseline were similar to those of patients 
treated with anthracycline-based chemotherapy from our population-based evaluation, 
see table 4.5. There was no statistically significant difference between both groups 
according to age, sex, and features at presentation except for a greater number of 
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patients presenting with nausea/vomiting (p=0.029) and a lower number of patients with 
diagnosed coeliac disease (p=0.02). 
 
Clinical parameter 
IVE/MTX 
No (%) 
Anthracycline 
chemotherapy 
No (%) 
p-value 
Median age (range) 
Female sex 
Lugano stage 
I 
II 1 
II 2 
II E 
II 1E 
II 2E 
IV 
Manchester stage 
Ia 
Ib 
IIa 
IIb 
IIc 
III 
IV 
Site of disease in GT 
Jejunum / ileum 
Stomach / duodenum 
Duodeno-jejunal flexure 
Ileocaecal 
Bone marrow involvement 
Presenting features 
Pain 
Lump 
Nausea / vomiting 
Weight loss 
Bowel upset 
Perforation 
Subacute obstruction 
56 (36 – 69) 
9/26 (35) 
 
4/26 (15) 
5/26 (19) 
2/26 (8) 
3/26 (12) 
6/26 (23) 
1/26 (4) 
5/26 (19) 
 
1/26 (4) 
3/26 (12) 
5/26 (19) 
5/26 (19) 
4/26 (15) 
3/26 (12) 
5/26 (19) 
 
22/26 (84) 
2/26 (8) 
2/26 (8) 
0/26 (0) 
1/22 (5) 
 
25/26 (96) 
1/26 (4) 
18/26 (69) 
19/26 (73) 
15/26 (58) 
8/26 (31) 
10/26 (39) 
56 (30 – 82) 
10/31 (32) 
 
6/30 (20) 
4/30 (13) 
5/30 (17) 
10/30 (33) 
0/30 (0) 
0/30 (0) 
5/30 (17) 
 
3/30 (10) 
3/30 (10) 
4/30 (13) 
3/30 (10) 
7/30 (23) 
5/30 (17) 
5/30 (17) 
 
30/31 (97) 
0/31 (0) 
1/31 (3) 
0/31 (0) 
1/23 (4) 
 
23/30 (77) 
1/30 (3) 
12/30 (40) 
16/30 (53) 
10/30 (33) 
12/30 (40) 
10/30 (33) 
0.284 
0.851 
 
0.055 
 
 
 
 
 
 
 
0.875 
 
 
 
 
 
 
 
0.231 
 
 
 
0.999 
 
0.056 
0.999 
0.029 
0.128 
0.067 
0.472 
0.690 
Table 4.5.A Patient characteristics – patients treated with IVE/MTX (n=26) vs patients 
treated with anthracycline-based chemotherapy (n=31). 
 262 
 
 
Clinical parameter 
IVE/MTX 
No (%) 
Anthracycline 
chemotherapy 
No (%) 
p-value 
ECOG > 1 
Pre-diagnosis symptom duration 
0 – 1 months 
1 – 3 months 
3 – 6 months 
> 6 months 
Presence of coeliac disease 
Prior to diagnosis 
At diagnosis 
Diagnosis at 
Surgery 
Endoscopy 
Post mortem 
Abnormal Hb 
Abnormal WBC 
Abnormal kidney function 
Abnormal liver function 
Abnormal LDH 
20/26 (77) 
 
6/25 (24) 
7/25 (28) 
5/25 (20) 
7/25 (28) 
19/26 (73) 
11/26 (42) 
8/26 (31) 
 
23/26 (89) 
3/26 (11) 
0/26 (0) 
11/26 (42) 
9/26 (35) 
11/25 (44) 
16/25 (64) 
9/19 (47) 
25/29 (86) 
 
11/28 (39%) 
7/28 (25%) 
6/28 (21%) 
4/28 (14%) 
28/29 (97) 
11/29 (38) 
17/29 (59) 
 
26/31 (84) 
4/31 (13) 
1/31 (3) 
14/28 (50) 
9/28 (32) 
8/29 (28) 
22/29 (76) 
6/19 (32) 
0.490 
 
0.567 
 
 
 
0.020 
 
 
 
0.999 
 
 
0.571 
0.847 
0.208 
0.341 
0.319 
Table 4.5.B Patient characteristics – patients treated with IVE/MTX (n=26) vs patients 
treated with anthracycline-based chemotherapy (n=31). 
 
The median age was 56 years (range 36 – 69 years) and 9/26 (35%) patients 
were female. The majority of patients 17/26 (66%) presented with advanced disease 
(Lugano stage II2, II E, II1 E, II2 E and IV or Manchester stage IIb, IIc, III and IV). In 
the majority of patients 22/26 (84%), the primary site of disease in the gastrointestinal 
tract was jejunum/ileum. Of the remaining four patients, two had involvement of 
stomach and duodenum and the other two the duodeno-jejunal flexure. Among 22 
patients with BM assessment at diagnosis, marrow involvement was confirmed in one. 
The performance status as measured by ECOG was greater than 1 in 20/26 (77%) 
patients. The most frequently presenting symptoms at diagnosis were: pain in 25/26 
(95%) patients, weight loss in 19/26 (73%) patients and nausea/vomiting in 18/26 (80%) 
patients. In half of the patients the symptoms had been present for less than 6 months. 
The majority of patients (19/26 (73%)) were diagnosed with coeliac disease; 11/26 
(42%) were known to have coeliac disease before the diagnosis of EATL and 8/26 
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(31%) were diagnosed co-incidentally with their lymphoma. In the majority of patients, 
23/26 (89%) the diagnosis of EATL was made at laparotomy. The laboratory tests most 
frequently abnormal were: liver function in 16/25 (64%) patients and serum LDH level 
in 9/19 (47%). 
 
4.3.2.b Treatment feasibility and toxicity 
All 26 patients who were assigned to the treatment went on to start it and were 
available for evaluation (figure 4.3). In 3 patients methotrexate was omitted from the 
scheduled chemotherapy because of kidney insufficiency or poor general condition. 
Five patients (19%) discontinued treatment prematurely; 4 because of toxicities (1 
severe sepsis, 1 severe encephalopathy, 1 BM failure and 1 gastrointestinal bleeding), 
and the other patient progressed after the initial cycle of CHOP. Of the remaining 21 
patients, 14 received ASCT. In the remaining 7 patients ASCT was omitted because of 
poor general condition in 3 patients, refractory disease in 2 patients, insufficient stem 
cell mobilisation in one, and one patient declined further treatment. Importantly, there 
was no statistically significant difference in the number of patients who discontinued 
treatment between the group of patients treated with IVE/MTX and the historical group 
of 31 patients treated with anthracycline-based regimens (54% vs. 65%; p=0.43). 
 
Figure 4.4 Flow diagram of patients with EATL included to IVE/MTX with auto 
SCT treatment. 
 
Drop out (n=5):
4 - toxicities
1 - progressive disease
Drop out (n=7):
2 - progressive disease
4 - poor general condition/patient's wish
1 - abort stem cell mobilisation
Melphalan / TBI or BEAM
ASCT
(n=14)
Final Assessment
before ASCT
(n=21)
CHOP
IVE / MTX (cycles 1 - 3)
Patients Avaiable for Evaluation
(n=26)
Patients Entered the Study
(n=26)
 
Figure 4.3 Flow diagram of patients with EATL treated with IVE/MTX. 
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Details of the conditioning regimen for the ASCT procedure were available in 
13 patients; 7 of them received BEAM and 6 HD melphalan/TBI. The source of stem 
cells was peripheral blood in the majority of patients, 11/13 (85%) Data on the number 
of CD34+ stem cells re-infused was available in 11 patients, and the median number was 
6.0 x106/kg (range 1.0 x106/kg to 14.8 x106/kg). Information on growth factor use after 
ASCT was available in 10 patients, 5 received granulocyte colony-stimulating factor. 
Table 4.6 provides detailed description of the transplant procedures. 
 
 No (%) 
Stem cell source 
Peripheral blood 
Bone marrow 
Median number of CD34+ re-infused 
 
Growth factor used after ASCT 
Conditioning regimen 
HD melphalan/TBI 
BEAM 
 
11/13 (85) 
2/13 (15) 
6.0 x106/kg 
(range 1.0 – 14.8 x106/kg) 
5 / 10 (50) 
 
7 / 13 (54) 
6 / 13 (46) 
Table 4.6 Characteristic of autologous stem cell transplant (n=13). 
 
The toxicity profile was acceptable for an intensive regimen. The most common 
toxicities were infection/sepsis in 14/26 (54%) patients. Other severe toxicities affecting 
1 patient each were encephalopathy, BM failure, gastrointestinal bleeding and chronic 
renal failure. Six patients had disease-related complications during the treatment; 4 
intestinal obstruction and 2 visceral perforation. 
 
4.3.2.c Responses and outcome 
Treatment results were compared with an historical control group treated with 
conventional anthracycline-based chemotherapy from our population-based series. 
There were no statistically significant differences between both groups according to age, 
sex and features at presentation, except for a greater number of patients presenting with 
nausea / vomiting (p=0.029) and a lower number of patients with diagnosed coeliac 
disease (p=0.02). Patients given IVE/MTX had an improved remission rate compared 
with patients treated with anthracycline-based chemotherapy (69% vs. 42%; p=0.06); 
table 4.7. 
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Death rates were significantly lower in patients treated with IVE/MTX, than in 
patients treated with anthracycline-based chemotherapy (39% vs. 81%; p=0.001). In 
both groups most deaths were due to underlying disease. Among the 14 patients who 
received a transplant, 2 died as a result of non-disease-related reasons: 1 because of 
Pneumocistis jiroveci pneumonia 4 months after ASCT and 1 because of sepsis and 
recurrent chest infections 12 months after ASCT. 
 
 
IVE/MTX 
No (%) 
Anthracycline 
chemotherapy 
No (%) 
p-value* 
Response to treatment 
CR 
PR 
failure 
Death 
Death lymphoma 
 
17/26 (65) 
1/26 (4) 
8/26 (31) 
10/26 (39) 
8/26 (31) 
 
13/31 (42) 
0/31 (0) 
18/31 (58) 
25/31 (81) 
19/25 (61) 
 
0.06 
 
 
0.001 
0.005 
Table 4.7 Patient outcome – patients treated with IVE/MTX (n=26) vs patients treated 
with anthracycline-based chemotherapy (n=31).*) p-value: patients treated with 
IVE/MTX vs patients treated with anthracycline-based chemotherapy from population-
based evaluation 
 
Five-year PFS and OS were significantly higher in patients receiving IVE/MTX 
than in those treated with anthracycline-based chemotherapy, (PFS: 52% vs. 22%; 
p=0.01 and OS: 60% vs. 22%; p=0.003). 
Evaluation of patients who entered the protocol and completed the scheduled 
treatment versus those who failed to complete it confirmed that the number of patients 
with remissions was statistically significantly higher in the former group than in the 
latter: 13 patients (93%) vs. 5 (41%), respectively; p=0.004. There were fewer deaths 
and EATL – related deaths in the group that completed the protocol compared with the 
group that did not; however the difference was not statistically significant: 4 (29%) and 
2 (14%) vs. 6 (50%) and 6 (50%); p=0.0422 and p=0.09, respectively. 5-years PFS and 
OS were both 68% for patients who completed the whole treatment and 33% and 50% 
for patients who did not; the difference is statistically significant for PFS (p=0.028) but 
not for OS (p=0.0251). 
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4.3.3 Discussion 
Our study describes the role of HD chemotherapy followed by ASCT for the 
primary treatment of EATL in a cohort of representative patients. The outcome of 
patients treated with HDCT and ASCT reported previously varies from no response to 
remissions lasting more than 32 months (Al-Toma et al., 2007b) (Okuda et al., 2002) 
(Rongey et al., 2006) (Jantunen et al., 2004) (Blystad et al., 2001). In some cases the 
ASCT was performed in first remission (Al-Toma et al., 2007b), and in some second 
and subsequent remissions (Okuda et al., 2002) (Rongey et al., 2006), or remission 
status was not specified (Blystad et al., 2001). Therefore it is difficult to make any valid 
conclusions. Generally, the patients were treated with several cycles of anthracycline-
based chemotherapy followed by myeloablative conditioning and ASCT. 
The high number of patients failing conventional anthracycline-based 
chemotherapy mainly due to primary refractory disease/ disease progression and 
toxicity in our observation study and those published by others (Daum et al., 2003) 
(Gale et al., 2000), prompted the SNLG to reconsider our approach to this difficult 
group of patients. The promising results using IVE in patients with refractory / relapsed 
lymphomas (Zinzani et al., 2002) (McQuaker et al., 1997) (Proctor et al., 2001), 
encouraged us to introduce this regimen as the first-line treatment of choice for patients 
with EATL. We added intermediate dose methotrexate to the protocol as prophylaxis 
against previously described relapse / progression of disease in the central nervous 
system (Berman et al., 1998) (Tutt et al., 1997). Treatment starts with one cycle of 
CHOP to establish initial disease control to minimize the risk of side effects such as 
perforation, anastomotic breakdown, or wound dehiscence (in the post surgery patient), 
and to allow a limited recovery period before the more intensive regimen begins. 
The new treatment was generally well tolerated compared with reports of 
anthracycline-based therapies from our group (64%) and other studies (Daum et al., 
2003) (Gale et al., 2000). Most patients benefit from parenteral nutrition at least 
initially. The toxicity profile was similar to that described in the literature for HDCT 
regimens with ASCT (Okuda et al., 2002) (Rongey et al., 2006) (Al-Toma et al., 
2007b). However, as expected, there was a higher incidence of neutropenic fever and 
sepsis when compared with anthracycline-based chemotherapy (Gale et al., 2000) 
(Daum et al., 2003). Significantly, stem cell harvest after IVE was successful in all 
 267 
except one patient and engraftment was successful in all patients who received a 
transplant. 
Patients treated with the novel regimen had statistically higher remission rates 
and lower mortality rates compared with patients receiving anthracycline-based 
chemotherapy from our population-based study (p=0.06 and p=0.001) and with series of 
patients from other studies (Gale et al., 2000) (Daum et al., 2003). Observed remissions, 
lasting up to 143 months, are longer than other published data on EATL treated with 
ASCT (Okuda et al., 2002) (Rongey et al., 2006) (Al-Toma et al., 2007b). The 5-years 
PFS and OS were also significantly higher compared with the group of patients treated 
with anthracycline-based chemotherapy from our population-based evaluation 
(p=0.01and p=0.003; respectively) and from other studies (Gale et al., 2000) (Daum et 
al., 2003).  
Patients developing de novo EATL without a previous history of coeliac disease 
present no treatment dilemmas, and we have described improved results with our 
intensive approach. By contrast, the time to initiate treatment in patients with type II 
refractory coeliac disease is controversial. Some investigators suggest the early 
introduction of therapy before a diagnosis of EATL (Al-Toma et al., 2007c) as large 
numbers of patients with type II refractory coeliac disease may sooner or later develop 
EATL (Al-Toma et al., 2007a). Additionally, treatment of established EATL is 
associated with increased complications (Daum et al., 2003). In our opinion, the 
IVE/MTX is a very powerful regimen with potential severe toxicities and should be 
reserved for patients with a confirmed diagnosis of EATL. Future studies should 
evaluate techniques for early diagnosis of EATL in patients with type II refractory 
coeliac disease for example capsule enteroscopy, CT (Mallant et al., 2007), or PET-CT. 
No simple effective treatment has yet been shown to prevent development of EATL in 
such patients, but promising results are reported (Hadithi et al., 2006). 
In conclusion, a novel treatment with IVE/MTX and ASCT was feasible with 
acceptable toxicities and could be applied to a majority of patients with de-novo EATL. 
The outcome of patients treated with the new regimen was significantly improved when 
compared with conventional treatment with anthracycline-based chemotherapy. Patients 
with EATL should be treated with systemic chemotherapy and where feasible with an 
aggressive treatment like IVE/MTX. 
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Chapter 5. IVE/MTX followed by ASCT for the treatment of PTCL 
other than EATL 
 
5.1 Introduction 
PTCL are characterised by an unsatisfactory outcome. The reported OS rates at 
5 years for PTCL treated with standard CHOP chemotherapy are 25-35%, (d'Amore, 
2010), with the exception of ALK positive PTCL which has a more encouraging 5 year 
OS of 70% (Vose et al., 2008). 
The prognostic impact of HDCT-ASCT in the treatment of PTCL was evaluated 
for the first time by the GELA group (Mounier et al., 2004). A matched pair analysis 
was performed for patients treated with HDCT-ASCT and patients receiving sequential 
consolidation for high-risk lymphomas, including PTCL, treated within studies LNH 87 
and LNH 93. There was a trend towards a better outcome in HDCT-ASCT for B-cell 
lymphomas and particularly high-risk B-cell lymphomas, but not in patients with non-
anaplastic T-cell lymphomas. There are several possible explanations for this finding. 
This study was the first to assess the role of HDCT–ASCT in the treatment of PTCL in 
a randomised fashion. 
With increasing experience and improving supportive care, ASCT has become a 
more popular treatment modality for all types of lymphomas including PTCL and 
several analyses have been performed and published. The British Society of Bone 
Marrow Transplantation and Australasian Bone Marrow Transplant Recipient Registry 
conducted a study on PTCL patients treated with ASCT (Feyler et al., 2007). Among 82 
evaluated patients, 31 received ASCT as consolidation therapy in first CR. The 2 year 
PFS and OS were 59% and 62%, respectively. The results are difficult to interpret as the 
study included many subtypes of PTCL namely ALCL, ATLL and cutaneous T-cell 
lymphoma. Additionally some of the patients received an allo-transplant. The Finnish 
survey on patients with PTCL treated with ASCT between 1990 and 2001 identified 37 
patients. Histologies included PTCL-NOS, ALCL and other non-characterised cases 
(Jantunen et al., 2004). The 5-year PFS and OS were 64% and 63% with ALCL patients 
having a significantly better outcome. A further Scandinavian series of 40 patients with 
PTCL treated at two centres also reported better outcomes for ASCT patients in 
comparison to patients treated with standard anthracycline-based regimens (Blystad et 
al., 2001). The 3-year PFS and OS were 48% and 58%, respectively, but again the study 
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included patients with different subtypes and of different remission status. The Spanish 
Lymphoma and Autologous Transplantation Group presented data on a more 
homogenous cohort of 74 patients with ASCT in first CR after an anthracycline-based 
induction (Rodriguez et al., 2007b). With a median follow-up time of 67 months from 
diagnosis, the 5-year PFS and OS were 63% and 68%, respectively and transplant 
related mortality (TRM) was 4%. Several other analyses have been published on 
specific subtypes of PTCL like angioimmunoblastic lymphoma (AIL) (Schetelig et al., 
2003) (Rodriguez et al., 2007a) with the biggest analysis by EBMT evaluating 146 
patients (Kyriakou et al., 2008), ALCL (Deconinck et al., 2000) and NK/T-cell 
extranodal lymphoma, nasal type (Au et al., 2003). All these studies reported better 
outcomes compared with the results previously published for PTCL (The Non-
Hodgkin's Lymphoma Classification Project, 1997) and its subtypes (Vose et al., 2008). 
All these studies were restricted only to evaluation of the conditioning regimen and the 
ASCT procedure itself. As most of the transplants were performed on patients in 
remission, they omitted the patients who never responded to induction chemotherapy. 
Additionally, most of the studies included patients of different remission status (first or 
subsequent remission, sensitive or non-sensitive disease). Thus, their value in evaluation 
of the role of HDCT and ASCT in improvement of 1st line treatment of PTCL is limited. 
Currently there are only four published studies and one conference abstract 
which assess the role of upfront ASCT in PTCL, evaluating all patients assigned to the 
procedure from the beginning of the protocol (Reimer et al., 2009) (Mercadal et al., 
2008) (Corradini et al., 2006) (Rodriguez et al., 2007c) (d'Amore et al., 2012). Even 
though none of the studies are randomized, they are presently our most reliable source 
of information. 
After achieving very good results with a new regimen IVE/MTX followed by 
ASCT in EATL, the subgroup of PTCL with one of the worst prognosis, we elected to 
assess the regimen in other subtypes of PTCL. This approach aimed to evaluate both the 
effect of replacing the standard anthracycline-based induction with the new HD regimen 
and the impact of an up-front ASCT. 
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5.2 Materials and methods 
 
5.2.1 Patients selection 
 From 1997 onwards, patients with a de-novo diagnosis of peripheral T-cell 
lymphoma including: ALCL, ALK negative, ALCL, ALK positive, PTCL, NOS, 
extranodal NK/T-cell lymphoma nasal type and hepatosplenic T-cell lymphoma were 
treated with the new protocol IVE/MTX-ASCT. The patients needed to be able to 
tolerate HD treatment. Patients were discussed at multidisciplinary unit meetings, and 
all patients who were assigned to receive the new treatment were evaluated. The data 
collection was performed with a help of a specially designed questionnaire, see 
Appendix IV. 
 
5.2.2 Study design and treatment 
The study protocol and regimen doses were the same as described in Chapter 4, 
paragraph 4.3.1.b Study design and treatment. 
 
5.2.3 Response assessment 
 Documentation of disease extent at diagnosis, treatment and toxicities as well as 
evaluation of response remission criteria were the same as described in Chapter 4, 
paragraph 4.3.1.c Response assessment. However the Ann Arbor classification was used 
instead of the Lugano and Manchester scores, as these are designed particularly for 
gastro-intestinal disease and would have been inappropriate for nodal lymphomas. For 
used questionnaire see Appendix IV. 
 
5.2.4 Statistics 
 The statistical methods used in the evaluation were the same as described in the 
Chapter 4, paragraph 4.2.1.d Statistics. 
 
5.3 Results 
 
5.3.1 Patient characteristics 
Between 1998 and 2009, 31 patients with a diagnosis of PTCL were treated with 
the novel regimen in 3 centres (Newcastle upon Tyne, Middlesbrough and Stockton on 
Tees) around the Northern Region of England. The histopathology of patients was 
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heterogeneous with PTCL NOS being the most representative group with 17/31 (55%) 
cases; followed by 6 cases of ALCL, ALK positive; 4 cases of extranodal NK/T-cell 
lymphoma nasal type; 3 cases of ALCL, ALK negative and one case of hepatosplenic 
T-cell lymphoma (table 5.1). 
 
Histopathological identity No (%) 
Peripheral T–cell Lymphoma not other specified 
Anaplastic large cell lymphoma (ALK positive) 
Extranodal NK/T-cell lymphoma, nasal type 
Anaplastic large cell lymphoma (ALK negative) 
Hepatosplenic T-cell lymphoma 
17 /31 (55) 
6 / 31 (19) 
4 / 31 (13) 
3 / 31 (10) 
1 / 31 (3) 
Table 5.1 Histopathological diagnosis of patients with PTCL treated with IVE/MTX, all 
patients (n=31). 
 
 The median age of the patients was 42 years (range 22 – 64) and approximately 
a third of patients were female. Most patients presented with a good performance status, 
with only 8/30 (27%) of patients having an ECOG >1. Early and advanced stages of 
disease were distributed equally within the group with 13/31 (42%) defined as early and 
18/31 (58%) defined as advanced stage. Half of all patients presented with B-symptoms. 
One fifth of patients had bulky disease and two thirds had extranodal organs involved; 
nasopharynx in 8/30 (27%) patients, lung and sinuses each in 5/30 (15%) patients and 
BM in 4/30 (13%) patients. aaIPI could be calculated in 26 patients; 4/26 (15%) were in 
the low risk group, 13/26 (50%) in the low intermediate risk group, 6/26 (23%) in the 
high intermediate risk group and 3/26 (12%) in the high-risk group. Seven of twenty-
nine (24%) patients had abnormal Hb and WBC levels at diagnosis and 14/27 (52%) 
had elevated LDH levels. Table 5.2 gives a summary of patient characteristics. 
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Clinical parameter No (%) 
Median age 
Female sex 
ECOG >1 
B – symptoms 
Clinical stage 
Early (I / II) 
Advanced (III / IV) 
aaIPI (for nodal disease origin only) 
Low 
Low intermediate 
High intermediate 
High 
Bulky disease 
Extranodal disease 
Extranodal organ involved 
Nasopharynx 
Lung 
Sinuses 
Marrow involvement 
Gastrointestinal tract 
Lever and biliary tract 
Spleen 
Tongue 
Breast 
Heart 
Pancreas 
Abnormal Hb 
Abnormal WBC 
Abnormal LDH 
42 (range 22 – 64) 
12 / 31 (39) 
8 / 30 (27) 
14 / 27 (52) 
 
13 / 31 (42) 
18 / 31 (58) 
 
4 / 26 (15) 
13 / 26 (50) 
6 / 26 (23) 
3 / 26 (12) 
6 / 30 (20) 
20 / 30 (66) 
 
8 / 30 (27) 
5 / 30 (17) 
5 / 30 (17) 
4 / 30 (13) 
3 / 30 (10) 
2 / 30 (7) 
2 / 30 (7) 
1 / 30 (3) 
1 / 30 (3) 
1 / 30 (3) 
1 / 30 (3) 
7 / 29 (24) 
7 / 29 (24) 
15 / 27 (52) 
Table 5.2 Characteristics of patients with PTCL treated with IVE/MTX, all patients 
(n=31). 
 
5.3.2 Treatment feasibility and toxicity 
 All 31 patients who were allocated the new regimen started it and were available 
for evaluation. In four patients the methotrexate treatment had to be adjusted. In one 
patient because of poor general condition at diagnosis it was omitted completely and in 
another it was omitted after the first cycle. In the third patient methotrexate was stopped 
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because of liver failure after cycle 1 and in the fourth patient methotrexate was 
discontinued because of the suspicion of disease progression after 1st cycle. All patients 
continued treatment with IVE. Four patients (13%) discontinued treatment prematurely, 
three because of rapid disease progression and one because of poor general condition. 
Of the remaining 27 patients, 20 (65%) received ASCT. The ASCT was omitted 
because of inadequate stem cell collection in 4 patients, progressive disease in 2 patients 
and poor general condition in one patient (figure 5.1). Twelve patients (39%) received 
radiotherapy. 
 !!!!!!!!!!!!!!!!
Figure 5.1!Flow!diagram!of!patients!with!PTCL!other!than!EATL!included!to!IVE/MTX!with!auto!SCT!treatment.!
Drop out (n=4):
3 - progressive disease
1 - poor general condition
Drop out (n=7):
2 - progressive disease
1 - poor general condition
4 - abort stem cell mobilisation
Melphalan / TBI or BEAM
ASCT
(n=20)
Final Assessment
before ASCT
(n=27)
CHOP
IVE / MTX (cycles 1 - 3)
Patients Avaiable for Evaluation
(n=31)
Patients Entered the Study
(n=31)
 
Figure 5.1 Flow diagram of patients with PTCL treated IVE/MTX. 
 
 Detailed information on ASCT was available in all transplanted patients (Table 
5.3). The majority of patients, 13 (63%) received HD melphalan based conditioning 
regimens including melphalan/TBI in 6 patients (30%), melphalan/etoposide in 5 
patients (25%) or melphalan alone in 2 patients (11%). The remaining 7 (35%) patients 
received BEAM conditioning. In all but one patient peripheral blood was the source of 
the CD34+ cells, the median number of transplanted cells was 5.2 x106/kg (range 1.7 – 
26.3 x106). 
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 No (%) 
Stem cell source 
Peripheral blood 
Bone marrow 
Median number of CD34+ re-infused 
 
Conditioning regimen 
BEAM 
HD melphalan / total body irradiation 
HD melphalan / etoposide 
HD melphalan alone 
 
19 / 20 (95) 
1 / 20 (5) 
6.0 x106/kg 
(range 1.7 – 26.3 x106/kg) 
 
7 / 20 (35) 
6 / 20 (30) 
5 / 20 (25) 
2 / 20 (10) 
Table 5.3 ASCT characteristic in patients with PTCL treated with IVE/MTX, all 
patients with ASCT (n=20). 
 
 The toxicity profile was acceptable for an intensive regimen. The most common 
acute toxicities were neutropenic sepsis / infection in 14/31 (45%) patients. Two 
patients suffered from severe nausea and vomiting requiring hospital admission. Other 
recorded severe toxicities occurring in one patient each were: deep fungal infection, 
haematuria, diarrhoea, visual hallucinations, pulmonary oedema, methotrexate induced 
liver failure and severe mucositis. Three patients suffered from late toxicities; two mood 
disorders, (in one patient accompanied by psoriasis arthritis) and one paraneoplastic 
pemphigus in the irradiated area. One patient developed a secondary malignancy: acute 
myeloid leukaemia. 
 
5.3.3 Response and outcome 
 At evaluation after completion of induction and before ASCT 26/31 (84%) 
patients were in remission; 24/31 (77%) in CR and 2/31 (7%) in PR; 5/31 (16%) had 
PD. At evaluation after ASCT all transplanted patients were in remission: 19/20 (95%) 
in CR and 1/20 (5%) in PR. Using an intention to treat analysis: at the end of treatment 
26/31 (84%) patients were in remission: 24/31 (77%) in CR and 2/31 (7%) in PR and 
5/31 (16%) patients had PD (Table 5.4). 
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all patients 
No (%) 
PTCL other than 
ALCL, ALK positive 
No (%) 
p-value 
Response to treatment 
CR 
PR 
Failure 
 
Death 
Death lymphoma 
 
24 / 31 (77) 
2 / 31 (7) 
5 / 31 (16) 
 
11 / 31 (35) 
10 / 31 (32) 
 
19 / 25 (76) 
2 / 25 (8) 
4 / 25 (16) 
 
10 / 25 (40) 
9 / 25 (36) 
 
>0.999 
 
 
 
0.786 
>0.999 
Table 5.4 Response to treatment and outcome of patients with PTCL treated with 
IVE/MTX, all patients (n=31) and PTCL other than ALCL, ALK positive (n=25). 
 
The remission rates remained the same when six patients with ALCL, ALK 
positive were excluded from the evaluation, with ORR of 21/25 (84%) with 19/25 
(76%) CR and 2/25 (8%) PR and 4/25 (16%) with PD; (p>0.999). At the median follow-
up time of 33 months, 11/31 (35%) patients had died, ten of them from lymphoma 
(32%) and one patient from infection complicating severe paraneoplastic pemphigus in 
the irradiated field. There were no differences in death rates after exclusion of ALCL, 
ALK positive cases with 10/25 (40%) patients dying (p=0.786); 9/25 (36%) from 
lymphoma (p>0.999). 
 The 3-year PFS for the whole group was 57% and OS 71% (figure 5.2). There 
were no differences in 3-year PFS (51%) and OS (68%) in an evaluation of all patients 
with PTCL and after exclusion of ALCL, ALK positive cases; p=0.709 and p=0.828 
(figure 5.3). The 3-year PFS and OS of histological subgroups were as follows: ALCL, 
ALK positive: both 83%, PTCL NOS: 45% and 64%, ALCL, ALK negative: 33% and 
67%, extranodal NK/T-cell lymphoma, nasal type: both 100% and for hepatosplenic T-
cell lymphoma: both 0% (figure 5.4). Although the ALCL, ALK positive cases seem to 
have better outcomes than other PTCL subtypes with 3-year PFS and OS of 83%, the 
differences were not statistically significant when compared with the whole group of 
PTCL patients (p=0.244 and p=0.469). 
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(A) 
 
(B) 
 
Figure 5.2 Kaplan-Meier plots for PFS and OS in patients with PTCL treated with 
IVE/MTX (n=31). (A) PFS and (B) OS. 
 
Figure 5.2 Kaplan-Meier for PFS and OS in pa ients with PTCL trea ed with 
IVE/MTX (n=31). (A) PFS and (B) OS. 
  
(A) 
 
(B) 
Figure 5.3 Kaplan-Meier plots for PFS and OS in patients with PTCL treated with 
IVE/MTX - all patients (n=31) vs PTCL other than ALK positive ALCL (n=26); 
p=0.709 and p=0.828, respectively. (A) PFS and (B) OS. 
 
Figure 5.3 Kaplan-Meier plots for PFS and OS in patients with PTCL treated with 
IVE/MTX, all patients (n=31) vs PTCL other than ALCL, ALK positive (n=26); 
p=0.709 and p=0.828, respectively. (A) PFS and (B) OS. 
  
(A) 
 
(B) 
Figure 5.4 Kaplan-Meier plots for PFS and OS in patients with PTCL treated with 
IVE/MTX, different histological subtypes - all patients (n=31); p<0.001 for both. (A) 
PFS and (B) OS. 
 
Figure 5.4 Kaplan-Meier plots for PFS and OS in patients with PTCL treated with 
IVE/MTX, different histological subtypes, all patients (n=31); p<0.001 for both. (A) 
PFS and (B) OS. 
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We observed a difference in PFS and OS between groups with low and low 
intermediate aaIPI and those with high and high intermediate aaIPI with 3-year PFS of 
70% vs. 28% (p=0.068) and 76% vs. 67% (p=0.247), (figure 5.5), respectively. 
  
(A) 
 
(B) 
Figure 5.5 Kaplan-Meier plots for PFS and OS in patients with PTCL treated with 
IVE/MTX, patients with low and low intermediate aaIPI (n=17) vs high and high 
intermediate aaIPI (n=9); p=0.068 and p=0.247, respectively. (A) PFS and (B) OS. 
 
Figure 5.5 aplan- eier plots for PFS and OS in patients with PTCL treated with 
IVE/MTX, patients with low and low intermediate aaIPI (n=17) vs high and high 
intermediate aaIPI (n=9); p=0.068 and p=0.247, respectively. (A) PFS and (B) OS. 
 
After exclusion of ALCL, ALK positive the figures were 66% vs. 17% (p=0.057) and 
73% vs. 67% (p=0.333), respectively (figure 5.6). The differences were however not 
statistically significant, probably because of small patients numbers. 
 
 
(A) 
 
(B) 
 
Figure 5.6 Kaplan-Meier plots for PFS and OS in patients with PTCL without ALK 
positive ALCL treated with IVE/MTX, patients with low and low intermediate aaIPI 
(n=15) vs. high and high intermediate aaIPI (n=6); p=0.057 and p=0.333, 
respectively. (A) PFS and (B) OS. 
 
Figure 5.6 Kaplan- eier plots for PFS and OS in patients with PTCL without ALCL, 
ALK positive treated ith I E/ TX, patients with low and low intermediate aaIPI 
(n=15) vs. high and high intermediate aaIPI (n=6); p=0.057 and p=0.333, respectively. 
(A) PFS and (B) OS 
 
 In an evaluation of response and failure patterns in all patients we observed that 
16% (5 patients) progressed during the treatment, 10% (3 patients) had early post 
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treatment relapses (within 1 year from the end of treatment), 16% (5 patients) had late 
post treatment relapses (later than 1 year after the end of treatment) and 55% (17 
patients) remained in long term remission. 
 
5.3.4 Role of ASCT 
In the evaluation of patients who completed the whole scheduled treatment 
including the ASCT and those who failed to complete it the ORR was statistically 
significantly higher in the former group than in the latter (table 5.5). 
 
 
Patients 
with ASCT 
No (%) 
Patients 
without ASCT 
No (%) 
p-
value 
Response to treatment 
CR 
PR 
Failure 
 
Death 
Death lymphoma 
 
19 / 20 (95) 
1 / 20 (5) 
0 / 20 (0) 
 
5 / 20 (25) 
4 / 20 (20) 
 
5 / 11 (45.5) 
1 / 11 (9) 
5 / 11 (45.5) 
 
6 / 11 (54.5) 
6 / 11 (54.5) 
 
<0.001 
 
 
 
0.132 
0.455 
Table 5.5 Response to treatment and outcome of patients with PTCL treated with 
IVE/MTX, patients with ASCT (n=20) vs. patients without ASCT (n=11). 
 
In the group who completed treatment all 20 patients achieved remission; 19/20 
(95%) CR and 1/20 (5%) PR. In the group of patients who failed to complete the 
regimen only 6/11 (55%) of patients achieved remission; 5/11 (45.5%) CR and 1/11 
(9%) PR (p<0.001). There were also fewer deaths in the group of patients who 
completed the protocol - 5/20 (25%) compared with the group of patients who did not 
complete the regimen 6/11 (55%). However, the difference was not significant 
(p=0.455). All four patients who relapsed during the IVE/MTX treatment or before the 
ASCT died shortly after of progressive disease. Of two patients who stopped the 
regimen due to poor condition (one after 2nd methotrexate), one is alive and in ongoing 
remission at 6 years and the other who stopped the treatment just before ASCT died at 3 
years. Three from four patients who stopped the regimen just before ASCT because of 
failed stem cell mobilisation are alive in remission at 3 years, 5 years and 6 years 
respectively; one patient relapsed after 2 years but is alive at 3 years. 
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The 3-year PFS and OS were 69% and 84%, respectively for patients who 
completed the whole treatment and 36% and 54% for patients who did not, the 
differences are not significant; p=0.072 and p=0.069, respectively (figure 5.7). 
  
(A) 
 
(B) 
Figure 5.7 Kaplan-Meier plots for PFS and OS in patients with PTCL treated with 
IVE/MTX, patients with ASCT (n=20) and patients without ASCT (n=11), all 
patients (n=31); p=0.072 and p=0.069, respectively. (A) PFS and (B) OS. 
 
Figure 5.7 Kaplan-Meier plots for PFS and OS in patients with PTCL treated with 
IVE/MTX, patients with ASCT (n=20) and patients without ASCT (n=11), all patients 
(n=31); p=0.072 and p=0.069, respectively. (A) PFS and (B) OS. 
 
The difference remained the same after exclusion of patients with ALCL, ALK positive: 
PFS: 59% and 40% (p=0.36), OS: 73% vs. 60% (p=0.294); (figure 5.8). 
 
 
(A) 
 
(B)  
Figure 5.8 Kaplan-Meier plots for PFS and OS in patients with PTCL without ALK 
positive ALCL treated with IVE/MTX, patients with ASCT (n=15) and patients 
without ASCT (n=10), p=0.36 and p=0.294, respectively. (A) PFS and (B) OS. 
 
Figure 5.8 Kaplan-Meier plots for PFS and OS in patients with PTCL without ALCL, 
ALK positive treated with IVE/MTX, patients with ASCT (n=15) and patients without 
ASCT (n=10), p=0.36 and p=0.294, respectively. (A) PFS and (B) OS. 
 
Comparison of patients who achieved CR/PR after completion of 3 cycles of IVE/MTX 
but did not receive ASCT due to insufficient stem cell harvest (4 patients) or poor 
general condition (1 patient), with those who received the whole protocol including 
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ASCT, revealed no differences in PFS and OS. The 3 year PFS and OS were 60% vs. 
69% (p=0.998) and 100% vs. 79% (p=0.692); respectively. 
 
5.4 Discussion 
In view of disappointing results with conventional CHOP based treatment and 
after achieving very promising results with the new intensive regimen IVE/MTX 
followed by a myeloablative ASCT in EATL, we prospectively assessed the value of 
this regimen in other PTCL. The new regimen was feasible with acceptable toxicities. 
The overall response rate was 84% with a 3-year PFS of 57% and OS of 71%. There 
was no difference in ORR (84%), 3 year PFS (51%) and OS (68%) after exclusion of 
ALCL, ALK positive. 
As previously mentioned, the study of Mounier et al was the first to assess 
HDCT-ASCT in patients with PTCL. A matched pair analysis was performed to assess 
the impact of phenotype on the role of HDCT-ASCT when compared with sequential 
consolidation for high-risk lymphomas treated within studies LNH 87 and LNH 93 
(Mounier et al., 2004). Patients received a standard induction of four cycles of a CHOP-
like regimen given every 2 weeks: doxorubicin 75mg/m2 (day 1), cyclophosphamide 
1200mg/m2 (day 1), vindesine 2mg/m2 (days 1 – 5), bleomycin 10mg/m2 (days 1 – 5) 
and prednisone 60mg/m2 with intrathecal methotrexate 15mg (day 2) or alternatively the 
same regimen with mitoxantrone 12mg/m2 (day 1) instead of doxorubicin (NCVBP). 
Patients achieving CR/CRu in the HDCT-ASCT group received two cycles of HD 
methotrexate 3000mg/m2 with leucovorin rescue, followed by myeloablative 
conditioning with CBV (cyclophosphamide 6000mg/m2, BCNU 300mg/m2 and 
etoposide 1000mg/m2) followed by ASCT. Patients in the sequential consolidation 
group received two cycles of HD methotrexate 3000mg/m2, with two cycles of 
ifosfamide 1500mg/m2 and etoposide 300mg/m2, one cycle of L-asparaginase 50000 
mg/m2 and a final two cycles of cytarabine 100 mg/m2 (days 1 - 4). A description of the 
regimens and doses is given in table 5.6. 
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There was an overall trend for better outcomes in the HDCT-ASCT group for B-cell 
lymphomas (5-year DFS: 72% vs. 67%; p=0.13 and OS: 79% vs. 77%; p=0.64). This 
was particularly marked in B-cell lymphomas with 2 - 3 aaIPI risk factors. This group 
of patients benefitted from HDCT-ASCT with statistically significance differences in 5-
year DFS: 75% vs. 63%, p=0.001 and OS: 78% vs. 72%, p=0.04. By contrast, among 28 
evaluable patients with non-anaplastic T-cell lymphoma there was no difference 
between HDCT-ASCT and sequential consolidation arms: with 5-year DFS of 49% and 
44%, p=0.87 and OS of 45% vs. 38%, p=0.89 (Table 5.7). There are several possible 
reasons why HDCT-ASCT might not have shown an advantage in this group of 
patients. Firstly the overall results were unexpectedly very good in both treatment 
groups compared with other studies. Secondly the standard arm included not only 
established anthracycline-based chemotherapy but also additional sequential 
chemotherapy with relatively high-doses of very effective drugs including methotrexate, 
ifosfamide, etoposide, L-asparaginase and cytosine arabinoside. Thirdly the total 
number of patients with T-cell lymphomas was rather small, making comparison 
difficult. Fourthly there were no available details on histology, therefore the number of 
potential cases with a better prognosis (for example ALCL, ALK positive) remains 
unknown. However, this was the first study assessing the role of HDCT–ASCT in the 
treatment of PTCL in a prospective randomised trial. 
Currently there are only four published studies and one conference abstract, 
which assess the role of upfront ASCT in PTCL and evaluate all patients assigned to the 
procedure from the beginning of the treatment (Reimer et al., 2009) (Mercadal et al., 
2008) (Corradini et al., 2006) (Rodriguez et al., 2007c) (d'Amore et al., 2012). These 
studies will be briefly described below. Tables 5.6 and 5.7 provide an overview of drugs 
doses and responses. 
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Reimer et al performed a prospective study evaluating up-front ASCT in patients 
with PTCL younger than 65 years; ALCL, ALK positive and primary cutaneous 
lymphomas were excluded (Reimer et al., 2009). The patients were treated with 4 – 6 
cycles of CHOP: cyclophosphamide 750mg/m2 (day 1), doxorubicin 50mg/m2 (day 1), 
vincristine 2mg (day1) and prednisone 100mg (days 1-5). This was followed by stem 
cell mobilizing therapy with either dexaBEAM: dexamethasone 8mg tds (days 1 – 7), 
melphalan 30mg/m2 (day 3), BCNU 60mg/m2 (day 3), etoposide 75mg/m2 (days 4 - 7), 
Ara-C 100mg/m2 twice daily (days 4 - 7) or ESHAP: etoposide 40mg/m2 (days 1 - 4), 
methylprednisolone 500mg/m2 (days 1 – 5), cytarabine 2000mg/m2 (day 5) and cisplatin 
25mg/m2 (days 1 – 4) and stem-cell collection. Patients in CR or PR underwent 
myeloablative chemotherapy with TBI and HD cyclophosphamide. Eighty-three 
patients were included in the study, 32 patients with PTCL NOS; 27 with AITL; 13 with 
ALCL, ALK negative; 5 with intestinal lymphoma; 4 with extranodal NK/T-cell 
lymphoma nasal type and 2 with hepatosplenic T-cell lymphoma. Fifty-five patients 
(66%) received the planned ASCT. ORR was 66% (56% CR and 8% PR). With a 
median follow-up of 33 months 48% of patients had died. The 3-year PFS and OS were 
36% and 48%, respectively. 
The biggest prospective phase II multicentre study of ASCT in PTCL has been 
completed by the Nordic Lymphoma Group. They assessed the impact of a dose-
intensified induction with 6 courses of two-weekly CHOEP: cyclophosphamide 
750mg/m2 (day 1), doxorubicin 50mg/m2 (day 1), vincristine 2mg (day1), etoposide 
100mg/m2 (days 1-3) and prednisone 100mg (days 1-5) consolidated in CR/PR with 
BEAM-ASCT (Reimer et al., 2009). The patients were previously untreated and aged 
18 – 67 years. ALCL, ALK positive; primary cutaneous; leukaemic and lymphoblastic 
subtypes were excluded. 160 patients with a confirmed histological diagnosis of PTCL 
were included, 62 PTCL NOS; 32 ALCL, ALK negative; 30 AITL; 21 EATL; 6 
panniculitis-like; 5 extranodal NK/T-cell nasal type and 5 hepatosplenic T-cell 
lymphomas. From the original cohort 155 patients were evaluable after induction and 
112 patients (72%) underwent ASCT. With a median follow-up time of 45 months, 46% 
of patients have died. The 3 / 5 year PFS and OS were: 48% / 43% and 57% / 50%; 
respectively. 
A multicentre phase II study of Mercadal et al included patients with PTCL in 
CS II - IV under the age of 65 (Mercadal et al., 2008). ALCL, ALK positive and 
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mycosis fungoides patients were excluded. Patients received 3 cycles of megaCHOP: 
cyclophosphamide 2000mg/m2 on day 1 (2.7 x standard CHOP), doxorubicin 90mg/m2 
on day 1 (1.8 x standard CHOP), vincristine 2mg on day 1 and prednisone 60mg on 
days 1 – 5, followed by three courses of standard ESHAP: etoposide 40mg/m2 (days 1 - 
4), methyprednisolone 500mg/m2 (days 1 – 5), cytarabine 2000mg/m2 (day 5) and 
cisplatin 25mg/m2 (days 1 – 4) and stem-cell collection. Patients with CR or PR were 
given myeloablative chemotherapy with BEAM or carmustine, etoposide, cytarabine 
and cyclophosphamide (BEAC) followed by ASCT. 41 patients were included in the 
trial: 20 PTCL NOS; 12 AITL 2 hepatosplenic T-cell lymphoma; 2 extranodal NK/T-
cell nasal type; 2 panniculitis like and one each of Sezary syndrome; ALCL, ALK 
positive and other γ/δ lymphoma. Seventeen (41%) patients received ASCT. ORR was 
58% (51% CR/CRu and 7% PR). With a median follow-up time of 3.2 years, 54% of 
patients have died. 3-year PFS and OS were 34% and 43%, respectively.  
In the study of Rodriguez et al 26 gallium-scan-positive patients with high-risk 
PTCL were treated with three courses of megaCHOP: cyclophosphamide 2000mg/m2 
on day 1 (2.7 x standard CHOP), doxorubicin 90mg/m2 on day 1 (1.8 x standard 
CHOP), vincristine 2mg on day 1 and prednisone 60mg on days 1 - 5 before they were 
re-evaluated (Rodriguez et al., 2007c). Patients with negative gallium scans received an 
additional cycle of megaCHOP and went on to ASCT, and patients, who remained 
gallium positive received two courses of salvage IFE: ifosfamide 10000mg/m2 
continuous infusion on days 1 - 3 and etoposide 150mg/m2 twice a day on days 1 – 3. 
All patients with at least PR received BEAM and ASCT. Twenty-six patients were 
included in this study: 11 PTCL NOS; 8 ALCL, ALK negative and 7 AITL. ASCT was 
performed in 19 (73%) patients. The ORR was 77% (19 CR – 69% and 1 PR – 8%), 
with a median follow-up time of 35 months. Thirty-one per cent of patients died and 3-
year PFS and OS were 53% and 73%. 
Corradini et al reported on sixty-two patients with PTCL: 28 PTCL NOS; 19 
ALCL, ALK positive; 10 AITL; 4 ALK negative PTCL and one EATL (Corradini et al., 
2006). Thirty-two patients received an intensified version of the HD sequential 
chemotherapy regimen, which consisted of: 
(i) A debulking phase with two cycles of APO: doxorubicin 75mg/m2 (days 1 
and 21), vincristine 1.4mg/m2 (days 1 and 21) prednisone 50mg/m2 (days 1 – 21) and 
two courses of DHAP: cisplatin 100mg/m2 (day 1), cytarabine 2000mg/m2 twice a day 
(day 2) and dexamethasone 40mg/m2 (days 1 – 4)  
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(ii) A HD phase, which involved the sequential administration of 
cyclophosphamide 7000mg/m2, cytarabine 2000mg/m2 twice daily for six days, cisplatin 
100mg/m2 and etoposide 2400mg/m2. The conditioning regimen for ASCT was HD 
mitoxantrone and melphalan.  
The remaining 30 patients were treated for 8 weeks with MACOP-B: methotrexate 
400mg/m2 (days 8 and 36), doxorubicin 50mg/m2 (days 1, 15, 29 and 43), 
cyclophosphamide 350mg/m2 (days 1, 15, 29 and 43), vincristine 1.4mg/m2 (days 8, 22, 
36, 50), bleomycin 10units/m2 (days 22 and 50) and prednisone 75mg (days 1 - 56), 
followed by intensification with a course of mitoxantrone 8 mg/m2 (days 1 – 3) with HD 
cytarabine 2000mg/m2 twice daily (days 1 – 3). The conditioning regimen for ASCT 
was BEAM. Thirty-five patients (56%) received ASCT. The ORR after ASCT was 74% 
(66% CR and 8% PR). The 3-year PFS and OS were: 49% and 62%. 
The other study worthy of closer scrutiny because of the treatment approach is 
the DSHNHL trial assessing maximum intensification of the CHOP regimen with 
additional etoposide in the treatment of aggressive lymphomas (Nickelsen et al., 2009). 
Separate evaluations were performed to compare the feasibility and efficacy of the 
regimen in lymphomas with T-cell and B-cell phenotype. Patients were randomised to 
four different dose levels: the total regimen doses and increase / decrease factor 
compared with the standard of 6 cycles of CHOP are given in brackets: 
cyclophosphamide (16500mg/m2 - 19500mg/m2; 3.7x – 4.3x), doxorubicin (280mg/m2 
– 420mg/m2; 0.93x – 1.4x), vincristine (8mg/m2 - 12mg/m2; 0.7x – 1x), etoposide 
(3130mg/m2 - 5200mg/m2; 1.7x – 2.9x) and prednisone (2000mg/m2 - 3000mg/m2; 0.7x 
– 1x). Patients received 4 or 6 cycles of the regimen, with stem cell support beginning 
from the second cycle. Thirty-three patients in this prospective study had T-cell 
phenotype lymphomas; 13 ALCL, ALK positive; 11 PTCL NOS; 4 AITL; 3 NK/T-cell 
lymphoma; 1 EATL and 1 lymphoblastic lymphoma. The outcome of T-cell lymphoma 
patients was significantly worse than B-cell lymphoma patients in all evaluated aspects, 
including, number of patients who completed the planned treatment (66.7% vs. 84.4%), 
ORR (55% vs. 76%), PFS and OS at 3 years (25.9% and 44.5% vs. 60.1% and 63.4%). 
Our novel regimen include a solitary initial cycle of standard CHOP followed by 
three cycles of high dose therapy with IVE/MTX (the cumulative regimen doses are 
given in brackets): ifosfamide 3000mg/m2 on days 1 – 3 (27000mg/m2), epirubicin 
50mg/m2 on day 1 (150mg/m2) and etoposide 200mg/m2 on days 1 -3 (1800mg/m2) 
alternating with intermediate dose methotrexate 1500mg/m2 by 24 hr infusion (4500 
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mg/m2). When compared with other studies our patients receive from the beginning of 
their treatment high doses of effective drugs in a unique combination. Ifosfamide was 
previously used in the treatment of PTCL in the sequential chemotherapy of the GELA 
group, but in a lower dose of 3000mg/m2 (Gisselbrecht et al., 1998) (Coiffier et al., 
1990), and at the higher dose of 30000mg/m2 in salvage therapy in combination with 
etoposide in the study of Rodriguez (Rodriguez et al., 2007c) compared with 
27000mg/m2 in our regime. Etoposide is a part of several other treatments mostly as an 
addition to CHOP or as part of a mobilisation regimen (ESHAP or DexaBEAM) 
(Mercadal et al., 2008) (Reimer et al., 2009), or salvage therapy (Rodriguez et al., 
2007c). Epirubicin was used in our study for the first time whilst other protocols use 
mostly doxorubicin as an anthracycline (Reimer et al., 2009) (d'Amore et al., 2012) 
(Mercadal et al., 2008). The final drug of our regimen methotrexate was used in an 
intermediate dose of 1500mg/m2 and has not been used in other regimens for PTCL 
except in the GELA sequential chemotherapy and HDCT-ASCT regimen (Mounier et 
al., 2004). 
All patients in our study who were assigned to receive the treatment were 
prospectively evaluated on intent to treat basis. This approach allowed us to assess this 
entirely new regimen in the first line treatment of other histological subtypes of PTCL 
after achieving promissing results in EATL patients (a group of patients with a dismal 
prognosis when treated with conventional therapies). 
In order to perform a better and more structure comparison of outcome of 
patients treated in the above-described prospective studies of PTCL, the studies can be 
divided into three categories according to the type of induction.  
(i) induction based on conventional CHOP-like regimens followed by a 
mobilising cycle with more intensive chemotherapy and a final myeloablative regimen 
with ASCT “conventional CHOP – myeloablative – ASCT”. The two largest studies of 
Reimer et al and D’Amore et al belong (Reimer et al., 2009) (d'Amore et al., 2012) to 
this category, and the second part of Corradini’s study, which includes treatment with 
MACOP-B followed by one cycle of mitoxantrone with HD cytarabine (Corradini et al., 
2006). 
(ii) induction with high dose CHOP (e.g. megaCHOP) either alone as in the 
standard arm of Rodriguez et al, or with additional HD cycles e.g. the intensified arm of 
Rodriguez et al (Rodriguez et al., 2007c) or the study of Mercadal - “HD CHOP – 
myeloablative - ASCT” (Mercadal et al., 2008). 
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(iii) The third category includes studies, which are not based on conventional 
CHOP but use different drugs in high doses “HD - myeloablative – ASCT”, for 
example, the present study and Corradini’s first study (Corradini et al., 2006). 
Comparison between the different studies is difficult, as several studies included 
different treatment arms, which were evaluated together (Corradini et al., 2006) 
(Rodriguez et al., 2007c). The most straightforward comparison is possible with studies, 
which included only one treatment regimen (d'Amore et al., 2012) (Reimer et al., 2009) 
(Mercadal et al., 2008). 
The general characteristics of our patients were comparable with those of 
patients in other prospective trials in PTCL. The median age was 42 years (range from 
43 years to 57 years in other trials), and the majority of patients were male with a male : 
female ratio of 1.6, in other studies this ranged from 1.6 to 2.72 (d'Amore et al., 2012) 
(Corradini et al., 2006) (Mercadal et al., 2008) (Rodriguez et al., 2007c). Performance 
status as measured by ECOG was less than 1 in 73% of patients and was comparable 
with those from the biggest studies of Reimer et al and d’Amore et al with 71% in both 
(d'Amore et al., 2012) (Reimer et al., 2009). However, the percentage of patients with a 
good performance status was higher than that reported in the studies of Rodriguez and 
Mercadal; 50% and 46%, respectively (Rodriguez et al., 2007c) (Mercadal et al., 2008). 
Over half of our patients (52%) presented with B-symptoms. In other studies this ranged 
between 54% and 63%. LDH was increased in 52% of patients and in other studies the 
range was between 54% and 62%. However, the percentage of our patients with 
advanced stage disease was at 58% lower when compared with other studies, where it 
ranged from 75% and 96% (Corradini et al., 2006) (Mercadal et al., 2008) (Reimer et 
al., 2009) (d'Amore et al., 2012). One possible explanation is the fact that some of the 
studies were specifically designed for high-risk patients and included patients with 
advanced stage disease only. 
 The response rates to induction treatment before ASCT were highest in our 
study, with an 84% overall response rate and 77% CR. The two biggest studies 
belonging to the category “conventional CHOP – myeloablative – ASCT”, reported 
comparable response rates with respect to overall response rate but the CR rate was 
significantly lower when compared with the present study; d’Amore at al 85% with 
52% CR (d'Amore et al., 2012) and Reimer et al 71% with 47% CR (Reimer et al., 
2009). In Mercadal’s study using “HD CHOP – myeloablative - ASCT” methodology 
with HD CHOP followed by 3 cycles of ESHAP the ORR was lowest with 59% (39% 
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CR) (Mercadal et al., 2008). Nickelsen et al applied the highest possible doses of drugs 
in their CHOP regimen (cyclophosphamide 3.7 – 4.3x dose increase, doxorubicin 0.93 – 
1.4x and etoposide 1.7 – 2.9x), but the results of the study were disappointing and did 
not support any further investigation of this approach (Nickelsen et al., 2009). In the 
third category of studies where different treatment modalities at high doses were 
employed the response rates were comparable with our study, 72% (56% CR) in the 
study of Rodriguez (Rodriguez et al., 2007c) and 77% (65% CR) in the study of 
Corradini et al (Corradini et al., 2006). Importantly, Corradini reported no differences 
between the HD part of his study (representing “HDCT – myeloablative - ASCT”) and 
the anthracycline-based followed by HDCT part, (representing “conventional CHOP – 
myeloablative – ASCT”) (Corradini et al., 2006). 
 The comparison of responses to ASCT is more straightforward as all studies 
used ASCT only for patients in CR or PR (Corradini et al., 2006) (Mercadal et al., 
2008) (Rodriguez et al., 2007c) (d'Amore et al., 2012). Despite the different 
conditioning regimens used all transplanted patients achieved CR or PR except in the 
studies of Rodriguez and d’Amore (d'Amore et al., 2012) (Rodriguez et al., 2007c). The 
latter study reported 13 (12%) patients with failure, and in the former one patient failed. 
One possible explanation for the failures is that both studies used almost the same 
induction (with minimal intensification in Reimer’s study). D’Amore et al reported an 
ORR after induction 14% higher than Reimer (Reimer et al., 2009) (d'Amore et al., 
2012). Some of these patients responded to the modified induction for a very short time 
only and relapsed quickly after ASCT. 
 With respect to ORR and rates of CR after the end of treatment the best response 
rates were achieved in the present study with 84% ORR and 77% CR, followed by the 
studies of Rodriguez, (77% ORR and 69% CR) (Rodriguez et al., 2007c) and Corradini 
(74% and 66%) (Corradini et al., 2006). Studies using induction with anthracycline-
based chemotherapy were characterised by the worst results; 66% ORR and 58% CR in 
Reimer et al (Reimer et al., 2009) and 59% ORR and 51% CR in Mercadal et al where 
an intensified CHOP regimen was applied (Mercadal et al., 2008). 
The 3-year PFS and OS were highest in the study of Rodriguez (53% and 73%) 
(Rodriguez et al., 2007c) and the present study (57% and 71%). Both studies were 
characterized by early intensification with ifosfamide and etoposide – in our approach in 
all patients and in the study of Rodriguez in patients selected by positive Gallium scans. 
The two biggest studies applying a “conventional CHOP – myeloablative - ASCT” 
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design reported significantly lower 3 year PFS and OS of 36% and 48% (Reimer et al., 
2009) and 48% and 57% (d'Amore et al., 2012). Results were worst in the study of 
Mercadal et al. using a HD CHOP-like regimen followed by HDCT with 3 year PFS of 
34% and OS of 43% (Mercadal et al., 2008), This study and that of Nickelsen et al 
(26% and 46%) confirm that there is no advantage to increasing the dose of CHOP-like 
regimens (Nickelsen et al., 2009). Corradini et al reported 3 year PFS and OS of 49% 
and 62%, however this study included a number of ALK positive T-cell lymphomas 
(Corradini et al., 2006). 
A comparison between outcomes of histological subgroups was possible for our 
study and the patients included in the ITLP (Vose et al., 2008). In our study the 3-year 
OS was improved for all histological groups except for one patient with hepatosplenic 
T-cell lymphoma; ALCL, ALK positive: 83% vs. 73%; PTCL NOS: 64% vs. 41%; 
ALCL, ALK negative: 67% vs. 54%; extranodal NK/T-cell lymphoma, nasal type: 
100% vs. 13%. In addition it is possible to compare our patients with PTCL NOS and 
ALCL, ALK negative with those treated in d’Amore’s study (d'Amore et al., 2012). The 
3-year PFS and OS was better for patients treated with our protocol for PTCL NOS: 
45% and 64% vs. 42% and 51% and but not for ALCL, ALK negative: 33% and 67% 
vs. 64% and 77%. This might suggest that patients with PTCL NOS benefit more from 
an intensified induction than patients with ALCL. However because of the small 
numbers of patients these results need to be viewed with some caution. 
In our study we observed a trend towards a longer PFS and OS according to 
aaIPI (high / intermediate high vs low / intermediate low), however these differences 
were not significant. Reimer et al also found a trend towards better survival in patients 
with a low and intermediate low aaIPI score (Reimer et al., 2009) and in the study of 
Corradini et al aaIPI predicted for significantly longer OS and a trend for PFS 
(Corradini et al., 2006). By contrast, Rodriguez et al did not find any predictive value 
for aaIPI score (Rodriguez et al., 2007c). However once again the numbers of patients 
were too small to make any valid conclusions on the significance of the aaIPI. 
In an evaluation of patients who completed the whole treatment including ASCT 
and those who did not we observed differences in PFS and OS for all patients, and after 
exclusion of ALCL, ALK positive cases, the differences were not statistically 
significant. By contrast, Reimer et al reported statistically significant differences 
between patients who received a transplant and those who did not (Reimer et al., 2009). 
We did not observe any such difference in our patients with and without a transplant in 
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an evaluation of patients who achieved CR / PR after induction. This might suggest that 
our intensive HD induction is powerful enough and does not necessarily require an 
ASCT as compared with conventional induction with CHOP. Mercadal et al did not 
notice a difference in the same evaluation in his study (Mercadal et al., 2008). Both 
studies used a more intensified induction than standard CHOP. This data may be 
important when we consider the treatment of elderly patients who may be suitable for 
IVE/MTX but not necessarily for a myeloablative ASCT.  
When evaluating the response and failure patterns we observed a 16% 
progression during treatment, 10% early post treatment relapses, 16% late post 
treatment relapses and 55% long-term remissions. A similar evaluation was performed 
by d’Amore et al (d'Amore, 2010) (d'Amore et al., 2012) and Reimer et al (Reimer et 
al., 2009). Progression during treatment was found in 30 – 35% of patients, early post 
treatment relapses in 15 – 20%, late post treatment relapses in 5% and long-term 
remissions in 35 – 50%. According to these results with the new regimen we are able to 
reduce the number of failures appearing during treatment, early post treatment relapses 
and to increase the number of long term remissions. However, the number of late 
relapses increased. 
 In conclusion, the novel intensified regimen was evaluated prospectively by an 
intention to treat method in all suitable patients presenting with PTCL in our region. 
The therapy was based on early intensive induction with a unique combination of very 
effective anti-neoplastic drugs, and moved away from conventional anthracycline-based 
induction therapies. The treatment was feasible with acceptable toxicities for a HD 
therapy. The achieved ORR, PFS and OS were better than those previously published. 
Particularly, the incidence of primary progressive patients and early relapses could be 
reduced. Importantly, the patients also benefitted from the treatment when they 
responded with CR/PR to the 3 cycles of induction therapy but did not proceed to the 
final myeloablative ASCT. This option may potentially be applied and further evaluated 
in more fragile and elderly patients. Furthermore, the newer folate analogues with 
significant powerful efficacy in PTCL (O'Connor et al., 2009) could be incorporated 
into the regimen and replace methotrexate in future when they become more widely 
available. 
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Chapter 6. Conclusive discussion 
 
6.1 Discussion 
The aim of this thesis was to perform several independent studies in order to 
improve treatment strategies for patients with aggressive lymphomas. Almost 45 years 
have past since the Working Formulation for NHL was presented in 1982 and the term 
‘aggressive lymphomas’ was introduced (National Cancer Institute, 1982). Despite 
significant improvement in the understanding of biology and pathology, including a 
new classification, there has been limited improvement in treatment strategies. The 
current standard treatment is based on a multidrug, anthracycline-based regimen CHOP 
which has been used since 1976 (McKelvey et al., 1976). Tumours of B-cell origin are 
treated with the addition of the anti-CD20 agent rituximab (Coiffier et al., 2002). 
Because of the limits of this thesis, the research was focused on several aspects only and 
it was not possible to cover all important issues. 
According to the recent WHO Lymphoma Classification the former group of 
aggressive lymphoma was subdivided into approximately 15-20 identities with different 
biology, prognosis and individual requirements for improvement of their treatment 
strategies (Swerdlow et al., 2008). The research of this thesis was focused on the 
DLBCL-NOS and PTCL with EATL particularly. 
 
Diffuse large B-cell lymphoma 
Diffuse large B-cell lymphoma is the most common and the most heterogeneous 
lymphoma in terms of pathobiology and outcome (Swerdlow et al., 2008). The current 
treatment for intermediate and advanced stage disease is 6 – 8 cycles of anthracycline-
based chemotherapy with CHOP in combination with rituximab and for early stage two 
cycles of CHOP with rituximab and adjuvant radiotherapy (Coiffier et al., 2002) 
(Coiffier et al., 2010) (Habermann et al., 2006) (Pfreundschuh et al., 2008b) 
(Pfreundschuh et al., 2008a) (Sehn et al., 2005). The outcome, particularly for patients 
with intermittent / advanced stage disease, is limited. The data justifying this approach 
in intermittent and advanced stage disease comes from clinical trials, which included 
mostly patients with intermittent stages only, leaving the advanced stage / high IPI 
cases. The data on patients with early stage disease is even less supported by clinical 
trials, all of which come from the pre-rituximab era (Bonnet et al., 2007) (Horning et 
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al., 2004) (Miller et al., 1998) (Reyes et al., 2005). Additionally, the majority of data on 
DLBCL comes from clinical trials usually performed on highly selected patients. Thus, 
the results may be biased and not always representative for patients presenting in 
clinical practice. 
Performing the population-based studies on DLBCL of nodal origin we could 
describe the epidemiological background of the disease, which should be successively 
used in the design of future research. We confirmed that DLBCL is a disease of the 
elderly population and is diagnosed in advanced stage. This group of patients has a 
worse outcome and is often treated inadequately or cannot tolerate the standard 
treatment and is switched to more palliative options. This group of patients was usually 
not included in clinical trials. Interestingly, a significant number of patients in the whole 
population have not received standard treatment. The other important finding was the 
fact that patients who achieved a better quality remission with first line treatment had a 
better outcome. This emphasizes the importance of the curative role of the first line 
treatment, particularly in view of very limited results for currently available salvage 
treatments. Our evaluation of patients treated with a combination of 
immunochemotherapy, although performed in selected NHS trusts, could only confirm 
the limited outcome of the treatment in patients with advanced stage disease, 
particularly in the elderly population. 
In conclusion, new treatment strategies should focus on advanced stage disease, 
in the fragile elderly population who often cannot tolerate standard anthracycline-based 
treatment. Recent progress in the understanding of the biology of DLBCL, resulting 
from the employment of next generation sequencing on whole genome / exome, 
provides some help (Pasqualucci and Dalla-Favera, 2015). New discovered oncogenic 
pathways can be targeted with novel anticancer drugs (Pasqualucci and Dalla-Favera, 
2015) (Schneider et al., 2011). The most advanced research focuses on the following 
targets: NF-κβ with Bortezomib or Lenalidomide or inhibitors of BCR cascade (e.g. 
SYK, BTK and PKCβ) with fostamatinib, ibrutinib and enzastaurin, all of them used in 
ABC-DLBCL (Sehn and Gascoyne, 2015). The new drugs proposed for GCB-DLBCL 
are PI3K inhibitor idelalisib, BCL2 inhibitor ABT-199 or EZH2 and BCL6 inhibitors 
(Sehn and Gascoyne, 2015). Finally, the new anti-CD20 and anti-CD79b antibodies can 
be used in all types of DLBCL (Sehn and Gascoyne, 2015). Most likely these new drugs 
can be added to the backbone of standard chemotherapy with CHOP-R or perhaps more 
rationally in studies of elderly or fragile patients to less intensive treatments like 
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bendamustine or DECC, which was successfully evaluated in palliative setting for 
patients with DLBCL in our group and showed very good results with an excellent 
toxicological profile (Proctor et al., 2010). 
The remaining question is if there is any place for intensification of the 
chemotherapy in the treatment strategies of patients with DLBCL? Studies of the role of 
high-dose chemotherapy with autologous stem cell transplant as first line treatment for 
patients with DLBCL deliver conflicting results (Greb et al., 2007) (Schmitz et al., 
2012) (Schmitz et al., 2012). However, their design was not optimal to answer the 
above question, as they usually recruited a very heterogeneous group of patients. Even 
very simple studies of intensified chemotherapy / autologous stem cell transplant in 
high risk IPI DLBCL are still missing. According to current knowledge the intensive 
approach can be reserved for the patients with advanced stage disease / high IPI with 
aggressive tumours in the group of patients suitable for high-dose treatment. The 
unresolved issues remain the selection of patients and choice of induction regimen / 
consolidation regimen. The use of IPI for selection of high-risk patients has limited 
success, as proven in our studies on a larger cohort of patients treated with 
anthracycline-based chemotherapy only and with addition of immunotherapy as well. 
Currently the intensification of treatment is postulated in patients with double 
translocations involving c-MYC and BCL2, so called “double hit” lymphoma 
(Friedberg, 2012). The double translocation occurs in approximately 5% of DLBCL 
cases, these cases are characterized by very poor response to standard treatment with 
CHOP-R with a median survival of approximately eight months only. Recently, since 
the introduction of improved antibodies against c-MYC, so called dual expressers of c-
MYC / BCL2 can also be considered for intensive treatment options (Johnson et al., 
2012). Depending on the evaluation/technical method approximately 25% of DLBCL 
patients belong to this group and their 5-years PFS is 25%. 
In our studies we attempted to establish a prognostic model based on the 
expression at the RNA level of c-MYC and HLA-DRβ. The choice of the prognostic 
genes was based on the results of the studies on the role of c-MYC in lymphomagenesis 
of DLBCL and Burkitt lymphoma (Joos et al., 1992) (Johnson et al., 2009), particularly 
we noticed the fact that since the intensification of chemotherapy with the introduction 
of specific regimens like CODOX-M/IVAC or GMAIL protocol in Burkitt lymphoma 
there has been a significant improvement in outcome. The role of the microenvironment 
and immunosurveillance justify the use of HLA-DRβ as a second prognostic gene 
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(Rimsza et al., 2004). In our model we also included the V2-transcript encoding the 17-
92 microRNA cluster, which has a previously described role in lymphomagenesis 
(Tagawa and Seto, 2005). We could not confirm the prognostic value of expression of 
the assessed genes in our cohort of patients. As discussed above, this could be due to 
methodological reasons like selection of the assessment method, extraction of RNA 
from samples, characteristic of the amplicon and of the primers and probe for V2-
transcript. These technical obstacles can be improved by using the improved technic of 
obtaining representative tumour samples (micro-sections from several separate sides of 
tumour) and applying other non–enzyme based gene expression assessment methods 
like NanoString (Scott et al., 2015). Particularly, given that recent data indicate that this 
technology can be successfully used in FFPE tissue samples in clinical practice (Scott et 
al., 2015). By contrast the whole genome / exome next generation sequencing methods, 
although very important in basic research, have very limited value in routine practice 
because of costs and requirement of fresh tissue. Additionally, the complex character of 
control of gene expression as in the case of c-MYC can contribute to our results. 
The choice of type of intensive treatment in DLBCL is also not yet determined. 
One of the options is based on a conventional anthracycline-based regimen with some 
modification such as the addition of etoposide (CHOEP or DA-EPOCH-R) (Petrich et 
al., 2014). Alternatively the regimen used in the treatment of Burkitt lymphoma could 
be applied. A final option is the use of a completely novel strategy such as the NEALL 
VI protocol, used primarily by SNLG for the treatment of ALL, but subsequently 
successfully used in patients with primary refractory DLBCL and bone marrow 
involvement (Sieniawski et al., 2009). From the view of tumour biology it seems that 
using the two latter options is more justified but this needs further assessment in 
randomized clinical trials. The role of consolidation with stem cell remains open, and if 
so, whether this should be autologous or allogeneic. 
 
Peripheral T-cell lymphoma 
 The outcome of patients with peripheral T-cell lymphoma was described as 
generally worse than the outcome of DLBCL. This conclusion is based on the 
subanalysis of the peripheral T-cell lymphomas treated within the trials for aggressive 
lymphomas before the rituximab era and evaluation of international cohort trials (Vose 
et al., 2008) (Mounier et al., 2004). Prospective population-based cohort trials would be 
a very helpful source of information about patients with peripheral T-cell lymphomas in 
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terms of patient characteristics, presentation and outcome of the standard treatment, 
particularly for those cases with rare subtypes. In our prospective population-based trial 
on EATL we collected the most accurate information on epidemiology and presentation 
of this entity. This also allowed the performance of an exact evaluation of the outcome 
of routinely applied treatments including surgery and chemotherapy and the very poor 
prognosis of patients when treated with conservative treatment was confirmed. This 
data subsequently led to implementation of new high dose regimen with IVE/MTX, 
which significantly improved the outcome of patients with EATL. 
The IVE/MTX regimen was then used in the treatment of other subtypes of 
PTCL including: PTCL NOS, ALCL ALK negative, ALCL ALK positive, extranodal 
NK/T-cell lymphoma, nasal type or hepatosplenic T-cell lymphoma. The outcome of 
treated patients was significantly better as compared with historical data for patients 
with these entities treated with standard anthracycline-based treatment with CHOP. In 
addition, in comparison to the largest study on modified anthracycline-based 
chemotherapy with CHOEP and up-front autologous stem cell transplant our results 
seem to be slightly better (d'Amore et al., 2012). Particularly, the number of cases with 
primary resistant disease and early relapses was reduced. Our cohort of patients is 
currently undergoing late follow-up and we are expecting very interesting data on the 
late events. 
The question remains if upfront high dose chemotherapy is needed for the 
treatment of PTCL. According to currently available data only ALCL ALK positive 
have more or less satisfactory outcome when treated with standard anthracycline-based 
treatment with CHOP (Vose et al., 2008). Because of heterogeneity and rarity of PTCL, 
the available data on the pathobiology of PTCL is very sparse and described 
abnormalities in oncological pathways would support use of several new drugs only, 
e.g.: the patients with mutations in TET2 and DNMT3A can be potentially treated with 
demethylating agents (Couronné et al., 2012) or the ROHA status can be helpful in 
directing targeted therapies (Palomero et al., 2014), finally the FYN mutations 
accounted in PTCL result in increased activation of the enzyme and could be potentially 
targeted with SRC kinase inhibitors (Palomero et al., 2014). Additionally, current data 
on new anticancer drugs used in PTCL would not support the idea of significant 
improvement on the standard anthracycline-based chemotherapy when given in 
combination. Obviously this combination can be used in fragile patients who would not 
tolerate the intensive treatment, see below. Thus there is still a need for the assessment 
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of more intensive treatment like CHOEP or IVE/MTX in consolidation with stem cell 
support. Both approaches have their positives and negatives. There is an option to add 
new drugs to induction with CHOEP but this would probably be more difficult with 
more intense IVE/MTX. In IVE/MTX the substitution of MTX by a novel antifolate 
could be an interesting possibility. Finally, the direct comparison of both regimens 
would be worthy of further consideration. 
 In conclusion this thesis focused on the chosen aspects of epidemiology, 
prognosis and treatment of aggressive lymphomas. This research can help prepare future 
studies on aggressive lymphomas. There is a significant discordance between the 
current knowledge of the biology of aggressive lymphomas and used therapies. 
Improvement in treatment strategies is greatly required, however it will require very 
close cooperation between haematooncology and particularly clinical pathology and 
other involved disciplines like radiotherapy or diagnostic imaging. However the accent 
should be put on the active role of pathological diagnostic. 
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Appendix I – SNLG questionnaire 
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Appendix II – Questionnaire for collection of immunochemotherapy 
data 
R-CHOP – Diffuse Large B-cells Lymphoma Questionnaire 
UPN (PI):  _____  Histopathology PR No: _________________  Research:  yes  no  NK/ND 
Hospital: ____ Hospital No: _______________ NHS No: ____________________ 
Gender:  male   female 
Date of birth:  ___ /___ / _____ (DD / MM / YYYY) 
Date of diagnosis: ___ /___ / _____ (DD / MM / YYYY) 
Disease status and investigations at diagnosis 
Clinical Stage:  I   II   III   IV  NK/ND 
ECOG:    0  1  2  3  4  5  NK/ND 
B-symptoms:    yes   no   NK/ND 
Marrow involvement:   yes   no   NK/ND 
Extranodal organs involvement excluding marrow:  yes   no  NK/ND 
Organs: __________________________________ No. of sites: ________ 
Bulk (defined as: single node >5cm or group of nodes >10cm or mediastinal bulk >30% of 
chest diameter):  yes   no   NK/ND 
Hb:  level: ______   normal   abnormal   NK/ND 
WBC: level: ______   normal   abnormal   NK/ND 
LDH: level: ______   normal   abnormal   NK/ND 
LDH:    lower limit ______  upper limit ______ 
ß2 – microglobuline:   normal   abnormal   NK/ND 
Albumin:    normal   abnormal   NK/ND 
Urea:     normal   abnormal   NK/ND 
Alkaline phosphatase:  normal   abnormal   NK/ND 
Treatment 
Planed chemotherapy completed:  yes   no   NK/ND 
No. CHOP-R cycles given: __ No CNOP-R cycles given: __ No. R cycles given: __ 
Reason for discontinuation of scheduled chemotherapy: 
 Progression  infection  organ failure   other   NA  NK/ND 
Radiotherapy:    yes   no   NK/ND 
Outcome 
Response after the end of first line treatment: 
 complete remission   partial remission   failure 
Progression:   yes   no 
Date progression: ___ /___ / _____ (DD / MM / YYYY) 
Death:    yes   no 
Date last seen or date of death: ___ /___ / _____ (DD / MM / YYYY) 
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Appendix III – Questionnaire for collection of IVE/MTX followed by 
ASCT for the treatment of EATL data 
 
EATL – QUESTIONNAIRE 
 
1. UPN (PI) 
____________________ 
2. Date of presentation (DD/MMM/YYYY) 
____________________ 
3. Age at presentation (years) 
____________________ 
4. Gender 
§ male 
§ female 
5. Presenting features at presentation 
§ pain 
§ lump 
§ nausea/vomiting 
§ weight loss 
§ bowel upset 
§ perforation 
§ subacute obstruction 
§ other, please specify ____________________ 
§ unknown / not done 
6. Duration of symptoms pre-diagnosis 
§ 0-1 month 
§ 1-3 months 
§ 3-6 months 
§ >6 months 
§ unknown / not done 
7. Diagnosis at 
§ surgery 
§ gastroscopy 
§ other, please specify ____________________ 
§ unknown / not done 
8. Site of disease 
§ Stomach 
§ Jejunum 
§ Ileum 
§ Ileocecal 
§ other, please specify ____________________ 
§ unknown / not done 
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9. General Fitness Rating (ECOG) at presentation 
§ ECOG 0 
§ ECOG 1 
§ ECOG 2 
§ ECOG 3 
§ ECOG 4 
§ ECOG 5 
§ unknown / not done 
10. B-symptoms at presentation 
§ yes 
§ no 
§ unknown / not done 
11. Hb level [g/dl] at presentation 
____________________ 
12. Hb at presentation 
§ normal (≥ 12 g/dl) 
§ abnormal (< 12 g/dl) 
§ unknown / not done 
13. WBC level [x109/L] at presentation 
____________________ 
14. WBC at presentation 
§ normal (4 x109/L – 11 x109/L) 
§ abnormal (< 4 x109/L or > 11 x109/L) 
§ unknown / not done 
15. Urea + electrolyte at presentation 
§ normal 
§ abnormal 
§ unknown / not done 
16. Liver function tests at presentation 
§ normal 
§ abnormal 
§ unknown / not done 
17. LDH at presentation 
§ normal 
§ abnormal 
§ unknown / not done 
18. Chest X ray at presentation 
§ normal 
§ abnormal 
§ unknown / not done 
19. CT abdomen at presentation 
§ normal 
§ abnormal 
§ unknown / not done 
20. CT chest at presentation 
§ normal 
§ abnormal 
§ unknown / not done 
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21. Ultrasound abdomen at presentation 
§ normal 
§ abnormal 
§ unknown / not done 
22. Bone marrow at presentation 
§ normal 
§ abnormal 
§ unknown / not done 
23. Lugano stage at presentation 
§ Stage I 
§ Stage II1 
§ Stage II2 
§ Stage II E 
§ Stage II1 E 
§ Stage II2 E 
§ Stage IV 
§ unknown / not done 
24. Manchester stage at presentation 
§ Stage Ia 
§ Stage Ib 
§ Stage IIa 
§ Stage IIb 
§ Stage IIc 
§ Stage III 
§ Stage IV 
§ unknown / not done 
25. Primary treatment description [text] 
_______________________________________________________________ 
26. Surgery 
§ yes 
§ no 
§ unknown / not done 
27. Type of surgery [text] 
_______________________________________________________________ 
28. Chemotherapy 
§ yes 
§ no 
§ unknown / not done 
29. Type of chemotherapy [text] 
_______________________________________________________________ 
30. Autologous stem cell transplant 
§ yes 
§ no 
§ unknown / not done 
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31. Chemotherapy completed 
§ yes 
§ no 
§ not applicable 
§ unknown / not done 
32. Outcome 
§ CR 
§ PR 
§ failure 
§ unknown / not done 
33. Progression Free Survival Event 
§ relapse / death 
§ no relapse / no death 
34. Progression Free Survival or Last Assessed Date (DD/MMM/YYYY) 
____________________ 
35. Overall Survival Event 
§ death 
§ no death 
36. Overall Survival or Last Seen Date (DD/MMM/YYYY) 
____________________ 
37. Cause of Death 
§ lymphoma 
§ treatment complications 
§ other, please specify ____________________ 
§ not applicable 
§ unknown / not done 
38. Presence of coeliac disease 
§ yes prior to lymphoma 
§ yes at presentation 
§ no 
§ unknown / not done 
39. Complications [text] 
_______________________________________________________________ 
40. Comments [text] 
_______________________________________________________________ 
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Appendix IV – Questionnaire for collection of IVE/MTX followed by 
ASCT for the treatment of PTCL other than EATL data 
 
T-cell – IVE / MTX – QUESTIONNAIRE 
 
41. UPN (PI) 
____________________ 
42. Date of presentation (DD/MMM/YYYY) 
____________________ 
43. Date of birth (DD/MMM/YYYY) 
____________________ 
44. Gender 
§ male 
§ female 
45. WHO classification 
§ copy of pathological report 
____________________ 
46. Site of disease 
____________________ 
47. Clinical stage 
§ copy of CT / chest RTX / ultrasound report 
§ I 
§ II 
§ III 
§ IV 
48. B-symptoms at presentation 
§ yes 
§ no 
§ unknown / not done 
49. Bulky disease 
§ yes 
§ no 
§ unknown / not done 
50. Site of bulky disease 
____________________ 
Extranodal disease 
§ yes 
§ no 
§ unknown / not done 
51.  Site of extranodal disease 
____________________ 
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52. General Fitness Rating (ECOG) at presentation 
§ ECOG 0 
§ ECOG 1 
§ ECOG 2 
§ ECOG 3 
§ ECOG 4 
§ ECOG 5 
§ unknown / not done 
53. Hb level [g/dl] at presentation 
____________________ 
54. Hb at presentation 
§ normal (≥ 12 g/dl) 
§ abnormal (< 12 g/dl) 
§ unknown / not done 
55. WBC level [x109/L] at presentation 
____________________ 
56. WBC at presentation 
§ normal (4 x109/L – 11 x109/L) 
§ abnormal (< 4 x109/L or > 11 x109/L) 
§ unknown / not done 
57. LDH at presentation 
§ normal 
§ abnormal 
§ unknown / not done 
58. Bone marrow at presentation 
§ normal 
§ abnormal 
§ unknown / not done 
59. Primary treatment description [text] 
_______________________________________________________________ 
60. CHOP – number of cycles 
____________________ 
61. IVE – number of cycles 
____________________ 
62. MTX – number of cycles 
____________________ 
63. Radiotherapy 
§ yes 
§ no 
§ unknown / not done 
64. Autologous stem cell transplant 
§ yes 
§ no 
§ unknown / not done 
65. Type of conditioninig 
____________________ 
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66. Chemotherapy completed 
§ yes 
§ no 
§ not applicable 
§ unknown / not done 
67. Outcome 
§ CR 
§ PR 
§ failure 
§ unknown / not done 
68. Progression Free Survival Event 
§ relapse / death 
§ no relapse / no death 
69. Progression Free Survival or Last Assessed Date (DD/MMM/YYYY) 
____________________ 
70. Overall Survival Event 
§ death 
§ no death 
71. Overall Survival or Last Seen Date (DD/MMM/YYYY) 
____________________ 
72. Cause of Death 
§ lymphoma 
§ treatment complications 
§ other, please specify ____________________ 
§ not applicable 
§ unknown / not done 
73. Complications [text] 
_______________________________________________________________ 
_______________________________________________________________ 
_______________________________________________________________ 
74. Comments [text] 
_______________________________________________________________ 
_______________________________________________________________ 
_______________________________________________________________ 
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T-cell – IVE / MTX – QUESTIONNAIRE FOLLOW-UP 
 
75. UPN (PI) 
____________________ 
76. Type of salvage treatment 
____________________ 
77. Salvage treatment completed 
§ yes 
§ no 
§ unknown 
 
78. Outcome of salvage treatment 
§ CR 
§ PR 
§ failure 
§ unknown / not done 
79. Cause of Death 
§ lymphoma 
§ treatment complications 
§ other, please specify ____________________ 
§ not applicable 
§ unknown / not done 
80. Comments [text] 
_______________________________________________________________ 
_______________________________________________________________ 
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